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Abstract 
Reversed-phase liquid chromatography (RPLC) is the most commonly used 
chromatographic technique in the pharmaceutical industry. In RPLC, a computer-assisted 
approach is capable of accelerating the process of method development by predicting the 
retention behaviour of compounds of interest, this would then be followed by an optimisation 
step to improve chromatographic performance. These objectives can be achieved using a 
combination of analytical routines and chemometric techniques, and quantitative structure-
retention relationship (QSRR) modelling is a promising solution from a variety of 
chemometric methods. QSRR aims to find meaningful relationships between chromatographic 
parameters and the molecular descriptors of the compounds of interest. QSRR has been applied 
for the characterisation of columns, the interpretation of retention mechanisms, the prediction 
of retention, and the identification of unknown compounds. 
The first part of this thesis illustrates the application of QSRR methodology to predict the 
retention times of compounds extracted from the literature. Several filters including Tanimoto 
similarity, log D and log P, dual-filtering, and the ratio of retention factors (k-ratio) were 
applied to yield training sets for the construction of QSRR models and the results were 
explored and compared. QSRR methodology seeks mathematical equations where the 
chromatographic parameters are expressed as functions of molecular descriptors that were 
generated, in this case, using Dragon software. To achieve that, the genetic algorithm (GA), 
employed as feature selection method, combined with a partial least squares (PLS) regression 
was utilised to correlate measured retention data to various computed molecular descriptors. 
Among the constructed models, the filter that utilised the ratio of retention factor appeared to 
be the most effective approach to minimizing prediction errors. But, since the k-ratio filter is 
impractical, it cannot be used directly in QSRR modelling for retention prediction. However, 
in QSRR modelling the concept of chromatographic similarity should be considered and 
implemented using a measure of similarity that adequately reflects the retention of compounds. 
The use of a Tanimoto similarity filter based on the chemical structures of the analytes resulted 
in unacceptable prediction errors because the level of similarity of compounds in the training 
sets to the target compounds was not sufficiently high (TS > 0.5). Retention predictions 
generated using log D, and log P filters, and a dual-filter were not sufficient for the purpose of 
screening in chromatographic method development. Results indicated the need for larger and 
more homogenous datasets for QSRR modelling, allowing sufficient numbers of compounds 
with a high pair-wise similarity to be found when using the Tanimoto filter. 
x 
 
The second part of this thesis demonstrated and compared the contribution of different 
resources of molecular descriptors to QSRR prediction performance where training sets were 
formed using different filtering approaches. Molecular descriptors of compounds were 
calculated using both Dragon, and VolSurf+. Filtering approaches including leave-one-out 
(LOO), training-test, local compound type (LCT), and local second dominant interaction after 
hydrophobicity (LSDI) were utilised to allocate compounds to training sets prior to deriving 
local QSRR models. Instead of predicting retention times directly, retention was predicted 
indirectly in this chapter by modelling the five solute coefficients of the Hydrophobic 
Subtraction Model (HSM). Among these four filtering approaches, the LSDI approach showed 
the best prediction for the five solute coefficients, followed by the LCT approach, 
demonstrating that approaches embedded with compound classification yielded better 
prediction of solute coefficients and hence, retention. In terms of the comparison of descriptor 
resources, no significant difference was observed given the comparable results obtained. The 
HSM is capable of indirectly providing sufficient accuracy of retention prediction by fitting 
the predicted solute coefficients and column parameters together.  
In the third and main part of the thesis, the utility of the QSRR approach for modelling 
solute coefficients in the HSM to predict retention times across a wide range of RPLC columns 
was demonstrated. Different approaches were utilised to cluster compounds for the training 
sets prior to deriving local QSRR models. The performance of each filtering approach in 
enhancing prediction accuracy was compared against the classical approach where a global 
QSRR model is derived using all the compounds in the training set without filtering. The 
predictive power of the established QSRR models was evaluated using a series of criteria and 
statistical analysis. In addition, a proof of concept demonstration of the use of QSRR was 
performed by predicting the retention times of five representative compounds on nine columns 
for which HS coefficients were known. It was shown that modelling the solute coefficient η’ 
in the HSM is all that is necessary to achieve sufficient prediction accuracy. Results showed 
improvement in prediction accuracy for the LSDI, LCT and Tanimoto approaches compared 
with global models derived from the whole dataset without filtering. Of these approaches, the 
LCT exhibited advantages in its ease of application and the larger number of compounds which 
can be modelled using this approach. However, the Tanimoto approach was the simplest to 
apply and, provided that there was a sufficient number of similar compounds in the dataset 
which meet the TS score cut-off, it yielded sufficiently accurate results. The predictions 
reported show sufficient accuracy to meet the major objective of this study, namely to 
determine the likelihood of co-elution of analytes. 
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In the last part of the thesis, retention index (RI) prediction QSRR models were developed 
that offer useful predictive ability for compounds having the same molecular weight, allowing 
false positives to be removed during the interpretation of structure identification in non-
targeted metabolomics (NTM). A novel dual-filtering approach combining structural 
similarity and chromatographic similarity was employed to build suitable training sets for 
target analytes for the accurate prediction of RI. The elimination of false positives from the 
list of potential candidate compounds produced by exact mass database searches is 
demonstrated using the proposed QSRR approach. The predicted RI values generated using 
the dual-filtering-based QSRR models were very well correlated with the measured data, 
presenting a percentage root mean square error of prediction (%RMSEP) value of 8.45%. By 
applying the retention index prediction filter to the modelled compounds in each exact-mass 
group, 53% of groups were found where at least one false positive could be eliminated. Results 
have shown that the QSRR modelling using dual-filtering as the strategy for the generation of 
training sets permits a robust and highly accurate prediction of retention index. Additionally, 
the results demonstrate that the developed QSRR strategy is capable of eliminating false 
positives, thereby increasing the confidence of structure identification in MS-based non-
targeted metabolomics. 
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1 Introduction 
1.1 Thesis overview 
Reversed-phase liquid chromatography (RPLC) has been widely used in the separation 
science community, especially in the field of the pharmaceutical industry. The availability of 
a broad range of RPLC stationary phases provides opportunities for meaningfully different 
retention and separation selectivity. With ever more diverse stationary phases available in 
RPLC, now it is more challenging for chromatographers to choose the most suitable columns 
for a given set of compounds, or even a starting point for method development. Traditional 
method development using trial-and-error methods is usually time-consuming and labour-
intensive. One option to speed up the process of chromatographic method development is 
using computer-based methods to predict the retention behaviour of the compounds of interest 
with good accuracy mainly based on their chemical structure. With the aid of a variety of 
chemometric approaches, like the quantitative structure-retention relationship (QSRR) 
methodology, chromatographers have devoted a great deal of effort to propose possible 
strategies to accelerate method development in RPLC. This thesis aims to explore strategies 
for the acceleration of method development in RPLC using QSRR methodology to perform 
computational retention prediction for compounds based solely on their structures. The 
developed QSRR strategy was successfully used for the retention prediction of new 
compounds that have never been used in the modelling process, and the elimination of false 
positives in non-targeted metabolomics (NTM) to improve the confidence of metabolite 
identification. 
This thesis comprises the development of QSRR models for retention prediction and the 
application of the proposed QSRR in NTM. The retention prediction was performed using 
three retention databases extracted from the literature, combined with a separate retention 
database generated from five new compounds and five new columns. The application of the 
developed QSRR in NTM was conducted on a database of 1882 compounds with known 
retention indices and molecular weight. To enhance the predictive ability of the QSRR models, 
the concept of molecular similarity was employed where different filtering approaches were 
created and utilised as compound classification filters to yield training sets for the construction 
of QSRR models. The proposed QSRR methodology has been used in column scoping and 
co-elution prediction in RPLC, as well as the elimination of false positive in NTM. 
1.2 Reversed-Phase Liquid Chromatography 
As the most widely used separation technology in the pharmaceutical industry, High-
Performance Liquid Chromatography (HPLC) has replaced spectroscopic methods and gas 
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chromatography in numerous quantitative and qualitative analysis applications in the last 
twenty years [1-3]. In comparison to other methods, a great advantage of HPLC is that it 
provides a quick, automated and highly accurate method to identify certain chemical 
components in a sample, combined with over hundreds of stationary phases that are available 
commercially, enabling the realisation of optimal separation for analytes of interest [4-6]. 
Additionally, liquid chromatography can be integrated with many types of detector systems 
like diode detectors, and electrochemical detectors, as well as integration with other systems 
such as Liquid Chromatography-Mass Spectrometry (LC-MS) and Liquid Chromatography-
Nuclear Magnetic Resonance (LC-NMR), another reason for the widespread applicability of 
this technique [7-10]. RPLC is by far the most popular mode of all types of chromatography 
which is shown by the fact that nearly 90% of small molecule separations are carried out using 
RPLC [3, 5, 9, 11]. 
1.2.1 High-Performance Liquid Chromatography  
HPLC, as a technique in the area of analytical chemistry, aims to identify, quantify and 
separate the components of a mixture [1, 12, 13]. As an integral and major analytical tool in 
the modern pharmaceutical industry, HPLC has been applied in all stages of method 
development, drug discovery and high-throughput screening [1-3]. Chromatography, which 
can be described as a mass transfer process usually involving adsorption, has been given 
intensive study for decades. HPLC relies on pumps to deliver the mobile phase liquid and the 
sample mixture through a column filled with adsorbent, leading to the separation of the 
components of the mixture. The adsorbent, as the active component of the column, is referred 
to as a "stationary phase", is typically a granular material made of particles of a porous solid 
(e.g. silica, polymers, etc.) [1, 14, 15]. Because of the different degrees of interactions with 
the adsorbent particles, components of the mixture can be separated from each other, leading 
to the elution of the components as they flow out the column. The pressurised liquid in the 
HPLC system is typically a mixture of solvents (e.g. water, acetonitrile and/or methanol) and 
is referred to as a "mobile phase" [13, 16]. During the separation process, the temperature and 
the composition of the mobile phase play a major role by influencing the interactions taking 
place between the analytes and stationary phase. These interactions are physical in nature, 
such as hydrophobic (dispersive), dipole–dipole and ionic interactions, and most often, a 
combination of interactions contributes to the separation [16, 17]. 
An HPLC instrument typically includes a degasser, sample injector, pumps, and a detector, 
as can be seen in Figure 1.1 [13, 16, 18, 19]. The degasser, as the solution to the problem of 
outgassing, is designed to remove the gas from the mobile phase solvents before they are used. 
The sample injector, as the name suggests, brings the samples into the mobile phase that 
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carries the components of sample into the column, while the pumps are used to deliver the 
desired flow and composition of the mobile phase. Various commercially available detectors 
are in common use now, such as ultraviolet/ visible absorption (UV/Vis), photodiode array 
(PDA) or detectors based on mass spectrometry. The detector generates a signal proportional 
to the number of components of the mixture emerging from the stationary phase, hence 
allowing the quantitative analysis of the analytes [1, 13]. In addition, with the development of 
the digital microprocessor and embedded software, the control of the HPLC instrument and 
data processing has been greatly simplified, making the HPLC system more user-friendly even 
for less experienced chromatographers [18, 20-22]. 
When separating a given mixture, since there are many combinations of stationary and 
mobile phases that can be employed, the nature of those phases can be used to classify several 
types of HPLC techniques [23-25]. Normal-Phase Liquid Chromatography (NPLC), with a 
solid polar stationary phase and non-polar mobile phase, is usually used to separate polar 
samples according to the polarity difference of analytes, leading to the least polar components 
being eluted first, while the most polar components separate last [26, 27]. RPLC, which is the 
opposite to NPLC, uses a polar liquid mobile phase with a non-polar stationary phase to 
separate analytes. The most polar components are eluted first, followed by components with 
lower polarity [1, 6]. Mixtures of water, methanol, and acetonitrile are commonly used as 
mobile phase, and the non-polar stationary phase can be made by coating silanised silica gel 
with a non-polar liquid such as a silicone or various hydrocarbons. As an alternative to this 
type of column, a bonded hydrophobic phase also can be used as the stationary phase, where 
a hydrophobic molecule is chemically bonded to the polar silica gel. Ion-Exchange or Ion 
Chromatography (IC), including anion-exchange and cation-exchange, is based on the affinity 
of the ions and polar molecules to the ion exchanger to separate and determine ions on columns 
carrying charged functional groups [12, 18]. Other varieties of liquid chromatography such as 
size exclusion chromatography (SEC) and hydrophilic interaction chromatography (HILIC), 
etc. also have been given intensive study. 
 
Figure 1.1. Diagram of HPLC system. 
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1.2.2 Retention mechanism in RPLC 
The term “reversed-phase” arises as this mode of chromatography was developed after 
normal phase chromatography in which a less polar mobile phase is used with a polar 
stationary phase, thus the mobile phase in RPLC is more polar than the stationary phase [7, 
28]. RPLC involves the separation of analytes based on hydrophobicity [29, 30]. In its simplest 
interpretation, the separation in RPLC mainly depends on the hydrophobic interaction between 
the hydrophobic nature of the molecule (e.g. the carbon backbone) and the non-polar 
stationary phase ligand (e.g. C18) [31, 32]. The hydrophobic interaction is a weak and 
transient binding force which includes hydrophobic and van der Waals interactions; the more 
hydrophobic a molecule is, the more retention it has in RPLC [3, 14, 32]. A schematic diagram 
showing the binding of an analyte to a reversed-phase surface is shown in Figure 1.2. 
Accordingly, it is reasonable to estimate the elution order based on the solute property of 
hydrophobicity or hydrophilicity. Figure 1.3 illustrates the general elution order of hydrophilic 
and hydrophobic analytes.  
 
Figure 1.2. Molecular interactions in RPLC. 
 
Figure 1.3. Representative reversed-phase chromatogram showing analyte retention order 
based on hydrophobicity or hydrophilicity. 
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Figure 1.4. Simplified representation of retention processes that correspond to various types 
of interactions in RPLC. Modified from [32]. 
It is nowadays generally accepted that the retention of analytes within a RPLC system is 
caused mainly by hydrophobic interactions between the analyte and the stationary phase [29]. 
With the intensive study of column characterisation and selectivity in RPLC for decades, other 
types of interactions between the analytes and the stationary phases which can significantly 
affect the retention behaviour of solutes have also been found [30, 33-36]. For example, a 
study performed for a group of alkyl silica phases (i.e., C3-C18) has shown that the retention 
of compounds on these columns are mainly governed by five different interactions, namely 
hydrophobicity, steric resistance, hydrogen-bond acidity, hydrogen-bond basicity, and ionic 
interactions between solute and stationary phase [29, 32, 34-36]. Figure 1.4 provides a 
simplified representation of these types of interactions. 
Given these types of interactions contribute to retention in RPLC, the relative importance 
of each interaction to solute retention has also been investigated [29, 30, 33]. Wilson and co-
workers explored the contribution of each type of interaction in terms of the average change 
in retention (δ log k) as a result of a maximum change in the column using a retention database 
which contained 67 compounds [29, 32]. As expected from the nature of RPLC separation, 
the hydrophobic interaction contributed most to changes in retention as a result of change in 
the column. The contribution of the remaining interactions was dependent on the particular 
compounds and columns [29, 34-36]. Although the remaining types of interaction contribute 
less than hydrophobicity to overall retention, for column selectivity these terms are still 
important [29, 37, 38]. 
1.2.3 Stationary phases in RPLC 
For a separation using a liquid chromatography system, the properties of packing materials 
for the stationary phase are of primary importance [14, 15, 39]. New types of commercial 
stationary phases for RPLC appear every year with improved stability, efficiency, peak 
symmetry and selectivity for various analytes [1, 13, 17]. When picking a stationary phase for 
a separation, the chromatographer should be able to decide which type of column (packed, 
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capillary, or monolithic column) and what desired characteristics of the column are needed 
(base material, bonded phase, and bonding density), as even the same types of columns can 
differ widely in the power of separation across a wide range of manufacturers [6, 7, 19]. In an 
HPLC system, the most commonly used packing materials are porous particles with average 
diameters between 3 and 10 μm, and it is highly recommended that 3 μm particle sizes are 
applied for most pharmaceutical applications. In the middle of the 1900s, small nonporous 
spherical particles were introduced to increase the efficiency by eliminating dual column 
porosity [16, 24, 40]. Another attempt to improve the column permeability was achieved by 
applying a monolithic column. The monolithic column is able to facilitate the accessibility of 
the adsorbent surface inside the mesopores of the skeleton as it is only 1 μm thick compared 
to the 5 or even 3 μm particles in conventional packed columns [16, 21]. 
In RPLC, separations are mainly performed on chemically-modified adsorbents, and 
analyte interactions with the stationary phase are the primary factors in the process of 
separation [41, 42]. Silica (SiO2), the most common substance on the earth, is the most 
frequently used base material [1, 43]. For the past two centuries, the properties, synthesis, and 
surface structure of silica have been given intensive study [1, 44]. As the most widely used 
base material for adsorbents, silica has an array of advantageous properties. Firstly, silica 
particles are hard enough to withstand harsh packing conditions and the flow of viscous liquids 
[1, 43]. Additionally, when exposed to different solvents, silica will not shrink or swell. Most 
importantly, porous silica, as the base material, can provide high surface area which is 
necessary for a complete separation of analytes. Most of the silica-based HPLC packings are 
uniform spherical porous particles with narrow particle and pore size distribution[43, 45]. 
Silica is, however, soluble in a high pH environment. The stability range of silica as a base 
material has recently been extended to over pH 10 with a chemical modification of a high 
bonding density of attached alkyl silanes. As an alternative, zirconia is quite stable across a 
wide pH range (from 1 to 14) [1, 45, 46] and has been suggested as another porous base 
material in the last decade [1]. But the limitation of zirconia is that it is more difficult to bond 
functional groups to the surface, which greatly limits its practical applicability. Polymer-based 
materials also can be used as the base materials and show high pH stability and chemical 
inertness [13, 16, 47]. Due to the presence of micro porosity in the polymer materials, the 
application for small molecules separation is somewhat limited. But for size-exclusion 
chromatography, polymers are the main packing materials [1, 42, 48]. As the most popular 
RPLC stationary phase, octadecyl carbon chain (C18)-bonded silica columns have been 
commercially available for decades [41, 49]. In addition, C8-bonded silica, cyano-bonded 
silica, and phenyl-bonded silica stationary phases are also used widely for the separation in 
RPLC [1, 17, 50]. 
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Chemical modification is used in the preparation of reversed-phase base materials for the 
purpose of converting the polar surface into a hydrophobic surface that results in dispersive 
interactions with the analytes [1, 23, 43]. The conversion of polar silica into a hydrophobic 
surface needs dense bonding of a thick organic layer, so that the surface of base silica can be 
shielded effectively [1, 51]. A wide range of different ligands such as C1, C4, C8, C18, Phenyl, 
Phenyl-hexyl, Nitrile (cyano), and so forth have been tested and bonded on the silica surface 
[51]. The silanols on the surface can react with different functional groups to form the bonded 
phase. Practically, almost all of the chromatographic phases that are commercially available 
are manufactured using a silanisation modification process [14, 15, 47, 50]. There are several 
types of bonded phases available commercially including alkyl-type phases (C1–C18, C30), 
phenyl-type phases, and polar embedded stationary phases [1, 15, 31].  
Alkyl-type phases are well known to chromatographers since almost 90% of reversed-
phase columns are based on these phases [43, 52]. Also, a large number of publications are 
devoted to the standardisation, characterisation, classification, and comparison of this kind of 
bonded phase. Among all the investigations, Snyder and co-workers’ research attracted a lot 
of attention and laid the foundation for the future work of column development and application 
[29-36]. In the book Practical HPLC Method Development, Snyder indicates that the retention 
of non-polar and non-ionic solutes follows the retention pattern: C1 < C4 < C8 ≈ C18 in 
RPLC [16]. Also, dramatic variation of retention for polar and non-polar solutes has been 
found on the same C18-type columns from different manufacturers even at the same 
conditions [16, 24, 42, 44].  
Phenyl-type bonded phases also have been studied for a long time, since the structure of 
a phenyl ring on the surface can introduce π–π interactions with some analytes [1, 13, 53]. 
Compared to alkyl-type bonded phases, phenyl phases show lower methylene selectivity, 
which means the separation of members of homologous series will be more selective on alkyl 
phases than phenyl phases [1, 13, 49].   
Polar embedded phases were introduced and developed due to the practical need for the 
separation of highly polar or ionic solutes using highly aqueous mobile phases, because the 
alkyl or phenyl bonded phases show some drawbacks under these conditions [1, 54]. On one 
hand, the hydrophobic surface of bonded phases has limited wettability in high aqueous 
mobile phases [1, 54]. On the other, it was observed that the “phase collapse” effect happens 
for alkyl chains in pure aqueous mobile phases which greatly decreases the retention of any 
solutes on the column after a period of use [1, 55, 56]. Polar embedded stationary phases, such 
as Symmetry-Shield RP18 (Waters) and Supel cosil ABZ (Supelco), contain non-ionised polar 
groups that are embedded into the train [1, 55, 56]. Another reason that polar groups have 
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been introduced to the bonded ligands is that these polar groups will inactivate the interactions 
between silanols and basic analytes by reacting with the residual silanols [1, 57-59].  
1.2.4 Mobile phases in RPLC 
Hydro-organic mixtures are commonly used as the mobile phases in RPLC [1, 13, 16]. 
Organic modifiers, such as methanol, acetonitrile and/or combinations of these two are most 
frequently used [60]. In reversed-phase separation, it is generally accepted that the retention 
of analytes is governed by the concentration of the organic modifier in the eluent [1, 60, 61]. 
Therefore, considerations like the compatibility between solvents, the solubility of the sample 
in the eluent, light transmission, etc. need to be taken into account when selecting an 
appropriate mobile phase for the separation of analytes of interest [1, 59, 62]. For example, 
methanol and acetonitrile are miscible so this mixture could be used as the mobile phase, while 
water and dichloromethane are immiscible at most compositions, therefore this mixture should 
not be used. Similarly, it is well known that a high level of organic solvents should not be used 
with a high concentration of phosphate buffer since eventually a precipitation will be produced. 
Additionally, HPLC grade solvents are highly recommended to minimise the contamination 
of stationary phases and reduce the background absorbance, because impurities exist if the 
solvent is not purified. Another important consideration for the choice of mobile phase is the 
light transmission when using UV detection in RPLC. One of the contributing factors to the 
wide use of acetonitrile as the solvent in reversed-phase separation is because of its low 
absorbance cut-off wavelength (<  190 nm) [1, 16, 63]. Solvents like acetone and ethyl acetate 
cannot be used for the separation of analytes at low wavelengths like 210 nm as their UV cut-
offs are 330 nm and 256 nm, respectively [1-3]. Like acetonitrile, solvent methanol, ethanol 
and isopropanol have relatively low UV cut-offs (< 205 nm), but it is always recommended to 
work at a suitable wavelength with these solvents, for example 210 nm [1-3]. 
When dealing with separations of the given mixtures using RPLC, besides the type of 
solvent, parameters such as the eluent composition and the strength of solvent also need to be 
considered during the process of chromatographic method development [1-3, 64]. RPLC 
retention also can be illustrated as the effect of the competitive interactions between the 
components of analytes and the molecules of eluent with the stationary phases [1, 49, 65]. 
This means that if the interaction between the molecules of eluent and the adsorbent surface 
of the stationary phases is strong, the interaction between the analytes and the adsorbent 
surface would be weak, thus the analytes will be eluted early, leading to lower retention [10, 
66]. Organic solvents, like acetonitrile and methanol, are considered strong solvents in the 
development of separation methods, solvent strength can be increased by increasing the 
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proportion of the organic part of mobile phase, allowing early elution of some species of a 
mixture [1, 64, 67, 68].   
Apart from the concentration of the organic solvent in mobile phase, the solvent strength 
also depends on the type of organic modifier used for the separation [1, 13, 64]. Therefore, the 
correlation between the concentrations of different organic solvents which are supposed to 
give similar retention of the analytes of interest has been given intensive study. For the most 
common organic solvents in RPLC, the ranking based on the solvent strength at the same 
volume percentage (v/v%) is: tetrahydrofuran > acetonitrile > methanol [1, 13, 64]. According 
to the different solvent strengths, some general rules have been applied in the process of 
method development. For example, in order to achieve a similar separation (or elution) on the 
same stationary phase for a given mixture, compared to an acetonitrile/water eluent, an 
increased proportion of methanol/water is needed in the mobile phase (a higher concentration 
of methanol is needed, about 10v/v% more of methanol for every 1v/v% of acetonitrile). Those 
rules only serve as an approximation as there are more parameters involved in the interactions 
between the analytes, the solvents, and/or the stationary phases. 
Water is usually the base solvent in a reversed-phase application, while other polar 
solvents such as acetonitrile, methanol, etc., are added in varying proportions [1, 13, 16]. An 
ideal eluent composition should not affect the selectivity between two species if their 
ionisation state is independent of the increased organic composition [64, 68, 69]. As we know, 
for neutral solutes, the selectivity will not be affected by increasing the organic composition. 
But the ionisation state of ionisable components might be affected when different proportions 
of organic solvent are used, leading to variations in selectivity [70]. Therefore, buffers are 
usually utilised to adjust the pH of the aqueous solvent to modify separations, because most 
pharmaceuticals contain ionisable functionalities such as amino, or carboxylic groups [1, 70]. 
In fact, the retention of most ionisable compounds is controlled by adjusting the composition 
and pH of the mobile phase to optimise the separation [16, 24]. It is noticeable that the pH 
specified for a particular separation is that of the aqueous solvent, and that the addition of 
organic solvent to the aqueous mixture results in a change in final pH of the mobile phase [1, 
13, 16]. 
1.3 Method development in RPLC 
1.3.1 Method development 
Three stages need to be considered in the development of a chromatographic method [71, 
72]. The first stage is to select the appropriate technique which can provide desired separation 
selectivity for the analytes of interest [38]. For example, several chromatographic techniques 
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can be used for the analysis of small-molecule pharmaceuticals, such as liquid 
chromatography (LC), gas chromatography (GC), supercritical fluid chromatography (SFC) 
and electrokinetic separations. In addition, the selection of the specific chromatographic 
technique within one of the above classes is also involved [38, 72]. As we know, within the 
broad classification of liquid chromatography, RPLC is the most widely used separation 
technique, but other complementary techniques include hydrophilic-interaction 
chromatography (HILIC) and ion chromatography (IC) [38, 72-74]. The second stage of 
method development is column scoping, which aims to identify the most suitable column 
(stationary phase, SP) offering adequate resolution for the separation of given analytes. This 
is often found through intensive experimentation [38, 72]. The final stage of method 
development is to optimise the precise details of the separation conditions, including 
parameters that are believed to affect the separation, such as the exact mobile phase (MP) 
composition, column length and temperature, and the flow-rate, etc [38, 72]. Basically, 
according to the properties of the desired analytes and the comparison across the available 
chromatographic techniques, one would be able to select a starting point to develop a 
chromatographic method. As the primary phase of method development, the selection of the 
preferred technique, the stationary phase (or column class) and type of mobile phase 
(especially the preferred type of organic modifier) is called “scoping” (Stages 1 and 2). Further 
optimisation of details of conditions can be performed via a subsequent phase called 
“optimisation” (Stage 3) by implementing some form of experimental design approach [6, 24, 
38, 40]. 
At present, much of the method development in the pharmaceutical industry is carried out 
by trial-and-error laboratory experimentation [16, 24, 75]. A lot of common parameters need 
to be considered when HPLC method development is required, such as the selection of the 
analytical method, sample preparation, the gradient/isocratic elution, column size, the detector, 
and the wavelength. Traditional approaches like the One-Variable-At-A-Time approach 
(OVAT) for method development vary one factor at a time while keeping the other factors 
constant [8, 19, 38]. During this process, all the factors will be examined sequentially until an 
adequately performing instrumental method is achieved. This process needs to screen different 
HPLC techniques and a large number of columns (especially for RPLC for which hundreds of 
columns are available commercially), under numerous conditions, thus it can be a significant 
waste of resources, as well as requiring excessive consumption of solvents [16, 76]. The 
process is not only time-consuming and labour-intensive but can lead to chromatographic 
methods that are not inherently robust and are poorly understood [1, 38].  
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1.3.2 Column selection 
Developing a robust and effective chromatographic method is a diverse and complex 
process [1, 13]. A comprehensive approach to explore the optimal combination for a 
separation would be the main investigation of the design space for any proposed analyte 
mixture and would include the stationary phase, mobile phase, flow-rate, temperature, etc [77, 
78]. Within the framework of chromatographic method development, choosing an appropriate 
technique which is expected to provide the desired separation selectivity is the first step, 
followed by the selection of a suitable stationary phase and the optimisation of details for the 
separation conditions including mobile phase composition, pH of aqueous solvent, flow-rate, 
temperature, and so forth [39, 78, 79]. At present, method development in chromatography is 
still mainly carried out by trial-and-error experimentation, which is not only time-consuming 
but also inefficient. Moreover, it has become one of the overriding issues in pharmaceutical 
industry given the fact that a much greater number of drug candidates than at any time in the 
past have been designed and synthesised [9, 27, 38, 80]. Accordingly, chromatographic 
method development must evolve to support the needs of the high throughput of drug 
discovery. 
Experienced chromatographers rely on expertise to choose an appropriate type of 
chromatography for a separation, but they may still struggle with the column selection, which 
is usually an experimental phase aiming to find the most suitable column (stationary phase) 
offering adequate resolution for the separation [1, 16, 78]. When selecting a column for the 
compounds to be analysed, it would be good that chromatographers know what the desired 
characteristics of a stationary phase are needed, such as base material, bonded phase, and 
bonding density. Normally, column choices can be narrowed down according to personal 
experience, literature review, or manufacturer’s recommendations, but the basic information 
provided by the manufacturer regarding the specific column does not allow the choice of a 
suitable column for a separation directly or even finding an equivalent column with similar 
separation patterns, given that the same general type of columns could differ greatly in 
separation power among different manufacturers [3, 5, 81]. This is even further complicated 
considering the suppliers do not use a standardised testing procedure. Currently, over 700 
RPLC stationary phases from various manufacturers are commercially available, and in many 
cases nominally identical, making it impossible to scope the whole selectivity landscape to 
choose the optimal stationary phase for a specific separation [62, 72]. Despite intensive study 
and unprecedented development of packing materials and columns, there is still no consensus 
on what properties the most suitable stationary phase should have for the selective analysis of 
diverse sets of analytes [4, 7, 40, 62]. 
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Besides the still repeatedly applied trial-and-error methods, more chromatographic 
method development is performed by statistical and/or computer-assisted tools [21, 22, 82, 
83]. It is well known that time and expenditure could be greatly reduced using an in silico 
approach to investigate chromatographic space [84, 85]. Various types of software packages 
that assist less experienced chromatographers to understand the mechanisms of separation and 
to optimise the separation conditions are becoming more attractive [25, 77]. Commercial 
method development software products such as ACD/LC Simulator (ACD/Labs), DryLab, 
ChromSword and Osiris, are typically built on initial experimentation with embedded 
databases to build models either based on molecular-structure-related simulations, retention 
modelling, or some statistical modelling [38, 72]. While the optimisation phase of method 
development can be accelerated using software tools, we are still left with the quandary of 
which column is most suitable for the specific separation of our desired analytes. 
Some open resources are very helpful in reducing column choice when replacing a used 
column for a particular separation. The United States Pharmacopeia Convention (USP) 
database was designed to assist chromatographers to find HPLC columns equivalent to those 
that had been used to develop and validate a particular chromatographic procedure [86]. The 
Product Quality Research Institute (PQRI) database, is capable of selecting an alternative or 
orthogonal column to a used column by comparing column coefficients [86]. Similarly, a 
Column Selectivity Database developed by Dwight Stoll and co-workers [87] which contains 
column parameters for nearly 700 reversed-phase HPLC columns, makes it possible to 
compare any columns in the database. With the benefit of these open resources, 
chromatographers can narrow down column selection across a wide range of stationary phases 
by choosing equivalent and/or orthogonal columns to the column of interest, however 
choosing the most suitable column for the separation of desired analytes is still not a 
straightforward process even for experienced chromatographers [4, 78, 81]. 
1.3.3 Method optimisation 
Chromatographic method optimisation is affected by a large number of experimental 
variables. The optimisation can be achieved in many ways, depending on how many variables 
are considered [18, 76, 79]. Variables include pressure, temperature, particle size, column 
length, and eluent velocity. Usually, the OVAT approach is used, which is univariate in nature, 
to achieve the goal of method optimisation. The OVAT is favoured by non-experts but a 
drawback of this approach is that it is time-consuming and inefficient, because there is a large 
number of experiments that must be conducted to determine the effect of each parameter on 
the retention of the compounds [3, 88]. This OVAT approach requires screening of multiple 
types of LC techniques and numerous chromatographic columns using a large number of 
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experimental conditions, which generates significant waste of resources (both human and 
instrumental) as well as excessive consumption of organic solvents [2, 19, 24, 38]. To 
maximise the efficiency of scientific discovery and minimise the waste and cost, researchers 
are keen to perform the fewest experiments that give the most information possible for method 
optimisation. 
Computer-assisted chromatographic optimisation has been intensively used as an 
alternative [1, 2]. The software packages for optimisation are the most common software tools 
used for chromatographic method development. These packages run on a premise that the 
retention of a compound of interest will change in a predictable manner as a function of 
virtually any continuous chromatographic variable [1, 11]. The most common application of 
this chromatographic optimisation method is eluent composition, commonly called solvent 
strength optimisation. For example, with at least two experiments varying the gradient slope 
for gradient separations or concentration of organic modifier for isocratic separations at a 
certain temperature, the system then can be used to model any gradient or concentration of 
organic modifier. Typically, the output from method optimisation package is a resolution map 
which shows the resolution of the critical pair (two closest eluting peaks) as a function of the 
parameter(s). The behaviour of certain parameters, including temperature or solvent strength 
is easily modelled, while other parameters such as the pH or buffer concentration are much 
more difficult. But, recently there has been renewed interest in automated chromatographic 
method development [1, 3]. This automated system directly interfaces with the instrument to 
run or suggest new experiments based on the prior results. Obviously, the advantage of that is 
the achievement of time-saving in relation to the method development time. However, the lack 
of maturity of automated optimisation limits its wide application, because this kind of method 
in principle should follow the logic of chromatographic theory and the mechanism of retention, 
which unfortunately is not yet fully developed to provide a logical guide [1, 10]. 
1.4 Quantitative Structure-Retention Relationships 
1.4.1 Theory and background 
QSRR, as the name suggests, are techniques for relating the variations between compound 
structures and their retention, and represent a powerful tool in chromatography [10, 89]. QSRR 
is a technique for relating the variations in one response variable (Y-variable) to the variations 
in several descriptors (X-variables), with predictive or explanatory purposes. Y-variables are 
often used as the dependent and X-variables as independent variables, Therefore, in QSRR 
generally Y-variables are related to the chromatographic retention of solutes, and X-variables 
encode the molecular structure of solutes [89, 90]. Thus, in chromatography, the principal aim 
of QSRR is to predict retention data from the molecular structure. QSRR has been applied for 
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the characterisation of columns by quantitative comparison of separation properties or utilised 
to provide information for the interpretation of retention mechanisms for various 
chromatographic conditions (stationary phase, mobile phase, etc.) [72, 91, 92]. Additionally, 
the QSRR method can also offer unique opportunities to predict retention of solutes or to 
identify analytes [67, 92]. In chromatography, the typical QSRR study comprises several steps: 
the compilation of a retention database of compounds with known chemical structures, the 
calculation of molecular descriptors for each structure, a descriptor selection method, QSRR 
model building, and validation [93, 94]. A scheme of the QSRR methodology is shown in 
Figure 1.5. 
 
Figure 1.5. Scheme of the QSRR methodology in chromatography. 
1.4.2 Molecular descriptors 
There are several common ways to represent structures [95], including whole molecule 
1D descriptors (sometimes known as 0D), 2D descriptors, and 3D descriptors. 1D descriptors 
express simple chemical information of a solute such as molecular weight or number of 
oxygen atoms in the structure, where 2D descriptors are computed from the chemical structure 
of the solutes of interest when represented by a connection table or a molecular graph. 3D 
molecular descriptors provide molecular information about the 3D arrangement of structural 
features and general molecular surfaces and volumes [95-97].  
In QSRR modelling, one of the crucial problems is how to represent the molecular 
structure for QSRR. Usually, molecular descriptors that encode the chemical structures are 
classified as physico-chemical, quantum-chemical, topological, etc. descriptors [95, 96]. One 
advantage of physico-chemical descriptors is that these descriptors are generally strongly 
related to the retention of solutes. However, they are often not available or have relatively 
large errors [89, 90, 93]. Quantum-chemical descriptors provide insights into the mechanism 
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of chromatographic retention on a molecular level [89, 93] but the correlation to the retention 
of solutes is often weak, and the calculation is also time-consuming. Topological descriptors 
are easily generated with present computing tools, but they are not necessarily related to 
retention phenomena [10, 89]. 
Computing software like Dragon and VolSurf+ is widely used to generate molecular 
descriptors based solely on their chemical structures [98-100]. These generated descriptors 
have been used to evaluate QSRR, quantitative structure-property relationships (QSPR) or 
quantitative structure-activity relationships (QSAR), as well as for similarity analysis and 
high-throughput screening of molecule databases [101, 102]. Typically, over 4000 molecular 
descriptors can be generated using Dragon 6.0 software [98, 103]. The 29 categories of Dragon 
molecular descriptors are detailed in Table 1.1. 
Table 1.1. The categories of molecular descriptors from Dragon and VolSurf+ software 
Block ID Dragon  VolSurf 
1 Constitutional descriptors Size and shape descriptors 
2 Ring descriptors Descriptors of hydrophilic regions 
3 Topological indices Descriptors of hydrophobic regions 
4 Walk and path counts INTEraction enerGY (= INTEGY) moments 
5 Connectivity indices Descriptors of H-bond donor / acceptor regions 
6 Information indices Mixed descriptors 
7 2D matrix-based descriptors Charge State descriptors 
8 2D autocorrelations 3D pharmacophoric descriptors 
9 Burden eigenvalues ADME model descriptors 
10 P_VSA-like descriptors  
11 ETA indices  
12 Edge adjacency indices  
13 Geometrical descriptors  
14 3D matrix-based descriptors  
15 3D autocorrelations  
16 RDF descriptors  
17 3D-MoRSE descriptors  
18 WHIM descriptors  
19 GETAWAY descriptors  
20 Randic molecular profiles  
21 Functional group counts  
22 Atom-centred fragments  
23 Atom-type E-state indices  
24 CATS 2D  
25 2D Atom Pairs  
26 3D Atom Pairs  
27 Charge descriptors  
28 Molecular properties  
29 Drug-like indices  
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Unlike Dragon, where a large number of molecular descriptors are calculated, VolSurf+ 
software can only generate 128 descriptors for the compounds of interest [99, 100, 104]. 
VolSurf+ can produce and explore the physico-chemical property space of a molecule (or 
library of molecules) starting from 3D maps of interaction energies between the molecule and 
chemical probes (GRID based Molecular Interaction Fields, or MIFs) [99, 105, 106]. One 
advantage of using VolSurf+ is that it compresses the information present in 3D maps into 
numerical descriptors optimised for ADME (absorption, distribution, metabolism, and 
excretion) models and virtual screening, making them are simple to understand and easy to 
interpret [105, 107]. Those 128 molecular descriptors can be classified into nine categories 
[100, 108]. The 9 categories of VolSurf+ molecular descriptors are also listed in Table 1.1. In 
QSRR modelling, chemometric methods are commonly utilised to identify the most suitable 
subset of molecular descriptors which shows the strongest ability to predict retention times 
and to build the mathematical relationships [109, 110].  
1.4.3 Feature selection and regression analysis 
The objective of utilising variable selection methods in QSRR modelling is to use the 
smallest number of molecular descriptors commensurate with a valid prediction of retention 
times from among a large number of generated molecular descriptors [38, 67, 72, 92]. A lot 
of variable selection methods have been elaborated and the proper feature selection is a key 
to building successful QSRR models. A reason that a proper feature selection method is 
important in QSRR modelling is because in a given data set some variables may be redundant, 
irrelevant or represent noise [38, 72]. An good feature selection method is capable of helping 
to avoid overfitting, reducing the model dimensions, and improving the performance of 
models [109, 111]. As reported, many feature selection methods like genetic algorithms (GA) 
and artificial neural networks (ANN) [112, 113] combined with multiple linear regression 
(MLR) [114] or partial least squares (PLS) [71, 111, 115], have been given intensive attention 
to build final model in QSRR studies. 
As a statistical tool that is commonly used in a QSRR study, MLR has been used widely 
to handle the selection of molecular descriptors for the construction of QSRR models [10, 89]. 
With the significant increase in the number of molecular descriptors that can be computed, 
some new chemometric modelling techniques have been introduced to QSRR modelling in 
order to manage the greater number of descriptors [109, 116, 117]. PLS is a linear, multiple 
regression method and it has been used frequently in chemometric and multivariate calibration 
studies. PLS is particularly useful in handling databases with a large number of variables 
compared to the number of objects and in the presence of co-linear, redundant, and noisy 
variables [71, 72, 91]. A PLS method can be expressed as 
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𝑦 = a1LV1 + a2LV2 +··· +amLVm         1.1 
where y is the dependent variable, a1, a2, ···, am are the regression coefficients, and LVi is 
the i-th latent variable. As can be seen from Eq. 1.1, PLS summarises the variation in the 
independent variables into a small set of linear, orthogonal, and latent variables (LVs) by 
maximising the covariance between descriptors and the dependent variable [111, 115, 118]. 
In addition, over-fitting in the models can be minimised by optimising the number of LVs. 
1.4.4 Model validation 
In QSRR modelling, a training set is used to build QSRR models, and a test set is needed 
for validation. For this purpose, the measured retention data of the test compounds is extracted 
and compared with the predicted retention data calculated from the derived QSRR models [67, 
72, 73, 102]. The statistical reliability of the formed QSRR models needs to be validated, and 
this can be performed by several approaches. The coefficient of determination (R2), the slope 
of the regression with no forced intercept, the mean absolute error (MAE) and the root-mean-
square error of prediction (RMSEP) are commonly used to evaluate the fitness and the 
predictive ability of the constructed QSRR models [72, 73, 91]. Additionally, the percentage 
root-mean-square error of prediction (RMSEP%) of retention time for the test set is also a 
frequently used error reporting method for external validation of the accuracy of QSRR 
models generated from the training sets. 
1.4.5 QSRR accuracy 
In many cases, the precision and accuracy of the QSRR models is low, but may still be 
useful for the interpretation of the retention mechanisms, or the optimisation for the separation 
of complex mixtures, or the preparation of experimental designs [10, 89, 90, 93]. The 
predictive accuracy of the QSRR models can be influenced by a number of factors: (i) the 
feature selection method employed to choose the most informative descriptors, (ii) the 
modelling approach used to build QSRR models, (iii) the model validation approach utilised, 
(iv) the number of molecular descriptors incorporated into the QSRR models, (v) the geometry 
optimisation method used, (vi) the size of the dataset employed in the study, and (vii) the range 
of diversity or similarity of the molecular structures or characteristics. 
In terms of the modelling approach employed for the construction of QSRR models, 
compound classification may provide greater predictive ability compared with the QSRR 
models derived from a diverse dataset [119]. As reported [119], compound classification has 
been achieved based on the log D profile similarity of compounds in a database and the 
performance of the subset-specific models was improved compared with a QSRR model using 
no compound classification. Another example can be found from the work by Muteki and co-
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workers [120], using a compound-classification-based QSRR methodology to improve the 
retention time predictability compared with the global models. 
1.4.6 Molecular similarity 
As the name suggests, structurally similar molecules are more likely to exhibit similar 
properties [121, 122]. From this, the interest has been increased for the prediction of properties 
for compounds based on molecular similarity [123, 124]. Compared to a diverse training set, 
a much more structurally similar subset of compounds in a training set could be generated 
using this concept and is likely to produce better prediction results. The degree of structural 
similarity between two compounds can be calculated with the assistance of some chemometric 
tools, allowing a similarity coefficient to be obtained [125].  
The Tanimoto coefficient, as the most commonly used similarity measurement of 
compounds, appears to be the gold standard in computing the fingerprint-based similarity used 
in QSRR or QSAR modelling [74, 91, 122, 125]. The Tanimoto coefficient for molecules A 
and B can be calculated using Eq. 1.2: 
𝑆𝐴,𝐵 =
𝑐
𝑎 + 𝑏 − 𝑐
          1.2 
Where, a and b are the bit sets in the fingerprints for A and B, and c is the bit set in 
common between the two fingerprints. The Tanimoto coefficient takes values between zero 
and unity, with 0 corresponding to no bits in common and 1 to identical fingerprints [121, 
126]. In this thesis, the Tanimoto similarity was employed as a basic filter to select structurally 
similar compounds to the target compound to form a training set to be used for the subsequent 
construction of the QSRR models. 
1.5 Hydrophobic-Subtraction Model 
1.5.1 Theory and background 
The Hydrophobic-Subtraction Model (HSM) was originally developed to describe column 
selectivity in RPLC [29, 30, 33]. Wilson and co-workers used a retention database of 67 
diverse compounds on 10 different C18 columns to derive a six-term equation for the 
correlation of retention as a function of solute and column [29, 30, 33]. As can be seen from 
the equation below (Eq. 1.3), the relative retention of a given compound is defined through a 
linear combination of five terms which represent the hydrophobicity (𝜂′𝐇), steric resistance 
(𝜎′𝐒∗), hydrogen-bond acidity (𝛽′𝐀), hydrogen-bond basicity (𝛼′𝐁), and ionic interactions 
(𝜅′𝐂), respectively. 
log 𝛼  log (
𝑘
𝑘EB
) = 𝜂′𝐇 − 𝜎′𝐒∗ + 𝛽′𝐀 + 𝛼′𝐁 + 𝜅′𝐂         1.3   
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Where α is the chromatographic selectivity, k is the retention factor of the solute, and kEB 
is the retention factor of the ethylbenzene. Each term in this equation corresponds respectively 
to each of the interactions mentioned above. Values of column coefficients for RPLC phases 
do not vary much under changing mobile phase composition, except that the C term increases 
with an increase in mobile phase pH. According to Wilson and co-workers, the HSM assumes 
that the major contribution of hydrophobicity to RPLC retention is subtracted first, in order to 
better see the remaining contributions to retention from other solute-stationary phase 
interactions [31, 32, 37]. 
The relative importance of each type of interaction in the HSM to retention has also been 
investigated. Results have shown that the contribution of the hydrophobicity term in retention 
is the largest, as expected from the nature of RPLC separation [29, 30, 33]. The relative 
importance of other types of interaction is dependent on the particular solutes [29, 30, 33]. 
Given this fact, the Eq. 1.3 can be transferred into an approximate HSM (see Eq. 1.4), 
log 𝛼  log (
𝑘
𝑘EB
) ≈ 𝜂′𝐇         1.4   
Where only the hydrophobicity is considered as the primary contribution to the retention 
of compounds in RPLC. The HSM was originally developed for column selectivity, now it 
has been intensively used to select the equivalent or orthogonal columns for the separation of 
compounds of interest. 
1.5.2 Column selectivity using the HSM  
One of the most important applications of the HSM is column selectivity in RPLC. In the 
original work, the contribution of the various terms of Eq. 1.3 to column selectivity was 
investigated [29, 30, 33]. The hydrophobicity term is the least important contribution to 
changes in column selectivity, as the term of hydrophobicity is highly correlated with the 
retention [29, 30, 33]. Apart from hydrophobicity, each of the remaining terms of Eq. 1.3 can 
be important in determining column selectivity [31, 32, 37]. Until now, the HSM has been 
used in many fields with different applications in chromatography. However, it is worth 
pointing out that the most important focus of the HSM is mainly on the selection of “equivalent” 
columns to obtain the same separation through the use of a column comparison function based 
on the values of H, S, A, B, and C for two columns, or the selection of columns with very 
different selectivity for the development of orthogonal RPLC methods and two-dimensional 
(2D) separation [32, 127]. For example, an on-line column selectivity database for column 
comparison has been created based on the HSM. By using a calculated similarity factor (Fs) 
based on Eq. 1.5, a column then can be compared with other columns of interest, allowing 
equivalent or orthogonal columns to be selected rapidly [32, 87]. 
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𝐹𝑠 = √(𝑤𝐻(𝐻1 − 𝐻2))2 + (𝑤𝑆(𝑆1 − 𝑆2))2 + (𝑤𝐴(𝐴1 − 𝐴1))2 + (𝑤𝐵(𝐵1 − 𝐵2))2 + (𝑤𝐶2.8(𝑐2.81 − 𝑐2.82))
2          1.5 
Where the H, S, A, B, and C are the column coefficients in the HSM for the column 1 and 
column 2, w is the weighting factor for the difference in each term of column coefficients for 
column 1 and column 2 [32, 87]. 
1.5.3 Retention prediction using the HSM  
As mentioned previously, the HSM was not originally aimed to facilitate retention 
prediction, but a prediction accuracy of ±1-2% in k is claimed using this model suggesting that 
it has great potential for the purpose of retention prediction as well [29, 32]. Additionally, such 
a high level of accuracy indicates that the major contributors to the retention mechanism in 
RPLC have been considered. At this time, column coefficients for nearly 700 commercial C8 
and C18 silica-based columns characterised using this HSM are available through an open-
access database hosted by the U.S. Pharmacopeia Convention (USP) website [38, 72, 86]. 
Therefore, there is a unique opportunity for predicting the retention of potentially any given 
compound on all of the characterised columns, provided that the compound coefficients of the 
HSM are available. 
1.6 Non-Targeted Metabolomics 
1.6.1 Concept and background 
Metabolomics studies can be targeted and non-targeted [128-130]. For targeted 
metabolomics, predefined metabolite-specific signals are often used for the quantitative 
measurement of a select group of known metabolites [129, 130]. In contrast, NTM involves 
high-throughput and comprehensive analysis of all the measurable analytes present in a given 
sample, thus it must be coupled to additional methods for subsequent interpretation by means 
of in silico or experimental routines [90, 130].  
  
Figure 1.6. Schematic of (a) Targeted and (b) Non-Targeted Metabolomics workflow. 
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As Figure 1.6 shows, for targeted metabolomics, the identity of the metabolites of interest 
is the first step, followed by data acquisition where multiple simultaneous fragmentations are 
generated and analysed [130, 131]. The last step is data analysis and data interpretation. The 
process in NTM is quite different (Figure 1.6). Steps include sample selection and pre-
treatment, sample analysis using NMR or MS coupled with separation techniques, data 
treatment and statistics, and finally, the identification and interpretation of metabolites using 
a commercial database or other analytical tools [132, 133]. 
In NTM, the ultimate goal is the identification of metabolites, allowing analytical data to 
be converted into meaningful biological knowledge [134-136]. However, a confident and 
unequivocal structure identification requires significant effort, which is multiplied 
dramatically in NTM where metabolites cover a diverse chemical space [130, 137]. Although 
integrated strategies like MS/NMR can provide much information for the identification of 
metabolites, authentic pure chemical standards of the metabolites of interest are still needed 
for unequivocal identification [28, 41, 134, 135]. At present, structure identification in NTM 
has remained costly, time-consuming, and frequently unsuccessful. This is because the process 
is complex and highly dependent on the robustness of the analytical platform and methods 
applied, as well as the databases and resources used for mass-based searching [132, 133, 138]. 
Metabolomics samples are typically complex and there are multiple interactions between 
metabolites in biological states, therefore, confident identification is still the bottleneck in 
NTM analysis. 
1.6.2 Metabolite identification in NTM  
LC-MS-based analysis is the most widely used analytical platform in NTM as it provides 
quantitative analysis with a combination of selectivity and sensitivity, and increases the 
possibility of identifying metabolites [28, 139]. The LC system for the separation of a sample 
can reduce ion suppression which is caused by co-eluting compounds, and isobaric 
interferences. In LC-MS-based NTM analysis, a target peak displaying metabolomics 
information is selected and the accurate mass of the eluted metabolite is identified [113, 140]. 
This accurate mass is then used to define potential molecular formulae corresponding to the 
chosen metabolite peak by searching on-line electronic resources, such as the Human 
Metabolome Database (HMDB), METLIN, LMSD, MassBank, RIKEN and PubChem [113, 
140]. Based on the exact mass of the metabolite of interest, potential candidates can be found 
from the databases, and the returned matches then can be identified and confirmed using 
additional experimental data. The limitation of using mass searching is that in many cases, the 
candidate is not found, or alternatively a number of candidates are returned, which means that 
some false positives need to be removed [113, 136]. Those metabolites often behave 
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differently in biological systems but similarly in analytical platforms with respect to mass, 
which increases the probability of misidentification [28, 141, 142]. In this thesis, retention 
prediction QSRR models are explored that offer useful predictive ability for compounds 
having the same molecular weight, allowing false positives to be removed during the 
interpretation of structure identification in NTM. 
1.7 Aims of project 
The first goal of this project is to develop predictive QSRR strategy, enabling rapid 
method development in RPLC to speed up the scoping phase of chromatographic method 
development. The second goal is using the proposed QSRR strategy to remove false positives 
in NTM, enhancing the confidence and accuracy of metabolite identification. The research 
comprised a series of highly integrated research topics which cover the areas of structure-
retention relationships for the RPLC mode, selection of the stationary phases based on 
predicted retention, co-elution prediction using the proposed strategy, and elimination of false 
positive identifications in NTM.   
Aim 1: To build QSRR models based on molecular descriptors computed from chemical 
structures utilising a combination of GA and PLS, allowing the scoping phase of method 
development in RPLC to be accelerated for target analytes. 
Aim 2: To develop strategies to improve the accuracy and predictivity of QSRR models 
using a combination of the concepts of structural similarity and chromatographic similarity. 
The employed strategies are to be based on different similarity filters combined with several 
approaches for compound classification to yield training sets for the construction of local 
QSRR models. 
Aim 3: To establish QSRR models by predicting five solute coefficients (η’, σ’, β’, α’, and 
κ’) in the HSM using the proposed QSRR strategy, allowing the retention of compounds of 
interest to be accurately predicted. The great advantage of QSRR modelling for the solute 
coefficients of analytes, is that nowadays over 700 columns in RPLC have been characterised 
by the HSM, and the parameters (H, S, A, B, and C) for all of those columns are available on 
an open database. So, there is a unique opportunity for predicting the retention of potentially 
any given solute on all of the characterised columns, albeit under only one isocratic condition, 
provided that the HSM solute coefficients can be accurately predicted for that solute.   
Aim 4: To evaluate the application of the proposed QSRR strategy in eliminating false 
positives having the same mass, and improve the confidence of metabolite identification for 
LC-MS based Non-Target Metabolomics (NTM). The retention of analytes, which provides 
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information orthogonal to mass, makes it possible to eliminate analytes from the list of 
candidates that have the same exact mass based on the predicted retention. 
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2 Experimental Section and Data Collection  
2.1 Databases 
2.1.1 Databases for retention prediction 
Three RPLC databases were employed in the present study. The first database (Dataset 1) 
was originally used by Wilson et al. to derive the Hydrophobic Subtraction Model (HSM), 
and consists of ten columns and 90 compounds [1]. The characteristics of the ten C18 Columns 
used in Dataset 1 are listed in Table 2.1 (numbered from 1 to 10), the compounds in Dataset 
1 are listed in Table 2.2. The second (Dataset 2), originally reported by Tan et al., was used 
by Wilson et al. in their work and consists of five columns and 87 compounds (Table 2.3) [2]. 
The five columns for Dataset 2 are: Zorbax SB-C18 (column number 11), Zorbax Rx-C18 
(column number 12), Hypersil C18 (column number 13), Hypersil C8 (column number 14) 
and Zorbax C8 (column number 15). The third database (Dataset 3) is an open-access database 
from Boswell Research group [3], containing the retention data of 112 compounds on a Zorbax 
Eclipse Plus C18 column (column number 16), the compounds are listed in Table 2.4. The 
retention factors of the compounds in each dataset were also extracted and listed below (Tables 
2.5 to 2.7).  The retention of compounds numbered from 68 to 90 in Dataset 1 was only 
performed on nine columns (column number 1-8, and column number 10), therefore the 
retention of these compounds on column number 9 was unavailable (Table 2.5).  
Table 2.1. Characteristics of ten C18 columns used in dataset 1 in present study; 5-μm 
particles, 150×4.6 mm column dimensions 
Column Abbr. 
Surface area 
(m2/g) 
Pore 
diameter 
(nm) 
% C μmol/m2 
Metal 
Fe AI 
GL Inertsil ODS-3 C1 436  9.5  14.7  1.74  2.8 <0.5 
Waters Symmetry C18 C2 343  9  19.7  3.13  <10 <10 
HP Zorbax SB C18 C3 186  8  10.4  2.08  <1 <1 
HP Zorbax SB C18 C4 188  8  9.2  1.79  <1 <1 
HP Zorbax SB-300 C18 C5 52  30  3.25  2.09  <1 <1 
HP Eclipse XDB-C18 C6 186  8  10.7  3  <1 <1 
YMC Pack Pro C18 C7 322  12.5  15.5  2.51  <10 <10 
YMC Pack Pro C18 C8 321  12.5  16.3  2.68  <10 <10 
YMC Pack Pro C18 C9 322  12.5  17  2.82  <10 <10 
Supelco Discovery C18 C10 190-220 17-20 12.5  3.12  <20 <1 
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Table 2.2. Compounds used (Dataset 1) in the present study 
ID Name ID Name 
1 benzene 46 amitriptyline 
2 toluene 47 diphenhydramine 
3 ethylbenzene 48 D,L-propanolol 
4 p-xylene 49 nortriptyline 
5 propylbenzene 50 prolintane 
6 butylbenzene 51 4-n-pentylaniline 
7 naphthalene 52 4-n-hexylaniline 
8 p-chlorotoluene 53 4-n-heptylaniline 
9 Dichlorobenzene 54 N-ethylaniline 
10 benzotrichloride 55 2-phenylpyridine 
11 bromobenzene 56 diclofenac 
12 1-nitropropane 57 mefenamic 
13 nitrobenzene 58 ketoprofen 
14 p-nitrotoluene 59 diflunisal 
15 p-nitrobenzylchloride 60 4-n-butylbenzoic acid 
16 N-benzylformamide 61 4-n-pentylbenzoic acid 
17 anisole 62 4-n-hexylbenzoic acid 
18 benzylalcohol 63 3-cyanobenzoic acid 
19 3-phenylpropanol 64 2-nitrobenzoic acid 
20 5-phenylpentanol 65 3-nitrobenzoic acid 
21 phenol 66 2,6-dimethylbenzoic acid 
22 p-chlorophenol 67 2-fluorobenzoic acid 
23 2,3-dihydroxynaphthalene 68 1,2-dinitrobenzene 
24 1,3-dihydroxynaphthalene 69 1,3-dinitrobenzene 
25 eugenol 70 nitrocyclohexane 
26 danthron 71 biphenyl 
27 n-propylformate 72 2-nitrobiphenyl 
28 methylbenzoate 73 3-nitrobiphenyl 
29 benzonitrile 74 2-biphenylmethanol 
30 Coumarin 75 2,2'-biphenol 
31 acetophenone 76 4,4'-biphenol 
32 benzophenone 77 diphenylbutyrolactone 
33 cis-chalcone 78 fluorescamine 
34 trans-chalcone 79 camphorquinone 
35 cis-4-nitrochalcone 80 ferrocene 
36 trans-4-nitrochalcone 81 N,N-diethylacetamide 
37 cis-4-methoxychalcone 82 3-nitrophenol 
38 trans-4-methoxychalcone 83 4-nitrophenol 
39 prednisone 84 2,4-dinitrophenol 
40 hydrocortisone 85 2-5-dinitrophenol 
41 mephenytoin 86 picric acid 
42 oxazepam 87 fisetin 
43 flunitrazepam 88 biochanin A 
44 5,5-dimethylhydantoin 89 4-phenylpyridine 
45 N,N-dimethylacetamide 90 N-butylaniline 
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Table 2.3. Compounds used (Dataset 2) in the present study 
ID Name ID Name 
1 1-butanol 45 3-phenyl propanol 
2 1-hexanol 46 benzaldehyde 
3 1-octanol 47 N-benzyl formamide 
4 2-propanol 48 methyl benzoate 
5 cyclohexanol 49 ethyl benzoate 
6 1-butanal 50 anisole 
7 1-hexanal 51 acetophenone 
8 1-heptanal 52 propiophenone 
9 1-octanal 53 benzophenone 
10 N,N-dimethyl formamide 54 benzonitrile 
11 N,N-diethyl formamide 55 m-toluenitrile 
12 N,N-dibutyl formamide 56 benzyl cyanide 
13 N,N-dimethyl acetamide 57 nitrobenzene 
14 N,N-diethyl acetamide 58 m-nitrotoluene 
15 n-propyl formate 59 o-nitrotoluene 
16 n-butyl acetate 60 p-nitrotoluene 
17 n-amyl acetate 61 p-nitrobenzyl bromide 
18 n-hexyl acetate 62 p-nitrobenzyl chloride 
19 ethyl propionate 63 fluorobenzene 
20 ethyl butyrate 64 chlorobenzene 
21 ethyl ether 65 bromobenzene 
22 n-propyl ether 66 lodobenzene 
23 n-butyl ether 67 benzyl bromide 
24 dioxane 68 p-chlorotoluene 
25 acetone 69 p-bromotoluene 
26 2-butanone 70 p-dichlorobenzene 
27 2-hexanone 71 benzene 
28 2-heptanone 72 toluene 
29 2-nonanone 73 ethylbenzene 
30 cyclopentanone 74 n-propylbenzene 
31 n-propionitrile 75 n-butylbenzene 
32 n-valeronitrile 76 tert.-butylbenzene 
33 n-hexanitrile 77 p-xylene 
34 n-hexyl cyanide 78 mesitylene 
35 n-heptyl cyanide 79 biphenyl 
36 n-octyl cyanide 80 naphthalene 
37 n-nitropropane 81 anthracene 
38 n-nitrobutane 82 phenol 
39 n-nitropentane 83 m-cresol 
40 methylene chloride 84 p-cresol 
41 chloroform 85 o-cresol 
42 dibromomethane 86 p-ethylphenol 
43 benzyl alcohol 87 p-chlorophenol 
44 2-phenyl ethanol   
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Table 2.4. Compounds used (Dataset 3) in the present study 
ID Name 
1 N-[1-hydroxy-3-(morpholin-4-yl)-1-phenylpropan-2-yl]decanamide 
2 2-(6-chloro-1H-indol-3-yl)acetic acid 
3 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one 
4 1-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)piperidine 
5 2-(3,4-dimethoxyphenyl)-5,6,7-trimethoxy-4H-chromen-4-one 
6 
4-[(R)-[(2S,5R)-2,5-dimethyl-4-(prop-2-en-1-yl)piperazin-1-yl](3-
methoxyphenyl)methyl]-N,N-diethylbenzamide 
7 6-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one 
8 1H-indole-6-carbonitrile 
9 2-(7-chloro-1H-indol-3-yl)acetic acid 
10 7-methyl-1H-indole 
11 
(1S,2R,10S,11S,14S,15S,17R)-14-acetyl-2,15-dimethyl-5-
oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-17-yl acetate 
12 
(1R,2S,4R,6S,7S,10S,11R,14S)-6-acetyl-7,11-dimethyl-5-
oxapentacyclo[8.8.0.0²,⁷.0⁴,⁶.0¹¹,¹⁶]octadec-16-en-14-yl acetate 
13 1-(4,6-dimethoxypyrimidin-2-yl)-3-[methanesulfonyl(methyl)sulfamoyl]urea 
14 1-(4-methoxybenzoyl)pyrrolidin-2-one 
15 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one 
16 1-{[2-(2,4-dichlorophenyl)-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazole 
17 
(1R,2S,10S,11S,13S,14R,15S,17S)-1-chloro-14,17-dihydroxy-14-(2-hydroxyacetyl)-
2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one 
18 
(1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-
2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one 
19 1-{[4-bromo-2-(2,4-dichlorophenyl)oxolan-2-yl]methyl}-1H-1,2,4-triazole 
20 1-[2-(2-chloroethoxy)benzenesulfonyl]-3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)urea 
21 [3-(2-chloro-10H-phenothiazin-10-yl)propyl]dimethylamine 
22 1-(2-chlorobenzenesulfonyl)-3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)urea 
23 
(3-{14-chloro-2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-2-
yl}propyl)dimethylamine 
24 
(1S,2R,10R,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-
dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one 
25 
(1S,2R,10S,11S,14S,15S,17S)-17-hydroxy-14-(2-hydroxyacetyl)-2,15-
dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one 
26 
2-[(1S,2R,10S,11S,14R,15S)-14-hydroxy-2,15-dimethyl-5,17-
dioxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl]-2-oxoethyl acetate 
27 2-(4-chlorophenyl)-3-cyclopropyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
28 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one 
29 N,N-diethyl-3-methylbenzamide 
30 7,8-dihydroxy-6-methoxy-3-(4-methoxyphenyl)-4H-chromen-4-one 
31 5,11-dimethyl-6H-pyrido[4,3-b]carbazole 
32 1-{[(2S,3R)-3-(2-chlorophenyl)-2-(4-fluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole 
33 1-{2-[(4-tert-butylphenyl)methyl]propyl}piperidine 
34 
2-(4-{1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-
methylpropanoic acid 
35 3-(4,6-dimethoxypyrimidin-2-yl)-1-{[3-(trifluoromethyl)pyridin-2-yl]sulfonyl}urea 
36 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 
37 1-(2-fluorophenyl)-1-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethan-1-ol 
38 
2-({[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]amino}sulfonyl)-3-formamido-N,N-
dimethylbenzamide 
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39 7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one 
40 methyl 2-[N-(2,6-dimethylphenyl)-1-furan-2-ylformamido]propanoate 
41 3,5,7-trimethoxy-2-phenyl-4H-chromen-4-one 
42 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one 
43 
(1R,2R,5R,8R,9S,10R,12S)-12-hydroxy-11-methyl-6-methylidene-16-oxo-15-
oxapentacyclo[9.3.2.1⁵,⁸.0¹,¹⁰.0²,⁸]heptadecane-9-carboxylic acid 
44 
(1R,2R,5R,8R,9S,10R,12S)-12-hydroxy-11-methyl-6-methylidene-16-oxo-15-
oxapentacyclo[9.3.2.1⁵,⁸.0¹,¹⁰.0²,⁸]heptadec-13-ene-9-carboxylic acid 
45 
(1R,2R,5R,8R,9S,10R)-11-methyl-6-methylidene-16-oxo-15-
oxapentacyclo[9.3.2.1⁵,⁸.0¹,¹⁰.0²,⁸]heptadecane-9-carboxylic acid 
46 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one 
47 
methyl 5-chloro-3-({[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]amino}sulfonyl)-2-
methyl-2,3-dihydro-1H-pyrazole-4-carboxylate 
48 
methyl 3-({[(4-methoxy-6-methyl-1,3,5-triazin-2-
yl)carbamoyl]amino}sulfonyl)thiophene-2-carboxylate 
49 2-(3,4-dimethoxyphenyl)-3,5,6,7-tetramethoxy-4H-chromen-4-one 
50 5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one 
51 
(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-
dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one 
52 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol 
53 1-[2-(2,4-dichlorophenyl)-2-(prop-2-en-1-yloxy)ethyl]-1H-imidazole 
54 
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-2-
yl}propyl)dimethylamine 
55 1H-indole-3-carboxylic acid 
56 2-(1H-indol-3-yl)acetic acid 
57 2-(1H-indol-3-yl)acetonitrile 
58 1H-indol-3-ylmethanol 
59 1H-indole-3-carbaldehyde 
60 3-(1H-indol-3-yl)-2-oxopropanoic acid 
61 1H-indole-4-carboxylic acid 
62 1H-indole-5-carboxylic acid 
63 3-(1H-indol-3-yl)propanoic acid 
64 5,7-dihydroxy-3-(3-hydroxy-4,5-dimethoxyphenyl)-6-methoxy-4H-chromen-4-one 
65 3-(2,3-dihydroxy-4-methoxyphenyl)-7-hydroxy-4H-chromen-4-one 
66 {[(2,6-dimethylphenyl)carbamoyl]methyl}triethylazanium 
67 
2-[(2R,6S)-6-[(2S)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethan-1-
one 
68 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide 
69 1-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-3,3-dimethyl-2,3-dihydro-1H-indol-2-one 
70 
(2R,17R)-12-hydroxy-2,6,6,14,17-pentamethyl-10-
oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-3,13-diene-5,11-dione 
71 
methyl 2-({[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]amino}sulfonyl)-4-
(methanesulfonamidomethyl)benzoate 
72 methyl 2-[N-(2,6-dimethylphenyl)-2-methoxyacetamido]propanoate 
73 2-chloro-N-(2-ethyl-6-methylphenyl)-N-(1-methoxypropan-2-yl)acetamide 
74 methyl 2-({[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)carbamoyl]amino}sulfonyl)benzoate 
75 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one 
76 2-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)hexanenitrile 
77 N-butylbenzamide 
78 1-ethyl-2,3-dihydro-1H-indol-2-one 
79 N-heptylbenzamide 
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80 N-hexylbenzamide 
81 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-chromen-4-one 
82 N-pentylbenzamide 
83 N-propylbenzamide 
84 oxetan-3-yl 2-({[(4,6-dimethylpyrimidin-2-yl)carbamoyl]amino}sulfonyl)benzoate 
85 2,3-dihydro-1H-indol-2-one 
86 (2S,3S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol 
87 
5-hydroxy-6-methoxy-2-(4-methoxyphenyl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
({[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-
4H-chromen-4-one 
88 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole 
89 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethan-1-ol 
90 
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-
dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-diene-5,17-dione 
91 5-hydroxy-2-phenyl-4H-chromen-4-one 
92 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine 
93 4-(dipropylcarbamoyl)-4-(phenylformamido)butanoic acid 
94 1-{10-[3-(dimethylamino)propyl]-10H-phenothiazin-2-yl}propan-1-one 
95 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one 
96 
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-
yl}acetamide 
97 4-[(1R,2S)-2-[(4-benzylpiperidin-1-yl)methyl]-1-hydroxypropyl]phenol 
98 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 
99 3,5,6,7-tetramethoxy-2-(4-methoxyphenyl)-4H-chromen-4-one 
100 1-(4-benzoylpiperazin-1-yl)propan-1-one 
101 1-(4-chlorophenyl)-4,4-dimethyl-3-(1H-1,2,4-triazol-1-ylmethyl)pentan-3-ol 
102 1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol 
103 2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione 
104 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine 
105 
(1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-13,14,17-trihydroxy-14-(2-hydroxyacetyl)-
2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one 
106 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine 
107 1-(4-fluorophenyl)-4-{4-hydroxy-4-[3(trifluoromethyl)phenyl]piperidin-1-yl}butan-1-one 
108 dimethyl({3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl})amine 
109 1-cyclohexyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol 
110 
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-2-yl}-2-
methylpropyl)dimethylamine 
111 2-(1H-indol-3-yl)ethan-1-ol 
112 N,N-diethyl-4-hydroxy-3-methoxybenzamide 
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Table 2.5. Retention factor (k) of compounds in Dataset 1 on ten columns (C1-C10) 
ID 
Retention factor (k) 
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 
1 4.73 3.81 3.05 3.02 0.94 3.24 3.37 3.27 3.39 1.80 
2 7.73 6.35 5.04 4.92 1.50 5.42 5.60 5.45 5.65 2.96 
3 12.30 10.23 8.13 7.85 2.34 8.85 9.02 8.89 9.06 4.70 
4 12.79 10.86 8.39 8.09 2.39 9.20 9.46 9.25 9.53 4.93 
5 20.99 17.66 13.90 13.27 3.85 15.42 15.63 15.28 15.70 7.96 
6 35.65 30.06 23.60 22.23 6.34 26.55 26.67 26.24 26.85 13.40 
7 11.19 9.08 7.24 7.13 2.15 7.76 8.17 7.93 8.18 4.26 
8 12.88 10.64 8.32 8.07 2.41 9.06 9.40 9.04 9.02 4.91 
9 13.18 10.89 8.47 8.24 2.47 9.23 9.57 9.38 9.68 5.02 
10 17.82 13.96 11.40 11.12 3.30 12.39 12.94 12.91 12.91 6.56 
11 8.95 7.19 5.71 5.60 1.71 6.12 6.40 6.21 6.44 3.37 
12 1.77 1.35 1.16 1.20 0.40 1.20 1.29 1.22 1.27 0.69 
13 3.32 2.44 2.15 2.22 0.72 2.20 2.38 2.25 2.34 1.24 
14 5.21 3.94 3.45 3.55 1.11 3.56 3.82 3.64 3.77 1.95 
15 5.26 3.86 3.45 3.56 1.13 3.58 3.87 3.67 3.80 1.96 
16 0.56 0.42 0.42 0.45 0.16 0.39 0.42 0.40 0.42 0.24 
17 4.20 3.28 2.74 2.75 0.87 2.86 3.04 2.91 3.03 1.59 
18 0.85 0.65 0.58 0.61 0.22 0.58 0.64 0.60 0.63 0.35 
19 1.60 1.25 1.12 1.19 0.41 1.11 1.21 1.15 1.20 0.66 
20 3.69 2.95 2.72 2.81 0.94 2.65 2.87 2.74 2.84 1.55 
21 1.14 0.86 0.74 0.77 0.27 0.76 0.84 0.79 0.83 0.47 
22 2.14 1.61 1.37 1.43 0.49 1.43 1.57 1.49 1.56 0.87 
23 1.44 1.07 0.91 0.93 0.37 0.91 1.09 1.06 1.08 0.58 
24 1.14 0.82 0.72 0.76 0.28 0.74 0.83 0.78 0.81 0.47 
25 3.35 2.61 2.25 2.30 0.78 2.34 2.54 2.42 2.52 1.35 
26 11.72 9.20 7.71 7.82 2.38 8.05 8.87 8.53 8.67 4.42 
27 1.66 1.31 1.14 1.17 0.38 1.15 1.21 1.15 1.20 0.66 
28 3.63 2.79 2.44 2.49 0.79 2.48 2.65 2.52 2.62 1.33 
29 2.39 1.78 1.59 1.66 0.54 1.60 1.73 1.63 1.70 0.91 
30 1.41 1.17 0.92 0.96 0.36 0.92 1.07 1.04 1.08 0.58 
31 2.17 1.65 1.50 1.55 0.51 1.48 1.59 1.51 1.57 0.84 
32 8.13 6.10 5.48 5.56 1.72 5.65 6.03 5.74 5.93 3.01 
33 10.81 8.13 7.35 7.45 2.26 7.66 8.15 7.74 7.98 3.99 
34 13.34 9.82 8.91 9.04 2.74 9.29 9.98 9.16 9.77 4.83 
35 9.73 6.98 6.56 6.75 2.08 6.76 7.35 6.92 7.13 3.51 
36 12.85 9.04 8.65 8.91 2.71 9.00 9.91 9.51 9.51 4.53 
37 9.82 7.21 6.67 6.67 2.09 6.90 7.41 7.03 7.24 3.59 
38 12.50 8.97 8.34 8.55 2.62 8.67 9.46 8.97 9.14 4.47 
39 0.75 0.53 0.61 0.69 0.24 0.52 0.60 0.56 0.58 0.31 
40 0.78 0.55 0.62 0.69 0.25 0.55 0.63 0.59 0.61 0.32 
41 1.33 0.99 0.90 0.94 0.34 0.91 1.00 0.95 0.99 0.54 
42 1.59 1.22 1.10 1.13 0.44 1.10 1.24 1.19 1.23 0.69 
43 2.81 2.00 1.95 2.05 0.70 1.92 2.11 1.99 2.05 1.07 
44 1.62 1.02 1.13 1.20 0.40 1.09 1.19 1.11 1.16 0.62 
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45 0.11 0.10 0.18 0.20 0.06 0.09 0.08 0.07 0.08 0.04 
46 0.49 0.47 0.77 0.75 0.39 0.68 0.60 0.70 0.72 0.58 
47 0.20 0.21 0.39 0.38 0.22 0.34 0.27 0.33 0.35 0.30 
48 0.10 0.11 0.23 0.23 0.13 0.20 0.15 0.19 0.20 0.19 
49 0.42 0.39 0.65 0.64 0.34 0.58 0.50 0.58 0.61 0.49 
50 0.18 0.18 0.35 0.34 0.18 0.31 0.23 0.28 0.30 0.25 
51 3.49 3.01 2.81 2.71 0.91 2.66 2.76 2.72 2.80 1.59 
52 5.98 5.27 4.84 4.61 1.53 4.61 4.79 4.71 4.88 2.74 
53 10.30 9.27 8.38 7.89 2.56 8.02 8.32 8.20 8.51 4.72 
54 1.15 0.91 0.86 0.79 0.26 0.82 0.86 0.83 0.86 0.49 
55 2.49 1.88 1.77 1.77 0.58 1.70 1.81 1.74 1.79 0.96 
56 7.66 5.82 5.35 5.20 1.85 5.18 5.81 5.57 5.74 3.05 
57 12.71 10.21 9.02 8.63 2.99 8.93 9.89 9.57 9.84 5.25 
58 3.02 2.28 2.12 2.12 0.78 2.07 2.34 2.23 2.30 1.25 
59 4.95 3.14 2.96 3.12 1.32 2.23 2.76 2.55 2.59 1.48 
60 5.89 5.08 4.42 4.38 1.58 4.29 4.70 4.56 4.75 2.71 
61 9.71 8.63 7.36 7.21 2.57 7.18 7.82 7.66 7.96 4.53 
62 16.07 14.76 12.39 11.97 4.23 12.11 13.15 13.30 13.49 7.64 
63 0.72 0.53 0.51 0.54 0.22 0.46 0.53 0.50 0.52 0.30 
64 0.54 0.37 0.34 0.36 0.16 0.29 0.36 0.33 0.34 0.20 
65 0.99 0.73 0.71 0.75 0.31 0.62 0.73 0.68 0.70 0.40 
66 1.40 1.08 0.96 0.96 0.37 0.94 1.05 1.00 1.04 0.59 
67 0.83 0.62 0.57 0.59 0.24 0.58 0.62 0.58 0.61 0.35 
68 2.88 2.07 1.87 1.95 0.65 1.91 2.10 1.97  1.08 
69 3.01 2.20 1.97 2.05 0.68 2.02 2.22 2.10  1.14 
70 4.92 3.82 3.33 3.39 1.07 3.47 3.67 3.49  1.89 
71 17.66 14.42 11.27 11.14 3.26 12.50 13.15 12.74  6.67 
72 9.73 7.15 6.38 6.53 2.02 6.71 7.19 6.81  3.55 
73 14.79 11.14 9.59 9.75 2.94 10.23 11.02 10.50  5.42 
74 3.69 2.81 2.51 2.58 0.86 2.58 2.82 2.69  1.47 
75 2.48 1.88 1.63 1.69 0.59 1.69 1.88 1.79  1.00 
76 1.02 0.69 0.67 0.71 0.27 0.66 0.75 0.70  0.40 
77 7.41 5.52 5.04 5.15 1.62 5.22 5.57 5.26  2.78 
78 7.96 5.60 5.24 5.46 1.72 5.41 5.86 5.48  2.84 
79 3.40 2.60 2.38 2.44 0.79 2.42 2.58 2.45  1.33 
80 13.09 12.22 9.82 9.66 2.79 10.86 11.17 10.86  5.64 
81 0.46 0.36 0.51 0.54 0.17 0.34 0.35 0.33  0.21 
82 1.53 1.12 0.99 1.04 0.37 1.01 1.13 1.06  0.61 
83 1.36 1.00 0.88 0.93 0.34 0.89 1.00 0.94  0.54 
84 1.90 1.71 1.21 1.26 0.46 1.17 1.34 1.26  0.70 
85 2.36 1.81 1.55 1.60 0.55 1.57 1.74 1.64  0.90 
86 2.51 2.20 0.62 0.73 0.31 0.64 1.21 1.14  0.48 
87 0.46 0.32 0.31 0.32 0.14 0.30 0.35 0.32  0.19 
88 4.78 3.30 3.08 3.23 1.08 3.14 3.60 3.37  1.74 
89 16.33 12.76 10.91 10.94 3.33 11.86 12.53 11.97  6.18 
90 5.83 4.61 3.82 3.79 1.16 4.18 4.36 4.26  2.20 
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Table 2.6. Retention factor (k) of compounds in Dataset 2 on five columns (C11-C15) 
ID 
Retention factor (k) 
C11 C12 C13 C14 C15 
1 0.50 0.44 0.41 0.38 0.45 
2 1.55 1.37 1.21 1.06 1.22 
3 4.67 4.15 3.52 2.76 3.21 
4 0.22 0.20 0.19 0.18 0.21 
5 0.75 0.64 0.58 0.53 0.61 
6 1.07 0.94 0.81 0.72 0.84 
7 3.27 3.13 2.39 1.86 2.41 
8 5.61 5.04 3.97 3.02 3.83 
9 9.71 8.89 6.78 4.76 5.70 
10 0.17 0.13 0.10 0.11 0.11 
11 0.41 0.31 0.28 0.28 0.33 
12 3.05 2.32 2.12 1.82 2.14 
13 0.20 0.15 0.10 0.12 0.14 
14 0.46 0.35 0.29 0.31 0.34 
15 1.27 1.11 1.05 0.92 1.09 
16 2.70 2.38 2.14 1.73 2.06 
17 4.58 4.06 3.58 2.73 3.34 
18 7.93 7.16 4.90 4.36 5.38 
19 1.57 1.38 1.29 1.08 1.30 
20 2.70 2.41 2.20 1.75 2.10 
21 1.11 1.04 0.88 0.72 0.86 
22 4.41 4.34 3.53 2.42 3.04 
23 14.59 14.55 11.40 6.67 8.61 
24 0.30 0.26 0.22 0.20 0.24 
25 0.33 0.29 0.28 0.26 0.31 
26 0.61 0.53 0.51 0.46 0.55 
27 1.85 1.60 1.50 1.23 1.49 
28 3.17 2.78 2.51 1.98 2.43 
29 9.55 8.63 7.24 5.01 6.28 
30 0.66 0.55 0.52 0.46 0.56 
31 0.55 0.46 0.48 0.45 0.52 
32 1.56 1.32 1.30 1.13 1.36 
33 2.64 2.25 2.18 1.80 2.15 
34 4.40 3.78 3.59 2.84 3.44 
35 7.45 6.50 6.03 4.48 5.45 
36 12.76 11.35 10.23 7.05 8.65 
37 1.33 1.13 1.14 1.00 1.21 
38 2.24 1.92 1.88 1.59 1.91 
39 3.77 3.26 3.12 2.51 3.03 
40 1.59 1.45 1.36 1.15 1.41 
41 2.81 2.59 2.34 1.89 2.33 
42 2.15 1.96 1.80 1.46 1.78 
43 0.62 0.52 0.55 0.49 0.58 
44 0.81 0.68 0.70 0.62 0.73 
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45 1.18 0.99 0.99 0.86 1.00 
46 1.56 1.32 1.27 1.06 1.28 
47 0.44 0.35 0.39 0.36 0.42 
48 2.72 2.40 2.21 1.71 2.08 
49 4.43 3.91 3.63 2.62 3.31 
50 3.09 2.82 2.52 1.94 2.35 
51 1.65 1.39 1.34 1.09 1.32 
52 3.01 2.60 2.44 1.84 2.24 
53 6.07 5.11 4.90 3.40 4.46 
54 1.80 1.50 1.49 1.26 1.53 
55 2.90 2.43 2.36 1.86 2.28 
56 1.79 1.47 1.51 1.28 1.54 
57 2.45 2.07 2.02 1.63 2.00 
58 4.06 3.47 3.36 2.48 3.16 
59 3.59 3.05 2.99 2.27 2.88 
60 3.85 3.30 3.21 2.37 3.00 
61 4.45 3.66 3.64 2.73 3.44 
62 3.91 3.23 3.20 2.42 3.08 
63 3.37 3.15 2.85 2.17 2.70 
64 5.48 5.35 4.54 3.18 4.03 
65 6.34 6.21 5.22 3.55 4.51 
66 8.26 8.15 6.70 4.36 5.58 
67 5.50 4.89 4.50 3.30 4.12 
68 9.29 9.38 7.59 4.89 6.31 
69 10.81 10.96 8.75 5.47 7.05 
70 9.51 9.62 7.73 4.91 6.37 
71 3.37 3.19 2.84 2.08 2.58 
72 5.57 5.45 4.61 3.16 4.02 
73 9.06 8.87 7.36 4.80 6.11 
74 15.70 15.67 12.50 7.59 9.84 
75 27.10 27.29 21.18 11.94 15.96 
76 19.36 18.79 15.21 9.23 12.11 
77 9.35 9.53 7.62 4.81 6.14 
78 15.74 16.07 12.62 7.35 9.59 
79 13.58 13.21 10.86 6.68 8.65 
80 8.15 8.02 6.59 4.34 5.50 
81 21.43 23.93 17.06 9.23 11.97 
82 0.82 0.70 0.74 0.67 0.83 
83 1.22 1.04 1.07 0.94 1.12 
84 1.21 1.03 1.06 0.93 1.12 
85 1.38 1.18 1.21 1.04 1.28 
86 1.92 1.65 1.66 1.40 1.63 
87 1.52 1.31 1.32 1.16 1.43 
87 1.52 1.31 1.32 1.16 1.43 
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Table 2.7. Retention factor (k) of compounds in Dataset 3 on Zorbax Eclipse Plus C18 
column (C16) 
ID k ID k ID k ID k 
1 22.91 29 11.48 57 6.46 85 1.12 
2 5.62 30 4.57 58 8.32 86 33.88 
3 16.60 31 1.38 59 2.00 87 2.14 
4 8.13 32 77.62 60 4.90 88 95.50 
5 17.78 33 13.49 61 1.58 89 4.79 
6 7.59 34 6.61 62 1.48 90 3.02 
7 53.70 35 5.50 63 3.98 91 93.33 
8 7.59 36 29.51 64 8.91 92 6.76 
9 5.62 37 12.30 65 2.63 93 7.94 
10 16.22 38 5.37 66 10.47 94 6.76 
11 48.98 39 12.02 67 2.95 95 3.16 
12 50.12 40 39.81 68 21.38 96 1.32 
13 10.96 41 35.48 69 4.37 97 1.70 
14 3.31 42 5.89 70 6.31 98 2.19 
15 6.17 43 13.18 71 16.98 99 50.12 
16 13.80 44 12.02 72 14.13 100 1.26 
17 8.51 45 42.66 73 85.11 101 91.20 
18 6.61 46 3.39 74 7.59 102 64.57 
19 47.86 47 64.57 75 2.24 103 1.66 
20 9.55 48 6.17 76 66.07 104 19.05 
21 9.77 49 30.20 77 6.76 105 1.26 
22 10.00 50 3.31 78 4.27 106 12.88 
23 11.75 51 3.24 79 75.86 107 5.62 
24 9.12 52 2.09 80 33.88 108 17.38 
25 8.13 53 5.50 81 28.18 109 5.25 
26 18.20 54 5.25 82 15.14 110 7.94 
27 42.66 55 1.58 83 3.09 111 2.24 
28 2.40 56 8.71 84 5.50 112 1.86 
2.1.2 Database for non-targeted metabolomics 
In this thesis, the application of retention prediction in Non-Targeted Metabolomics (NTM) 
is also evaluated. To achieve this, a database of compounds with information about molecular 
weight and retention was required. A database originally used by Hall et al. to derive QSRR 
models by artificial neural networks (ANN), consisting of 1882 compounds for which 
retention index information and mass values are reported was utilised [4]. In the original data 
collection, compound mixtures were analysed on an HPLC/MS system, where an Agilent 1100 
HPLC (Agilent, Santa Clara, CA, USA) system interfaced to a QTOF-2 mass spectrometer 
(Waters Associates, Beverly, MA, USA). A Zorbax SBC18 (1 mm × 150 mm, 3.5 um particle 
size) column containing a Zorbax Stable Bond (1 mm × 17 mm, 5 mm particle size) OptiGuard 
precolumn was used for the separation [4]. Solvent A was 0.01% heptafluorobutryic acid 
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(HFBA) in water and solvent B was 0.01% HFBA, in 90:10 acetonitrile:water. The flow-rate 
was 75 μL/min with a linear solvent gradient from 0% solvent B to 100% solvent B in 17 min, 
followed by a 5-min isocratic hold at 100% B. Finally, retention index (RI) values of 
compounds in the database were determined experimentally with a wide range from 204 to 
1041 [4].  
The Tanimoto similarity analysis of this database indicates a large diversity in the 1882 
compounds although some isomers were found. To evaluate the performance of the 
established QSRR models in eliminating false positives, groups of representative compounds 
with the same mass values were selected. In all, 34 groups of compounds (248 compounds in 
total) were chosen with at least five compounds having the same mass value in each group. 
The 1882 compounds can be found in Appendix 1, and the 248 representative compounds are 
listed in Table 2.8. 
2.2 Data collection 
2.2.1 Sample preparation 
Most of the retention information for compounds used for RPLC QSRR modelling in this 
study was obtained from literature [1, 4]. However, to evaluate the predictive ability of the 
proposed QSRR approach, five new compounds including an acid, a base and three neutrals 
that never been used in the modelling process were selected and tested on five new reversed-
phase columns. Therefore, five analytical grade compounds were purchased from Sigma-
Aldrich (St. Louis, MO, USA): pindolol, 8-dihydroxynaphthalene, 4-ethylnitrobeneze, 2-
phenylbutane and 4-heptylbenzoic acid. HPLC grade Acetonitrile and methanol were supplied 
by VWR International (Melbourne, VIC, Australia) and Sigma-Aldrich (St. Louis, MO, USA), 
respectively. 18.2 MΩ Milli-Q water produced using a Millipore Gradient water purification 
(Millipore, Bedford, MA, USA) system, was used to prepare mobile phase and sample 
solutions. Standard stock solutions (1000 µg/mL) of each compound were obtained by 
dissolving an appropriate amount of each standard in acetonitrile-water (50:50) solution.  
2.2.2 Instrumentation 
All experiments were performed using a Thermo Fisher Scientific Ultimate 3000 
instrument (Lane Cove, Australia) equipped with a DGP-3600RS pump, a DAD-3000RS 
diode array detector, a WPS-3000TRS autosampler with temperature control, and a TCC-
3000RS column compartment. Chromeleon software (ver. 7.1.2) was used for system control 
and data processing. 
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Table 2.8. 34 groups (248) of representative compounds used for the elimination of false 
positives 
ID Name MW RI 
111 N,N-dimethylallylamine 85.1486 459 
142 (R)-(-)-2-methylpyrrolidine 85.1486 474 
213 cyclopentylamine 85.1486 509 
1493 1-methylpyrrolidine 85.1486 428 
1508 piperidine 85.1486 492 
137 N,N-dimethylisopropylamine 87.1644 472 
306 1,2-dimethylpropylamine 87.1644 538 
335 1-ethylpropylamine 87.1644 542 
352 2-aminopentane 87.1644 545 
1513 N-methylbutylamine 87.1644 534 
67 4-aminobutan-2-ol 89.137 381 
75 2-amino-2-methylpropan-1-ol 89.137 401 
79 (2-methoxyethyl)(methyl)amine 89.137 408 
113 3-methoxypropan-1-amine 89.137 461 
1597 2-dimethylaminoethanol 89.137 343 
101 3-aminopyridine 94.1158 447 
108 4-aminopyridine 94.1158 456 
132 3-methylpyridazine 94.1158 470 
157 2-aminopyridine 94.1158 484 
288 4-methylpyrimidine 94.1158 533 
1561 1-vinylimidazole 94.1158 474 
181 triethylamine 101.191 497 
333 N,N-dimethylbutylamine 101.191 541 
340 N-ethylbutylamine 101.191 543 
544 1,3-dimethylbutylamine 101.191 589 
1512 diisopropylamine 101.191 524 
48 2-methoxypropanamide 103.121 334 
55 gamma aminobutyric acid 103.121 344 
1608 dimethylglycine 103.121 246 
1636 L-alpha-aminobutyric_acid 103.121 278 
1638 2-aminoisobutyric_acid 103.121 287 
1703 glycine_ethyl_ester 103.121 475 
200 2,6-lutidine 107.155 506 
237 2,5-lutidine 107.155 517 
244 2,3-lutidine 107.155 518 
248 2-ethylpyridine 107.155 519 
262 2,4-lutidine 107.155 527 
271 3,4-lutidine 107.155 528 
282 3,5-lutidine 107.155 532 
296 3-ethylpyridine 107.155 535 
299 4-ethylpyridine 107.155 536 
404 N-methylaniline 107.155 557 
501 o-toluidine 107.155 577 
511 p-toluidine 107.155 579 
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1514 benzylamine 107.155 552 
1563 m-toluidine 107.155 577 
77 p-phenylenediamine 108.143 404 
122 m-phenylenediamine 108.143 465 
206 4-(aminomethyl)pyridine 108.143 507 
218 2-(methylamino)pyridine 108.143 511 
219 4-(methylamino)pyridine 108.143 511 
247 o-phenylenediamine 108.143 518 
443 2,6-dimethylpyrazine 108.143 568 
458 2,5-dimethylpyrazine 108.143 570 
468 4,6-dimethylpyrimidine 108.143 572 
536 2-ethylpyrazine 108.143 587 
211 1-ethylpiperidine 113.202 509 
425 heptamethyleneimine 113.202 563 
449 N-methylcyclohexylamine 113.202 568 
554 cycloheptylamine 113.202 593 
614 cyclohexanemethylamine 113.202 609 
162 1,4-dimethylpiperazine 114.190 486 
205 4-(aminomethyl)piperidine 114.190 507 
221 1-methylhomopiperazine 114.190 512 
229 (R)-(+)-3-(dimethylamino)pyrrolidine 114.190 515 
236 trans-2,5-dimethylpiperazine 114.190 516 
243 1-ethylpiperazine 114.190 518 
250 2,6-dimethylpiperazine 114.190 520 
279 2-(aminomethyl)piperidine 114.190 531 
322 1,2-diaminocyclohexane 114.190 540 
442 N-benzylmethylamine 121.182 567 
491 N,N-dimethylaniline 121.182 576 
522 N-ethylaniline 121.182 583 
552 2-methylbenzylamine 121.182 592 
567 3-methylbenzylamine 121.182 596 
568 4-methylbenzylamine 121.182 596 
604 2,3-dimethylaniline 121.182 607 
636 N-methyl-o-toluidine 121.182 615 
658 3,5-dimethylaniline 121.182 622 
1504 2,4,6-collidine 121.182 544 
1517 1-phenylethylamine 121.182 578 
1520 phenethylamine 121.182 595 
212 2,6-diaminotoluene 122.169 509 
270 2-(dimethylamino)pyridine 122.169 528 
273 2-(2-pyridyl)ethylamine 122.169 529 
277 2,4-diaminotoluene 122.169 530 
415 2,3-diaminotoluene 122.169 560 
435 3,4-diaminotoluene 122.169 566 
1562 4-dimethylaminopyridine 122.169 533 
367 N-isopropyl-N-methyl-tert-butylamine 129.245 548 
535 N,N-diethylbutylamine 129.245 586 
600 diisobutylamine 129.245 606 
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687 dibutylamine 129.245 628 
714 N,N-dimethylhexylamine 129.245 638 
850 2-amino-6-methylheptane 129.245 691 
1496 N,N-diisopropylethylamine 129.245 546 
1518 di-sec-butylamine 129.245 586 
1526 octylamine 129.245 727 
115 (1,4-dioxan-2-ylmethyl)methylamine 131.174 462 
201 (3S,4R)-4-ethoxyoxolan-3-amine_hydrochloride 131.174 507 
1649 L-isoleucine 131.174 482 
1651 leucine 131.174 494 
1652 L-norleucine 131.174 502 
1653 6-aminocaproic_acid 131.174 506 
1655 beta-leucine 131.174 521 
323 5-aminoindole 132.165 540 
395 1-methylbenzimidazole 132.165 556 
420 2-methylbenzimidazole 132.165 562 
486 6-aminoindole 132.165 575 
537 5-methylbenzimidazole 132.165 587 
613 7-aminoindole 132.165 609 
483 1,2,3,4-tetrahydroquinoline 133.193 575 
520 2-methylindoline 133.193 582 
530 1,2,3,4-tetrahydroisoquinoline 133.193 586 
550 1-aminoindan 133.193 592 
623 4-aminoindan 133.193 612 
652 5-aminoindan 133.193 621 
882 N-allylaniline 133.193 706 
473 N,N-dimethylbenzylamine 135.208 573 
488 N,N-dimethyl-o-toluidine 135.208 575 
523 N-ethylbenzylamine 135.208 583 
571 (S)-(-)-N,alpha-dimethylbenzylamine 135.208 598 
584 N-methyl-phenethylamine 135.208 601 
597 3-methyl-N-methylbenzylamine 135.208 605 
601 N-isopropylaniline 135.208 606 
618 N,N-dimethyl-p-toluidine 135.208 610 
649 N,N-dimethyl-m-toluidine 135.208 620 
676 N-ethyl-m-toluidine 135.208 626 
690 N-ethyl-o-toluidine 135.208 629 
804 4-isopropylaniline 135.208 671 
806 4-propylaniline 135.208 674 
821 2,4,6-trimethylaniline 135.208 681 
845 o-isopropylaniline 135.208 689 
879 2-propylaniline 135.208 705 
1521 L-amphetamine 135.208 612 
254 N-ethyl-4-pyridinemethylamine 136.196 521 
263 3-(2-pyridyl)propylamine 136.196 527 
285 N,N-dimethyl-p-phenylenediamine 136.196 532 
295 2-(2-methylaminoethyl)pyridine 136.196 535 
331 m-xylylenediamine 136.196 541 
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334 o-xylylenediamine 136.196 541 
533 2,3,5,6-tetramethylpyrazine 136.196 586 
587 4,5-dimethyl-1,2-phenylenediamine 136.196 602 
89 3-amino-2-methylbenzamide 150.180 426 
147 (4-aminophenyl)-N-methylcarboxamide 150.180 478 
220 N-(2-aminophenyl)acetamide 150.180 511 
233 2-amino-2-phenylacetamide 150.180 516 
444 2-amino-N-phenylacetamide 150.180 568 
112 2-(4-hydroxyphenyl)acetamide 151.165 461 
126 2-hydroxy-2-phenylacetamide 151.165 467 
308 2-(aminomethyl)benzoic_acid 151.165 538 
424 5-amino-2-methylbenzoic_acid 151.165 563 
434 2,5-dimethylpyrrole-3,4-dicarbaldehyde 151.165 566 
775 (2-hydroxyphenyl)-N-methylcarboxamide 151.165 660 
1648 2-phenylglycine 151.165 458 
1679 acetaminophen 151.165 494 
1689 N-phenylglycine 151.165 599 
496 2-(ethylamino)-4-methylphenol 151.208 577 
598 methyl(2-phenoxyethyl)amine 151.208 605 
630 3-phenoxypropylamine_chloride 151.208 613 
640 4-methoxy-2,3-dimethylphenylamine 151.208 617 
737 2-amino-4-propylphenol 151.208 646 
951 1-ethyl-2,5-dimethylpyrrole-3-carbaldehyde 151.208 735 
1664 N-benzylethanolamine 151.208 560 
417 ((3S)-3-1,2,3,4-tetrahydroisoquinolyl)methan-1-ol 163.219 562 
609 8-methoxy-1,2,3,4-tetrahydroquinoline 163.219 608 
785 2,3-dimethyl-5,6,7-trihydroindol-4-one 163.219 665 
1006 4-phenylmorpholine 163.219 760 
1601 methcathinone 163.219 601 
104 3-amino-3-phenylpropanoic_acid 165.191 453 
154 2-propylpyridine-4-carboxylic_acid 165.191 482 
251 4-(4-pyridyl)butanoic_acid 165.191 520 
347 methyl_3-(3-pyridyl)propanoate 165.191 544 
432 N-(4-hydroxyphenyl)-N-methylacetamide 165.191 565 
498 methyl_2-amino-2-phenylacetate 165.191 577 
1605 2-dimethylaminobenzoic_acid 165.191 498 
1606 3-dimethylaminobenzoic_acid 165.191 618 
1607 4-dimethylaminobenzoic_acid 165.191 731 
1656 phenylalanine 165.191 521 
1691 3,5-dimethylanthranilic_acid 165.191 745 
1692 N-ethylanthranilic_acid 165.191 776 
1718 benzocaine 165.191 767 
773 4-hydroxy-1-methylhydroquinolin-2-one 175.187 659 
932 1-methylindole-3-carboxylic_acid 175.187 727 
945 1,7-dimethylbenzo[d]azolidine-2,3-dione 175.187 732 
1085 methyl_indole-3-carboxylate 175.187 805 
1152 1-methylindole-2-carboxylic_acid 175.187 841 
1697 indole-3-acetic_acid 175.187 678 
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1726 indoxyl_acetate 175.187 834 
1834 citrulline 175.187 253 
210 1,2,3,4-tetrahydroisoquinoline-3-carboxylic_acid 177.202 509 
437 1-(4-hydroxyphenyl)pyrrolidin-2-one 177.202 567 
590 N-(3-acetylphenyl)acetamide 177.202 603 
1113 4,6-dimethoxyindole 177.202 821 
1796 5-hydroxytryptophol 177.202 530 
293 N-[(4-hydroxyphenyl)ethyl]acetamide 179.218 534 
341 2-amino-3-phenylbutanoic_acid_chloride 179.218 544 
477 3-(1,3-dioxan-2-yl)phenylamine 179.218 574 
783 6-propyl-2H-benzo[d]1,3-dioxolene-5-ylamine 179.218 663 
889 1-cyclohexylazoline-2,5-dione 179.218 709 
1251 ethyl_2-(phenylamino)acetate 179.218 891 
1693 2-ethylanilinoacetic_acid 179.218 794 
831 2-(2-naphthyloxy)ethylamine 187.241 686 
832 3-(phenylamino)cyclohex-2-en-1-one 187.241 687 
849 2,7,8-trimethylquinolin-4-ol 187.241 691 
878 8-ethyl-2-methylquinolin-4-ol 187.241 704 
1009 1,2,3-trimethylcyclohepta[1,2-c]pyrrol-6-one 187.241 761 
1147 1,2,3,4,9-pentahydro-4aH-carbazol-1-ol 187.241 840 
1190 1-phenyl-2-pyrrolylethan-1-ol 187.241 859 
622 3,3-dimethyl-2-phenyl-1-pyrrolin-5-ol 189.257 612 
1051 (2Z)-3-(dimethylamino)-1-(3-methylphenyl)prop-2-en-1-one 189.257 788 
1191 2-(1-ethylindol-3-yl)ethan-1-ol 189.257 859 
1396 1,2-dimethyl-1,2,3,4-tetrahydroquinoline-6-carbaldehyde 189.257 977 
1436 4-piperidylbenzaldehyde 189.257 1002 
1181 8-ethylthioquinoline 189.275 856 
192 2-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic_acid 191.229 502 
572 3-(3-hydroxypropyl)indolin-2-one 191.229 598 
669 3-oxo-N-benzylbutanamide 191.229 625 
704 2-acetyl-3-methyl-4-oxo-5,6,7-trihydroindole 191.229 634 
787 2-hydroxyphenyl_pyrrolidinyl_ketone 191.229 665 
874 1-(4-methoxyphenyl)pyrrolidin-2-one 191.229 701 
703 N-(4-methoxy-2,6-dimethylphenyl)acetamide 193.245 633 
732 3,4-diacetyl-1,2,5-trimethylpyrrole 193.245 645 
745 methyl_3-(3-amino-4-methylphenyl)propanoate 193.245 649 
970 N-[2-(4-methylphenoxy)ethyl]acetamide 193.245 747 
1354 butyl_4-aminobenzoate 193.245 952 
1704 L-phenylalanine_ethyl_ester 193.245 641 
605 4-methylpyridino[3,2-h]quinoline 194.235 607 
659 acridine-4-ylamine 194.235 622 
665 acridine-9-ylamine 194.235 624 
731 2-phenylbenzimidazole 194.235 645 
927 2-(3-pyridyl)indole 194.235 725 
805 5,6,7,8,10-pentahydroacridin-9-one 199.252 671 
893 2-methyl-1H,3H-naphtho[1,2-e]1,3-oxazine 199.252 710 
896 4-(phenylmethoxy)phenylamine 199.252 711 
1130 2-methoxy-5-phenylphenylamine 199.252 831 
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1350 2,5-dimethyl-1-phenylpyrrole-3-carbaldehyde 199.252 948 
1176 5,6,7,8,9-pentahydro-4aH-carbazole-3-carboxylic_acid 215.251 854 
1220 3-(5-phenylpyrrol-2-yl)propanoic_acid 215.251 870 
1241 2-(2,5-dimethylpyrrolyl)benzoic_acid 215.251 884 
1260 1,2,3,4,9-pentahydro-4aH-carbazolecarboxylic_acid 215.251 899 
1329 3-(2,5-dimethylpyrrolyl)benzoic_acid 215.251 936 
1351 4-(2,5-dimethylpyrrolyl)benzoic_acid 215.251 948 
441 N-[4-(4-pyridylmethyl)phenyl]acetamide 226.277 567 
722 4-{[4-(dimethylamino)phenyl]azamethylene}cyclohexa-2,5-dien-1-one 226.277 641 
1053 (4-aminophenyl)-N-(4-methylphenyl)carboxamide 226.277 789 
1129 (3,4-dimethylphenyl)-N-(2-pyridyl)carboxamide 226.277 831 
1317 (2-aminophenyl)-N-(4-methylphenyl)carboxamide 226.277 928 
The five HPLC columns employed in this study were obtained from Thermo Fisher 
Scientific: an AcclaimTM 120 C18 column (4.6 × 150 mm, 5.0 μm); an Accucore C18 column 
(4.6 × 150 mm, 2.6 μm); a Hypersil GOLD C8 column (4.6 × 150 mm, 5.0 μm); a Hypersil 
GOLD C18 column (4.6 × 150 mm, 5.0 μm) and a Hypersil ODS C18 column (4.6 × 150 mm, 
5.0 μm). The mobile phase was prepared exactly as for Wilson’s study [1]: For neutral 
compounds, the mobile phase was acetonitrile-water, mixed on-line at 50% (v/v). For acidic 
or basic compounds, the mobile phase was acetonitrile-buffer, where the buffer is 31.2 mM 
potassium phosphate (pH 2.80) prepared by titrating phosphoric acid with KOH; i.e., pH 
measurements were carried out on the buffer, prior to the addition of acetonitrile. All data 
were collected using UV detection at 205 nm, with a column temperature of 35 °C, and a flow 
rate of 1.5 ml/min. Columns were equilibrated with 15-20 column volumes of eluent to 
guarantee stable equilibrium situations. The void time was measured for each column by the 
injection of uracil. 
2.2.3 Retention data collection 
Retention data of the five new compounds and the five new columns are listed in Table 
2.9. 
Table 2.9. Measured retention time (min) of five new representative compounds on five 
columns 
Compound tR 
Measured retention times (min)  
AcclaimTM 
120  
Accucore  
Hypersil 
GOLD  
Hypersil 
GOLD  
Hypersil 
ODS  
uracil (marker) t0 0.924 0.824 1.182 1.157 1.015 
ethylbezene (reference) tref 11.249 6.207 5.315 6.307 6.990 
pindolol (C1) t1 1.040 0.890 1.290 1.257 1.465 
1, 8-dihydroxynaphthalene (C2) t2 3.024 1.782 2.390 2.465 2.357 
4-ethylnitrobeneze (C3) t3 7.882 4.190 4.282 4.882 5.315 
2-phenylbutane (C4) t4 26.740 14.382 10.049 13.107 15.765 
4-heptylbenzoic acid (C5) t5 27.249 14.382 10.924 15.299 18.440 
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2.3 QSRR model generation 
2.3.1 Software 
MarvinSketch version 16.2.15 from ChemAxon (Budapest, Hungary) was used for 
drawing the molecular structures [5]. Initial conformational searches to find the 50 lowest 
energy structures were performed using a Merck Molecular Force Field (MMff94) 
implemented in Balloon [6-11]. Geometry optimisation using the semi-empirical Parametric 
Method number 7 (PM7) [12] was performed in Molecular Orbital PACkage (MOPAC) [12], 
followed by further geometry optimisation of the lowest energy structure using density 
functional theory implemented in Gaussian 09 [13-15]. Dragon 6.0 (Talete, Milano, Italy) and 
VolSurf+ 1.0.7.1 (Molecular Discovery Ltd., Hertfordshire, UK) was employed for 
calculation of molecular descriptors [16]. A genetic algorithm (GA) in Matlab R2013b (The 
Mathworks Inc., Natick, MA, USA) was utilised to select the most important descriptors and 
to build the QSRR models for each stationary phase material [17]. Statistical evaluation of the 
data and multivariate data analysis has also been performed in Matlab. For more information 
go to the user manual in Section 2.4. 
2.3.2 Calculation of molecular descriptors 
The Dragon 6.0 (Talete, Milano, Italy) and VolSurf+ 1.0.7.1 (Molecular Discovery Ltd., 
Hertfordshire, UK) software tools were employed to generate molecular descriptors. The 
procedure for the generation of molecular descriptors using Dragon was as follows. The 
structures of the molecules were sketched in MarvinSketch. Initial conformational searches to 
find the 50 lowest energy structures were performed using Balloon with a Merck Molecular 
Force Field (MMff94) [6-8]. The lowest energy conformer was taken as the input structure for 
geometry optimisation using a semi-empirical PM7 method implemented in MOPAC [9, 18], 
the resulting geometry was further refined with the Gaussian program applying the Becke 3-
parameter (exchange) with correlation by Lee Yang and Parr, (B3LYP) [13, 19, 20] functional 
and the 6-31G-(d) basis set [21]. Optimisations were performed in acetonitrile using the 
integral equation formalism variant of the polarizable continuum model (IEFPCM) [22]. 
Following each geometry optimisation, harmonic frequency analysis was carried out to 
confirm the nature of each stationary point as an equilibrium structure. The resulting minimum 
energy conformations of the compounds in this study were input into Dragon to calculate 
molecular descriptors. Dragon software was able to calculate over 4000 molecular descriptors, 
consisting of constitutional, topological, geometrical, electrostatic, physical, shape, and 
quantum chemical descriptors. To minimize subsequent problems of chance correlation, 
descriptors with constant or near constant values, descriptors with a standard deviation less 
than 0.0001, descriptors which were strongly correlated to other descriptors (using a 
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correlation coefficient >0.95) and those descriptors not available for all compounds were 
excluded [23, 24]. After this reduction step, 128 molecular descriptors were obtained. Before 
statistical analysis, all the descriptors were scaled to zero mean and unit variance (auto-scaling 
procedure) because the numerical values of the descriptors varied significantly. The resulting 
descriptor sets were used to build predictive models for the experimental chromatographic 
retention data. 
In terms of the calculation of molecular descriptors using VolSurf+, Molecular descriptors 
were calculated from the canonical simplified molecular-input line entry system strings 
(SMILES) of compounds using VolSurf+ at a user-defined pH (pH=2.5) [25, 26]. The 
VolSurf+ software was able to calculate 128 molecular descriptors based on 3D Molecular 
Interaction Fields (MIFs) produced by GRID [27, 28], which is a computational tool for 
determining energetically favourable binding sites on molecules of known structure [27-30]. 
Vol-Surf+ descriptors are produced from 3D interaction energy grid maps, which are 
particularly ADME relevant (absorption, distribution, metabolism, and excretion), and are 
easy to interpret as the information present in 3D maps is compressed into 2D numerical 
descriptors [28, 29]. In all, 128 molecular descriptors were calculated following the 3D 
structure conversion and conformational analysis of structures. All descriptors were auto-
scaled (i.e., to have zero mean and unit variance) before use for the modelling process. For 
more information go to the user manual in Section 2.4 
2.3.3 Genetic algorithm 
In QSRR, retention is expressed as a function of molecular descriptors. Given the huge 
number of molecular descriptors that can be generated using either Dragon or VolSurf+ 
software, an appropriate variable selection method is highly desired to choose the most 
informative descriptors to build models. The GA, introduced by Holland [31], is a stochastic 
search procedure inspired by the rules of natural selection to select features without making 
any assumptions about the search space. By relying on bio-inspired operators such as mutation, 
crossover, and selection, it has been used to generate high-quality solutions to optimisation 
and search problems [11, 32, 33]. In a GA, each variable is called a gene, and a set of variables 
is called a chromosome. The relationship is more like a bit and a bit string in genetic terms. 
Generating an initial population of chromosomes by random choice of variables is the first 
step of a GA optimisation [25, 34]. After that, pairs of chromosomes are chosen randomly as 
parents and crossover operations performed so that a new generation of child chromosomes 
are produced with better fitness. For the last step, a mutation is performed to maintain genetic 
diversity from the initial random population to the next generations [11, 32]. The cycle of the 
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evaluation, selection, crossover, and mutation processes is then repeated until a stopping 
criterion is satisfied. 
The GA optimisation relies on a randomly generated initial population, which can 
potentially limit its capability to find the most relevant variables within a large search domain 
[34]. Therefore, the final results of replicate runs could be very different. To pick the most 
informative subset of molecular descriptors to build QSRR models within a reasonable 
computational time, 100 runs with different initial populations were generated and the 
frequency with which each variable was selected as the top chromosome of each run was 
calculated [24, 25, 35]. Moreover, a popular version of a GA-PLS algorithm, originally written 
by Leardi in Matlab (The Mathworks Inc., Natick, MA, USA) was used for descriptor 
selection [32, 33]. The parameters of the GA in the present study were: 50 chromosomes in 
the original population; a maximum of 20 variables per chromosome (average probability of 
selection of 10 variables), 1% probability of mutation, 50% probability of cross-over, and a 
backward elimination phase after every 100 evaluations. The minimum number of compounds 
in the training set was set at five. To cope with the variability of the results arising from the 
intrinsic random selection nature of the GA, the GA-PLS modelling was repeated five times 
and the results were averaged [24, 26]. 
2.3.4 Partial least square 
An excessive number of molecular descriptors has been generated to describe the 
molecules in the retention databases used in this thesis, and many of those generated 
descriptors are redundant, co-linear and can be regarded as noise [33, 36, 37]. In this case, the 
use of an appropriate descriptor selection method like multiple linear regression (MLR) or 
partial least squares regression (PLS) is highly desirable to reduce the risk of over-fitting and 
chance correlation by excluding the noise from the model [24-26, 34, 35].  As a linear multiple 
regression method, PLS has been used commonly in in chemometric and multivariate 
calibration solutions [33, 36].  
PLS can deal with databases which contain more variables than the number of samples. 
Also, it is particularly helpful in handling many variables even in the presence of co-linearity 
and noise in the independent and dependent variables [36]. In this work, GA-PLS was utilised 
to choose the most informative molecular descriptors for the construction of the QSRR models. 
The chance of over-fitting was minimised by optimizing the number of latent variables (LVs). 
PLS models with a number of latent variables up to 5 were investigated and the optimum 
number of LVs in each model was selected by applying the first standard deviation rule [32, 
37, 38]. 
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2.3.5 Types of QSRR model 
Two types of models can be generated in a QSRR study. The first is a global model, where 
a single model is built for the retention prediction of all compounds. The second is a local 
model, where a new model is derived for each new compound for which retention is to be 
predicted. The global modelling approach is popular in QSRR modelling because of its 
simplicity, but its major drawback is that the accuracy of prediction is generally low. On the 
other hand, local modelling where each compound has its own specific model, generally 
provides higher prediction accuracy. For both modelling approaches, a suitable training set is 
critical as this plays a major role in the prediction performance of the constructed QSRR model. 
Compounds in training sets can be selected either randomly or using targeted strategies to 
identify the best training set. The latter approach can be described as database “filtering” and 
this term is used throughout this thesis to describe the process of identifying the most 
appropriate compounds to be used in the training set. For example, filtering can be performed 
using the concept of structural similarity between the target analyte and the database 
compounds, based on the premise that a training set comprising structurally similar 
compounds would give a more accurate QSRR model than if the training set compounds had 
been selected randomly. Other parameters which can form the basis of filtering methods 
include analyte physico-chemical parameters (for example, log D which reflects the 
hydrophobicity), the nature of compounds (acids, bases, and neutrals), or the retention of 
compounds (retention time, retention factor). A more complex filtering approach using the 
second dominant interaction between compounds and stationary phase after hydrophobicity is 
another option. Regardless of which filtering method is applied, finding the final training set 
which provides the highest prediction accuracy is the ultimate goal. 
2.3.6 Model validation 
In QSRR modelling, a training set is used to build QSRR models using the most 
informative molecular descriptors, selected by the GA, and a test set is needed for validation 
[39-42]. Also, to evaluate the predictive ability of the constructed QSRR models, a separate 
external set is required [26, 43]. For this purpose, the measured chromatographic retention 
data of the test compounds were extracted and compared with their predicted retention data 
calculated from derived QSRR models. To generate test sets, a D-optimal algorithm was 
employed to split compounds in the dataset into a training set and a test set, respectively.  
In this work, the coefficient of determination (R2), the slope of the regression with no 
forced intercept, the mean absolute error (MAE) and the root-mean-square error of prediction 
(RMSEP) were utilised to evaluate model fitness and the predictive ability of the constructed 
QSRR models, with the requirement for the slope to be within the range of 0.85 to 1.15 [26, 
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34, 35]. The percentage root-mean-square error of prediction (RMSEP%) of retention time for 
the test set was measured to externally validate the accuracy of GA-PLS models generated 
from the training set. 
MAE was defined as: 
MAE =
1
𝑛
∑ │
𝑛
𝑖=1
𝑦𝑖 − ?̂?𝑖│          2.1 
Where the yi and ?̂?𝑖  are, respectively, the experimental and predicted values of the 
response for the i-th compound in the dataset, and n is the number of compounds. 
RMSEP was defined as: 
𝑅𝑀𝑆𝐸𝑃 = √
∑ (𝑦𝑖(𝑒𝑥𝑝) − 𝑦𝑖(𝑝𝑟𝑒𝑑))𝑛𝑖=1
2
𝑛
          2.2 
Where the yi(exp) and yi(pred) are, respectively, the experimental and predicted values 
of the response for the i-th compound in the dataset, and n is the number of compounds. 
%RMSEP was defined as:  
%𝑅𝑀𝑆𝐸𝑃 =
√∑ (
𝑦𝑖(𝑒𝑥𝑝) − 𝑦𝑖(𝑝𝑟𝑒𝑑)
𝑦𝑖(𝑒𝑥𝑝)
)𝑛𝑖=1
2
𝑛
× 100          2.3 
Where the yi(exp) and yi(pred) are the experimental and predicted retention times of the 
response for the i-th compound, and n is the number of compounds. 
In Chapter 4, several filtering approaches were employed to generate training sets for the 
construction of QSRR models, and the predictive ability of the yielded models was evaluated 
by inspecting the Regression Error Characteristic (REC) curves obtained by plotting the 
prediction error range against the percentage of data points predicted within that range [44]. 
Furthermore, the overall performance of the above constructed models was further compared 
using the sum of ranking difference (SRD) approach where parameters for each model were 
compared to a series of reference values, and each model ranked according to how large was 
the difference between its parameters and the reference values [45, 46]. The rankings were 
also compared to a confidence interval generated by using randomly ranked numbers [45, 46]. 
More detail can be found in Chapter 4. 
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3 Direct Prediction of Retention using Quantitative Structure-Retention 
Relationships in Reversed-Phase Liquid Chromatography 
3.1 Introduction 
Analytical method development (MD) is a key element of any pharmaceutical 
development program but it is often a time-consuming and labour-intensive process [1-4]. The 
workflow of systematic chromatographic method development contains two phases: scoping 
and optimisation [5-7]. As the primary phase of method development, scoping involves the 
selection of the preferred chromatographic technique, stationary phase, and broad composition 
of mobile phase. A subsequent phase, called optimisation, can then be performed to optimise 
and fine tune the selected chromatographic conditions by implementing experimental design 
approaches [5, 8]. An HPLC analysis method is developed to identify, quantify or purify 
compounds of interest, thus successful MD requires the experience and expertise of the 
chromatographer [9-11].  
Computer-aided MD has been given intensive study as it can accelerate the MD process 
significantly if sufficiently accurate retention models exist [12, 13]. Nowadays, a wide variety 
of in silico tools have been used to speed up chromatographic MD based upon predicting 
retention from chemical structures [14, 15]. Commercial software such as Drylab (Molnár-
Institute for Applied Chromatography, Berlin, Germany), ChromSword (ChromSword, Riga, 
Latvia) and ACD/ChromGenius (ACD/Labs, Toronto, Canada) have been utilised in 
chromatographic method development, optimisation, and validation [14, 15]. These software 
packages rely on experimental retention data and calculations for the chemical structures of 
compounds to predict retention under the same chromatographic conditions that have been 
used for compounds in the embedded database. In addition, when using these computer-aided 
MD software packages, the systematic experimentation that is undertaken also allows the 
implementation of Quality-by-Design (QbD) practices by providing tools to improve the 
robustness of the chosen chromatographic method and reduce labour and solvent consumption 
by limiting the required number of experiments [16, 17]. 
For the scoping phase of computer-aided MD a prediction error of up to 10% can be 
tolerated for the purpose of choosing some broad method parameters [4, 18, 19], including the 
most suitable chromatographic technique (such as reversed-phase [RPLC] [20, 21], 
hydrophilic interaction liquid chromatography [HILIC] [22], ion chromatography [IC] [8] or 
supercritical fluid chromatography [SFC] [23]), the stationary phase and mobile phase, etc. 
While for optimisation, prediction errors as low as one or two percent are needed to be able to 
find the optimal conditions for the separation of given compounds [24]. Quantitative 
Structure-Retention Relationship (QSRR) methodology has the potential to speed up the 
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scoping phase as exploratory experimentation can be replaced by retention prediction based 
solely on the chemical structures of molecules. Then, the best starting point for the 
optimisation phase of MD can be selected, after comparing retention prediction across a broad 
range of chromatographic techniques for a group of compounds [5, 25, 26]. The optimisation 
phase will always involve detailed experiments to measure retention accurately [27, 28]. 
QSRR provides a tool to generate more extensive information for retention phenomena 
including mechanism investigation, retention prediction and method development in 
chromatography [29, 30]. A QSRR model is usually created from a set of descriptors, either 
experimentally determined or theoretically computed from a symbolic representation of the 
molecules using commercial software tools [5, 30]. For some simple QSRR models, a limited 
number of pre-selected physico-chemical parameter descriptors are used. Examples can be 
found in ChromSword software where descriptors of the molecular volume and the energy of 
interaction with water are employed [11, 31]. Another software tool, ACD/ChromGenius uses 
more parameters such as log P, the log of the compound distribution coefficient (log D), polar 
surface area, molecular volume, molecular weight, molar refractivity and the number of 
hydrogen bond donor and acceptor sites on the molecule as descriptors to build QSRR models 
[5, 32].  
As an alternative, a large pool of molecular descriptors can be generated using commercial 
software, such as Dragon [5, 8, 22, 33]. However, this should be followed by an appropriate 
variable selection strategy to extract the most relevant and informative descriptors for their 
subsequent use in QSRR modelling. A QSRR model with too few descriptors could be under-
fitted and hence be insufficiently predictive, but a model with too many descriptors can 
increase the risk of over-fitting and introduce noise [1, 5]. Considering the large number of 
descriptors generated, implementing a suitable variable selection method, such as a genetic 
algorithm (GA), which is often combined with multiple linear regression (MLR) or partial 
least squares regression (PLS), becomes necessary to exclude noise from the model and reduce 
the risk of over-fitting and chance correlation [12, 15]. PLS regression is particularly useful 
in the presence of co-linear, redundant and noisy variables, and in handling databases with a 
high number of variables compared to the number of sample compounds [5, 34]. It has been 
shown that the performance of PLS modelling can be improved significantly by applying a 
suitable feature selection method [34, 35]. As reported by P Žuvela et al. [36], a combination 
of GA and PLS was best for selecting the most important and relevant descriptors compared 
to other optimisation algorithms in terms of computational cost, accuracy and robustness of 
the constructed QSRR models. 
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QSRR models either can be built using the whole dataset (all compounds except the target 
compound), or a group of compounds from that dataset, as the training set [18]. The use of the 
whole dataset as training set is popular in QSRR modelling, but the drawback of this approach 
is that, most of the time, the accuracy of prediction is unsatisfactory [18, 37]. The use of a 
specific training set of compounds can improve the accuracy of prediction results as the 
concept of similarity is often used to form training sets. It has been shown that smaller, more 
similar training sets to the target compound lead to greater prediction accuracy [18, 38, 39]. 
Similar compounds to the target can be selected using some criterion, such as the similarity of 
chemical structures between molecules, the proximity of physico-chemical properties, or the 
retention parameters of the compounds of interest. 
In the present study, the ratio of retention factor was used as a chromatographic similarity 
filter to yield training sets for the construction of QSRR models. Furthermore, the Tanimoto 
approach, which can be seen the gold standard in computing fingerprint-based similarity, was 
also investigated and compared as a filter for building training sets for QSRR modelling. In 
addition, in order to find a chromatographic similarity index which is comparable with the k-
ratio filter, the representative molecular descriptors log D and log P were also explored as 
filters for the training sets. Finally, the effectiveness of a dual filter that uses Tanimoto or log 
D as the primary, and the k-ratio as the secondary filter was also evaluated. 
3.2 Materials and methods 
3.2.1 Database 
Three retention datasets used in the present study have been described previously in 
section 2.1, Chapter 2, including the names of compounds (Tables 2.1, 2.3 and 2.4 in Chapter 
2), the retention information (Tables 2.5, 2.6 and 2.7 in Chapter 2), the characteristics of the 
columns (section 2.1 and Table 2.1 in Chapter 2), and the chromatographic conditions used. 
Retention predictions were performed for compounds in Dataset 1 on ten columns (column 
number 1 to 10), compounds in Dataset 2 on five columns (column number 11 to 15), and 
compounds in Dataset 3 on a Zorbax Eclipse Plus C18 column (column number 16). 
3.2.2 Calculation of molecular descriptors 
In this study, Dragon descriptors were calculated and employed. The Dragon 6.0 software 
[40] is able to calculate in excess of 4000 molecular descriptors, consisting of constitutional, 
topological, geometrical, electrostatic, physical, and quantum chemical descriptors [41]. The 
calculations of molecular descriptors were performed as detailed in section 2.3.2, Chapter 2. 
The resulting descriptor sets were used to build predictive models for the experimental 
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chromatographic retention data. Finally, 1448 descriptors were calculated and exported for 
each compound in the three datasets. 
3.2.3 Similarity ranking 
In the present study, several filters for similarity ranking were applied to the datasets to 
generate suitable training sets. Each compound in each dataset was subsequently utilised as a 
‘target compound’. Its retention time was then predicted using models made up from a subset 
of the other compounds in the dataset, by treating the other compounds with various filters. 
Filters included Tanimoto (based on the similarity of chemical structure), physico-chemical 
properties such as Log D and Log P, the chromatographic similarity reflected by the ratio of 
retention factor (k-ratio), and a dual filter, using Tanimoto or log D as the primary, and k-ratio 
as the secondary filter. 
Tanimoto similarity: in the first modelling approach, filtering was performed based on the 
Tanimoto Similarity (TS) index. One compound (the target compound) was left out of the 
dataset and the rest sorted based on their pairwise TS index in relation to the target.  Then the 
top ten compounds were used as a training set to derive a separate QSRR model for retention 
factors.  If ten compounds could not be found in the training set, the target compound was not 
modelled. The derived models were then used to predict the retention factor for the target and 
this process was repeated for each of the compounds in the dataset. The TS-values were 
calculated using JChem for Excel (ChemAxon, Budapest, Hungary). 
Physico-chemical parameter similarity (represented by log D and log P): some 
representative descriptors such as log D and log P can be used as filters to derive training sets. 
In the log D approach, filtering was performed based on the log D values. One compound (the 
target compound) was left out of the dataset with the rest being sorted based on the difference 
of log D in relation to the target. The largest difference allowed for filtering was 0.2. Similarly, 
for the log P approach, compounds in the training set were selected based on the ratio of log 
P (with the ratio always > 1) to the target compound and the largest ratio allowed was 1.2. 
Finally, the selected compounds were used as a training set to derive a QSRR model for the 
retention factor of the target compound. The minimum number of compounds in the training 
set was five, if five compounds below the respective cut-off similarities could not be found, 
the target compound was not modelled. The log D and log P values at the pH of the RPLC 
mobile phase (pH = 2.8) were calculated using InstantJChem (ChemAxon).  
Chromatographic similarity (represented by k-ratio index): it is well known that the design 
of a practically useful similarity index should in fact correspond to the chromatographic 
similarity between compounds in order to establish accurate predictive QSRR models [5]. 
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Therefore, the ratio of retention factors was also considered as a filter in the present study 
although it cannot be applied in practice. For k-ratio filtering, the compounds in the database 
were ranked according to the ratio of the compound’s retention factor k with the k-value of the 
reference compound (with k-ratio always > 1). The training set was then built using a certain 
k-ratio threshold (k-ratio < 1.5 in this study) to construct predictive QSRR models. The 
minimum number of compounds in the training set was five. 
Dual filter: the k-ratio approach cannot be applied in practice because the retention of the 
target compound is unknown. The proposed k-ratio filter is therefore useful only as a 
benchmark. However, the retention of the compound could be used as a secondary filter after 
the initial application of a Tanimoto or log D (or log P) filter. Therefore, a secondary k-ratio 
filter was applied to datasets that had been determined using Tanimoto, log D, or log P as the 
primary filter. The rationale is to first select a training set based on a primary filter (such as 
Tanimoto or log D) and to then scrutinise the retention times of the training set compounds 
and to remove any compounds which have very diverse retention times. 
3.2.4 QSRR modelling  
In the present study, the QSRR models were obtained via a PLS regression in combination 
with a GA as the variable selection method [5, 35]. The parameters of the GA were detailed 
in section 2.3.3, Chapter 2. The similarity ranking, descriptor selection, and QSRR modelling 
were performed in an automated fashion using Matlab software. To enable this, the original 
GA-PLS Matlab routines from Leardi were modified [34]. 
3.2.5 Statistics 
The coefficient of determination (R2), the slope of the regression with no forced intercept 
and the mean absolute prediction errors (MAE) were used to evaluate model fitness (as 
detailed in section 2.3.6, Chapter 2) with the requirement for the slope to be within the range 
of 0.85 to 1.15 [42]. The correlation coefficient R2 between the predicted and the experimental 
retention factors was calculated by constructing the corresponding scatter plot and performing 
a linear regression in Excel. 
3.3 Results and discussion 
3.3.1 Role of chromatographic similarity (k-ratio filter) 
A fundamental premise of this study is that basing QSRR models on those compounds in 
the retention database that are chromatographically similar to the target compound will yield 
more accurate predictions than using the entire database to derive the models [5, 18, 35]. To 
illustrate this point, for each dataset, QSRR modelling was performed based only on those 
compounds in the dataset where a training set could be compiled that showed a retention factor 
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k-ratio < 1.5 to the target compound. Retention factor prediction was therefore performed for 
90 compounds in Dataset 1 on ten columns (number 1 to number 10), 87 compounds in Dataset 
2 on five columns (column number 11 to number 15), and 112 compounds in Dataset 3 on one 
column (column number 16).  
Figure 3.1 shows the correlation between predicted and observed retention factors for the 
90 compounds in Dataset 1 on ten columns. The QSRR modelling shows very high 
correlations between predicted and observed retention factors in all cases, with slopes ranging 
from 1.054 (Figure 3.1j) to 1.1019 (Figure 3.1i), and a correlation coefficient (R2) range from 
0.970 (Figure 3.1g) to 0.992 (Figure 3.1j), in addition, very small prediction errors were 
obtained for compounds in Dataset 1 on all ten columns, with MAE values from 0.099 (Figure 
3.1e) to 0.565 (Figure 3.1a). The same trend was observed for the 87 compounds in Dataset 2 
on all five columns as can be seen in Figure 3.2, with MAEs between 0.248 (Figure 3.2d) and 
0.519 (Figure 3.2a). Similarly, data points are very close to the trend line with a range of 
correlation coefficients (R2) from 0.961 (Figure 3.2b) to 0.974 (Figure 3.2d). The same 
approach resulted in a higher prediction error (MAE = 1.805, Figure 3.3) for the 112 
compounds in Dataset 3 compared to previous datasets. The reason could be the much larger 
retention window (maximum retention factor > 95) for compounds on column number 16 
compared to the retention windows for compounds in other two datasets. Also, as can be seen 
from Figure 3.3, especially for early eluted compounds, a very good correlation was observed 
(R2 = 0.992), while the data points are more scattered for the more retained compounds 
(compounds with retention factor greater than 60).  
It is worth noting that the retention factor filter cannot be applied in practice because the 
retention times of the target compounds are unknown. Therefore, an alternative filtering tool 
is required which enables the formation of a training set that contains the same compounds 
that were clustered into a training set by the retention factor filter. In this study, the use of a 
structural similarity index (Tanimoto Similarity Index) has been investigated in order to 
evaluate whether it can be used to attain similar prediction accuracy to that achieved by k-ratio 
filtering. Also, physico-chemical parameters (log D and log P) and a dual filter approach were 
also investigated. 
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Figure 3.1. Predicted retention factors (k) of 90 compounds (Dataset 1) on ten columns 
using the k-ratio 1.5 filter. Numbering of the graphs from (a) to (j) represents the ten 
columns (number 1 to number 10). 
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Figure 3.2. Predicted retention factors (k) of 87 compounds (Dataset 2) on five compounds 
using the k-ratio 1.5 filter. Numbering of the graphs from (a) to (e) represents the five 
columns (number 11 to number 15) utilised for Dataset 2. 
 
Figure 3.3. Predicted retention factors (k) of 112 compounds (Dataset 3) on Zorbax Eclipse 
Plus C18 (column number 16) using the k-ratio 1.5 filter. 
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3.3.2 QSRR modelling using Tanimoto similarity 
The Tanimoto coefficient as a measure of molecular similarity was used to carry out TS 
searching in this study [32, 43]. When TS searching was employed, using the top 10 ranked 
similar compounds, the resulting models gave unacceptable prediction errors. Specifically, the 
Tanimoto approach resulted in a range of MAE from 0.687 (Figure 3.4e) to 3.732 (Figure 3.4a) 
for Dataset 1, multiplying the k-ratio errors ten-fold (Figure 3.1). The prediction error of 0.687 
(Figure 3.4e) seems acceptable but it is worth pointing out that the retention window is quite 
narrow with values all less than 5. Meanwhile, the maximum value of the correlation 
coefficient was only 0.876 (Figure 3.4i), which is far less than expected. Almost 5-fold higher 
prediction errors were observed for the 87 compounds in Dataset 2 (column number 11 to 15) 
using the Tanimoto approach compared to the k-ratio approach (MAE values can be seen in 
Figure 3.5). As expected, a larger error of retention prediction (MAE = 15.859) resulted for 
Dataset 3 which contains many highly retained compounds on column number 16 (Figure 3.6). 
Large errors of prediction were obtained even for early eluted compounds using Tanimoto 
searching, indicating that the selected top ten compounds in the training set were not similar 
enough to the target compound. The high prediction errors obtained using the Tanimoto 
approach suggested the need to screen compounds into training sets where more similar 
compounds are kept and dissimilar compounds excluded. In other studies, it has been found 
that Tanimoto similarities of 0.7 and higher are necessary for accurate retention prediction [8, 
44]. The training sets for this study had some compounds of TS 0.5 and lower. It is expected 
that an adequate threshold of similarity offering training sets with high enough average TS-
values could significantly improve the accuracy of prediction in QSRR modelling.  
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Figure 3.4. Predicted retention factors (k) of 90 compounds (Dataset 1) on ten columns 
using the Tanimoto filter. Numbering of the graphs from (a) to (j) represents the ten columns 
(number 1 to number 10). 
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Figure 3.5. Predicted retention factors (k) of 87 compounds (Dataset 2) on five compounds 
using the Tanimoto filter. Numbering of the graphs from (a) to (e) represents the five 
columns (number 11 to number 15) utilised for Dataset 2. 
 
Figure 3.6. Predicted retention factors (k) of 112 compounds (Dataset 3) on Zorbax Eclipse 
Plus C18 (column number 16) using the Tanimoto filter. 
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3.3.3 QSRR modelling using Physico-chemical parameter similarity (represented by log 
D and log P) 
Some important physico-chemical parameters – log D and log P were also investigated in 
this study as they represent the significant contribution of the hydrophobic interaction to 
retention in RPLC. As a further study, the absolute difference in log D between each 
compound in the dataset and the target compound was used to rank the compounds with a cut-
off 0.2. For the log P filter, the only difference was in the selection of the threshold, instead 
of using the absolute difference of 0.2, a ratio of 1.2 was employed while other conditions 
were kept as same as for the log D approach. The log D approach was applied to compounds 
in all three datasets and columns, but it was not performed on the number 9 column in Dataset 
1 as the retention data for some compounds on that column were not available (Table 2.5 in 
Chapter 2). The log P filter was only performed for compounds in Dataset 2 on columns 11 
and 15. Figures 3.7 – 3. 10 show the correlations of measured and predicted retention factors 
using the log D and log P approaches, respectively.  
As can be seen from Figures 3.7 – 3.9, much smaller retention prediction errors were 
obtained for compounds in each dataset compared to the MAE generated using the Tanimoto 
approach, but prediction errors were still larger than the k-ratio approach, as expected. The 
maximum and minimum MAE values of 2.538 (Figure 3.7a) and 0.502 (Figure 3.7e) were 
observed for 90 compounds in Dataset 1, both smaller than for the Tanimoto approach models 
generated using the same compounds and columns (MAE of 3.732 and 0.687, respectively). 
Similarly, the log D filter also resulted in much smaller MAEs for compounds in Dataset 2 on 
five columns compared to the models from the Tanimoto filter employing the same 
compounds and columns (Figure 3.8 and Figure 3.5). Again, although scattered data points 
for 112 compounds in Dataset 3 were still observed using the log D approach on column 
number 16, the correlation coefficient (R2 = 0.820) and MAE (11.349) were both much 
improved compared to the Tanimoto approach (R2 = 0.787 and MAE = 15.859, respectively).  
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Figure 3.7. Predicted retention factors (k) of 90 compounds (Dataset 1) on nine columns 
using the log D filter. Numbering of the graphs from (a) to (i) represents the nine columns 
(number 1 to number 8 and column number 10). 
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Figure 3.8. Predicted retention factors (k) of 87 compounds (Dataset 2) on five compounds 
using the log D filter. Numbering of the graphs from (a) to (e) represents the five columns 
(number 11 to number 15) utilised for Dataset 2. 
 
Figure 3.9. Predicted retention factors (k) of 112 compounds (Dataset 3) on Zorbax Eclipse 
Plus C18 (column number 16) using the log D filter. 
In terms of the log P approach, it was evaluated only for the 87 compounds in Dataset 2 
on columns 11 and 15. The prediction errors were larger (MAE of 2.549 for column 11 and 
1.556 for column 15, Figure 3.10) than MAE values for the log D approach (MAE of 1.292 
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and 0.885, respectively), and even larger than for the Tanimoto approach (MAE of 1.724 and 
0.929, respectively). Therefore, it can be assumed that log P does not explain the physico-
chemical properties of the compounds that are most involved in chromatographic retention. 
 
Figure 3.10. Predicted retention factors (k) of 87 compounds (Dataset 2) on two columns 
using the log P filter. Numbering of representative columns in graph: (a), Zorbax SB-C18 
(column number 11); (b), Zorbax C8 (column number 15). 
It is to be noted that very large prediction errors were observed for the 112 compounds in 
Dataset 3 no matter which approach was applied except when the k-ratio was used as a filter. 
Dataset 3 consisted of 112 compounds with a large range in k-values (varying between 0.5 
and 95.6). Also, Dataset 3 was sparsely populated for k-values higher than 20. However, those 
compounds are unlikely to be used in practical chromatographic method development. For 
Dataset 3, again only the filter using the k-ratio resulted in acceptable retention prediction. 
The log D filter resulted in much better results and there is a clear improvement compared 
to the Tanimoto QSRR modelling. But since the errors are larger than 10%, which was the 
cut-off for scoping purposes, the log D filter still cannot be used in practice. In this study log 
D and log P descriptors were selected as the filters because they can reflect the main 
hydrophobicity interaction which has been recognised as the primary contributor to retention 
in RPLC. Using only log D or log P as the single filter did not yield acceptable retention 
prediction, and this is not surprising as in fact there is not a strong linear correlation between 
log D (or log P) and their retention factors. As can be seen from Figure 3.11 and Figure 3.12 
as the log D (or log P) values increase, the corresponding retention factors also increase but 
the data points are very scattered from the trendline, and correlation coefficients are very small 
in all cases. 
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Figure 3.11. Correlation between values of the log D descriptor and retention factor (k) for: 
(a) 90 compounds in Dataset 1 and column number 1; (b) 87 compounds in Dataset 2 and 
column number 11, and (c) 112 compounds in Dataset 3 on column number 16. 
 
Figure 3.12. Correlation between values of the log P descriptor and retention factor (k) for 
87 compounds in Dataset 2 on (a) Zorbax SB-C18 column (column number 11) and (b) 
Zorbax C8 column (column number 15). 
3.3.4 QSRR modelling using dual filter 
The previous section has shown the superior predictive ability of the QSRR models when 
a k-ratio filter is used to build the training set. As stated previously, this approach cannot be 
applied in practice but might be used as a secondary filter after the initial application of the 
primary filter. The workflow is to select a training set based on a primary filter first and then 
scrutinise the retention factors of the training set compounds and remove any compounds 
which have very diverse retention factors. To investigate this approach, a secondary k-ratio 
filter was applied to datasets that had been determined using Tanimoto and log D as the 
primary filter. This dual filter approach was examined on the compounds in three datasets and 
the corresponding columns. 
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A k-ratio filter with a cut-off of 1.5 was applied to the compounds in the dataset after using 
Tanimoto or log D as the primary filter. Instead of applying the k-ratio filter to the target 
compound, the most similar compound in the training set identified from the Tanimoto or log 
D filter was used as a surrogate for the target compound, then the secondary filter was used to 
build the final training set. In the present study, the k-ratio secondary filter was tested on 
Datasets 1, 2, and 3, where Tanimoto and log D was used as the primary filter. As can be seen 
from Figure 3.13 and Figure 3.14, none of these dual filters resulted in improved predictions 
compared to the use of a single, primary filter (Tanimoto or log D). For Tanimoto – k-ratio 
dual filter, prediction errors (MAE) of 3.863 and 2.754 were observed for the 90 compounds 
in Dataset 1 on the columns 1 and 6, quite similar to the prediction errors yielded using 
Tanimoto as the single filter (MAE of 3.732 and 2.620, Figure 3.4a and 3.4f). Unfortunately, 
the dual filter resulted in MAE values of 3.135 and 1.944 for the 87 compounds in Dataset 2, 
which were much higher than the MAEs of 1.724 and 0.929 (Figure 3.5a and 3.5e) that 
resulted when only Tanimoto filtering was used for the same columns (column numbers 11 
and 15). Similarly, for Dataset 3, a MAE of 15.211 was obtained after using the dual filter 
which is very close to the prediction error of MAE = 15.859 found using the Tanimoto filter 
alone (Figure 3.6).  
For the second dual filter, log D combined with the k-ratio filter, much higher prediction 
errors and poorer correlations were observed for all three datasets. Specifically, the log D – k-
ratio dual filter resulted in much higher prediction errors (MAE = 3.221 and 2.405, 
respectively) than MAE of 2.538 and 1.999 (Figure 3.7a and 3.7f) obtained using the log D 
single filter for Dataset 1 on columns 1 and 6. For the compounds in Dataset 2, larger 
predictions (MAE of 1.644 and 0.921) were yielded again compared to the log D approach 
(MAE of 1.292 and 0.885, Figure 3.8a and 3.8e). Similarly, a MAE of 9.474 was obtained 
after using k-ratio as the secondary filter for 112 compounds in Dataset 3, comparable to the 
errors using the log D filter only (MAE of 11.349, Figure 3.9).  
These results are perhaps not surprising because the primary filter used here, Tanimoto 
for example, still stands on the similarity of chemical structure, which has proved to be 
inadequate in reflecting the chromatographic similarity for the more complex separation 
modes of RPLC. But, this situation is expected to improve when the dataset contains a large 
number of similar compounds [8, 44]. 
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Figure 3.13. Predicted retention factors (k) of compounds using the dual filter: Tanimoto 
combined with k-ratio for (a), 90 compounds 1 in dataset and GL Inertsil ODS-3 (column 
number 1); (b), 90 compounds in Dataset 1 and HP Eclipse XDB-C18 (column number 6); (c) 
87 compounds in Dataset 2 and Zorbax SB-C18 (column number 11); (d) Zorbax C8 (column 
number 15) and (e), 112 compounds in Dataset 3 and Zorbax Eclipse Plus C18 (column 
number 16). 
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Figure 3.14. Predicted retention factors (k) of compounds using the dual filter: log D 
combined with k-ratio for (a), 90 compounds 1 in dataset and GL Inertsil ODS-3 (column 
number 1); (b), 90 compounds in Dataset 1 and HP Eclipse XDB-C18 (column number 6); (c) 
87 compounds in Dataset 2 and Zorbax SB-C18 (column number 11); (d) Zorbax C8 (column 
number 15) and (e), 112 compounds in Dataset 3 and Zorbax Eclipse Plus C18 (column 
number 16). 
3.3.5 The importance of high Tanimoto score for QSRR modelling 
It is expected that much better retention prediction will be obtained using structurally 
similar compounds to the target when building the training set. However, in this study when 
the Tanimoto top ten approach was applied, poor correlations between experimental and 
predicted retention were observed for all three datasets. Here, the training set was built using 
the top ten compounds in the dataset based on their Tanimoto similarity score to the target 
compound, which means there is a great possibility that some dissimilar compounds were also 
included. This speculation was confirmed by analysing the Tanimoto similarity scores of each 
training set (top ten similar compounds to the target). For the 90 compounds in Dataset 1, the 
average TS-values for the training sets identified for each target compound varied between 
0.089 and 0.648 (an overall average of 0.432). For the 87 compounds in Dataset 2, slightly 
higher average TS-values were observed with a range of 0.108 to 0.719 (average of 0.494). 
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Very similar average TS-values for 112 compounds in Dataset 3 were obtained with a range 
between 0.186 and 0.715 (average of 0.434). The lower TS-values for some training sets 
indicated that many dissimilar compounds to the target had been selected to construct the 
training sets and QSRR models. Thus, the retention of the target compound was often 
modelled and predicted using a number of dissimilar compounds. One solution that can be 
considered is to use a threshold of Tanimoto similarity score to screen compounds, which 
would allow training sets for each target to be built based only on similar compounds. 
Research on the retention prediction in hydrophilic interaction liquid chromatography [HILIC] 
has shown a general trend towards smaller prediction errors at high TS-values (TS > 0.8), 
suggesting that a training set of sufficient similarity to the target compound should produce 
low prediction errors [8, 18, 22]. In present study, the maximum score of the average TS-
values is only 0.719, showing that these datasets do not contain sufficient numbers of high-
similarity compounds to provide training sets in which all compounds have TS > 0.8. This 
limitation of the database can be solved by including more diverse compounds so that the 
probability of finding a sufficient number of highly similar compounds is much higher.  
3.4 Conclusions 
In the present study, modelling strategies for retention prediction were investigated and 
evaluated in QSRR modelling. Strategies for compound filtering were employed and 
compared, including the ratio of retention factor (k), the Tanimoto similarity, the difference 
of log D, the ratio of log P, and dual filters. Among the models, the filter that utilised the ratio 
of retention factors appeared to be the most effective approach to minimizing prediction errors. 
Therefore, in QSRR modelling the concept of chromatographic similarity should be 
considered and implemented using a measure of similarity that adequately reflects the 
retention of compounds. In other words, the design of other measures of similarity should 
select the same compounds in the dataset as does the k-ratio filter to establish accurate 
predictive QSRR models with acceptable prediction errors. Since the k-ratio filter is 
impractical, it cannot be used directly in QSRR modelling for retention prediction but is 
relevant as a benchmark for the minimum achievable prediction error in the QSRR modelling 
and to compare the performance of other practical filters.  
The use of a Tanimoto filter based on the similarity of chemical structures resulted in 
much higher prediction errors when compared with the k-ratio similarity filter. Moreover, the 
low average Tanimoto score of the top ten compounds in the training set for each target 
compound in all three datasets also indicated the need for larger and homogenous datasets, 
allowing sufficient numbers of compounds with a high pair-wise similarity to be found when 
using the Tanimoto filter. Alternatively, the use of a Tanimoto cut-off score to identify the 
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best training set might be a better option.  In general, the prediction errors were slightly 
improved using a log D filter which represents the hydrophobic interaction in reversed-phase 
retention, while the log P filter did not give the same improvement in error and therefore does 
not reflect hydrophobic interaction well. Similarly, the design of the dual filter, in which the 
Tanimoto filter or log D filter (the primary filter) was combined with a k-ratio filter (the 
secondary filter) did not lead to any improvements in retention prediction in all three datasets. 
Since the dual filter is still based on the similarity of chemical structures it could still be 
beneficial in the case of larger and more homogenous datasets by including compounds with 
greater chromatographic similarity. 
3.5 References 
1. Davis, J.M. and J.C. Giddings, Statistical theory of component overlap in multicomponent 
chromatograms. Analytical Chemistry, 1983. 55(3): p. 418-424. 
2. De Beer, M., F.d. Lynen, K. Chen, P. Ferguson, M. Hanna-Brown, and P. Sandra, 
Stationary-phase optimized selectivity liquid chromatography: development of a linear 
gradient prediction algorithm. Analytical Chemistry, 2010. 82(5): p. 1733-1743. 
3. Dong, M.W., HPLC Column Standardization in Pharmaceutical Development: A Case 
Study. LCGC Asia Pacific, 2016. 19(3): p. 27-31. 
4. Karmarkar, S., R. Garber, Y. Genchanok, S. George, X. Yang, and R. Hammond, Quality 
by design (QbD) based development of a stability indicating HPLC method for drug and 
impurities. Journal of Chromatographic Science, 2011. 49(6): p. 439-446. 
5. Talebi, M., S.H. Park, M. Taraji, Y. Wen, R.I. Amos, P.R. Haddad, R. Shellie, R. Szucs, 
C. Pohl, and J.W. Dolan, Retention time prediction based on molecular structure in 
pharmaceutical method development: A perspective. LCGC North America, 2016. 34(8): 
p. 550-558. 
6. Vogt, F.G. and A.S. Kord, Development of quality‐by‐design analytical methods. Journal 
of Pharmaceutical Sciences, 2011. 100(3): p. 797-812. 
7. Young, C.S. and R.J. Weigand, An efficient approach to column selection in HPLC 
method development. LCGC North America, 2002. 20(5): p. 464-473. 
8. Park, S.H., P.R. Haddad, M. Talebi, E. Tyteca, R.I. Amos, R. Szucs, J.W. Dolan, and C.A. 
Pohl, Retention prediction of low molecular weight anions in ion chromatography based 
on quantitative structure-retention relationships applied to the linear solvent strength 
model. Journal of Chromatography A, 2017. 1486: p. 68-75. 
9. Abate-Pella, D., D.M. Freund, Y. Ma, Y. Simón-Manso, J. Hollender, C.D. Broeckling, 
D.V. Huhman, O.V. Krokhin, D.R. Stoll, and A.D. Hegeman, Retention projection 
enables accurate calculation of liquid chromatographic retention times across labs and 
methods. Journal of Chromatography A, 2015. 1412: p. 43-51. 
10. Dong, M.W., A Universal Reversed-Phase HPLC Method for Pharmaceutical Analysis. 
LCGC North America, 2016. 34(6): p. 408-419. 
11. Hewitt, E.F., P. Lukulay, and S. Galushko, Implementation of a rapid and automated high 
performance liquid chromatography method development strategy for pharmaceutical 
drug candidates. Journal of Chromatography A, 2006. 1107(1-2): p. 79-87. 
12. García-Lavandeira, J., B. Losada, J. Martínez-Pontevedra, M. Lores, and R. Cela, 
Computer-assisted method development in liquid chromatography–mass spectrometry: 
New proposals. Journal of Chromatography A, 2008. 1208(1): p. 116-125. 
13. Zamora, I., F. Fontaine, B. Serra, and G. Plasencia, High-throughput, computer assisted, 
specific MetID. A revolution for drug discovery. Drug Discovery Today: Technologies, 
2013. 10(1): p. 199-205. 
Chapter 3    Direct prediction of retention using quantitative structure-retention relationships in 
reversed-phase liquid chromatography 
78 
 
14. Bolanča, T., Š. Ukić, M. Novak, and M. Rogošić, Computer assisted method development 
in liquid chromatography. Croatica Chemica Acta, 2014. 87(2): p. 111-122. 
15. Tyteca, E., S.H. Park, R.A. Shellie, P.R. Haddad, and G. Desmet, Computer-assisted 
multi-segment gradient optimization in ion chromatography. Journal of Chromatography 
A, 2015. 1381: p. 101-109. 
16. Molnár, I., H.-J. Rieger, and R. Kormány, Chromatography modelling in high 
performance liquid chromatography method development. Chromatography Today, 2013. 
6(1): p. 3-8. 
17. Kormány, R., J. Fekete, D. Guillarme, and S. Fekete, Reliability of simulated robustness 
testing in fast liquid chromatography, using state-of-the-art column technology, 
instrumentation and modelling software. Journal of Pharmaceutical and Biomedical 
Analysis, 2014. 89: p. 67-75. 
18. Tyteca, E., M. Talebi, R. Amos, S.H. Park, M. Taraji, Y. Wen, R. Szucs, C.A. Pohl, J.W. 
Dolan, and P.R. Haddad, Towards a chromatographic similarity index to establish 
localized quantitative structure-retention models for retention prediction: use of retention 
factor ratio. Journal of Chromatography A, 2017. 1486: p. 50-58. 
19. Schmidt, A.H., M. Stanic, and I. Molnár, In silico robustness testing of a compendial 
HPLC purity method by using of a multidimensional design space build by 
chromatography modeling—Case study pramipexole. Journal of Pharmaceutical and 
Biomedical Analysis, 2014. 91: p. 97-107. 
20. Borges, E.M., How to select equivalent and complimentary reversed phase liquid 
chromatography columns from column characterization databases. Analytica Chimica 
Acta, 2014. 807: p. 143-152. 
21. Claessens, H. and M. Van Straten, Review on the chemical and thermal stability of 
stationary phases for reversed-phase liquid chromatography. Journal of Chromatography 
A, 2004. 1060(1): p. 23-41. 
22. Taraji, M., P.R. Haddad, R.I. Amos, M. Talebi, R. Szucs, J.W. Dolan, and C.A. Pohl, 
Prediction of retention in hydrophilic interaction liquid chromatography using solute 
molecular descriptors based on chemical structures. Journal of Chromatography A, 2017. 
1486: p. 59-67. 
23. Desfontaine, V., D. Guillarme, E. Francotte, and L. Nováková, Supercritical fluid 
chromatography in pharmaceutical analysis. Journal of Pharmaceutical and Biomedical 
Analysis, 2015. 113: p. 56-71. 
24. Kormány, R., I. Molnár, J. Fekete, D. Guillarme, and S. Fekete, Robust UHPLC 
separation method development for multi-API product containing amlodipine and 
bisoprolol: the impact of column selection. Chromatographia, 2014. 77(17-18): p. 1119-
1127. 
25. Dolan, J., A. Maule, D. Bingley, L. Wrisley, C. Chan, M. Angod, C. Lunte, R. Krisko, J. 
Winston, and B. Homeier, Choosing an equivalent replacement column for a reversed-
phase liquid chromatographic assay procedure. Journal of Chromatography A, 2004. 
1057(1): p. 59-74. 
26. Euerby, M.R. and P. Petersson, Chromatographic classification and comparison of 
commercially available reversed-phase liquid chromatographic columns containing polar 
embedded groups/amino endcappings using principal component analysis. Journal of 
Chromatography A, 2005. 1088(1): p. 1-15. 
27. Kromidas, S., HPLC made to measure: a practical handbook for optimization. 2008: John 
Wiley & Sons. 
28. Siouffi, A. and R. Phan-Tan-Luu, Optimization methods in chromatography and capillary 
electrophoresis. Journal of Chromatography A, 2000. 892(1): p. 75-106. 
29. Andrić, F. and K. Héberger, How to compare separation selectivity of high-performance 
liquid chromatographic columns properly? Journal of Chromatography A, 2017. 1488: p. 
45-56. 
Chapter 3    Direct prediction of retention using quantitative structure-retention relationships in 
reversed-phase liquid chromatography 
79 
 
30. Ghasemi, J. and S. Saaidpour, QSRR prediction of the chromatographic retention 
behavior of painkiller drugs. Journal of Chromatographic Science, 2009. 47(2): p. 156-
163. 
31. Tyrkkö, E., A. Pelander, and I. Ojanperä, Prediction of liquid chromatographic retention 
for differentiation of structural isomers. Analytica Chimica Acta, 2012. 720: p. 142-148. 
32. Kazakevich, Y.V. and R. Lobrutto, HPLC for pharmaceutical scientists. 2007: John Wiley 
& Sons. 
33. Perisic-Janjic, N., R. Kaliszan, P. Wiczling, N. Milosevic, G. Uscumlic, and N. Banjac, 
Reversed-phase TLC and HPLC retention data in correlation studies with in silico 
molecular descriptors and druglikeness properties of newly synthesized anticonvulsant 
succinimide derivatives. Molecular Pharmaceutics, 2011. 8(2): p. 555-563. 
34. Leardi, R. and A.L. Gonzalez, Genetic algorithms applied to feature selection in PLS 
regression: how and when to use them. Chemometrics and Intelligent Laboratory Systems , 
1998. 41(2): p. 195-207. 
35. Talebi, M., G. Schuster, R.A. Shellie, R. Szucs, and P.R. Haddad, Performance 
comparison of partial least squares-related variable selection methods for quantitative 
structure retention relationships modelling of retention times in reversed-phase liquid 
chromatography. Journal of Chromatography A, 2015. 1424: p. 69-76. 
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4 Retention Prediction in Reversed-Phase Liquid Chromatography using 
Quantitative Structure-Retention Relationships: Application to the 
Hydrophobic Subtraction Model 
4.1 Introduction 
In many laboratory situations it is important to make an early assessment of the probable 
retention times of compounds. One significant example is in early stage drug discovery in the 
pharmaceutical industry when a variety of potential synthetic routes are being considered for 
a desired new active pharmaceutical compound. The evaluation of these synthetic routes must 
consider a range of parameters, including the likelihood of co-elution of predicted impurity 
compounds with each other or, more importantly, co-elution of these impurities with the active 
pharmaceutical compound. Failure to predict such co-elution may lead to costly or intractable 
analytical problems in downstream phases of drug development, especially in producing the 
required analytical data for registration of a new drug product. Computer tools that permit 
reasonably accurate prediction of retention times based only on the chemical structures of the 
compounds under consideration would clearly be highly beneficial in drug discovery 
applications, as well as in a wide range of other industries. 
It is important to note that the goal of these predictions is not to identify the precise 
combination of mobile phase composition and stationary phase that would constitute the final 
chromatographic method for the separation of a group of target compounds. Rather, the 
objective is to derive rapidly, without experimentation, an overview of the retention behaviour 
of the target compounds on a range of stationary phases. It is recognised that a subsequent 
optimisation step, usually involving extensive experimentation, would be necessary before the 
final separation conditions are selected. Therefore, retention prediction tools used to obtain an 
overview of compound retention behaviour can be calculated from a retention database 
obtained under a very limited range of mobile phase conditions. In the present study, retention 
data obtained using a single mobile phase composition will be used.  
As mentioned in the introduction, Quantitative Structure-Retention Relationships (QSRR) 
methodology aims to find meaningful relationships between chromatographic retention times 
and the chemical structure of compounds in the form of mathematical models [1]. A QSRR 
model is usually derived from a set of molecular descriptors, which are either determined 
experimentally (e.g. the log of the octanol-water partition coefficient (log P), molar refractivity, 
dipole moment, polarizability and other physico-chemical properties of compounds), or are 
computed theoretically from a symbolic representation of the molecules using molecular 
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modelling software, such as Dragon (Talete, Milano, Italy) or VolSurf+ (Molecular Discovery 
Ltd., Hertfordshire, UK). 
There are two approaches to the prediction of retention using QSRR modelling. The first 
is based on a limited number of preselected descriptors which are calculated using built-in 
algorithms embedded into the software. ACD/ChromGenius (ACD/Labs, Toronto, Canada), 
for example, uses descriptors such as log P, the log of the compound distribution coefficient 
(log D), polar surface area, molecular volume, molecular weight, molar refractivity and the 
number of hydrogen bond donor and acceptor sites on the molecule as descriptors to build 
QSRR models. While the simple models generated using such tools are easy to interpret, this 
benefit could be offset (particularly in the case of more complex compounds) by a 
commensurate decrease in prediction accuracy arising from the simplification of the predicted 
retention mechanism due to the use of a very limited set of simple descriptors [2]. As an 
alternative, a large pool of molecular descriptors generated using molecular modelling 
software can be explored to extract the most relevant and informative descriptors. The 
appropriate incorporation of these additional descriptors has been shown in numerous studies 
to improve the prediction accuracy of models [3, 4]. Considering the large number of 
descriptors generated, implementing a suitable descriptor selection method, such as a genetic 
algorithm (GA), which is often combined with multiple linear regression (MLR) or partial 
least squares regression (PLS), becomes necessary to exclude noise from the model and reduce 
the risk of over-fitting and chance correlation [5, 6]. Multidimensional datasets often contain 
a much greater number of descriptors than compounds, and many of these descriptors are co-
linear, redundant or can be regarded as noise [7, 8]. 
It has also been demonstrated in Chapter 3 and in other studies that QSRR prediction can 
benefit greatly from the localisation of predictive models, where individual models are built 
for each test compound using training sets formed from clusters of similar compounds in the 
dataset [8, 9]. Accordingly, different measures of similarity can be used, such as log D for 
physico-chemical similarity or Tanimoto similarity (TS) index for structural similarity based 
on 2D fingerprints [10]. While some improvements in prediction accuracy have become 
evident from these types of database filtering approaches, simple similarity measures like 
these appear to be less efficient for datasets containing compounds with more complex 
structures [3, 10]. This is because other compound properties (e.g., charge state or hydrogen 
bonding) may also collectively contribute to the retention behaviour of compounds and need 
to be taken into account for more accurate filtering [3, 11].  
A practical limitation that prevents widespread applicability of many QSRR models is the 
use of retention data for only a single stationary phase and mobile phase for modelling, which 
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consequently allows retention prediction for new compounds only within the confines of the 
specified conditions for the database. One solution to overcome this limitation might be to 
extend the scope of modelling by including more chromatographic conditions and columns in 
a structured experimental design. However, this approach is inevitably time and resource 
intensive. A more viable option with less demand on labour and time is modelling retention 
indirectly by predicting relevant coefficients in representative equations or models describing 
retention mechanisms, such as the Linear Solvent Strength (LSS) model in ion 
chromatography (IC) or the Hydrophobic Subtraction Model (HSM, see Eq. 4.1 below) in 
RPLC. In previous studies by the Haddad group, the benefits of this approach have been 
demonstrated in IC by predicting a and b coefficients in the LSS model and subsequently 
using these coefficients to predict the retention of ionised compounds over a wide range of 
eluent concentrations [12, 13]. In the development of the HSM, Snyder and co-workers 
concluded that retention and column selectivity in RPLC using alkyl silica phases (i.e., C3-
C18) are governed chiefly by five different physico-chemical properties, namely 
hydrophobicity, steric resistance, hydrogen-bond acidity, hydrogen-bond basicity, and ionic 
interactions between compound and stationary phase (see section 1.5.1 Chapter 1) [11, 14-18].  
log 𝛼  log (
𝑘
𝑘EB
) = 𝜂′𝐇 − 𝜎′𝐒∗ + 𝛽′𝐀 + 𝛼′𝐁 + 𝜅′𝐂          4.1   
While the HSM was not originally aimed at retention prediction, a prediction accuracy of 
±1-2% in k claimed using this model suggests that it has great potential for the purpose of 
retention prediction as well [15]. Additionally, such a high level of accuracy suggests that all 
major contributors to the retention mechanism in RPLC (using common C8 and C18 phases) 
are taken into account. Therefore, it makes sense to expect strong correlations between a 
solute’s coefficients and its chemical properties on one hand, and similarly between column 
coefficients and column properties, such as ligand length (i.e., C8, C18, etc.), particle pore 
diameter, etc. on the other [19]. At present, column coefficients for nearly 700 commercial C8 
and C18 silica-based stationary phases characterised using the HSM are available through an 
open access database hosted by the U.S. Pharmacopeia Convention (USP) website [20, 21]. 
Therefore, there is a unique opportunity for predicting the retention of potentially any given 
compound on all of the characterised columns, albeit under only one isocratic condition, 
provided that the HSM solute coefficients are available for that compound. While 
experimental determination of solute coefficients is feasible through collecting the necessary 
retention data on at least five different columns, this approach is time and resource intensive. 
As an alternative, coefficients for any given compound might be predicted from their 
correlations with molecular descriptors derived only from the chemical structure of the 
compound.  
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The aim of this study was to demonstrate the utility of the proposed approach of modelling 
solute coefficients of the HSM, by fitting the predicted solute coefficients combined with the 
column coefficients into the HSM, allowing retention times of compounds to be predicted 
across a wide range of RPLC columns. The contribution of different resources of molecular 
descriptors was evaluated and compared. Additionally, the importance of the five terms of the 
HSM to retention prediction was investigated. Different approaches were used to cluster 
compounds into the training sets prior to deriving local QSRR models. The performance of 
each filtering approach in enhancing the prediction accuracy was then compared against the 
classical approach where a global QSRR model is derived using compounds in training set 
without filtering. The predictive power of the established models was evaluated using a series 
of criteria and statistical analysis and a proof of concept demonstration of the use of QSRR 
was performed by predicting the retention times of five representative compounds on nine 
columns for which HS coefficients were known. 
4.2 Materials and methods 
4.2.1 Datasets 
Compounds from Dataset 1 [14, 15] for which five experimentally-derived solute 
coefficients (', σ', β', α', κ') are reported, and compounds from Dataset 2 [22], for which only 
three solute coefficients (', σ', β') were found sufficient for their representation [15, 22], were 
employed in the present study. In dataset 1 there are 63 neutral compounds, 13 acids and 12 
bases, and in dataset 2 the compounds are all neutral. The Tanimoto similarity analysis 
indicates a large diversity of compounds in both datasets. Instead of modelling the retention 
of compounds in Dataset 1 for all ten columns, here, retention of compounds for the GL 
Inertsil ODS-3 column (Table 2.1, Chapter 2) was modelled. 
Compounds in Dataset 2 were employed as well because a column was found in common 
between Datasets 1 and 2, which was a HP Zorbax SB C18 (Column 3, 150 mm × 4.6 mm i.d., 
5µm) column (denoted as Zorbax StableBond C18 in Dataset 2) from Agilent Technologies 
(Newport, DE, USA). Due to the lack of information about the void time and the dimensions 
of the column used in Dataset 2, an estimated void time was calculated by correlating the 
retention factors of the overlapping compounds between these two databases and then using 
this void time to calculate retention times for the 60 remaining compounds in Dataset 2. Since 
small differences in solute coefficients were observed for the compounds in common, likely 
related to the 10 °C difference in column temperature employed during data collection for the 
two separate studies [15], t-tests were performed on solute coefficients of the compounds in 
common before combining the two datasets. Results confirmed the null hypothesis that the 
means of the two populations were indeed equal for all solute coefficients. Nevertheless, a 
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porting equation for each solute coefficient was derived by regressing the coefficient values 
in Dataset 1 against those in Dataset 2 and this equation was then used to readjust the values 
of solute coefficients for the remaining 60 compounds in Dataset 2 before merging them with 
Dataset 1 and obtaining the combined dataset. The coefficients of columns used in Dataset 1 
(numbered from 1 to 10) and 2 (numbered from 11 to 15) are listed in Table 4.1. The solute 
coefficients of 88 compounds from Dataset 1 and 60 compounds from Dataset 2 (the 
overlapping compounds were subtracted) are shown in Table 4.2. The retention of these 
compounds on the corresponding columns has been described previously in the section 2.1.1, 
Chapter 2 (Tables 2.5 and 2.6). 
Table 4.1. Coefficients of columns used in Dataset 1 and Dataset 2  
Column 
Column coefficients 
H S A B C (pH 2.8) 
C1. GL Inertsil ODS-3 1.0048 -0.0126 -0.1285 -0.0255 -0.3501 
C2. Waters Symmetry C18 1.0498 -0.0588 0.0104 -0.0289 -0.2071 
C3. HP Zorbax SB C18 0.9981 0.0211 0.2715 0.0064 0.0854 
C4. HP Zorbax SB C18 0.9666 0.0418 0.2642 0.0093 0.0505 
C5. HP Zorbax SB-300 C18 0.8945 0.0426 0.1092 0.0761 0.2204 
C6. HP Eclipse XDB-C18 1.0355 -0.0084 -0.0202 -0.0325 0.0443 
C7. YMC Pack Pro C18 1.0022 0.0022 -0.1362 -0.0128 -0.0960 
C8. YMC Pack Pro C18 1.0195 -0.0077 -0.1317 -0.0105 0.0088 
C9. YMC Pack Pro C18 1.0106 -0.0067 -0.1357 -0.0099 0.0135 
C10. Supelco Discovery C18 0.9861 -0.0226 -0.1279 0.0163 0.1899 
C11. Zorbax StableBond C18 0.9907 0.0118 0.3429   
C12. Zorbax Rx-C18 1.0651 -0.0557 0.3853   
C13. Hypersil C18 0.9635 -0.0065 0.0967   
C14. Hypersil C8 0.8536 0.0170 0.0409   
C15. Zorbax C8 0.8267 0.0055 0.0643   
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Table 4.2. Solute coefficients of compounds used in Dataset 1 (Compound ID 1 to 88) and 
Dataset 2 (Compound ID 89 to 148) 
ID Name 
Solute coefficients 
η' σ' β' α' κ' 
1 benzene -0.42 -0.20 0.01 -0.04 -0.02 
2 toluene -0.21 -0.13 0.00 -0.01 -0.01 
3 ethylbenzene 0.00 0.00 0.00 0.00 0.00 
4 p-xylene 0.02 -0.12 0.00 0.01 0.00 
5 propylbenzene 0.23 0.13 -0.01 0.03 0.00 
6 naphthalene -0.05 0.06 -0.02 0.15 -0.02 
7 p-chlorotoluene 0.01 -0.09 0.01 0.15 -0.02 
8 dichlorobenzene 0.02 -0.04 -0.02 0.14 -0.02 
9 benzotrichloride 0.15 0.41 -0.05 0.13 -0.03 
10 bromobenzene -0.15 -0.05 -0.01 0.09 -0.03 
11 1-nitropropane -0.84 -0.04 0.01 -0.11 0.00 
12 nitrobenzene -0.58 0.32 -0.01 0.01 -0.04 
13 p-nitrotoluene -0.38 0.43 -0.01 0.04 -0.03 
14 p-nitrobenzylchloride -0.37 0.60 -0.03 0.02 -0.03 
15 N-benzylformamide -1.31 0.04 0.07 0.04 0.03 
16 anisole -0.47 0.04 0.00 -0.05 -0.02 
17 benzylalcohol -1.15 -0.14 0.01 -0.10 0.02 
18 3-phenylpropanol -0.87 0.01 0.02 0.12 0.02 
19 5-phenylpentanol -0.49 0.21 0.04 0.37 0.03 
20 phenol -1.03 -0.17 -0.02 -0.04 0.02 
21 p-chlorophenol -0.76 -0.04 -0.04 0.15 0.00 
22 2,3-dihydroxynaphthalene -0.93 -0.01 -0.11 0.61 -0.03 
23 1,3-dihydroxynaphthalene -1.04 -0.04 -0.06 0.20 0.00 
24 eugenol -0.55 0.12 -0.03 0.15 0.01 
25 danthron -0.02 0.47 -0.04 0.29 -0.04 
26 n-propylformate -0.87 -0.17 0.05 -0.19 0.01 
27 methylbenzoate -0.53 0.30 0.03 -0.04 -0.04 
28 benzonitrile -0.72 0.25 0.02 -0.02 -0.03 
29 coumarin -0.93 -0.55 -0.02 0.65 -0.04 
30 acetophenone -0.75 0.19 0.04 -0.05 -0.01 
31 benzophenone -0.18 0.66 -0.01 0.09 -0.03 
32 cis-chalcone -0.05 0.82 -0.02 0.07 -0.02 
33 trans-chalcone 0.03 0.92 -0.03 0.18 -0.04 
34 cis-4-nitrochalcone -0.10 1.10 -0.04 0.07 -0.04 
35 trans-4-nitrochalcone 0.02 1.43 -0.08 0.01 -0.04 
36 cis-4-methoxychalcone -0.10 0.97 -0.03 0.06 -0.03 
37 trans-4-methoxychalcone 0.01 1.17 -0.06 0.13 -0.04 
38 prednisone -1.17 0.98 0.09 0.02 0.02 
39 hydrocortisone -1.15 0.97 0.05 0.10 0.03 
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40 mephenytoin -0.96 0.11 -0.02 0.05 0.02 
41 oxazepam -0.86 0.02 -0.06 0.58 0.03 
42 flunitrazepam -0.63 0.75 -0.01 0.16 -0.02 
43 5,5-dimethylhydantoin -0.88 1.28 -0.05 -0.45 0.03 
44 N,N-dimethylacetamide -1.92 0.00 1.00 0.00 0.00 
45 amitriptyline -1.10 0.05 -0.03 0.32 0.83 
46 diphenhydramine -1.41 -0.06 0.00 0.16 1.02 
47 D,L-propanolol -1.65 -0.18 0.01 -0.33 1.23 
48 nortriptyline -1.17 0.06 -0.04 0.38 0.83 
49 prolintane -1.48 0.13 0.05 -0.53 1.08 
50 4-n-pentylaniline -0.50 -0.25 0.08 0.26 0.09 
51 4-n-hexylaniline -0.26 -0.21 0.08 0.42 0.09 
52 4-n-heptylaniline -0.02 -0.18 0.07 0.58 0.09 
53 N-ethylaniline -1.01 -0.41 0.06 -0.58 0.09 
54 2-phenylpyridine -0.69 0.21 0.05 -0.05 -0.01 
55 diclofenac -0.19 0.40 -0.04 0.86 -0.03 
56 mefenamic 0.04 0.26 -0.04 0.92 -0.01 
57 ketoprofen -0.59 0.30 -0.04 0.55 0.01 
58 diflunisal -0.47 0.17 0.15 3.10 -0.43 
59 4-n-butylbenzoic acid -0.27 -0.28 0.02 1.02 0.04 
60 4-n-pentylbenzoic acid -0.05 -0.31 0.02 1.19 0.05 
61 4-n-hexylbenzoic acid 0.18 -0.30 0.01 1.35 0.06 
62 3-cyanobenzoic acid -1.22 -0.06 0.03 0.91 -0.04 
63 2-nitrobenzoic acid -1.39 -0.19 0.02 1.45 -0.20 
64 3-nitrobenzoic acid -1.08 -0.02 0.05 1.21 -0.07 
65 2,6-dimethylbenzoic acid -0.93 -0.22 -0.02 0.46 0.01 
66 2-fluorobenzoic acid -1.15 -0.15 0.00 0.36 0.03 
67 1,2-dinitrobenzene -0.64 0.48 -0.03 0.12 -0.04 
68 1,3-dinitrobenzene -0.61 0.46 -0.03 0.02 -0.03 
69 nitrocyclohexane -0.39 0.31 0.00 -0.03 0.00 
70 biphenyl 0.15 0.23 -0.04 0.10 -0.02 
71 2-nitrobiphenyl -0.11 0.80 -0.04 0.14 -0.04 
72 3-nitrobiphenyl 0.08 0.75 -0.05 0.22 -0.04 
73 2-biphenylmethanol -0.51 0.37 -0.03 0.08 0.01 
74 2,2'-biphenol -0.69 0.15 -0.05 0.17 0.01 
75 4,4'-biphenol -1.08 0.49 -0.06 0.20 -0.01 
76 diphenylbutyrolactone -0.22 0.74 -0.02 0.09 -0.02 
77 fluorescamine -0.20 1.05 -0.04 0.15 -0.05 
78 camphorquinone -0.55 0.42 0.01 -0.09 0.01 
79 N,N-diethylacetamide -1.34 0.40 0.41 0.10 0.07 
80 3-nitrophenol -0.91 0.14 -0.04 0.16 -0.01 
81 4-nitrophenol -0.96 0.06 -0.03 0.22 -0.02 
82 2,4-dinitrophenol -0.82 -1.06 0.13 1.06 -0.16 
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83 2-5-dinitrophenol -0.72 0.10 0.00 0.18 -0.04 
84 picric acid -0.93 -3.19 -0.09 4.04 -0.98 
85 fisetin -1.41 0.14 -0.07 0.41 0.01 
86 biochanin A -0.42 1.00 -0.09 0.24 -0.05 
87 4-phenylpyridine 0.13 0.69 -0.05 0.17 -0.01 
88 N-butylaniline -0.33 0.24 -0.03 -0.36 0.02 
89 1-butanol -1.28 -0.47 0.17   
90 1-hexanol -0.79 -0.06 0.12   
91 1-octanol -0.32 0.34 0.09   
92 isopropanol -1.63 -0.95 0.22   
93 cyclohexanol -1.13 -0.23 0.22   
94 1-butanal -0.98 -0.11 0.23   
95 1-hexanal -0.50 0.36 0.16   
96 1-heptanal -0.27 0.49 0.15   
97 1-octanal -0.05 0.49 0.19   
98 N,N-dimethyl formamide -1.98 -0.22 0.84   
99 N,N-diethyl formamide -1.47 0.23 0.46   
100 N,N-dibutyl formamide -0.54 1.05 0.18   
101 n-butyl acetate -0.54 0.17 0.06   
102 n-amyl acetate -0.31 0.36 0.03   
103 n-hexyl acetate -0.08 0.50 0.03   
104 ethyl propionate -0.77 -0.04 0.06   
105 ethyl butyrate -0.53 0.09 0.03   
106 ethyl ether -0.96 -0.56 0.22   
107 di-n-propyl ether -0.35 -0.26 0.11   
108 di-n-butyl ether 0.16 0.10 0.08   
109 dioxane -1.60 -0.54 0.49   
110 acetone -1.46 -0.61 0.20   
111 butane-2-one -1.18 -0.37 0.13   
112 heptane-2-one -0.47 0.28 0.04   
113 nonane-2-one -0.01 0.55 0.04   
114 cyclopentanone -1.18 -0.11 0.22   
115 n-propionitrile -1.20 -0.26 0.05   
116 n-valeronitrile -0.75 0.19 -0.01   
117 n-hexanitrile -0.52 0.33 -0.03   
118 n-hexyl cyanide -0.26 0.49 -0.18   
119 n-heptyl cyanide -0.07 0.62 -0.09   
120 n-octyl cyanide 0.16 0.71 -0.10   
121 n-nitrobutane -0.58 0.25 -0.06   
122 n-nitropentane -0.35 0.41 -0.08   
123 methylene chloride -0.73 -0.17 -0.03   
124 chloroform -0.48 -0.02 -0.04   
125 dibromomethane -0.61 -0.08 0.00   
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126 2-phenyl ethanol -1.04 -0.14 0.04   
127 3-phenyl propanol -0.88 0.01 0.04   
128 benzaldehyde -0.77 0.14 0.07   
129 ethyl benzoate -0.31 0.32 -0.01   
130 propiophenone -0.50 0.25 0.06   
131 m-toluenitrile -0.50 0.44 0.01   
132 benzyl cyanide -0.68 0.33 -0.04   
133 m-nitrotoluene -0.34 0.46 -0.04   
134 o-nitrotoluene -0.39 0.45 -0.05   
135 p-nitrobenzyl bromide -0.30 0.69 -0.05   
136 fluorobenzene -0.41 -0.04 -0.04   
137 chlorobenzene -0.21 -0.09 -0.02   
138 lodobenzene -0.06 -0.02 0.02   
139 benzyl bromide -0.21 0.40 -0.05   
140 p-bromotoluene 0.06 -0.06 0.01   
141 n-butylbenzene 0.45 0.35 -0.02   
142 tert.-butylbenzene 0.31 0.43 -0.03   
143 mesitylene 0.21 0.02 0.02   
144 anthracene 0.33 -0.35 0.07   
145 m-cresol -0.83 0.01 -0.06   
146 p-cresol -0.83 0.01 -0.06   
147 o-cresol -0.77 0.05 -0.07   
148 p-ethylphenol -0.64 0.10 -0.07   
4.2.2 Calculation of the molecular descriptors 
In the present study, different resources of molecular descriptors were employed and 
compared to improve the performance of the QSRR models. Molecular descriptors were 
calculated either using Dragon 6.0 (Talete, Milano, Italy) or VolSurf+ 1.0.7.1 (Molecular 
Discovery Ltd., Hertfordshire, UK), as detailed in section 2.3.2, Chapter 2. Besides using 
molecular descriptors generated from Dragon and VolSurf+ separately, a combination of 
molecular descriptors from both was also generated and tested.  
4.2.3 Filtering approaches for Dataset 1 
In this study, both global and local models (as described in section 2.3.5, Chapter 2) were 
created and compared for the prediction of solute coefficients. The five solute coefficients of 
the HSM were predicted as functions of molecular descriptors for their subsequent use in 
retention prediction. A popular version of a GA-PLS algorithm, originally written by Leardi 
[23] in Matlab (The Mathworks Inc., Natick, MA, USA) was modified and used for descriptor 
selection and modelling solute coefficients. To cope with the variability of the results arising 
from the intrinsic random selection nature of the genetic algorithm, the GA-PLS modelling 
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was repeated five times and the results were averaged. This part of work was performed for 
the 88 compounds in Dataset 1 for the GL Inertsil ODS-3 column with different resources of 
molecular descriptors (Dragon, VolSurf+ and the combined descriptors).  
Leave-one-out (LOO) filtering: In this filtering method one compound was taken out as 
the target compound, the rest of the compounds were used as a training set for QSRR 
modelling. In this way, each target compound has its own local model for the prediction of 
five solute coefficients, created using information from the compounds in the entire dataset. 
Different resources of molecular descriptors were investigated and compared. 
The Global approach: rather than building a model for each compound, another option for 
QSRR modelling which is easy to interpret is building just one model for all the compounds 
using a randomly allocated training set while the rest of the compounds in the database were 
treated as an external test set. In this work, a D-optimal algorithm suggested by Todeschini et 
al. [24] was used to allocate compounds into a training set (70%) and a test set (30%), 
respectively. This distance-based selection approach ensures homogenous sampling from a 
database leading to a uniform distribution of compounds between the resulting subsets [24]. 
Compounds in the training set were used to build QSRR models through GA-PLS, and 
compounds in the test set were employed to evaluate the predictive ability of the constructed 
QSRR models. Again, different resources of molecular descriptors were investigated and 
compared. 
Local Compound Type (LCT) filtering: Another approach for QSRR modelling involves 
the classification of compounds. In this way, instead of building a local model for each 
compound separately, or one model to describe the whole dataset, a model was built for a 
group of compounds which lay within the same classification. For LCT, compounds were 
clustered according to their type (bases, acids, and neutrals), therefore, compounds belonging 
to the same type were classified into the same cluster. Each cluster was then divided, as for 
the global model, into a training set and a test set. A QSRR model was then derived for each 
cluster for the prediction of solute coefficients and the resources of molecular descriptors 
compared. 
Local Second Dominant Interaction (LSDI) filtering: in Wilson’s work [25], the HSM 
solute coefficients were experimentally generated based on the classification of compounds 
according to the interaction between compounds and stationary phase. “Ideal compounds” for 
which the retention was determined entirely by the hydrophobic interaction were used to yield 
the hydrophobicity coefficient [25]. Then, other solute coefficients were generated using a 
group of compounds that have been clustered according to their secondary dominant 
interaction after the hydrophobic interaction. Thus, compounds in Wilson's study were 
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allocated to different clusters, each corresponding to one of the terms in the HSM [25]. 
Following the subtraction of the effect of hydrophobicity, retention for compounds in each 
cluster was assumed to be predominantly influenced by the type of interaction linked to that 
cluster. Five clusters were identified, namely η' (hydrophobicity only), σ' (steric bulk), β' 
(hydrogen bonding basicity), α' (hydrogen bonding acidity), and κ' (charged compound) 
clusters, containing 25, 21, 4, 16 and 7 compounds, respectively [25]. Compounds for which 
retention appeared to be substantially influenced by more than one type of interaction 
(excluding hydrophobicity) were not assigned to any cluster by Wilson and co-workers, but 
have been allocated into a separate cluster (cluster 6) in the present study. After compound 
classification using this approach, and separation of each cluster into training and test sets, a 
QSRR model was built for each cluster and the solute coefficients were predicted and the 
resources of molecular descriptors compared. 
4.2.4 Filtering approaches for the combined dataset 
The prediction of ported solute coefficients and retention times was also performed on a 
combined dataset which contained 148 compounds (88 compounds from Dataset 1 and 60 
compounds from Dataset 2). Again, both global and local QSRR models were built through 
PLS equations using a Matlab platform. This part of the study was performed for the retention 
data of the combined 148 compounds on a common column with molecular descriptors 
generated using VolSurf+ only. 
Local Tanimoto Similarity (LTS) and Local Log D (LLD) filtering: previous results have 
shown that with a group of compounds in a training set having a sufficient level of similarity 
to the target, acceptable performance of retention prediction can be obtained [26]. In the LTS 
method, filtering was performed based on the Tanimoto Similarity (TS) index where the 
dataset was sorted based on the compounds’ pairwise TS indices in relation to the target. Then, 
the top five compounds with pairwise TS indices of at least 0.5 were used as a training set to 
derive a separate QSRR model [26, 27]. If five compounds with a TS index of greater than 0.5 
could not be found, the compound was not modelled.  
In the LLD, compounds were sorted based on the ratio of their log D value to the log D of 
the target. Then, the top five compounds with log D ratio less than 1.1 were used as the training 
set [26]. Other conditions were the same as for the LTS approach. It is worth pointing out that, 
using either the LTS or the LLD approach, each compound has its own separate model for the 
prediction of solute coefficients. 
The Global approach: this approach used all the compounds in the dataset to build one 
global model without any compound classification for the retention prediction of all 
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compounds [27]. Here, global PLS models (using 126 or 34 VolSurf+ descriptors, refer to the 
G126 and G34 below) were derived as the benchmark to gauge the improvements that the 
implementation of GA-PLS could bring to the final models. Before the modelling process, a 
D-optimal approach was used for splitting the combined dataset into a training set and an 
external test set. Then, a global QSRR model was built to predict solute coefficients and 
retention by fitting the predicted solute coefficients and their complementary column 
coefficients into the HSM.   
Local Compound Type (LCT) filtering: the LCT filter as mentioned above was also 
applied to the 148 combined compounds based on their chemical nature, three clusters 
containing 13 acids, 12 bases, and 123 neutrals were obtained, respectively. Approximately 
70% compounds of each cluster were then selected using a D-optimal approach for modelling 
and the remaining compounds were used for the external validation of the corresponding 
model.  
Local Second Dominant Interaction (LSDI) filtering: as previously described, six clusters 
were obtained for 88 compounds from Dataset 1 using this filtering approach. For modelling 
the combined 148 compounds, the β' cluster, representing compound hydrogen-bond basicity, 
was expanded to seven by adding three more compounds with the same property from Dataset 
2. Similarly, 70% of compounds in each cluster were allocated into the training set using a D-
optimal algorithm, where the rest of the compounds in each cluster were taken as test sets. The 
applicability of this approach for predicting retention time for new test compounds was also 
demonstrated by using Dataset 2 as an external test set. To allocate new test compounds into 
the corresponding cluster so that the correct model could be used, TS searching was introduced. 
The structural similarity of each compound in Dataset 2 was investigated against training 
compounds (Dataset 1) in each cluster with the aim of finding one training compound with a 
pairwise Tanimoto structural similarity of at least 0.5. If such a similar compound was found 
the target compound was assigned to the same LDSI cluster as the compound with the greatest 
pairwise similarity. In total, 28 compounds out of 57 in Dataset 2 were assigned to clusters as 
follows: ' cluster (19 compounds), σ' cluster (6 compounds) and cluster 6 (3 compounds). 
The other 29 compounds in Dataset 2 were excluded since their pairwise TS indices were less 
than 0.5 when calculated against every compound in Dataset 1. 
4.2.5 Statistics  
The coefficient of determination (R2), the slope of the regression with no forced 
intercept and root-mean-squared error of prediction (RMSEP) were used to evaluate model 
fitness with the requirement for the slope to be within the range of 0.85 to 1.15 [28]. The 
percentage root-mean-square error of prediction (RMSEP%) of retention time for the test set 
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was measured to externally validate the accuracy of GA-PLS models generated from the 
training set. The equations of the RMSEP and the RMSEP% were detailed in section 2.3.6, 
Chapter 2 (Eq. 2.2 and Eq. 2.3). 
The predictive ability of the models was evaluated by inspecting the Regression Error 
Characteristic (REC) curves obtained by plotting the prediction error range against the 
percentage of data points predicted within that range [29, 30]. The null model, which can be 
regarded as the baseline model, was obtained by using the mean of the dependent variable 
(response) as a naïve predicted value for all compounds. REC curves were used to show the 
differences between regression models and have the advantage that the ranking of models is 
independent of the error measure used [30]. 
In addition, the overall performance of all generated models was further compared using 
the sum of ranking difference (SRD) approach [31-33] where parameters for each model 
were compared to a series of reference values, and each model ranked according to how 
large was the difference between its parameters and the reference values. The rankings were 
also compared to a confidence interval generated by using randomly ranked numbers [32, 
34]. This ordering method provides a simple way to evaluate the models by comparing their 
SRD values (the closer the SRD value to zero, the better the approach) [31]. 
4.3 Results and Discussion 
4.3.1 QSRR Prediction for Dataset 1 
For the LOO approach, 88 compounds in Dataset 1 were used for the prediction of the 
five solute coefficients through QSRR models with different resources of molecular 
descriptors. The combined molecular descriptors were performed by running the GA to choose 
the Dragon descriptors first, and then running the same process to select VolSurf+ descriptors. 
Finally, the selected descriptors from Dragon and VolSurf+ were combined as a pool of 
combined descriptors for modelling. Figures 4.1 – 4.5 show the performance of solute 
coefficient predictions using three resources of descriptors. 
Among the prediction of five solute coefficients, only the predictions of η’ were 
acceptable based on the generated slope and correlation coefficient. Data points of prediction 
for the other four solute coefficients were either scattered on both sides of the trend line, or 
aggregated around the origin, and showed poor correlation between the measured and 
predicted solute coefficients. For η’ prediction, as can be seen from Figure 4.1, a range of 
correlation coefficients between 0.6388 to 0.6894 was obtained with RMSEP values ranging 
from 0.28 to 0.30. Very similar results (the slope, the R2, the RMSEP) were observed for all 
the different resources of descriptors using the same LOO approach, suggesting that there was 
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no significant improvement gained from using diverse types of descriptors or even from the 
combined descriptors. The same trend was also observed from the prediction of the other four 
solute coefficients, with almost identical plots being generated between measured and 
predicted coefficients for each resource of molecular descriptors. Additionally, regardless of 
the resource of descriptors used, or which solute coefficients were predicted, the same 
compounds were found to be outliers – i.e., poorly predicted with high prediction errors.  
 
Figure 4.1. Solute coefficient (’) prediction using the LOO approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
 
Figure 4.2. Solute coefficient (’) prediction using the LOO approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
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Figure 4.3. Solute coefficient (’) prediction using the LOO approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
 
Figure 4.4. Solute coefficient (’) prediction using the LOO approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
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Figure 4.5. Solute coefficient (’) prediction using the LOO approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
Unlike the LOO approach, where each target compound has its own model, a group of 
compounds can be predicted using just one global model where training and test sets are 
employed. As shown in Figures 4.6 – 4.10, five solute coefficients were predicted, and the 
RMSEP errors are reported. Compared to the LOO approach, a slight improvement of 
prediction error was observed for the prediction of η’ coefficient, RMSEP values of 0.28, 0.20, 
and 0.23 were obtained using Dragon, VolSurf+, and combined descriptors, respectively, 
while using the LOO approach but the same resources of descriptors resulted in RMSEP of 
0.28, 0.30, and 0.28 for η’ coefficient prediction. This indicated again that the resource of 
molecular descriptors has almost no influence on the prediction of solute coefficients. In terms 
of the prediction of the other four coefficients, as in the performance of the LOO approach, 
poorly correlated coefficients and much higher prediction errors were obtained with the global 
model. 
As can be seen from the above approaches, neither the LOO nor the Global approach 
yielded acceptable prediction accuracy of solute coefficients. One thing in common between 
these two approaches is that compounds used for QSRR model construction were quite diverse 
with a wide range of molecular characteristics. In the LOO approach, one compound was taken 
out as the target analyte while the rest were used as the training set. In terms of the Global 
approach, 70% compounds of the whole dataset were used as the training set. Since this dataset 
is highly diverse (based on the Tanimoto similarity analysis), in the QSRR models generated 
using the LOO or the Global approach, compounds with widely diverse molecular 
characteristics were included, causing much higher prediction errors. 
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Figure 4.6. Solute coefficient (’) prediction using the Global approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
 
Figure 4.7. Solute coefficient (’) prediction using the Global approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
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Figure 4.8. Solute coefficient (’) prediction using the Global approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
 
Figure 4.9. Solute coefficient (’) prediction using the Global approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors.
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Figure 4.10. Solute coefficient (’) prediction using the Global approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
 
Figure 4.11. Solute coefficient (’) prediction using the LCT approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
It has been shown that smaller, more similar training sets to the target compounds leads 
to greater prediction accuracy. Compound classification based on the type of the molecules 
was therefore investigated. The predictions for the five solute coefficients are listed in Figures 
4.11 – 4.15. The accuracy of prediction for all the five solute coefficients was improved 
significantly compared to the LOO and the Global approach. In terms of the comparison of 
molecular descriptors, Dragon, VolSurf+, and combined descriptors demonstrated comparable 
results in the prediction of the five solute coefficients. 
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Figure 4.12. Solute coefficient (’) prediction using the LCT approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors.
Figure 4.13. Solute coefficient (’) prediction using the LCT approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
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Figure 4.14. Solute coefficient (’) prediction using the LCT approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
 
Figure 4.15. Solute coefficient (’) prediction using the LCT approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
Results obtained for the LCT approach suggested that better selection of the training set 
might improve the overall prediction accuracy of the models. In this context, the LSDI 
approach was investigated. Prediction of the five solute coefficients was performed using the 
same GA-PLS method and the results can be seen in Figures 4.16 – 4.20. Compared to the 
LCT approach, the LSDI approach improved the performance of the QSRR models. Linear 
correlations between measured and predicted solute coefficients were obtained and supported 
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by the distribution of data points around the trend line (much higher R2 values were obtained). 
Again, a change in the resource of molecular descriptors made no difference to the prediction 
of coefficients, which consistent with the previous results (the LOO method, the Global 
method, and the LCT method). 
 
Figure 4.16. Solute coefficient (’) prediction using the LSDI approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
 
Figure 4.17. Solute coefficient (’) prediction using the LSDI approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
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Figure 4.18. Solute coefficient (’) prediction using the LSDI approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
 
Figure 4.19. Solute coefficient (’) prediction using the LSDI approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
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Figure 4.20. Solute coefficient (’) prediction using the LSDI approach with (a) Dragon 
descriptors, (b) VolSurf+ descriptors, and (c) combined descriptors. 
4.3.2 Performance comparison of filtering approaches 
Table 4.3 shows the comparison of the prediction of five solute coefficients using the 
above-mentioned filtering approaches. As can be seen, in terms of the prediction of solute 
coefficients, the LSDI approach shows comparable performance to the LCT approach. Results 
of prediction using the LOO and the Global approach are not acceptable considering the poor 
correlation coefficients and large errors of prediction. It is worth pointing out that the LCT 
approach showed the best performance in the prediction of α’ and κ’ coefficients. The best 
values of R2 and RMSEP for α’ coefficient prediction obtained from the LCT approach are 
0.9536 and 0.14, respectively, which are superior to the values of 0.9034 and 0.19 using the 
LSDI approach. Similarly, in terms of κ’ coefficient prediction, the LCT approach generated 
R2 = 0.9907 and RMSEP = 0.03, slightly better than the LSDI approach which gave R2 = 
0.9816 and RMSEP = 0.04. 
Table 4.3 shows that the makeup of the training sets is a prime factor in determining the 
accuracy of the resulting QSRR models. In terms of the LOO and the Global approach, more 
diverse compounds were employed to build the models, while less diverse compounds were 
used in the LCT and the LSDI approaches. When compared to the LCT approach, the LSDI 
approach involved filtering compounds based on the second dominant interaction after 
hydrophobicity, thus more groups of compounds were generated (six groups). Compounds in 
each group were representative of a certain type of interaction between compounds and 
stationary phase, which is more specific than the LCT approach where only three groups were 
obtained. 
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Table 4.3. Parameters of prediction of five solute coefficients using different approaches 
SCs MDs 
LOO Global LCT LSDI 
R2 RMSEP R2 RMSEP R2 RMSEP R2 RMSEP 
η'  
Dragon  0.69 0.28 0.65 0.28 0.82 0.21 0.94 0.12 
VolSurf+ 0.64 0.30 0.83 0.20 0.90 0.16 0.99 0.06 
combined 0.69 0.28 0.67 0.23 0.91 0.15 0.98 0.06 
σ'  
Dragon  0.40 0.44 0.54 0.34 0.83 0.23 0.92 0.16 
VolSurf+ 0.34 0.48 0.61 0.30 0.87 0.20 0.86 0.21 
combined 0.39 0.46 0.71 0.27 0.87 0.21 0.93 0.14 
β'  
Dragon  0.06 0.13 0.22 0.05 0.43 0.09 0.99 0.01 
VolSurf+ 0.08 0.12 0.24 0.04 0.45 0.09 0.98 0.02 
combined 0.07 0.14 0.66 0.03 0.91 0.04 0.99 0.01 
α'  
Dragon  0.22 0.56 0.22 0.14 0.93 0.17 0.87 0.23 
VolSurf+ 0.30 0.54 0.11 0.19 0.95 0.14 0.80 0.28 
combined 0.27 0.55 0.39 0.13 0.95 0.14 0.90 0.19 
κ'  
Dragon  0.53 0.18 0.78 0.02 0.86 0.10 0.98 0.04 
VolSurf+ 0.47 0.21 0.71 0.02 0.99 0.03 0.96 0.05 
combined 0.45 0.20 0.79 0.02 0.99 0.03 0.98 0.04 
Furthermore, the performance of retention prediction using the five predicted solute 
coefficients generated from these filtering approaches was also compared. To achieve that, the 
predicted five solute coefficients combined with the corresponding five column parameters 
were fitted into the HSM to calculate compound retention (expressed as the selectivity 
coefficient (α) relative to ethylbenzene), as detailed in Figures 4.21 – 4.23. As can be seen, no 
matter which resource of molecular descriptors employed, the LSDI approach showed the best 
correlation between measured α and predicted α with prediction errors of 0.12, 0.09 and 0.07 
for Dragon descriptors, Volsurf+ descriptors, and combined descriptors, respectively.  
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Figure 4.21. Predicted selectivity coefficients (α=k/kEB) via the full HSM using (a) the LOO, 
(b) the Global, (c) the LCT, and (d) the LSDI approach with Dragon descriptors. 
 
Figure 4.22. Predicted selectivity coefficients (α=k/kEB) via the full HSM using (a) the LOO, 
(b) the Global, (c) the LCT, and (d) the LSDI approach with VolSurf+ descriptors. 
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Figure 4.23. Predicted selectivity coefficients (α=k/kEB) via the full HSM using (a) the LOO, 
(b) the Global, (c) the LCT, and (d) the LSDI approach with combined descriptors. 
4.3.3 Significance of hydrophobicity term in the HSM 
There are five terms in the HSM and each term is representative of a certain type of 
interaction between the compound and the stationary phase. The hydrophobic interaction is 
well-known for being the primary contributor to the retention in RPLC, as described by the 
solvophobic theory [19]. The HSM tries to quantify contributions to separation selectivity 
from other weaker interactions, so it would be interesting to see the relative importance of 
these interactions regarding their contribution to retention. To this end, the above predicted 
retention (using predicted solute coefficients) obtained from either Eq. 4.1 using five 
experimental solute coefficients (i.e., the full HSM), or alternatively Eq. 4.2 using only the 
hydrophobicity coefficient ' (which we describe here as the approximate HSM) was plotted 
against the measured retention for 88 compounds in Dataset 1. 
log 𝛼  log (
𝑘
𝑘EB
) ≈ 𝜂′𝐇          4.2 
The five predicted solute coefficients modelled using different filtering approaches, 
combined with the corresponding column coefficients were fitted into Eq. 4.1 (Figures 4.21 – 
4.23). Then, the predicted η’ values were extracted and fitted into Eq. 4.2 with the same 
column coefficients for the calculation of retention, Figures 4.24 – 4.26. The approximate 
HSM using only the hydrophobicity term generated comparable predictions to those obtained 
using the full HSM where five terms were involved. This indicated that the hydrophobicity 
term (η’ H) gives the most important contribution to the retention among the five terms. 
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Figure 4.24. Predicted selectivity coefficients (α=k/kEB) via the approximate HSM using (a) 
the LOO, (b) the Global, (c) the LCT, and (d) the LSDI approach with Dragon descriptors. 
 
Figure 4.25. Predicted selectivity coefficients (α=k/kEB) via the approximate HSM using (a) 
the LOO, (b) the Global, (c) the LCT, and (d) the LSDI approach with VolSurf+ descriptors. 
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Figure 4.26 Predicted selectivity coefficients (α=k/kEB) via the approximate HSM using (a) 
the LOO, (b) the Global, (c) the LCT, and (d) the LSDI approach with the combined 
descriptors. 
Additionally, the calculated retention time (using measured solute coefficients) using both 
Eq. 4.1 and 4.2 was also plotted against the measured retention time for 88 compounds. Very 
high correlations were obtained in both cases (Figure 4.27), however the approximate HSM 
resulted in three times higher error compared with the full HSM (RMSEP of 5.4s vs. 1.8s, 
respectively). Nevertheless, the accuracy of the approximate HSM is sufficient for prediction 
of the likelihood of co-elution of the compounds. Therefore, for the combined dataset, we 
have focused on modelling only the hydrophobicity coefficient (') for each target compound 
and the subsequent use of the approximate HSM (Eq. 4.2) for the prediction of retention times. 
Given the fact that almost identical results were obtained when different resources of 
molecular descriptors used, and that VolSurf+ generated many fewer descriptors, therefore 
taking less time and effort for calculations, VolSurf+ descriptors were chosen for the 
modelling of the combined dataset (148 compounds). 
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Figure 4.27. Measured retention time versus calculated retention time using (a) five 
experimental solute coefficients via the full HSM and (b) experimental hydrophobicity 
coefficient (') only via the approximate HSM. 
4.3.4 QSRR prediction for the combined dataset using the approximate HSM 
As a first step, a global PLS model (using a training and test set) was derived using all 126 
generated VolSurf+ descriptors for the combined dataset. We will refer to this model as Global 
126 (G126) to indicate that all descriptors were used for modelling and that one model was 
generated to be applied to all compounds in the test set. Figure 4.28a illustrates the correlations 
obtained between experimental and predicted ' for the 148 compounds. However, pairing the 
predicted ' values with the column coefficient H resulted in an %RMSEP of 24.27 in 
retention time for the external test set, with errors being generally more pronounced for the 
longer retained compounds (Figure 4.29a). Additionally, almost identical plots were obtained 
(Figure 4.30) upon using the full HSM (i.e., by fitting the predicted values of ' obtained from 
the G126 model but experimental values of other four coefficients into Eq. 4.1) and the 
approximate HSM (i.e., by fitting the predicted values of ' obtained from the G126 model 
into Eq. 4.2) for compounds in Dataset 1. This confirmed that the errors obtained for the 
reference global modelling approach cannot be attributed to the use of the approximate HSM.   
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Figure 4.28. Measured ' versus predicted ' using (a) G126 (n=44), (b) LTS (TS ≥ 0.5, 
n=51), (c) LLD (log D ratio < 1.1, n=119), (d) LCT (n=49), (e) LSDI (TS ≥ 0.5, n=55) and 
(f) G34 (n=44). RMSEP of test set is shown, n is the number of test compounds modelled in 
each approach. Training and test compounds are highlighted as blue and orange, 
respectively. 
 
Figure 4.29. Measured retention time versus predicted retention time via the approximate 
HSM using (a) G126 (n=44), (b) LTS (TS ≥ 0.5, n=51), (c) LLD (log D ratio < 1.1, n=119), 
(d) LCT (n=49), (e) LSDI (TS ≥ 0.5, n=55) and (f) G34 (n=44). %RMSEP of test set is 
shown, n is the number of test compounds modelled in each approach. Training and test 
compounds are highlighted as blue and orange, respectively. 
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Figure 4.30. Comparison of retention time prediction using (a) predicted ' only obtained 
from the G126 model via the approximate HSM and (b) predicted ' obtained from the G126 
model and other four measured solute coefficients via the full HSM. 
Some conclusions can be obtained based on the relatively high errors obtained for the 
G126 model and the previous results of the prediction for Dataset 1. First, it is known that 
QSRR models derived from using a large pool of descriptors often benefit from employing a 
suitable variable selection technique to identify only the most relevant descriptors to improve 
the prediction accuracy [9, 13]. Second, previous results have shown that improvement in 
prediction accuracy can be achieved following compound classification within the dataset to 
identify the most appropriate set of compounds to yield the QSRR model. Third, local models 
often provide better performance of prediction than global models [35, 36].  
A simple approach for filtering compounds in a dataset can be based on structural 
similarities derived from the 2D chemical structure of compounds, using the Tanimoto 
similarity index (the LTS approach). Alternatively, filtering based on a physico-chemical 
property, such as log D (the LLD approach) can be used. Log D was preferred to log P in this 
study in order to take into account the ionisation state of the target compound [8, 37]. In 
implementing either of these two approaches at least five compounds fulfilling the assigned 
criterion for similarity were required for the training set to make a given target compound 
eligible for modelling. As can be seen from Figure 4.28b and 4.28c, predictions of 𝜂′ obtained 
using the LTS approach were superior to those for the LLD approach, with stronger correlation 
(R2 = 0.9387 vs. 0.6860). However, only 51 (out of 148) compounds could be modelled using 
the LTS approach, compared with 119 using the LLD approach, because in many cases a 
training set of 5 compounds having TS ≥ 0.5 could not be identified. Additionally, in a manner 
similar to the Global model (G126), the accuracy of retention time prediction in both 
approaches appeared to be markedly higher for compounds that were eluted early (Figure 
4.29b and 4.29c). Nevertheless, the average prediction error obtained using the LTS approach 
translated to about 70 s in retention time, which is reasonably promising to facilitate early 
prediction of co-elution of compounds, provided there are sufficient similar compounds (with 
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pairwise TS index of at least 0.5) to each new target in the dataset. Previous results have also 
showed that even smaller prediction errors can be expected for similarity thresholds greater 
than 0.5 [8, 13].  
As an alternative to the localisation of modelling by deriving one model for each 
individual eligible compound in the dataset, one model can be derived for each group of 
similar compounds in the database. The immediate benefit of this approach is a reduced 
demand for computational resources since fewer QSRR models need to be derived. It has been 
shown in section 4.2.3 that a simple classification approach could be based on the type (or 
chemical nature) of compounds (i.e. division of compounds in the database into acids, bases 
or neutrals) [3]. This approach is referred to as the LCT approach. As can be seen in Figure 
4.28d and 4.29d, the overall accuracy of using three QSRR models derived from these three 
clusters of compounds appears to be notably better than the Global model (G126) derived 
without filtering, being evident from smaller prediction errors and relatively lower scatter of 
data points. The prediction accuracy given by this method (%RMSEP = 23.18) is also better 
than the LLD approach (%RMSEP = 36.87) but is just slightly inferior to the LTS approach 
(%RMSEP = 17.53). However, the advantage of the LCT approach is the simplicity of 
compound classification as compound groups are made simply by inspecting the chemical 
structure of compounds and calculating pKa values. 
 
Figure 4.31. Comparison between the LCT (right of compound ID) and the LSDI (left of 
compound ID) approaches in allocating compounds. 
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Results obtained for the LCT approach suggested that more localisation of modelling, by 
identifying more clusters from the dataset, might improve the overall prediction accuracy. As 
described previously, a compound classification based on the secondary dominant interaction 
can be used as an underlying premise for a filtering approach (the LSDI approach). Figure 
4.31 summarises a comparison between the LCT and the LSDI approaches in allocating 
compounds to different clusters. As can be seen, most neutral compounds are distributed 
almost equally between ' and σ' clusters. Two other neutral compounds together with two 
weak bases create the β' cluster, while the α' cluster comprises both neutral compounds and 
undissociated acids. Strong bases create the κ' cluster, whereas the remaining weak bases 
together with some acids and neutrals were not assigned to any cluster in the original study, 
based on the conclusions that their retention was affected by more than one secondary 
interaction and they could not be allocated with confidence to a specific cluster [15]. These 
compounds comprise cluster 6 of the LSDI approach. As can be seen from Figure 4.28e and 
4.29e, considerable improvement in prediction accuracy compared to the Global method was 
again achieved using this approach.  More specifically, the much lower deviation of data 
points from the correlation line and an %RMSEP of 21.91 in retention time prediction was 
obtained for 27 test compounds from Dataset 1 (Figure 4.32a). Additionally, 28 new test 
compounds (out of 57) from Dataset 2 that were able to be modelled following the restrictions 
imposed using this approach (i.e., TS ≥ 0.5), exhibited excellent prediction accuracy for all 
but the two most retained compounds (%RMSEP = 19.66, Figure 4.32b). It is to be hoped that 
with a larger database containing more compounds with longer retention times, the overall 
error would be diminished due to increased similarity between compounds. Also, as can be 
seen in Figure 4.33, while there does not appear to be any strong correlation between absolute 
prediction error in ' and pairwise TS score, the magnitude of the error remains consistent 
only at similarities greater than 0.5. This supports previous studies suggesting a TS threshold 
of 0.5 as a minimum for a reliable prediction in TS-based QSRR modelling [8, 13].  
Residual plots of QSRR models using different approaches have been created. Figure 4.34 
shows the residuals on the vertical axis and the independent variable (measured tR) on the 
horizontal axis. The residual plots for the Global models, and the LLD model, are reasonably 
evenly distributed around the x-axis with a slight bias towards higher retention times. The 
LCT shows that early eluted compounds are somewhat better predicted than later eluted 
compounds. However, the LTS and the LSDI have a more even distribution of residuals, 
showing a better overall prediction. 
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Figure 4.32. Retention prediction using the LSDI approach via the approximate HSM for (a) 
27 test compounds from Dataset 1 and (b) 28 new test compounds from Dataset 
2. %RMSEP of test set is shown, n is the number of test compounds modelled. Training and 
test compounds are highlighted as blue and orange, respectively. 
 
 
Figure 4.33. Correlation between absolute error in ' and pairwise Tanimoto similarity (TS) 
score. 
 
 
Figure 4.34. Residual plots of QSRR models for retention prediction using different filtering 
approaches. Training and test compounds are highlighted as blue and orange, respectively. 
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Table 4.4. Summary of descriptors selected from the LSDI approach 
Clusters Descriptors 
η' MetStab' 'WO1' 'WO2' 'WO3' 'LgD9' 'DRDRDO' 'CW1' 'LgD8' 'CD2' 
σ' WO1' 'WO2' 'LOGP c-Hex' 'L3LgS' 'DRACDO' 'SKIN' '%FU10' 'MetStab' 'LgD7' 
β' DD4' 'WN1' 'W3' 'D1' 'LOGP c-Hex' '%FU5' 'D2' 'WN2' 'SKIN' 
α' LgD10' 'LgD9' 'PB' 'LOGP c-Hex' 'LgD5' 'DD1' 'HSA' 'AUS7.4' 
κ' S' 'G' '%FU7' 
cluster 6 LgD5' '%FU8' '%FU7' 'L4LgS' 'LOGP c-Hex' 'L1LgS' 
Further examination of the six QSRR models derived following the LSDI approach 
revealed that 34 descriptors were selected by at least one of these models (Table 4.4). This 
suggested that the reduction in error could be due to the selection of specific descriptors rather 
than the local modelling. Therefore, another global PLS model was derived using only these 
34 selected descriptors and 70% of the combined dataset as the training set, and was tested 
using the remaining 30% of compounds as the test set. To avoid ambiguous terminology, this 
model is called Global 34 (G34). As can be seen in Figure 4.28f and 4.29f, the prediction 
accuracy of the G34 was far inferior to the overall accuracy of the six local models (Figure 
4.28e and 4.29e) despite using the same set of significant descriptors. This comparison reveals 
the significant advantage of localisation of modelling following an appropriate filtering 
approach over the global counterpart as the classical approach in QSRR modelling. 
4.3.5 Regression Error Characteristics  
REC curves provide a valid comparison of the performance of regression models by 
plotting the error tolerance against the percentage of data points predicted within the tolerance, 
which is here called the prediction frequency. One can quickly assess the relative merits 
between various regression models and with the null model by examining the relative position 
of their REC curves [30].  
Figure 4.35 illustrates the REC curves obtained for all the derived models, as well as the 
null (baseline) model and the ideal model (obtained using the approximate HSM and 
experimental (rather than predicted) ' values). As can be seen, all the developed QSRR 
models are significantly more predictive than the null model but are inferior to the ideal model, 
which exhibits prediction errors less than 30s for nearly 95% of the compounds. In comparison, 
QSRR models obtained following LSDI, LCT and LTS approaches give similar performance 
to each other, with a 30s prediction error being achieved for about 70% of the test compounds 
for each approach. Using a 60s prediction error as criterion, the LSDI approach was slightly 
superior to the LCT and LTS approaches, with less than 60s prediction error being observed 
for about 83% of test compounds. As expected, the remaining models, i.e. the models derived 
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from the LLD approach, and the Global models derived using 126 and 34 selected descriptors, 
were all clearly inferior to the local models and exhibited a prediction accuracy of less than 
30s for only 50% of the test compounds which could be modelled. 
 
Figure 4.35. REC curves of test compounds comparing the performance of derived models 
with the null model and the ideal model. The null model was obtained using the mean of the 
dependent variable (response) as a naïve predicted value for all compounds. The ideal model 
was obtained using the approximate HSM and experimental (rather than predicted) ' 
values. 
4.3.6 Sum of Ranking Difference analysis  
Another overall performance comparison of the proposed approaches can be undertaken 
using sum of ranking difference (SRD) analysis which has been used for comparison of QSRR 
models, as well as for other diverse fields [32]. In this work, objects including R2, Q2, 
the %RMSEP of the test set, and the slope of the regression line were selected and evaluated 
(Table 4.5).   
Table 4.5. Input matrix with nine objects and six variables (models) for the Sum of Ranking 
Difference (SRD) analysis 
Analyte G126 G34 LTS LLD LCT LSDI 
Gold 
Standard 
R2 0.7005 0.5395 0.9189 0.676 0.824 0.9232 0.9943 
Q2 0.6844 0.5523 0.9100 0.6697 0.8173 0.9234 0.9922 
slope  0.6284 0.6096 1.0097 0.6695 0.7629 0.9450 1.0000 
RMSEP% 24.27 31.56 17.53 36.87 23.18 20.79 4.37 
no. of test compounds 44 44 51 119 49 55 148 
no. of descriptors used 126 34 45 22 7 7 7 
no. of models constructed 1 1 51 119 3 6 1 
Prediction frequency with 
absolute error < 30s 
0.49 0.49 0.49 0.67 0.71 0.71 0.94 
Prediction frequency with 
absolute error < 60s 
0.68 0.71 0.79 0.64 0.79 0.83 0.97 
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Moreover, as the applicability of each proposed approach is also important, the number of 
test compounds, the average number of descriptors used for modelling, the number of 
constructed models for each approach and the prediction frequency with absolute error less 
than 30s and 60s based on the REC curves were also taken into account. A given benchmark 
generated from the ideal correlation obtained using the approximate HSM and experimental 
' values was used as the gold standard.  
An overview of the ranking and probability level can be seen from Figure 4.36. The LSDI 
and LCT approach were ranked closest to the gold standard, which demonstrated that these 
two approaches provided slightly better performance than others and were practically 
indistinguishable from each other. The LTS approach was ranked third, but still superior to 
the Global models and the LLD approach. It is not surprising to see that the LLD approach 
ranked last given the prediction accuracy that was obtained. However, the SRD values for all 
models were still smaller than those for 95% of models created from randomly ranked 
numbers, indicating that all proposed approaches can be considered to be predictive. While 
the LSDI approach provided high prediction accuracy, the allocation of new target compounds 
to LSDI clusters requires experimental work, which dramatically limits the advantages of the 
approach. The LCT approach is therefore a more practical and straightforward method, since 
it is easy to allocate new compounds to clusters. Furthermore, for the databases used in this 
study, the LCT approach could be applied to 148 compounds, compared to 121 for the LSDI 
and 51 for the LTS approaches.  
 
Figure 4.36. SRD-CRRN test results of the data matrix given in Table 4.5. SRD values are 
plotted on x axis and left y axis, right y axis shows the relative frequencies (%). 
4.3.7 Molecular descriptors  
One distinctive feature of VolSurf+ descriptors is their versatility and ease of 
interpretation given that their calculation is based on generic physico-chemical properties of 
molecules [38]. Another advantage of VolSurf+ descriptors over other descriptor generator 
platforms is that all the prerequisite steps before descriptor calculations, including 3D 
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structure generation, conformational analysis and geometry optimisation are performed 
automatically by the software, making descriptor calculation both user- and platform-
independent and therefore less prone to error. In addition, the number of generated descriptors 
is much less than other platforms, so a descriptor selection method like GA-PLS can be 
performed simply and rapidly. 
 
Figure 4.37. PLS variable importance to projection for the optimised GA-PLS models 
generated for the LSDI model. 
 
Figure 4.38. PLS variable importance to projection for the optimised GA-PLS models 
generated for the LCT model. 
Table 4.4 summarises the 34 unique descriptors selected by at least one of the six QSRR 
models derived from the LSDI approach, many of which were also found in common with the 
LCT approach. The variable importance to projection (VIP) plot (Figures 4.37 – 4.38) shows 
the relative importance of each descriptor in the optimised GA-PLS models. Not surprisingly, 
the strongest correlations are observed for log D descriptors. Other significant descriptors with 
more apparent contribution to the RPLC retention mechanism include log P, H-bond donor 
volumes (WO), the percentage of unionised species at different pH (%FU), descriptors 
representing hydrophilicity/hydrophobicity or in direct relationship with them, including the 
accessible surface area of the molecule by water as a hydrophilic probe (S), molecular 
globularity (G), which represents both molecular bulkiness and molecular flexibility, 
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descriptors relating to the hydrophilic volume (W and CW), the hydrophobic volume (D, DD 
and CD).  
4.3.8 Co-elution prediction using the proposed QSRR method 
The primary objective in this study of QSRR modelling of retention time was its 
subsequent use for predicting retention times of compounds based on their chemical structure. 
Since Dataset 1 involves 88 compounds and 10 reversed-phase columns, it is possible to 
evaluate the application of retention prediction on a range of columns. Five representative 
compounds, 2-nitrobenzoic acid, 2,5-dinitrophenol, N-butylaniline, toluene and p-
chlorotoluene were selected. It is noteworthy that these test compounds include acidic, basic 
and neutral compounds. The retention of these compounds was modelled on nine of the ten 
columns in the dataset as the YMC Pack Pro C18 column (column number 9 in Wilson’s work) 
was excluded since the retention times of 2,5-dinitrophenol and N-butylaniline were not 
available for that column [14, 15]. Predicted ' coefficients of the five compounds obtained 
using the LSDI QSRR model were used to predict retention times and Table 4.6 lists the 
predicted and actual retention times on nine columns. Predicted chromatograms of the five 
compounds on the nine columns were simulated using Microsoft Excel Macros [39] and two 
examples of the simulated chromatograms, together with the actual retention time of each 
compound, are shown in Figure 4.39, with the remaining chromatograms being shown in 
Figure 4.40. In all cases, the predicted retention times were very close to the actual retention 
times. The accuracy of retention prediction using QSRR combined with the approximate HSM 
indicates that this approach is appropriate for determining the potential of co-elution of the 
target compounds, based only on their chemical structures. 
 
Figure 4.39. Simulated chromatograms of five representative compounds on column 2 
(Symmetry) and column 5 (SB-300). The red lines represent the actual retention times. 
Numbering of representative compounds in graph: 1, 2-nitrobenzoic acid; 2, 2,5-
dinitrophenol; 3, N-butylaniline; 4, toluene and 5, p-chlorotoluene. 
Chapter 4    Retention prediction in reversed-phase liquid chromatography using quantitative 
structure-retention relationships: application to the Hydrophobic Subtraction Model 
120 
 
Table 4.6. Experimental and predicted retention time (s) of five representative compounds 
on nine columns (C1 to C8, and C10) 
Representative 
compounds 
C 1 C 2 C 3 C 4 C 5 
Exp Pred Exp Pred Exp Pred Exp Pred Exp Pred 
2-nitrobenzoic acid 85 85 75 77 67 69 70 72 68 68 
2,5-dinitrophenol 184 171 155 145 129 122 135 127 91 88 
N-butylaniline 375 373 310 312 243 245 248 249 127 130 
toluene 479 481 405 404 305 311 307 313 148 151 
p-chlorotoluene 762 768 642 652 471 484 470 481 201 204 
Representative 
compounds 
C 6 C 7 C 8 C 10   
Exp Pred Exp Pred Exp Pred Exp Pred   
2-nitrobenzoic acid 66 69 84 86 81 84 81 83   
2,5-dinitrophenol 132 125 168 157 161 152 129 125   
N-butylaniline 265 259 328 322 320 313 218 220   
toluene 329 333 405 411 392 400 269 271   
p-chlorotoluene 515 530 638 645 611 633 401 405   
 
Figure 4.40. Simulated chromatograms of five representative compounds on the remaining 
seven columns. The red lines represent the actual retention times. Numbering of 
representative compounds in graph: 1, 2-nitrobenzoic acid; 2, 2,5-dinitrophenol; 3, N-
butylaniline; 4, toluene and 5, p-chlorotoluene. Numbering of columns in graph: 1, Inertsil; 
3, SB-100; 4, SB-90; 6, Eclipse; 7, YMC 15; 8, YMC 16 and 10, Discovery. 
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4.3.9 Retention prediction for new compounds using the proposed QSRR method 
Given the robust performance of the constructed QSRR models with the five 
representative compounds selected from the database, the predictive ability for new 
compounds that have never been used in the modelling process was also investigated. To 
achieve this, five analytical grade compounds including an acid, a base and three neutral 
compounds were selected and purchased from Sigma-Aldrich (St. Louis, MO, USA): pindolol, 
1, 8-dihydroxynaphthalene, 4-ethylnitrobeneze, 2-phenylbutane and 4-heptylbenzoic acid.  
The columns employed in this study were all obtained from Thermo Fisher Scientific, an 
AcclaimTM 120 C18 column (4.6 × 150 mm, 5.0 μm); an Accucore C18 column (4.6 × 150 
mm, 2.6 μm); a Hypersil GOLD C8 column (4.6 × 150 mm, 5.0 μm); a Hypersil GOLD C18 
column (4.6 × 150 mm, 5.0 μm) and a Hypersil ODS C18 column (4.6 × 150 mm, 5.0 μm). 
The HSM coefficients for the columns used in this work were extracted from the USP website.  
Solute coefficients of η’ for the five new compounds were predicted using both the LCT and 
LSDI approaches. Retention data were collected under the same chromatographic conditions 
as Wilson’s previous work [25]. Uracil was used to determine the void time of the columns. 
Ethylbenzene was chosen as the reference compound for calculation of predicted retention 
times. 
Before approaching QSRR modelling, the five new compounds were allocated into 
clusters. For the LCT approach, pindolol, and 4-heptylbenzoic acid were allocated into the 
base and the acid cluster, respectively, and the other three neutrals were allocated into the 
neutrals cluster. Unlike the LCT approach, for the LSDI filtering, a Tanimoto similarity 
analysis was involved to ensure that the new compounds could be allocated into the correct 
cluster based on structural similarity by finding the nearest similar compound from the 
previously used database. 1, 8-dihydroxynaphthalene and 2-phenylbutane was allocated into 
the η’ cluster, pindolol was assigned into the κ’ cluster, and 4-heptylbenzoic acid and 4-
ethylnitrobenzene was grouped into the α’ cluster and cluster 6, respectively. Their η’ 
coefficients were therefore predicted using the corresponding clusters in the database as the 
training sets. Finally, the predicted η’ coefficients combined with the available column 
parameters were fitted into the approximate HSM to yield their retention times, and predicted 
retention times were compared to the measured retention times. 
Table 2.9 in Chapter 2 lists the measured retention times of the five new representative 
compounds on the five columns used for data collection. Figure 4.41 shows the correlation 
between the predicted and measured retention times of the five compounds using the LCT and 
the LSDI approaches, respectively. As can be seen, good correlations were observed for both 
cases with R2 of 0.9634 and 0.9861, respectively. In terms of prediction error, the LCT 
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approach generated a %RMSEP of only 15.41, superior to the LSDI approach with 
a %RMSEP of 28.67. The powerful performance of the models illustrates the feasibility of 
using the proposed approaches to predict retention for new compounds. As mentioned 
previously, compared to the LSDI approach, the LCT is a straightforward method where 
training sets can be formed easily based on the compound’s type. However, the LSDI approach 
requires further allocation of test compounds to choose the correct training set for modelling, 
which increases the complexity of the application. 
 
Figure 4.41. Comparison of retention time prediction for five new compounds on five 
columns using (a) the LSDI approach and (b) the LCT approach via the approximate HSM. 
4.4 Conclusions 
This study has evaluated the feasibility of utilising the HSM and QSRR for predicting 
retention times in RPLC. This was achieved through modelling only the solute coefficient ' 
representing compound hydrophobicity in the HSM. It was shown that modelling other solute 
coefficients in the HSM is not necessary to achieve sufficient prediction accuracy. The 
resources of molecular descriptors have almost no contribution to the performance of 
predictive ability for the constructed QSRR models. Different approaches were used for 
filtering the dataset to derive local models. Results showed improvement in prediction 
accuracy for the LSDI, LCT and LTS approaches compared with global models derived from 
the whole dataset without filtering. Of these approaches, the LCT exhibits advantages in its 
ease of application and the larger number of compounds which can be modelled using this 
approach. However, the LTS approach was the simplest to apply and provided that there was 
a sufficient number of similar compounds in the dataset which met the TS score cut-off, it 
yielded sufficiently accurate results.  
It is recognised that modelling based only on ' can predict only the hydrophobic 
selectivity of compounds and that the predicted elution order of target compounds is 
determined solely by their ' values. Nevertheless, the predictions reported here show 
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sufficient accuracy to meet the major objective of this study, namely to determine the 
likelihood of co-elution of compounds. Future work includes improving the prediction 
accuracy of the models by including descriptors from other resources, modelling more of the 
HSM coefficients to better describe selectivity, and using more advanced filtering approaches, 
such as dual-filtering [9]. The scope of modelling can also be expanded by investigating more 
columns and including more compounds of greater Tanimoto similarity in the database. With 
column coefficients being already available for nearly 700 commercial C8 and C18 phases, 
the proposed approach is anticipated to assist drug development in the pharmaceutical industry 
and to find application in other industries. 
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5 Retention Index Prediction to Improve Structure Identification in Non-
Targeted Metabolomics 
5.1 Introduction 
Targeted and non-targeted strategies are involved in metabolomics studies [1-3]. For the 
targeted strategy, the known metabolites are often measured quantitatively based on the 
predefined metabolite-specific signals [2, 3]. In contrast, all the unknown metabolites present 
in a sample of interest need to be measured in non-targeted metabolomics (NTM) which 
involves high-throughput and comprehensive analysis. Therefore, additional methods for the 
subsequent interpretation by means of in silico or experimental routines must be employed [2, 
4]. For example, analytical platforms like nuclear magnetic resonance spectroscopy (NMR) 
and mass spectrometry (MS) coupled to liquid chromatography as a separation technique, 
have enabled rapid detection in NTM for a large number of metabolites [5, 6]. For the non-
targeted strategy, many steps are involved including sample selection, sample analysis, data 
treatment, and metabolite identification ,which is the ultimate goal in NTM, allowing 
analytical data to be converted into meaningful biological knowledge [7, 8]. However, a 
confident metabolite identification requires significant effort compared to the targeted strategy 
given the fact that the unknown metabolites cover a diverse chemical space in NTM [5, 9]. 
Although advanced strategies like MS/NMR can provide much information to speed up the 
identification of metabolites, authentic pure chemical standards are still needed for 
unequivocal identification in NTM [4, 10]. Until now, confident metabolite identification is 
still a bottleneck because it is often time-consuming, costly, and frequently unsuccessful. The 
process of metabolite identification in NTM is complex and highly dependent on the 
robustness of the analytical techniques applied, as well as the databases and resources utilised 
for mass-based searching [3, 4, 11].  
An advantage of the LC-MS-based technique in NTM is that it increases the possibility of 
metabolite identification with a combination of sensitivity and selectivity [6, 12, 13]. There 
are several steps of metabolite identification in LC-MS-based NTM analysis. Firstly, an 
accurate mass of the eluted metabolite is identified based on a target peak displaying 
metabolomics information. Then, the potential molecular formulae corresponding to the target 
peak are defined through mass-based searching using electronic resources like the Human 
Metabolome Database (HMDB), METLIN, LMSD, MassBank, RIKEN and PubChem [1, 8]. 
Finally, the returned matches based on the exact mass of the metabolite then can be identified 
and confirmed using additional experimental data. This routine method has been used years 
for the identification of metabolites in NTM, however, a limitation still exists. For example, a 
candidate compound corresponding to the exact mass may not be found, or in many cases, an 
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excessive number of candidates may be returned, which means that eliminating these false 
positives is necessary [4, 6, 14]. The candidate metabolites often behave similarly with respect 
to their exact mass but differently in biological systems, which increases the probability of 
misidentification [5, 15].  
Chromatographic retention, a specific property that is readily available for LC-MS-based 
data, has been used as a feature for the identification of metabolites. For example, Kaliszan’s 
group has used retention comparison to remove false positive identifications during the 
interpretation of metabolomics data in the area of doping control [4]. Moreover, Aicheler and 
co-workers have improved the identification rate in non-targeted lipidomic approaches by 
using a retention time filter to reduce the rate of false positives [1]. There is a strong demand 
for a tool to predict chromatographic behaviour, and as a result, to identify new analytes and 
their metabolites [4, 8, 16, 17]. These objectives can be achieved using a combination of 
analytical routines and chemometric techniques, and quantitative structure–retention 
relationship (QSRR) modelling is a promising solution from a variety of chemometric 
methods [4, 18-22]. 
One of the aims of QSRR is to quantitatively determine the relationships between 
chromatographic retention parameters and compound structures [20, 23, 24]. Usually, QSRR 
models are built as functions of molecular descriptors that are generated based on the 
structures of compounds [25, 26]. Besides retention prediction, QSRR also plays an important 
role in other fields like column characterisation [20, 21], the interpretation of retention [4, 26], 
and column selection (equivalent or orthogonal) [27, 28]. Given the strong performance of 
retention prediction, QSRR combined with high resolution mass spectrometry (HRMS) has 
been considered a powerful tool in metabolite analysis [4].  
Some commercial software packages such as  Chromsword (Merck KGaA, Darmstadt, 
Germany) [22, 26] or ACD/ChromGenius (ACD/Labs, Toronto, Canada), provide a limited 
number of molecular descriptors that are used to build QSRR models. As an alternative, a 
large pool of molecular descriptors can be calculated which provides more options for the 
construction of QSRR models [20, 22, 23]. By employing more molecular descriptors into the 
models, a risk of over-fitting needs to be addressed considering the fact that too many 
descriptors can introduce noise to the models [26, 29]. As a solution, an appropriate regression 
method in combination with a variable selection procedure can be used during the QSRR 
process, allowing only the most informative molecular descriptors to be used. Partial Least 
Squares (PLS), is particularly useful in handling datasets with a high number of variables 
compared to the number of objects, and in the presence of co-linear, redundant, and noisy 
variables [20, 26, 29]. In addition, as reported, the use of a Genetic Algorithm (GA) as a 
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variable method has shown superiority in terms of prediction accuracy and robustness of 
constructed QSRR models compared to other optimisation algorithms [24, 29]. Therefore, the 
performance of QSRR models in terms of predictive capacity can be improved significantly 
by employing a suitable variable selection method [29].  
In Chapters 3-4 and in previous QSRR studies by the Haddad group, a variety of models 
have been built for retention prediction by a linear modelling technique, using partial least 
squares regression combined with a genetic algorithm as the variable selection method [20, 
22, 23, 26]. In this chapter, retention index (RI) prediction QSRR models are examined that 
offer useful predictive ability for compounds having the same molecular weight, allowing 
false positives to be removed during the interpretation of structure identification in NTM. A 
novel dual-filtering approach combining structural similarity and chromatographic similarity 
has been employed to build suitable training sets for target analytes for the accurate prediction 
of RI. The elimination of false positives from the list of potential candidate compounds 
produced by exact mass database searches is demonstrated using the proposed QSRR 
approach. 
5.2 Materials and methods 
5.2.1 Datasets 
A database originally used by Hall et al. to derive artificial neural network QSRR models, 
consisting of 1882 compounds for which retention index information and mass values are 
reported, was used in this study (more detail of the 1882 compounds can be found in Appendix 
1, Chapter 2) [8]. In his work, they defined the RI value at the retention time of each nitro-n-
alkane as 100 times the number of carbon atoms in the respective nitro-n-alkane reference 
compound [8]. For the original data collection, compound mixtures were analysed by 
HPLC/MS, where an Agilent 1100 HPLC (Agilent, Santa Clara, CA, USA) system interfaced 
to a QTOF-2 mass spectrometer (Waters Associates, Beverly, MA, USA) were used [8]. A 
Zorbax SBC18 (1 mm × 150 mm, 3.5 um particle size) column combined with a Zorbax Stable 
Bond (1 mm × 17 mm, 5 mm particle size) OptiGuard precolumn were used for the separation 
[8]. Finally, retention index (RI) values of compounds in the database were determined 
experimentally and the values of RI for the database compounds exhibited a wide range from 
204 to 1041.  
The Tanimoto similarity analysis of this database indicates a large diversity in the 1882 
compounds although some isomers are found. In order to evaluate the performance of the 
established QSRR models in eliminating false positives having the same mass as the target 
metabolite, groups of representative compounds with the same mass values were selected from 
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the Hall et al. database. In all, 34 groups of compounds (see Table 2.8 in section 2.1.2, Chapter 
2) were chosen, with at least five compounds having the same mass value in each group.  
5.2.2 Calculation of the molecular descriptors 
Molecular descriptors were calculated from the canonical simplified molecular-input line 
entry system strings (SMILES) of compounds using VolSurf+ 1.0.7.1 software (Molecular 
Discovery Ltd., Hertfordshire, UK) at a user-defined pH (pH=2.5). The process of the 
calculation has been detailed in section 2.3.2, Chapter 2. In all, 128 molecular descriptors were 
calculated following the 3D structure conversion and conformational analysis of structures. 
All descriptors were auto-scaled (i.e., to have zero mean and unit variance) before use for 
modelling process.  
5.2.3 Dual-filtering 
Local modelling was used throughout this study, wherein the training set of compounds 
used for QSRR modelling, and the QSRR model itself, were unique for each target compound 
for which retention index was predicted. The training set of compounds was identified using 
a modification of a published procedure [22, 30] where an initial subset of compounds was 
identified using a Tanimoto Similarity Index filter, followed by a secondary filter based on RI. 
For each target compound, a Tanimoto similarity analysis of the 1882 compounds in the Hall 
et al. database was carried out first using JChem for Excel (ChemAxon, Budapest, Hungary), 
and filtering was performed by sorting the database compounds based on their pairwise TS 
index in relation to the target, with the compounds having pairwise TS indices of at least 0.5 
being selected as an initial training subset [26]. A correlation analysis between molecular 
descriptors and RI values was then performed for compounds in this initial training subset to 
find the descriptor which was most correlated to RI (correlation coefficient > 0.8). The initial 
training subset of compounds was then ranked according to the absolute difference in the value 
of the chosen descriptor between the initial dataset compounds and the target compound [30]. 
The initial training dataset compound having the lowest difference was identified as the 
nearest neighbour compound to the target analyte. The RI-ratio between the nearest neighbour 
compound and each initial training dataset compound was then calculated and a filter applied 
by retaining in the final training dataset only those compounds having a RI-ratio of ≥1.1 to the 
nearest neighbour. This dual-filtering process, which is illustrated schematically in Figure 5.1, 
ensured that the training set used in the QSRR modelling consisted only of those compounds 
which are structurally and chromatographically similar to the target analyte. This has been 
shown to greatly improve the accuracy of QSRR predictions [30].  
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Figure 5.1. Schematic diagram of the dual-filtering process used in the present study. 
5.2.4 QSRR modelling 
The QSRR models predicting retention index as a function of selected molecular 
descriptors were obtained via partial least squares regression in combination with a genetic 
algorithm as the variable selection method. A popular version of a GA-PLS algorithm was 
used for the QSRR modelling process including descriptor selection and retention index 
prediction, as described in section 2.3, Chapter 2.  
5.2.5 Statistics 
The coefficient of determination (R2) between the predicted and the experimental RI was 
calculated by constructing the corresponding scatter plot and performing a linear regression 
in Excel. The slope of the regression with no forced intercept was also generated with the 
requirement to be within the range of 0.85 to 1.15 [22, 26]. The percentage root-mean-square 
error of prediction (RMSEP%) of retention index for the test analyte was measured to 
externally validate the accuracy of GA-PLS models generated from the training set (see 
section 2.3.6, Chapter 2).  
5.3 Results and Discussion 
5.3.1 Prediction of retention index using a dual-filtering approach 
Chapters 3 – 5, and previous work from the Haddad group have shown the superiority of 
localised models compared to global models for improving the accuracy of QSRR models [21-
23, 26]. Here, a local model refers to the fact that for each compound studied, a unique QSRR 
model is derived. Thus, in this study, localised QSRR models were built for the 248 
representative compounds, and subsequently their RI values were predicted. Specifically, each 
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representative compound was used successively as a test analyte by removing it from the 
dataset and then a training set was formed for model construction using the dual filter 
described under Materials and Methods [22, 26].  
Tanimoto similarity (TS) searching as a filter to yield training sets has been used 
successfully for retention prediction in reversed-phase liquid chromatography (RPLC), 
hydrophilic interaction liquid chromatography (HILIC) and ion chromatography (IC) [21-23, 
26]. Previous studies suggest that a training set comprising database compounds having a TS 
threshold of 0.5 (compared to the target analyte for which the QSRR model is to be derived) 
is the minimum necessary for a reliable prediction in TS-based QSRR modelling, with a higher 
TS similarity threshold leading to even greater accuracy of retention prediction [20, 22]. The 
accuracy of retention prediction for TS-based models can meet the requirement to speed up 
the process of chromatographic method development [20, 26], but for metabolomics studies, 
a more accurate prediction is highly desirable so that more false positives can be eliminated 
[1, 4].  
In this thesis, and in previous studies by the Haddad group, in order to improve the 
performance of QSRR models, the role of chromatographic similarity has been investigated 
to define the optimal training set of compounds using as a filter the ratio between the retention 
time of the target compound and database compounds, with excellent prediction accuracy 
being obtained [21, 22, 31]. However, retention filtering is not applicable practically as the 
retention time for the target analyte must be known.  For this reason, it becomes necessary to 
identify a “nearest neighbour” database compound which shows the most similar retention 
behaviour to the target compound in order to perform retention filtering. This approach has 
proved to be successful in HILIC, where a dual-filtering approach which combines the concept 
of structural similarity and chromatographic similarity was created for retention time. The 
developed dual-filtering-based QSRR models improved the retention predictability 
significantly with an average root mean square error in prediction (RMSEP) of 11.01% being 
observed [30]. Therefore, in the present study, a similar dual-filtering strategy which 
combined TS searching as the primary filter and RI similarity searching as the secondary filter 
was employed to yield suitable training sets for the generation of localised QSRR models. 
The proposed dual-filtering strategy involves TS searching of the full Hall et al. database 
first, followed by RI similarity searching of the initial training dataset identified by Tanimoto 
similarity using the nearest neighbour in the initial training subset instead of the target analyte 
itself, to construct the final training dataset. The QSRR models were then derived using the 
dual-filtered training set for the consequent prediction of the RI of the target compound. A 
comparison between the measured and predicted RI values using the dual-filtering-based GA-
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PLS models with the corresponding %RMSEP is depicted in Figure 5.2. In the present study, 
248 compounds forming 34 representative groups sorted by molecular weight were selected 
for modelling and 191 of those compounds were able to be modelled using the dual-filtering 
approach. For the remaining 57 compounds training sets were not able to be formed as five 
similar compounds to the surrogate compound were not found. 
 
Figure 5.2. Predictive ability of dual-filter-based QSRR models for 191 analytes. For 91% 
of compounds (173/191) the experimental RI falls within the prediction filter (highlighted as 
blue). For 9% of predictions (18/191) the experimental RI falls outside the prediction filter 
(highlighted as red). 
As shown in Figure 5.2, the predicted RI values generated using the dual-filter-based 
QSRR models were very well correlated with the measured data, presenting a %RMSEP value 
of 8.45% (which corresponds to a MAE of 33 and a standard deviation of 46). The distribution 
of the prediction errors of the 191 compounds is shown in Figure 5.3a and can be seen to be 
normally distributed. RI values of 89 compounds (46.6%) were predicted with an absolute 
prediction error less than 20, while 158 compounds (82.7%) were modelled with absolute 
prediction errors of less than 60. In addition, a residual plot of QSRR models using the dual-
filtering approach has been created, showing that the linearity of the equation is supported by 
the uniform distributions of residuals (Figure 5.3b), where the residuals are on the vertical axis 
and the independent variable (measured retention index values) is on the horizontal axis. The 
distribution of the residuals on both sides of the zero line indicates that there is no systematic 
error in the obtained QSRR models.  
 
Figure 5.3. The distribution of prediction errors (a) and residual plot of prediction errors (b) 
using dual-filter-based GA-PLS models for 191 test analytes. 
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5.3.2 Retention index prediction filter 
Given the strong overall performance of the constructed QSRR models using the dual-
filtering approach, an evaluation was undertaken of the utility of the proposed QSRR protocol 
for the identification of compounds that are encountered during the interpretation process in 
non-targeted metabolomics. Here, RI provides information orthogonal to mass, making it 
possible to identify compounds from the list of candidates that have the same exact mass as 
the target metabolite based on the predicted RI, provided this prediction is sufficiently accurate. 
To achieve this, an appropriate filter range of RI for eliminating false positive identification 
is needed. Given that the population of errors of prediction is normally distributed (see Figure 
5.3a), therefore 95% of the errors will fall within the range of ± 2 standard deviations from 
the mean error. The mean error and the standard deviation of the population of prediction 
errors were calculated, and a window of RI was then placed around each predicted retention 
index value (predicted RI ± 2 SD) as a filter.  
Of the RI predictions, 91% were found to fall within the ± 2 SD filter (173 out of 191 
compounds), 9% of predicted retention indices fell out of the filter range (18 out of 191 
compounds) and are highlighted in red (see Figure 5.2). Scattered data points out of the filter 
range were poorly predicted with an average MAE of 111, the worse prediction of those data 
points may be due to the insufficient similarity of compounds in each training set to the target 
analyte, as the average TS index of those training sets was just slightly greater than 0.5, which 
was the minimum threshold of structural similarity in the dual-filtering approach. 
5.3.3 Elimination of false positives   
Database searching based on the exact mass is essential during the structure identification 
process in NTM. One of the dilemmas encountered in mass-based searching is that it may 
return false positives for metabolites with the same mass as the target metabolite but different 
behaviour in biological (and chromatographic) systems. Such false positives can be removed 
using the predicted retention filter, therefore narrowing down the number of candidates and 
accelerating the process of identification. In the present study, compounds with identical mass 
values were chosen to demonstrate the elimination of false positives using the ± 2 SD filter 
range. For each candidate molecule suggested from the mass database search, RI was predicted 
using the proposed QSRR approach and the predicted RI was compared with that of the target 
metabolite using the ± 2 SD filter range. Candidate molecules falling outside the RI filter range 
were classified as false positives on the basis of their RI values.  
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Figure 5.4. An example of the application of the retention index filter to eliminate false 
positives. 
Figure 5.4 depicts the process of elimination of false positives using as an example a target 
metabolite with an observed RI of 727 and a mass of 129.245 au. Possible compounds from 
the database having the molecular weight of 129.245 au are listed in Figure 5.4. The values of 
RI for all of these possibilities were predicted using the dual-filtering approach, then a filter 
range of the predicted retention index ± 2 SD was applied to remove false positives. 
Compound N-isopropyl-N-methyl-tert-butylamine (ID 367) has a predicted RI of 520 and a 
filter range of 427 to 614, so we know that this is not a possibility for the target metabolite as 
the measured RI of the target (727) is outside that range. Similarly, in total, seven false 
positives were removed while only two viable candidates were retained. This filter range has 
been applied to the modelled compounds in each exact-mass group (34 groups in total), and 
53% of groups (18 out of 34) were found where at least one false positive could be eliminated. 
The elimination of false positives for the representative compounds in each group is shown in 
Table 5.1, and more details can be found in Table 5.2. The presented method shows promise 
for using retention predicted by QSRR models for compound identification in non-targeted 
metabolomics since it allows the elimination of false positives and therefore minimises the 
number of candidates corresponding to the target analyte. 
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Table 5.1. False positives elimination using retention index filter for representative 
compounds in each exact-mass group 
MW Target RI No. candidates No. false positives eliminated 
103.121 344 3 1 
108.143 518 4 1 
113.202 509 5 1 
129.245 727 9 7 
133.193 706 7 4 
135.208 705 15 7 
151.165 599 7 3 
151.208 735 6 4 
163.219 608 3 1 
165.191 767 6 4 
175.187 805 4 2 
177.202 603 4 1 
179.218 794 2 1 
187.241 840 3 2 
189.257 977 2 1 
191.229 701 3 2 
215.251 948 4 1 
226.277 928 2 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5    Retention index prediction to improve structure identification in non-targeted 
metabolomics 
136 
 
Table 5.2. Elimination of false positives for representative compounds from 18 groups 
MW ID Measured RI 
Filter range 
Min Max 
103.121 1608 246 120.3 307.5 
1636 278 205.5 392.7 
55 344 229.7 416.9 
108.143 77 404 225.6 412.8 
122 465 403.7 590.9 
218 511 413.9 601.1 
247 518 436.8 624.1 
113.202 211 509 441.3 628.6 
425 563 435.9 623.1 
449 568 503.8 691 
554 593 508.7 695.9 
614 609 576.3 763.5 
129.245 1496 546 477.7 664.9 
367 548 426.8 614.1 
535 586 490.6 677.8 
1518 586 504.2 691.4 
600 606 499.2 686.4 
687 628 520 707.2 
714 638 564.2 751.4 
1526 727 678.7 865.9 
133.193 483 575 501.2 688.4 
520 582 491 678.2 
530 586 495.5 682.7 
550 592 493.8 681 
623 612 548.2 735.5 
652 621 559.4 746.6 
882 706 518.7 706 
135.208 473 573 511.3 698.6 
488 575 518.9 706.2 
523 583 505.5 692.7 
571 598 506.9 694.1 
584 601 517.6 704.8 
597 605 496.7 683.9 
601 606 553.3 740.5 
618 610 521.9 709.1 
1521 612 506 693.2 
676 626 512.5 699.8 
690 629 527.2 714.4 
804 671 520 707.2 
821 681 572.6 759.8 
845 689 562.7 749.9 
879 705 550.6 737.8 
151.165 1648 458 416 603.2 
112 461 381.1 568.3 
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126 467 388.5 575.7 
1679 494 403.2 590.4 
308 538 440.9 628.1 
424 563 489.3 676.5 
1689 599 581.4 768.6 
151.208 1664 560 482.6 669.8 
496 577 503.4 690.6 
598 605 576.4 763.7 
640 617 491 678.2 
737 646 524.3 711.5 
951 735 700.3 887.5 
163.219 417 562 395.5 582.7 
1601 601 534.4 721.6 
609 608 484.1 671.3 
165.191 104 453 439.2 626.4 
1656 521 424.1 611.3 
432 565 439 626.2 
498 577 448.5 635.7 
1691 745 627.7 814.9 
1718 767 616.3 803.5 
175.187 1834 253 204.3 391.5 
1697 678 535 722.2 
945 732 701.7 888.9 
1085 805 670.8 858.1 
177.202 210 509 402.5 589.7 
1796 530 439 626.2 
437 567 518.8 706 
590 603 528.6 715.8 
179.218 341 544 444.7 631.9 
1693 794 643.4 830.6 
187.241 849 691 534.1 721.3 
878 704 542 729.2 
1147 840 742.9 930.1 
189.257 1191 859 783.5 970.7 
1396 977 818.8 1006 
191.229 192 502 401.4 588.6 
572 598 480.7 667.9 
874 701 609.5 796.7 
215.251 1176 854 721.2 908.4 
1260 899 770.9 958.1 
1329 936 803.9 991.1 
1351 948 881.9 1069.1 
226.277 1053 789 640 827.2 
1317 928 815 1002.2 
In many cases the exact-mass groups contained significant numbers of structural isomers 
and the proposed QSRR approach showed limited ability to exclude isomers as false positives 
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as these isomers generally also exhibited similar RI values. For example, 3-aminopyridine, 4-
aminopyridine and 2-aminopyridine all have a mass of 94.1158 au and their RI values were 
447, 456 and 484, respectively. By virtue of their structural and chromatographic similarities, 
such isomers will always be included in the training set. With a ± 2 SD retention index filter, 
no false positives could be removed in these cases.  
5.3.4 Interpretation of selected descriptors 
Starting from 3D maps of interaction energies between the molecule and chemical probes, 
VolSurf+ explores the physico-chemical property space of a molecule [32, 33]. One distinctive 
feature of VolSurf+ descriptors is their versatility and ease of interpretation. VolSurf+ 
compresses the information present in 3D maps into numerical descriptors, thus the 
calculation is based mainly on the generic physico-chemical properties of molecules [32, 34]. 
Another advantage of VolSurf+ over other software packages for descriptor generation is that 
all the prerequisite steps before descriptor calculation, including molecule superposition, 3D 
structure generation and conformational analysis are performed automatically, making 
descriptor calculation both user- and platform-independent and therefore less prone to error 
[32, 35, 36]. In addition, the number of calculated descriptors is much less than other 
commercial tools, so a variable selection method like GA-PLS can be performed simply and 
rapidly [32, 35]. VolSurf+ generates a total of 128 descriptors using different probes including 
OH2 probe, DRY probe, probe O and probe N1, plus non-MIF derived descriptors [32, 34, 
35]. Specifically, a number of blocks of molecular descriptors were calculated and interpreted 
including size and shape descriptors, hydrophobic or hydrophilic regions descriptors, H-bond 
donor/acceptor regions descriptors, charge state and mixed descriptors, as well as 3D 
pharmacophoric descriptors and ADME model descriptors [32, 37-39]. 
A partial least squares regression combined with a genetic algorithm as the variable 
selection method was employed in the dual-filtering QSRR modelling. GA, as an optimisation 
technique inspired by the process of natural selection, has been used commonly to generate 
high-quality solutions to optimisation and search problems by relying on bio-inspired 
operators including mutation, crossover, and selection [40-42]. To avoid losing the most 
relevant and informative descriptors in the present study, the GA was run 100 times from 
different initial populations. After that, the frequency with which each descriptor was selected 
in the top chromosome in each run was calculated, in order to determine the best subset of 
descriptors to be used to build the final model. Finally, the entire process was repeated five 
times and the prediction errors obtained from the generated QSRR models were averaged.  
The presented QSRR analysis yields models incorporating a wide range of VolSurf+ 
descriptors selected by the GA. Since a localised model was built for each target analyte, the 
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frequency of selection and the type of molecular descriptors incorporated in each QSRR model 
vary between target analytes. However, a brief overview of the most frequently selected 
descriptors appearing in the QSRR models is summarised in Table 5.3. The VolSurf+ 
descriptors selected in this work belong mainly to three different blocks: mixed descriptors, 
ADME model descriptors, and descriptors of hydrophobic regions. Not surprisingly for 
modelling based on reversed-phase HPLC data, Log D and Log P descriptors belonging to the 
family of mixed descriptors contribute most to the final QSRR models. Other significant 
descriptors in this family with frequent contribution to the models include the ratio between 
the polar surface area and the surface (PSAR), the hydrophobic surface area (HAS) and the 
average molecular polarizability (POL). The descriptors encoding information on the 
hydrophobic regions are mainly hydrophobic volumes-related. It should be also pointed out 
that the ADME descriptors reflecting the solubility at various pH values (LgS3-LgS11), the 
log Blood-Brain barrier distribution (LgBB), the intrinsic solubility (SOLY), the solubility 
profiling coefficients (L2LgS) and the % of protein binding (PB) were also included. 
Table 5.3. Symbols and description for VolSurf+ descriptors retained most frequently in 
final QSRR models 
Block Symbol Definition 
Mixed descriptors LgD9, LgD7, LgD6, LgD5, LgD10 LogD octanol/water 
LOGP n-Oct LogP octanol/water 
LOGP c-Hex LogP cyclohexane/water 
POL The average molecular 
polarizability 
HAS Hydrophobic Surface Area 
PSAR The ratio between the PSA 
and the S 
Descriptors of 
hydrophobic 
regions 
D1, D3, D6, D8 Hydrophobic volumes 
CD4 Capacity Factor 
ADME model 
descriptors 
LgS11, LgS9, LgS8, LgS7.5, LgS6, 
LgS4, LgS3 
Solubility at various pH 
LgBB Log Blood-Brain Barrier 
distribution 
L2LgS Solubility profiling 
coefficients 
SOLY Intrinsic solubility 
PB % of protein binding 
5.4 Conclusions 
Liquid chromatography-mass spectrometry (LC-MS), as a powerful analytical tool, has 
been used widely in non-targeted metabolomics. The aim of this work was to develop 
appropriate QSRR models which provide sufficient predictive capability to speed up the 
interpretation of structure identification for non-targeted metabolomic research. Here, we 
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show that the QSRR modelling using dual-filtering as the strategy for the generation of 
training sets permits a robust and highly accurate prediction of retention index. GA, as a 
variable selection method to choose the most informative and important descriptors, was 
applied successfully in combination with PLS, to build reliable QSRR models. The obtained 
results demonstrate that the developed QSRR strategy is capable of eliminating false positives, 
thereby increasing confidence of structure identification in MS-based non-targeted 
metabolomics. Future work includes improving the predictive ability of QSRR models by 
employing other molecular descriptors and using advanced similarity filtering approaches to 
generate training sets. The scope of modelling can also be expanded by including more 
compounds of greater structural similarity in the database.  
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6 General Conclusions 
Traditional method development in the pharmaceutical industry is mainly carried out by 
trial-and-error laboratory experimentation, which is time-consuming and costly [1-3]. 
Moreover, given the fact that a wide variety of equipment, columns, eluent and operational 
parameters are involved, this means that the developed chromatographic methods may not be 
inherently robust and can be poorly understood [4, 5]. Within the broad classification of liquid 
chromatography, reversed-phase liquid chromatography (RPLC) is still the most widely used 
separation technique in the pharmaceutical and other industries, but other chromatographic 
techniques including hydrophilic-interaction chromatography (HILIC) or ion chromatography 
(IC) are also frequently used as complementary methods [6-8]. The detailed retention 
mechanism applicable in RPLC has been given intensive study which is useful to the process 
of method development [8, 9], but considering the excessive number of stationary phases 
available for RPLC, method development in RPLC is still a complex task [8, 10, 11]. 
Computer-assisted approaches can accelerate method development by accurately predicting 
the retention of analytes, leading to optimisation of chromatographic performance [12]. There 
is a strong demand for a tool to predict chromatographic behaviour, and as a result, to speed 
up the scoping phase of chromatographic method development [5, 12]. This objective can be 
achieved using a combination of analytical routines and chemometric techniques, and 
quantitative structure-retention relationship (QSRR) modelling, which has been has already 
found some use for retention prediction, is a promising solution from a variety of chemometric 
methods [13, 14]. QSRR methodology aims to find the mathematical relationships between 
the chromatographic parameters and the molecular descriptors that are generated based on the 
structures of the analytes [12, 15, 16]. 
This thesis describes the development of retention prediction models using QSRR 
methodology for a variety of differently structured pharmaceutical compounds and 
commercially available stationary phases employed in the RPLC mode. In addition, the 
application of the proposed QSRR approach in the prediction of co-elution, retention 
prediction for new compounds, and the elimination of the false positives in Non-Targeted 
Metabolomics (NTM) was explored and investigated. 
Firstly, the QSRR models were developed to directly predict the retention times of 
compounds in three datasets obtained from the literature and an internet open database on 
different RPLC stationary phases, with a view to selecting the most suitable stationary phase(s) 
for the separation of a given set of compounds. The study was conducted using compounds in 
three databases as target compounds. Molecular descriptors of each compound were generated 
using Dragon 6.0 software (Talete, Milano, Italy), based on their chemical structures that had 
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been optimised using density functional theory. Given the huge number of molecular 
descriptors calculated, a genetic algorithm (GA) was employed to choose the most informative 
molecular descriptors for the subsequent QSRR modelling process. Those selected molecular 
descriptors were then used to form QSRR models via a partial least squares (PLS) regression. 
The constructed models were then used to predict the retention times for the target compounds. 
For this part of the study, several strategies for compound filtering to identify the optimal 
training set of compounds for QSRR calculations, including the ratio of retention factor (k-
ratio), the Tanimoto similarity (TS), the log D and log P similarity, plus a dual-filtering 
strategy, were evaluated and compared. Local QSRR models generated using the above 
filtering approaches were built to predict retention. Among the constructed QSRR models, the 
filter that used the ratio of retention factor appeared to be the most effective approach to 
minimising prediction errors. However, the k-ratio filter was impractical as it required the 
retention of the target compound to be known before modelling, therefore it cannot be used 
directly in QSRR modelling for retention prediction. However, the k-ratio filter is relevant as 
a benchmark for the minimum achievable prediction errors in the QSRR modelling, and to 
compare the performance of other more practical filters. For the QSRR models using 
Tanimoto similarity as the filter, training sets using the top ten most similar compounds 
resulted in much higher prediction errors than those using the k-ratio similarity filter. The 
prediction errors yielded using the log D filter, which represents the hydrophobic interaction 
in reversed-phase retention, were slightly improved compared to the Tanimoto filter, but the 
log P filter did not produce acceptably low prediction errors. The dual-filtering method, in 
which Tanimoto similarity (or, alternatively, log D) was taken as the primary filter, then 
combined with k-ratio similarity as the secondary filter, did not lead to meaningful 
improvements in retention prediction. It is worth noting that the low average similarity score 
of the top ten compounds used in the training sets contributed most to the poor retention 
prediction when the Tanimoto filter was applied. The low average similarity score also 
indicated that a larger and more homogenous database was highly desirable for the 
construction of training sets, allowing sufficient numbers of compounds with a high pair-wise 
similarity to be found when using the Tanimoto filter. The dual filter was still based on the 
similarity of chemical structures of compounds, and therefore its accuracy could also be 
improved in the case of larger and more homogenous datasets by including more compounds 
with greater chromatographic similarity. 
Next, retention prediction in RPLC was performed indirectly using the Hydrophobic 
Subtraction Model (HSM). QSRR models were developed to predict solute coefficients of the 
HSM using several compound classification approaches and employing different resources of 
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molecular descriptors. Both global model and local models were built for the prediction. 
Filtering approaches to yield local models including the Leave-One-Out (LOO) approach, the 
compound type (LCT) approach, and the secondary dominant interaction after hydrophobicity 
(LSDI) approach. In this part of the work, molecular descriptors of compounds were calculated 
using both Dragon (Talete, Milano, Italy), and VolSurf+ (Molecular Discovery Ltd., 
Hertfordshire, UK). Finally, the five predicted solute coefficients combined with the five 
known column parameters were fitted into the HSM to calculate the retention of the given 
target compounds. Among the above-mentioned filtering approaches, the LSDI showed the 
best prediction for the solute coefficients compared to other filters, followed by the LCT. The 
LOO and the global approaches resulted in poor prediction for solute coefficients. It can be 
expected that better predictions of solute coefficients would be obtained using the LCT and 
the LSDI approach because compound classification was involved which allowed better suited 
training sets to be constructed. In terms of the comparison of the resources of molecular 
descriptors, no significant difference was observed between Dragon, VolSurf+, and combined 
descriptors. Since the number of molecular descriptors generated from VolSurf+ was much 
less than for Dragon (VolSurf+ generated 128 descriptors only), therefore the genetic 
algorithm (GA) as a variable selection method can be performed more rapidly, making 
VolSurf+ a more attractive option for the subsequent modelling. Additionally, the importance 
of the hydrophobic interaction term of the HSM to retention prediction was investigated. 
Results showed that an approximate HSM using the hydrophobicity term only yielded 
comparable results to those using the full HSM which consisted of five terms. 
To further investigate the feasibility of using the HSM and QSRR for retention prediction 
in RPLC, a combined retention dataset of 148 compounds was employed. Retention prediction 
was achieved through modelling only the solute coefficient ' representing solute 
hydrophobicity in the HSM. Molecular descriptors were calculated using VolSurf+ only. 
Results showed improvement in prediction accuracy for the LSDI, the LCT, and the local 
Tanimoto similarity (LTS) approaches compared with global models derived from the whole 
dataset without filtering. Of these approaches, the LCT exhibited advantages in its ease of 
application and the larger number of compounds which could be modelled using this approach. 
However, the LTS approach was the simplest to apply, and provided that there was a sufficient 
number of similar compounds in the dataset, it yielded sufficiently accurate results. It is 
recognised that modelling based on ' can predict only the hydrophobic selectivity of analytes 
and that the predicted elution order of target compounds was determined solely by their ' 
values. Nevertheless, the predictions reported here showed sufficient accuracy to meet the 
major objective of this study, namely to determine the likelihood of co-elution of analytes in 
applications such as early stage drug development.   
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Given the robust performance of the constructed QSRR models, the predictive ability for 
new compounds on columns that had never been used in the modelling process was also 
investigated. Five analytical grade compounds: pindolol, 1, 8-dihydroxynaphthalene, 4-
ethylnitrobeneze, 2-phenylbutane and 4-heptylbenzoic acid were investigated. The five 
columns employed were all obtained from Thermo Fisher Scientific: an AcclaimTM 120 C18 
column (4.6 × 150 mm, 5.0 μm); an Accucore C18 column (4.6 × 150 mm, 2.6 μm); a Hypersil 
GOLD C8 column (4.6 × 150 mm, 5.0 μm); a Hypersil GOLD C18 column (4.6 × 150 mm, 
5.0 μm) and a Hypersil ODS C18 column (4.6 × 150 mm, 5.0 μm). After retention data 
collection of the five new compounds on the five new columns, their retention times were 
predicted using the proposed QSRR method via the approximate HSM. Very good correlations 
between the predicted and measured retention times of the five test compounds using the LCT 
and the LSDI approaches were obtained. R2 values (between predicted and observed retention 
times) of 0.9634 and 0.9861 were observed for the LSDI and the LCT approach, respectively. 
In terms of prediction error, the LCT approach generated a %RMSEP of 15.41, the LSDI 
approach resulted in a %RMSEP of 28.67. The powerful performance of the QSRR models 
illustrated the feasibility of using the proposed approaches to predict retention of new 
compounds.   
QSRR has been applied in many fields, including the characterisation of columns, the 
interpretation of retention mechanisms and retention prediction of compounds [13, 14]. 
Considering this advantage, a predictive QSRR methodology combined with high-resolution 
mass spectrometry (HRMS) could be a powerful tool in metabolite analysis [17]. For an LC-
MS-based database, chromatographic retention has been used as a feature for the identification 
of metabolites. In MS-based non-targeted metabolomics (NTM) analysis, an accurate mass is 
usually used to define molecular formulae by searching electronic resources [17-19]. Based 
on the exact mass of the metabolite, potential candidates can be found from the database, but 
the limitation of mass searching is that in many cases, an excessive number of candidates are 
returned, meaning that false positives need to be removed [17, 20]. In the present study, QSRR 
models that offered robust predictive ability for compounds with the same molecular weight 
were developed using a novel dual-filtering approach which combined structural and 
chromatographic similarity, allowing false positives to be removed using predicted retention 
which provides information orthogonal to mass during the interpretation of structure 
identification in non-targeted metabolomics. 
The proposed dual-filtering strategy involved Tanimoto searching first, followed by 
retention similarity searching using the nearest neighbour in the initial subset instead of the 
target analyte itself, to construct the final training set. A retention index database of 1882 
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compounds with known molecular weights was employed. VolSurf+ molecular descriptors 
were calculated for 1882 compounds, and 34 groups of compounds (248 compounds in total) 
were chosen as target compounds with at least five compounds having the same mass value 
in each group. Dual-filtering was used for each target compound to build a local training set 
and these constructed training sets were used to form QSRR models. Finally, 191 of those 
compounds were modelled using the dual-filtering approach. For the remaining 57 compounds 
training sets were not able to be formed, as five similar compounds to the target compound 
were not found. The dual-filter-based QSRR models generated good retention prediction with 
a %RMSEP value of 8.45%, 89 compounds (46.6%) were accurately predicted with an 
absolute prediction error of retention index less than 20, while 158 compounds (82.7%) were 
modelled with absolute prediction errors of retention index of less than 60. 
To evaluate the feasibility for the elimination of false positives, a retention index window 
was placed around each predicted retention index (predicted RI ± 2 SD) as a filter used to 
eliminate false positives. Results showed that 91% of retention index predictions fell within 
the ± 2 SD filter (173 out of 191 compounds), with 9% of predicted retention indices falling 
out of the filter range (18 out of 191 compounds). In terms of elimination, a target analyte was 
identified first, and the retentions of other analytes with identical molecular weight were 
predicted. Then the retention indices were compared using the above retention index filter to 
eliminate those where the target analyte RI fell outside the predicted RI ± 2 SD range of the 
possible matches. After applying this retention index filter range to the modelled compounds 
in each group (34 groups in total), 53% of groups (18 out of 34) were found where at least one 
false positive could be eliminated. The presented method shows promise for using retention 
predicted by QSRR models for compound identification in non-targeted metabolomics since 
it allows the elimination of false positives and therefore minimises the number of candidates 
corresponding to the target analyte.  
However, the proposed approach showed limited ability to eliminate false positives when 
these compounds were structural isomers of the target compound, since these isomers 
exhibited similar retention indices to the target compound. Possible methods to solve this issue 
include improving the performance of the QSRR models by employing more compounds in 
the database, or providing more accurate RI predictions using better similarity filters, allowing 
sufficient training sets to be built with an elevated level of similar compounds to the target. 
This thesis comprised the development of QSRR models for retention prediction and the 
application of the proposed QSRR in non-targeted metabolomics. The QSRR strategy was 
applied successfully to RPLC with good accuracy in retention prediction and thereby showed 
good potential to accelerate the process of chromatographic method development. 
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Furthermore, with the accurate retention prediction of compounds having the same molecular 
weight, the proposed QSRR methodology can be seen to be a useful tool in eliminating false 
positives, and improving the confidence and the efficiency of metabolite identification in 
NTM. 
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Appendix 
Appendix 1. Database of 1882 compounds  
1882 compounds with known molecular weight (MW) and retention index (RI) was 
employed for the Non-Targeted Metabolomics (NTM) analysis [1]. 
Appendix 1. Molecular weights (MW) and retention indices (RI) of 1882 compounds 
ID Name MW RI 
1 tris(phosphonomethyl)amine 299.051 204 
2 bis(phosphonomethyl){2-[bis(phosphonomethyl)amino]ethyl}amine 436.126 206 
3 (2,3-diphosphonopropyl)diethylamine 275.178 211 
4 5-amino-2,6-dioxo-1,3-dihydropyrimidine-4-sulfonic_acid 207.161 213 
5 3-oxo-1,2,4-triazoline-5-carboxylic_acid 129.075 216 
6 2,6-dioxo-1,3-dihydropyrimidine-4-carboxylic_acid 156.098 225 
7 urea 60.055 227 
8 3-phosphonopropylamine 139.091 230 
9 4,5-dihydroxyimidazolidin-2-one 118.092 233 
10 3-aminobenzenesulfonic_acid 173.186 238 
11 2-(aminocarbonylamino)-3-carbamoylpropanoic_acid 175.144 239 
12 pyrimidine-2,4-diol 112.088 243 
13 
1-({[(2-oxopyrrolidinyl)methyl](hydroxyphosphoryl)}methyl)pyrrolidin-
2-one 
260.229 245 
14 1-methylpyridine-3-carboxylic_acid_chloride 138.146 245 
15 N-[1-(acetylamino)-2,3,4,5,6-pentahydroxyhexyl]acetamide 280.277 246 
16 5-methyl-2,6-dioxo-1,3-dihydropyrimidine-4-carboxylic_acid 170.124 247 
17 1-methyl-2,6-dioxo-1,3-dihydropyrimidine-4-carboxylic_acid 170.124 248 
18 2-(5-carbamoyl-2,4-dioxo-1,3-dihydropyrimidinyl)acetic_acid 213.149 249 
19 2-(acetylamino)butanedioic_acid 175.141 251 
20 2-oxo-4-imidazoline-4-carboxylic_acid 128.087 254 
21 acetamide 59.068 260 
22 N,N-dimethylformamide 73.094 276 
23 N-methylformamide 59.068 276 
24 2,3-dihydroxybutanedihydrazide 178.147 278 
25 pyrimidin-2-ol 96.0884 278 
26 1,2,4-triazole 69.0658 284 
27 N-[di(acetylamino)methyl]acetamide 187.198 284 
28 pyrimidine-4-carboxylic_acid 124.099 287 
29 1,3-dimethylurea 88.109 290 
30 2-(2,4-dioxo(1,3-dihydropyrimidinyl))-N-(2-hydroxyethyl)acetamide 213.193 290 
31 5-methyl-1H-1,2,3,4-tetraazole 84.0804 292 
32 2-(2,4-dioxo-1,3-dihydropyrimidin-5-yl)acetic_acid 170.124 293 
33 5-oxo-1-(4-sulfophenyl)-2-pyrazoline-3-carboxylic_acid 284.243 294 
34 1H-1,2,3-triazole 69.0658 296 
35 3,4,5-trihydroxybenzamide 169.137 298 
36 3-(2,5-dioxo-1,3-diazolidin-4-yl)propanoic_acid 172.14 301 
37 4-hydroxybutanehydrazide 118.135 306 
38 5,6-dimethylpyrazine-2,3-dicarboxylic_acid 196.162 314 
39 2-(acetylamino)propanoic_acid 131.131 315 
40 5-(trimethylamino)-3-hydropyrimidin-2-one 154.191 320 
41 
(2S,3S,5S,1R)-5-amino-3-(hydroxymethyl)cyclopentane-1,2-
diol_chloride 
147.174 321 
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42 3-[(methylamino)methyl]-1,2,4-triazolin-5-one 128.133 326 
43 2-(methylamino)ethan-1-ol 75.11 328 
44 2,3-dihydroxy-N,N-dimethyl-N',N'-dimethylbutane-1,4-diamide 204.225 328 
45 5-hydro-4-imidazolino[4,5-c]pyridine-2,4-dione 151.124 329 
46 pyrazino[2,3-d]pyridazine-5,8-diol 164.123 329 
47 3-amino-6-methyl-4H-1,2,4-triazin-5-one 126.118 333 
48 2-methoxypropanamide 103.121 334 
49 6-amino-2-methyl-3-hydropyrimidin-4-one 125.13 335 
50 piperazine-1-carbaldehyde 114.147 337 
51 piperidin-4-ol 101.148 338 
52 5-(hydroxymethyl)pyrrolidin-3-ol 117.147 340 
53 1-methyl-5-oxopyrrolidine-3-carboxylic_acid 143.142 341 
54 4-methylpyrimidin-2-ol 110.115 344 
55 gamma aminobutyric acid 103.121 344 
56 imidazole 68.078 344 
57 3-aminohydropyridin-2-one 110.115 346 
58 pyridine-3,5-dicarboxylic_acid 167.121 347 
59 1-methyl-6-oxo-1,4,5-trihydropyridazine-3-carboxylic_acid 156.141 352 
60 pyridine-2,6-dicarboxylic_acid 167.121 354 
61 3-aminopiperidin-2-one 114.147 361 
62 N-(4-pyridylcarbonylamino)acetamide 179.178 363 
63 4-aminopyrimidine 95.1036 365 
64 piperazine-1,4-dicarbaldehyde 142.157 367 
65 1-methylimidazole 82.1048 378 
66 amino-N-(2-pyridylmethyl)amide 151.168 379 
67 4-aminobutan-2-ol 89.137 381 
68 6-amino-3-(2,3-dihydroxypropyl)-3-hydropyrimidin-2-one 185.182 394 
69 6-oxohydropyridine-3-carboxylic_acid 139.11 394 
70 1,3,5-triazine-2,4,6-triamine 126.121 396 
71 2H-3,4,5,6-tetrahydropyran-4-ylamine 101.148 396 
72 3-pyridylmethan-1-ol 109.127 396 
73 2-(hydroxymethyl)-2-(2-pyridyl)propane-1,3-diol 183.207 399 
74 2-methyl-1-pyrroline 83.1328 399 
75 2-amino-2-methylpropan-1-ol 89.137 401 
76 2-methylimidazole 82.1048 404 
77 p-phenylenediamine 108.143 404 
78 pyridazine 80.089 405 
79 (2-methoxyethyl)(methyl)amine 89.137 408 
80 methylthiocarboxamidine_iodide 90.1428 409 
81 propylamine 59.1108 415 
82 pyridin-4-ol 95.1006 415 
83 1,3-dimethyl-2,4-dioxo-1,3-dihydroquinazoline-6-sulfonic_acid 270.259 418 
84 1-methyl-6-oxohydropyridine-4-carboxylic_acid 153.137 420 
85 1-(2-(1,2,4-triazolyl)ethyl)-1,2,4-triazole 164.169 421 
86 3-oxo-N-[2-(3-oxobutanoylamino)ethyl]butanamide 228.247 421 
87 5-(3-pyridyl)-1H-1,2,3,4-tetraazole 147.139 424 
88 2-(3-methyl-2,4-dioxo-1,3-dihydropyrimidin-5-yl)acetic_acid 184.151 425 
89 3-amino-2-methylbenzamide 150.18 426 
90 diethylamine 73.1376 426 
91 1,3-thiazoline-2-ylamine 102.154 431 
92 2H-3,4,5,6-tetrahydropyran-3-carboxamide 129.158 432 
93 N-[(acetylamino)-4-pyridylmethyl]acetamide 207.232 434 
94 piperidine-2-carboxamide 128.174 437 
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95 purine 120.113 438 
96 4-[(carbamoylmethyl)amino]benzamide 193.205 439 
97 6-amino-5-methyl-3-hydropyrimidin-2-one 125.13 441 
98 2,5-diaminopyridine 109.13 442 
99 2-aminopurine 135.128 446 
100 2-methylquinoline-4-carboxylic_acid 187.198 447 
101 3-aminopyridine 94.1158 447 
102 2-[(propan-2-yl)amino]ethan-1-ol 103.164 448 
103 3-amino-3-methylbutan-2-one 101.148 451 
104 3-amino-3-phenylpropanoic_acid 165.191 453 
105 pyridazine-3,4,5,6-tetraamine 140.147 454 
106 [6-(hydroxymethyl)-2-pyridyl]methan-1-ol 139.154 455 
107 4(5)-methylimidazole 82.1048 455 
108 4-aminopyridine 94.1158 456 
109 N-(2-methyl-6-oxohydropyrimidin-4-yl)acetamide 167.167 456 
110 3-(2-hydroxyethyl)-4,6-dimethyl-3-hydropyrimidin-2-one 168.195 458 
111 N,N-dimethylallylamine 85.1486 459 
112 2-(4-hydroxyphenyl)acetamide 151.165 461 
113 3-methoxypropan-1-amine 89.137 461 
114 pyrimidine 80.089 461 
115 (1,4-dioxan-2-ylmethyl)methylamine 131.174 462 
116 2-(cyclohexylamino)ethanesulfonic_acid 207.287 462 
117 5-aminoindazole 133.152 462 
118 (2R)-2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutanamide 205.253 463 
119 2-[(carboxymethyl)methylamino]benzoic_acid 209.201 463 
120 5-[(2-hydroxy-tert-butyl)amino]-1,3-dihydropyrimidine-2,4-dione 199.209 463 
121 6-amino-2-(4-methylpiperazinyl)-3-hydropyrimidin-4-one 209.25 463 
122 m-phenylenediamine 108.143 465 
123 N-[1-carbamoyl-2-(4-hydroxyphenyl)ethyl]acetamide 222.243 465 
124 
2-(5,7-dimethyl-2,4,6-trioxo-3,5,7-trihydro-5,7-diazaindol-3-
yl)acetic_acid 
253.214 466 
125 4-methyl-3-(4-pyridyl)-1,2,4-triazole 160.178 466 
126 2-hydroxy-2-phenylacetamide 151.165 467 
127 
N-[7-(methoxymethyl)-5-oxo-4-hydro-1H-1,2,4-triazolino[1,5-
a]pyrimidin-2-yl]acetamide 
237.218 467 
128 N-methylpropylamine 73.1376 467 
129 2-(trimethylamino)ethyl_acetate_chloride 146.209 468 
130 6-methylpurine 134.14 468 
131 3-(2-pyridyl)pentanedioic_acid 209.201 470 
132 3-methylpyridazine 94.1158 470 
133 3-methyl-3-[(2-oxopropyl)amino]butan-2-one 157.212 471 
134 6-amino-5-methyl-3-hydrobenzimidazol-2-one 163.179 471 
135 1,3,5-triacetyl-1,3,5-triazaperhydroine 213.236 472 
136 1,3-dimethyl-1,3,5-triazaperhydroine-2,4,6-trione 157.129 472 
137 N,N-dimethylisopropylamine 87.1644 472 
138 N-ethyl-N'-ethylpropane-1,3-diamide 158.2 472 
139 3,4-diaminobenzoic_acid 152.152 473 
140 4-aminopyrazolo[3,4-d]pyrimidine 135.128 473 
141 pyrazine 80.089 473 
142 (R)-(-)-2-methylpyrrolidine 85.1486 474 
143 2-amino-6-methylhydropyrimidin-4-one 125.13 474 
144 2-methylthio-2-imidazoline 116.181 474 
145 1,1-dimethylpiperidin-1-ium_chloride 114.21 476 
146 ethylenediamine 60.0986 477 
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147 (4-aminophenyl)-N-methylcarboxamide 150.18 478 
148 2-picoline 93.128 478 
149 4-azabenzimidazole 119.126 478 
150 3,5-di(acetylamino)-2-methylbenzoic_acid 250.254 481 
151 
methyl_2-{2-[2-
(acetylamino)propanoylamino]propanoylamino}propanoate 
287.315 481 
152 (2E)-3-(dimethylamino)prop-2-enal 99.132 482 
153 2-ethylimidazole 96.1316 482 
154 2-propylpyridine-4-carboxylic_acid 165.191 482 
155 2,6-diaminopyridine 109.13 483 
156 3-(diethylamino)propan-1-ol 131.217 483 
157 2-aminopyridine 94.1158 484 
158 
2-(3,5-dimethyl-2,4,6-trioxo(1,3,5-triazaperhydroinyl))-N-
methylacetamide 
228.207 485 
159 2,3-diaminopyridine 109.13 485 
160 N-[5-(acetylamino)-2-hydroxyphenyl]acetamide 208.216 485 
161 1,3-diacetyl-4,5-dihydroxy-2-oxoimidazolidine 202.166 486 
162 1,4-dimethylpiperazine 114.19 486 
163 3-piperazinylpropanamide 157.215 487 
164 triethyl(methyl)azanium_chloride 116.226 487 
165 6-methyl-2-oxohydropyridine-3-carboxylic_acid 153.137 488 
166 5-(dimethylamino)-1,3-dihydropyrimidine-2,4-dione 155.156 489 
167 quinoxaline-2,3-diol 162.148 490 
168 4-aminopiperidine 100.163 492 
169 N-(2-pyridyl)acetamide 136.153 492 
170 N-[(4,6-dimethylpyrimidin-2-yl)amino]acetamide 180.209 492 
171 4-picoline 93.128 493 
172 (3-aminophenyl)methan-1-ol 123.154 495 
173 
N,N-dimethyl-2-(1,3,5-trioxo(4,6,7,3a,7a-pentahydroisoindol-2-
yl))acetamide 
252.269 495 
174 4-(1-amino-2-carboxyethyl)benzoic_acid 209.201 496 
175 4-(3-pyridyl)pyrazole 145.163 496 
176 5-(aminomethyl)-3-hydrobenzimidazol-2-one 163.179 496 
177 amino(iminomorpholin-4-ylmethyl)carboxamidine_chloride 171.202 496 
178 isobutylamine 73.1376 496 
179 methylpyrazin-2-ylamine 109.13 496 
180 7-aminohydroquinoxalin-2-one 161.163 497 
181 triethylamine 101.191 497 
182 1-(ethylamino)butan-2-ol 117.191 498 
183 1-[(tert-butyl)amino]acetone 129.202 499 
184 4-amino-4-methylpentan-2-one_oxalic_acid 115.175 499 
185 6-aminohexan-1-ol 117.191 499 
186 methyl_2-oxopiperidine-3-carboxylate 157.169 499 
187 1,2-diaminopropane 74.1254 500 
188 methyl_2-(6-oxohydropyridazinyl)acetate 168.152 500 
189 piperazine 86.1364 500 
190 {2-[3-(hydroxymethyl)-2-pyridyl]-3-pyridyl}methan-1-ol 216.239 501 
191 2-(3-pyridyl)imidazole 145.163 502 
192 2-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic_acid 191.229 502 
193 3-(dimethylamino)-2,2-dimethylpropan-1-ol 131.217 504 
194 4-phenylpyridine-2,5-dicarboxylic_acid 243.218 504 
195 3-hydroxy-1,2-dimethylhydropyridin-4-one 139.154 505 
196 8-methyl-8-azatricyclo[6.2.2.0<2,7>]dodecan-4-ol 196.312 505 
197 ethenodeoxyadenosine 275.266 505 
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198 1-(2-aminoethyl)piperazine 129.205 506 
199 1-propylpiperidine-3-carboxamide 170.254 506 
200 2,6-lutidine 107.155 506 
201 (3S,4R)-4-ethoxyoxolan-3-amine_hydrochloride 131.174 507 
202 1-methylpiperazine 100.163 507 
203 2-methylpiperazine 100.163 507 
204 4-(2-methoxyphenyl)-1,2,4-triazolidine-3,5-dione 207.188 507 
205 4-(aminomethyl)piperidine 114.19 507 
206 4-(aminomethyl)pyridine 108.143 507 
207 N,N,N',N'-tetramethylguanidine 115.178 507 
208 1-(2-(2-pyridyl)ethyl)pyrrolidin-2-one 190.244 508 
209 N,N-dimethylethylenediamine 88.1522 508 
210 1,2,3,4-tetrahydroisoquinoline-3-carboxylic_acid 177.202 509 
211 1-ethylpiperidine 113.202 509 
212 2,6-diaminotoluene 122.169 509 
213 cyclopentylamine 85.1486 509 
214 N,N'-dimethylethylenediamine 88.1522 509 
215 N-methylethylenediamine 74.1254 509 
216 5-amino-1,3-dimethyl-3-hydrobenzimidazol-2-one 177.205 510 
217 N-(2-(2-piperidyl)ethyl)acetamide 170.254 510 
218 2-(methylamino)pyridine 108.143 511 
219 4-(methylamino)pyridine 108.143 511 
220 N-(2-aminophenyl)acetamide 150.18 511 
221 1-methylhomopiperazine 114.19 512 
222 4-[(2-aminophenyl)carbonyl]piperazin-2-one 219.243 512 
223 (2S)-1-benzylpyrrolidine-2-carboxylic_acid 205.256 513 
224 (6-oxohydropyridazin-3-yl)-N-(3-pyridyl)carboxamide 216.199 513 
225 1-dimethylamino-2-propylamine 102.179 513 
226 imidazo[5,4-g]benzimidazole 158.162 513 
227 (4-aminophenyl)-N,N-dimethylcarboxamide 164.207 514 
228 4-aminobenzenecarboxamidine 135.168 514 
229 (R)-(+)-3-(dimethylamino)pyrrolidine 114.19 515 
230 ethyl_(2R)-5-oxopyrrolidine-2-carboxylate 157.169 515 
231 (2-aminophenyl)methan-1-ol 123.154 516 
232 
2-[(iminomorpholin-4-ylmethyl)amino]-6-methyl-3-hydropyrimidin-4-
one 
237.261 516 
233 2-amino-2-phenylacetamide 150.18 516 
234 2-ethyl-4-methylimidazole 110.158 516 
235 N'-(3-hydroxypropyl)-N-(methylethyl)ethane-1,2-diamide 188.226 516 
236 trans-2,5-dimethylpiperazine 114.19 516 
237 2,5-lutidine 107.155 517 
238 2-isopropylimidazole 110.158 517 
239 2-phenylpiperidine-2-carboxylic_acid 205.256 517 
240 3-{N-[4-(acetylamino)phenyl]carbamoyl}propanoic_acid 250.254 517 
241 4-(2H-benzo[d]1,3-dioxolen-5-yl)-1,2,4-triazolidine-3,5-dione 221.172 517 
242 1-(3-aminopropyl)imidazole 125.173 518 
243 1-ethylpiperazine 114.19 518 
244 2,3-lutidine 107.155 518 
245 ethyl_2-acetyl-3-amino-5-oxo-3-pyrazoline-4-carboxylate 213.193 518 
246 N-(5-quinolyl)acetamide 186.213 518 
247 o-phenylenediamine 108.143 518 
248 2-ethylpyridine 107.155 519 
249 5-[((1E)-2-(3-pyridyl)-1-azavinyl)amino]-2H-1,2,4-triazin-3-one 216.202 519 
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250 2,6-dimethylpiperazine 114.19 520 
251 4-(4-pyridyl)butanoic_acid 165.191 520 
252 leucinamide_hydrochloride 130.189 520 
253 3-(3-aminophenyl)-1-methyl-1,3-diazolidine-2,4-dione 205.216 521 
254 N-ethyl-4-pyridinemethylamine 136.196 521 
255 2-methylquinoline-4-carboxamide 186.213 522 
256 butylamine 73.1376 522 
257 1-acetyl-4-(propylamino)piperidine 184.281 524 
258 2,2,5-trimethyl-1,2,6-trihydropyridin-3-one 139.197 524 
259 3-(3-aminophenyl)-5-methyl-1,3-diazolidine-2,4-dione 205.216 525 
260 ((1R,2R)-6-azabicyclo[4.4.0]dec-2-yl)methan-1-ol 169.266 526 
261 hexamethylenediamine 116.206 526 
262 2,4-lutidine 107.155 527 
263 3-(2-pyridyl)propylamine 136.196 527 
264 4-(2-morpholin-4-ylethyl)morpholine 200.28 527 
265 4-(3-aminophenyl)-1,2-dimethyl-1,2,4-triazolidine-3,5-dione 220.23 527 
266 aniline 93.128 527 
267 decahydroquinolin-4-one 153.224 527 
268 1-(3-aminophenyl)-2-methyl-2-imidazolin-5-one 189.216 528 
269 1,2,6-trimethylhydropyridin-4-one 137.181 528 
270 2-(dimethylamino)pyridine 122.169 528 
271 3,4-lutidine 107.155 528 
272 pyridino[3,2-h]quinoline-4,7-diol 212.207 528 
273 2-(2-pyridyl)ethylamine 122.169 529 
274 2-propylpyridine-4-carboxamide 164.207 529 
275 quinazoline-4-ylamine 145.163 529 
276 2,2-dimethyl-3-(pyrrolidin-1-yl)propanal 155.239 530 
277 2,4-diaminotoluene 122.169 530 
278 imidazo[5,4-g]quinoxaline 170.173 530 
279 2-(aminomethyl)piperidine 114.19 531 
280 3-(2-imidazolin-2-yl)phenylamine 161.206 531 
281 N'-[3-(dimethylamino)propyl]-N-cyclopropylethane-1,2-diamide 213.279 531 
282 3,5-lutidine 107.155 532 
283 4,5-dimethoxycyclohexa-3,5-diene-1,2-dione 168.149 532 
284 N,N'-diethylethylenediamine 116.206 532 
285 N,N-dimethyl-p-phenylenediamine 136.196 532 
286 pyrazole 68.078 532 
287 2-imidazolin-2-ylpyrazin-2-ylamine 163.182 533 
288 4-methylpyrimidine 94.1158 533 
289 1-cyclopropyl-2-pyridylethan-1-one_iodide 162.211 534 
290 3-(diethylamino)propylamine 130.233 534 
291 6-methyl-2-(methylethyl)pyrimidin-4-ol 152.196 534 
292 N,N,N',N'',N''-pentamethyldiethylenetriamine 173.301 534 
293 N-[(4-hydroxyphenyl)ethyl]acetamide 179.218 534 
294 1-allylpiperazine 126.201 535 
295 2-(2-methylaminoethyl)pyridine 136.196 535 
296 3-ethylpyridine 107.155 535 
297 1,3-dimethyl-1,3-diazinan-2-one 128.174 536 
298 1-isopropylpiperazine 128.217 536 
299 4-ethylpyridine 107.155 536 
300 5,6,7-trihydrocyclopenta[2,1-d]pyrimidine-2-ylamine 135.168 536 
301 methyl_2-(2,4-diaminophenyl)acetate 180.206 536 
302 N-[4,6-di(acetylamino)pyrimidin-2-yl]acetamide 251.244 536 
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303 1-(N-propylcarbamoyl)piperidine-3-carboxamide 213.279 537 
304 4-amino-2,6-dimethylphenol 137.181 537 
305 N-(4-aminophenyl)[(4-aminophenyl)amino]carboxamide 242.28 537 
306 1,2-dimethylpropylamine 87.1644 538 
307 1-acetyl-4-(4-piperidyl)piperidine 210.319 538 
308 2-(aminomethyl)benzoic_acid 151.165 538 
309 5-amino-3-hydroisobenzofuran-1-one 149.149 538 
310 8-methyl-2-morpholin-4-ylimidazolidino[1,2-e]1,3,5-triazin-4-one 237.261 538 
311 diallylmethylamine 111.186 538 
312 N,N,N-trimethylanilinium_chloride 136.216 538 
313 pyrrole-2-carbaldehyde 95.1006 538 
314 (3,4-dimethoxyphenyl)-N-(???methyl)carboxamide 253.257 539 
315 1-(2-aminoethyl)piperidine 128.217 539 
316 2-(pyrrolidinylmethyl)pyridine 162.234 539 
317 3,5-dimethylpyrazole 96.1316 539 
318 4-(2-(4-pyridyl)ethyl)pyridine 184.24 539 
319 N-propylethylenediamine 102.179 539 
320 (2-(2-pyridyl)ethyl)pyrimidin-4-ylamine 200.243 540 
321 (3-amino(4-pyridyl))dimethylamine 137.184 540 
322 1,2-diaminocyclohexane 114.19 540 
323 5-aminoindole 132.165 540 
324 methyl_3-piperidylpropanoate 171.239 540 
325 N,N,N'-triethylethylenediamine 144.259 540 
326 pyrazin-2-yl-N-(3-pyridyl)carboxamide 200.199 540 
327 (2S)-2-amino-2-phenylethan-1-ol 137.181 541 
328 1-(4-aminophenyl)pyrrolidin-2-one 176.218 541 
329 2-(4-oxo-3-hydroquinazolin-3-yl)acetic_acid 204.185 541 
330 2,7-dimethylimidazo[5,4-g]benzimidazole 186.216 541 
331 m-xylylenediamine 136.196 541 
332 N,N'-dimethyl-1,6-hexanediamine 144.259 541 
333 N,N-dimethylbutylamine 101.191 541 
334 o-xylylenediamine 136.196 541 
335 1-ethylpropylamine 87.1644 542 
336 6-quinolylmethylamine 158.202 542 
337 1-(aminomethyl)cyclohexan-1-ol 129.202 543 
338 2-amino-5-diethylaminopentane 158.286 543 
339 4-morpholin-4-ylbenzene-1,3-diamine 193.248 543 
340 N-ethylbutylamine 101.191 543 
341 2-amino-3-phenylbutanoic_acid_chloride 179.218 544 
342 3-(2-hydroxyethyl)-1,3-dihydroquinazoline-2,4-dione 206.201 544 
343 3,6-dimethyl-1-(3-pyrrolidinylpropyl)-1,3-dihydropyrimidine-2,4-dione 251.328 544 
344 4-(3-(4-pyridyl)propyl)pyridine 198.267 544 
345 5-methyl-4-azabicyclo[4.4.0]decan-1-ol 169.266 544 
346 benzamide 121.138 544 
347 methyl_3-(3-pyridyl)propanoate 165.191 544 
348 
N-(2-pyridylmethyl)[(4-{[(2-
pyridylmethyl)amino]carbonylamino}butyl)amino]carboxamide 
356.427 544 
349 N-methyl-2-(3-oxo(1,2,4-trihydroquinoxalin-2-yl))acetamide 219.243 544 
350 2-(phenylcarbonylamino)acetic_acid 179.175 545 
351 2,3-dimethylquinoxaline-6-ylamine 173.217 545 
352 2-aminopentane 87.1644 545 
353 5-methyl-5-azabicyclo[4.4.0]decan-2-one 167.25 545 
354 benzimidazole 118.138 545 
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355 bis(3-pyridylmethyl)amine 199.255 545 
356 methyl[(1-methylpyrrol-2-yl)methyl]amine 124.185 545 
357 quinoxaline-6-ylamine 145.163 545 
358 (4S,5R)-2,4,5-tri(4-pyridyl)-2-imidazoline 301.35 546 
359 1-methyl-3-[4-(2-pyrrolidinylacetyl)piperazinyl]azolidine-2,5-dione 308.38 546 
360 4-(pyrrolidinylmethyl)phenylamine 176.261 546 
361 4,4-dimethylazaperhydroine-2,6-dione 141.169 546 
362 N-((1S,6R)-5-methyl-5-azabicyclo[4.4.0]dec-2-yl)acetamide 210.319 546 
363 (3S)-3-amino-2,4-dimethylpentan-2-ol 131.217 547 
364 4-methoxy-6-pyrrolidinyl-1H-1,3,5-triazin-2-one 196.208 548 
365 6-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-1,3,5-triazine-2,4-diamine 296.294 548 
366 N-{4-[N-(2-pyridylmethyl)carbamoyl]phenyl}acetamide 269.302 548 
367 N-isopropyl-N-methyl-tert-butylamine 129.245 548 
368 trans-N,N'-dimethylcyclohexane-1,2-diamine 142.244 548 
369 amino(imino-1,4-thiazaperhydroin-4-ylmethyl)carboxamidine 187.262 549 
370 
2-ethyl-4-methylspiro[2,4,5,6,3a,6a-hexahydro-2,5-diazapentalene-6,3'-
indoline]-1,3,10-trione 
299.329 550 
371 N,N-diisopropylethylenediamine 144.259 550 
372 5-[3-(dimethylamino)propyl]-5-azabicyclo[4.4.0]decan-2-ol 240.388 551 
373 1-(2-piperazinylacetyl)-4-piperidylpiperidine-4-carboxamide 337.464 552 
374 4-amino-6-(tert-butyl)-1-methyl-1,3,5-triazin-2-one 182.225 552 
375 cis-1,8-diamino-p-menthane 170.297 552 
376 N,N,N',N'-tetraethylethylenediamine 172.313 552 
377 N,N,N',N'-tetramethyl-1,3-propanediamine 130.233 552 
378 [4-(2-aminoethyl)phenyl]diethylamine 192.303 553 
379 1,8-diaminooctane 144.259 553 
380 1-acetyl-5-amino-2-methylindoline 190.244 553 
381 2-(cyclohexylamino)ethan-1-ol 143.228 553 
382 3-morpholin-4-ylphenylamine 178.233 553 
383 methyl_6-aminohexanoate 145.201 553 
384 N,N,N',N'-tetraethyl-1,3-propanediamine 186.34 553 
385 [2-(2-amidinothioethylthio)ethyl]thiocarboxamidine 238.383 554 
386 
3-[5-(carboxymethyl)-3-oxo-5-hydro-1,2,4-triazino[2,3-a]benzimidazol-
2-yl]propanoic_acid 
316.273 554 
387 (2S,1R)-1-aminoindan-2-ol 149.192 555 
388 
1-[(3,4-dihydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-
diol_bromide 
287.315 555 
389 3-amino-1,3,4-trihydroquinolin-2-one 162.191 555 
390 ethyl_5-(amidinoamino)-2-aminopentanoate_chloride 202.256 555 
391 phenylurea 136.153 555 
392 (1-methyl(4-piperidyl))(3-pyridylmethyl)amine 205.302 556 
393 1,5-dimethyl-3-(2-oxopropyl)-1,3,5-triazaperhydroine-2,4,6-trione 213.193 556 
394 1-{[(2-phenylethyl)(hydroxyphosphoryl)]methyl}pyrrolidin-2-one 267.264 556 
395 1-methylbenzimidazole 132.165 556 
396 5-(3,5-dimethylpyrazolyl)-1H-1,2,3,4-tetraazole 164.169 556 
397 aminodimethylbenzylamine 151.231 556 
398 indoline 119.166 556 
399 (2-methylpropyl)(2-morpholin-4-ylethyl)amine 186.297 557 
400 1-(4-pyridylmethyl)-4-(2-pyridylmethyl)piperazine 268.361 557 
401 7-azaindole 118.138 557 
402 ethyl_2-(1,4-dimethylpiperazin-2-yl)acetate 200.28 557 
403 N,N'-diisopropyl-1,3-propanediamine 158.286 557 
404 N-methylaniline 107.155 557 
405 pyridino[3,2-h]quinoline-5,6-dione 210.192 557 
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406 quinoline 129.161 557 
407 2,3-diaminobenzoic_acid 152.152 558 
408 3-(carboxymethyl)indole-2,5-dicarboxylic_acid 263.206 558 
409 3-amino-1-(3-methylpiperidyl)propan-2-ol 172.27 558 
410 4-quinolylamine 144.176 558 
411 
N-[(2,2,6,6-tetramethyl(4-piperidylidene))azamethyl]-N'-[(2,2,6,6-
tetramethyl(4-piperidylidene))azamethyl]ethane-1,2-diamide 
392.543 558 
412 1-[4-amino-3-(2-oxopyrrolidinyl)phenyl]pyrrolidin-2-one 259.307 559 
413 2,2-diprop-2-enylpiperazine_chloride_chloride 166.266 559 
414 2-(2-pyrrolidinylacetylamino)benzamide 247.296 560 
415 2,3-diaminotoluene 122.169 560 
416 2-amino-1-phenylethan-1-one 135.165 560 
417 ((3S)-3-1,2,3,4-tetrahydroisoquinolyl)methan-1-ol 163.219 562 
418 [1-(3-methoxypropyl)pyrrolidin-3-yl]methanamine 172.27 562 
419 1H-2,4,5,6,7-pentahydroindazol-3-one 138.169 562 
420 2-methylbenzimidazole 132.165 562 
421 amino[(4-oxocyclohexa-2,5-dienylidene)azamethyl]carboxamidine 164.166 562 
422 N,N-diethyl(4-methylpiperazinyl)carboxamide 199.295 562 
423 N,N-dimethyldipropylenetriamine 159.274 562 
424 5-amino-2-methylbenzoic_acid 151.165 563 
425 heptamethyleneimine 113.202 563 
426 
N-(oxolan-2-ylmethyl)[(4-{[(oxolan-2-
ylmethyl)amino]carbonylamino}butyl)amino]carboxamide 
342.437 563 
427 5-amino-1,3,3-trimethylcyclohexanemethylamine 170.297 564 
428 N-[(2-hydroxyindol-3-ylidene)azamethyl]acetamide 203.2 564 
429 2-(2-oxoindolin-3-yl)acetic_acid 191.186 565 
430 3-(4-methylquinolyl)propanoic_acid_bromide 216.259 565 
431 bis(hexamethylene)triamine 215.381 565 
432 N-(4-hydroxyphenyl)-N-methylacetamide 165.191 565 
433 2,4-dimethylquinoline-7-carboxylic_acid 201.224 566 
434 2,5-dimethylpyrrole-3,4-dicarbaldehyde 151.165 566 
435 3,4-diaminotoluene 122.169 566 
436 N-(2-aminoethyl)-1,3-propanediamine 117.194 566 
437 1-(4-hydroxyphenyl)pyrrolidin-2-one 177.202 567 
438 2-(acetylamino)-3-methylpentanoic_acid 173.211 567 
439 3-(2-aminoethyl)-3-hydroquinazolin-4-one 189.216 567 
440 N-(4-aminophenyl)butanamide 178.233 567 
441 N-[4-(4-pyridylmethyl)phenyl]acetamide 226.277 567 
442 N-benzylmethylamine 121.182 567 
443 2,6-dimethylpyrazine 108.143 568 
444 2-amino-N-phenylacetamide 150.18 568 
445 3,3'-diamino-N-methyldipropylamine 145.247 568 
446 5,6-dimethoxyindolin-2-one 193.202 568 
447 
N-(2-hydroxyethyl)-2-(4-methyl-1-oxo(2-hydrophthalazin-2-
yl))acetamide 
261.28 568 
448 N-allylcyclopentylamine 125.213 568 
449 N-methylcyclohexylamine 113.202 568 
450 (4-pyridylmethyl)(2,2,6,6-tetramethyl(4-piperidyl))amine 247.383 569 
451 2-(pyrrolidinylmethyl)benzoic_acid 205.256 569 
452 2-[(N-phenylcarbamoyl)amino]acetic_acid 194.19 569 
453 
3-[(1E)-3,3-bis(hydroxymethyl)-4-hydroxy-2-azabut-1-enyl]-4-hydroxy-
6-methylhydroquinolin-2-one 
306.318 569 
454 methyl_3-(3-piperidyl)propanoate 171.239 569 
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455 
N-(2,2,6,6-tetramethyl(4-piperidyl))-N'-(2,2,6,6-tetramethyl(4-
piperidyl))ethane-1,2-diamide 
366.546 569 
456 N,N'-di-tert-butyl-ethylenediamine 172.313 569 
457 1-butyl-1-methylpyrrolidin-1-ium_chloride 156.29 570 
458 2,5-dimethylpyrazine 108.143 570 
459 2-methyl-4-[(4-methylpiperazinyl)carbonyl]-2-hydrophthalazin-1-one 286.333 570 
460 4-[2-(methylpiperidyl)ethylidene]-1,3-dioxolane_iodide 198.285 570 
461 methyl_2-(3-amino-4,6-dimethyl-2-oxohydropyridyl)acetate 210.232 570 
462 
N-(3-pyridylmethyl)[(3-{[N-(3-
pyridylmethyl)carbamoyl]amino}phenyl)amino]carboxamide 
376.417 570 
463 N,N-dimethyl-N'-ethylethylenediamine 116.206 570 
464 1,10-diaminodecane 172.313 571 
465 3,3'-iminobis(N,N-dimethylpropylamine) 187.328 571 
466 5-[3-(dimethylamino)propyl]-5-azabicyclo[4.4.0]decan-2-one 238.372 571 
467 1-butylimidazole 124.185 572 
468 4,6-dimethylpyrimidine 108.143 572 
469 2-imino-5-hydro-3H-1,3,5-triazino[6,1-b]benzoxazol-4-one 202.172 573 
470 3-pyrazin-2-yl-5-(2-pyridyl)-1H-1,2,4-triazole 224.224 573 
471 amino-N-methyl-N-[2-(phenylamino)ethyl]amide 193.248 573 
472 N-((1S)-1-carbamoyl-2-indol-3-ylethyl)acetamide 245.28 573 
473 N,N-dimethylbenzylamine 135.208 573 
474 triethylenetetramine 146.235 573 
475 1,7-dimethylquinoline 158.223 574 
476 1-butylpyrrolidine 127.229 574 
477 3-(1,3-dioxan-2-yl)phenylamine 179.218 574 
478 3-(carboxymethyl)indole-2,6-dicarboxylic_acid 263.206 574 
479 4-(aminomethyl)-1-methyl-1,3,4-trihydroquinolin-2-one 190.244 574 
480 N-(5,7-dimethylpyridino[3,2-e]pyridin-2-yl)acetamide 215.254 574 
481 piperidine-1-carbaldehyde 113.159 574 
482 1-(piperidin-4-yl)butan-1-one 155.239 575 
483 1,2,3,4-tetrahydroquinoline 133.193 575 
484 1-benzylpiperidine-4-carbaldehyde 203.283 575 
485 2-ethylbenzimidazole 146.191 575 
486 6-aminoindole 132.165 575 
487 N-((1E)-2-(3-pyridyl)-1-azavinyl)-2-pyridylcarboxamide 226.237 575 
488 N,N-dimethyl-o-toluidine 135.208 575 
489 N-acridin-9-ylacetamide 236.273 575 
490 4-[benzylamino]butan-1-ol 179.261 576 
491 N,N-dimethylaniline 121.182 576 
492 N,N-dimethylcyclohexylamine 127.229 576 
493 (4-aminophenyl)-N-(cyclopentylideneazamethyl)carboxamide 217.27 577 
494 [(2-hydroxyethyl)methylamino]-N-benzamide 194.233 577 
495 1-ethyl-4-pyrazol-3-ylpyrazole 162.194 577 
496 2-(ethylamino)-4-methylphenol 151.208 577 
497 3-[4-(acetylamino)phenyl]propanoic_acid 207.229 577 
498 methyl_2-amino-2-phenylacetate 165.191 577 
499 
N-(2,2,6,6-tetramethyl(4-piperidyl)){2-[N-(2,2,6,6-tetramethyl(4-
piperidyl))carbamoyl]phenyl}carboxamide 
442.643 577 
500 N-(2-amino-4,6-dimethylphenyl)acetamide 178.233 577 
501 o-toluidine 107.155 577 
502 [2-(pyrrolidinylmethyl)phenyl]methan-1-ol 191.272 578 
503 1,1,4,7,10,10-hexamethyltriethylenetetramine 230.396 578 
504 1-[3-(methylamino)propyl]-3-hydrobenzimidazol-2-one 205.259 578 
505 N,N',N''-trimethylbis(hexamethylene)triamine 257.462 578 
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506 (indol-3-ylmethyl)dimethylamine 174.245 579 
507 1-(2-aminoethyl)-3-methyl-1,3-dihydroquinazoline-2,4-dione 219.243 579 
508 1,1,2,3-tetramethylpiperidin-4-one 156.247 579 
509 4-pyrrolidinylpyridine 148.207 579 
510 methyl_2-(4-oxo-2-piperidyl-3,5,6-trihydropyrimidin-5-yl)acetate 253.3 579 
511 p-toluidine 107.155 579 
512 [2-(5,5-dimethyl(1,3-dioxolan-4-ylidene))ethyl]trimethylamine_iodide 186.273 580 
513 2-prop-2-enylisoquinoline_bromide 170.233 581 
514 3-acetyl-4-methylpyrrole 123.154 581 
515 4,5-dimethoxy-2-morpholin-4-ylphenylamine 238.286 581 
516 4-[4-(dimethylamino)phenyl]butan-2-ol 193.288 581 
517 1,4-bis[(3-methyl(2-pyridyl))methyl]piperazine 296.414 582 
518 1-[(3,4-dimethoxyphenyl)methyl]-4-piperidylamine 250.34 582 
519 2-(phenylcarbonylamino)propanoic_acid 193.202 582 
520 2-methylindoline 133.193 582 
521 2-[(2-carboxyethyl)amino]benzene-1,4-dicarboxylic_acid 253.211 583 
522 N-ethylaniline 121.182 583 
523 N-ethylbenzylamine 135.208 583 
524 2-aminobenzimidazole 133.152 584 
525 
N-(4-aminophenyl){3-[N-(4-
aminophenyl)carbamoyl]phenyl}carboxamide 
346.388 584 
526 methyl(2-(2-pyridyl)ethyl)(2-pyridylmethyl)amine 227.308 585 
527 
N-(2,2,6,6-tetramethyl(4-piperidyl))-2-[(2,2,6,6-tetramethyl(4-
piperidyl))amino]acetamide 
352.562 585 
528 [4-({[3-(dimethylamino)propyl]amino}methyl)phenyl]diethylamine 263.425 586 
529 1-(phenylcarbonyl)-4-piperidylpiperidine-4-carboxamide 315.414 586 
530 1,2,3,4-tetrahydroisoquinoline 133.193 586 
531 1,2-bis(3-aminopropylamino)ethane 174.289 586 
532 2-(cyclohexylcarbonylamino)acetic_acid 185.222 586 
533 2,3,5,6-tetramethylpyrazine 136.196 586 
534 4-(2,4,6-trimethylphenyl)-1,3-thiazolin-2-imine_bromide 218.316 586 
535 N,N-diethylbutylamine 129.245 586 
536 2-ethylpyrazine 108.143 587 
537 5-methylbenzimidazole 132.165 587 
538 (4,6-dimethylpyrimidin-2-yl)(5-methyl(4H-1,2,4-triazol-3-yl))amine 204.234 588 
539 3-aminoindolin-2-one 148.164 588 
540 4-(3-methyl-5-oxo-2-pyrazolinyl)benzoic_acid 218.212 588 
541 8-methoxy-2-methylquinoline 173.214 588 
542 N-(2-aminophenyl)[(2-aminophenyl)amino]carboxamide 242.28 588 
543 1,3-dimethyl-5-[(propylamino)methyl]-3-hydrobenzimidazol-2-one 233.313 589 
544 1,3-dimethylbutylamine 101.191 589 
545 
methyl_3-(N-{3-[N-
benzylcarbamoyl]propanoylamino}carbamoyl)propanoate 
335.359 589 
546 2-pyridyl-N-(3-pyridyl)carboxamide 199.212 590 
547 2-(1,5-dimethylpyrazol-4-yl)benzimidazole 212.254 591 
548 3-(3-pyridyl)-1,3-dihydroquinazoline-2,4-dione 239.233 591 
549 
N-[1,1-bis(hydroxymethyl)-2-hydroxyethyl]-N'-phenylethane-1,2-
diamide 
268.269 591 
550 1-aminoindan 133.193 592 
551 2-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-hydropyrimidin-4-one 275.307 592 
552 2-methylbenzylamine 121.182 592 
553 5,6-dimethylquinoxaline-2,3-diol 190.201 592 
554 cycloheptylamine 113.202 593 
555 isoquinolylmethylamine 158.202 593 
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556 tris[2-(isopropylamino)ethyl]amine 272.476 593 
557 
[(1E)-1-amino-2-(4,6-dimethylpyrimidin-2-yl)-2-azavinyl](3-
pyridylmethyl)amine 
256.31 594 
558 1-ethyl-3-methyl-4-pyrazol-3-ylpyrazole 176.221 594 
559 2-(4-pyridyl)quinoline-4-carboxylic_acid 250.256 594 
560 
2-hydroxy-2-(6-hydroxy-2-oxocyclohex-1(6)-enyl)-2-
hydrocyclopenta[1,2-a]benzene-1,3-dione 
272.257 594 
561 cyclohexylurea 142.2 594 
562 [(2,3-dimethoxyphenyl)methyl]methylamine 181.234 595 
563 
1-((4aS,9bR)-2,8-dimethylpiperidino[4,3-b]indolin-5-yl)-2-
piperidylethan-1-one 
327.469 595 
564 2-piperidylphenol 177.246 595 
565 
4-{2-oxo-2-[4-benzylpiperazinyl]ethyl}-2,5-diazabicyclo[4.4.0]decan-3-
one 
370.494 595 
566 2-(3-pyridyl)benzimidazole 195.223 596 
567 3-methylbenzylamine 121.182 596 
568 4-methylbenzylamine 121.182 596 
569 cyclohexanecarboxamide 127.186 596 
570 
[(4R,5R)-5-(N,N-dimethylcarbamoyl)-2,2-dimethyl(1,3-dioxolan-4-yl)]-
N,N-dimethylcarboxamide 
244.29 597 
571 (S)-(-)-N,alpha-dimethylbenzylamine 135.208 598 
572 3-(3-hydroxypropyl)indolin-2-one 191.229 598 
573 6-benzyl-1,3,5-triazine-2,4-diamine 201.23 598 
574 8-methyl-3-phenyl-1,3,4,8-tetraazaspiro[4.5]decan-2-one 246.311 598 
575 N-(1-methyl-2-oxo-2-piperidylethyl)-3-pyridylcarboxamide 261.323 598 
576 N-(3,5-diamino-2-methylphenyl)benzamide 241.292 598 
577 propyl_piperidine-2-carboxylate 171.239 598 
578 allylcyclohexylamine 139.24 599 
579 3-(pyrrolylmethyl)pyridine 158.202 600 
580 N-((1E)-2-(4-pyridyl)-1-azavinyl)benzamide 225.249 600 
581 
N-(3-(2-imidazolin-2-yl)phenyl)[(3-(2-imidazolin-2-
yl)phenyl)amino]carboxamide 
348.407 600 
582 2,5-dimethylbenzimidazole 146.191 601 
583 methyl_2-(2,2,6,6-tetramethyl-4-piperidyl)acetate 213.319 601 
584 N-methyl-phenethylamine 135.208 601 
585 phenylpiperazine_chloride 162.234 601 
586 1-cyclohexyl-3-(2,2,6,6-tetramethyl(4-piperidyl))imidazolidin-4-one 307.478 602 
587 4,5-dimethyl-1,2-phenylenediamine 136.196 602 
588 [4-amino-6-(dimethylamino)(1,3,5-triazin-2-yl)]dimethylamine 182.228 603 
589 4-phenyl-1-(4-piperidyl)-4-imidazolin-2-one 243.308 603 
590 N-(3-acetylphenyl)acetamide 177.202 603 
591 
2-(4-methyl-1-oxo(2-hydrophthalazin-2-yl))-N-(2-
pyridylmethyl)acetamide 
308.339 604 
592 2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-6-ol 191.272 604 
593 3-(4-pyridylmethyl)benzo[d]1,2,3-triazin-4-one 238.248 604 
594 
5,5-dimethyl-2-{[(2-piperazinylethyl)amino]ethylidene}cyclohexane-
1,3-dione 
293.408 604 
595 quinoxaline-2-carboxamide 173.174 604 
596 2-(2-piperazinylethyl)benzo[c]azolidine-1,3-dione 259.307 605 
597 3-methyl-N-methylbenzylamine 135.208 605 
598 methyl(2-phenoxyethyl)amine 151.208 605 
599 3,5-bis(2-oxopyrrolidinyl)benzoic_acid 288.302 606 
600 diisobutylamine 129.245 606 
601 N-isopropylaniline 135.208 606 
602 1,1-diethoxy-2-piperidylethane 201.308 607 
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603 2,2,4,4-tetramethyl-3-pentanone_imine 141.256 607 
604 2,3-dimethylaniline 121.182 607 
605 4-methylpyridino[3,2-h]quinoline 194.235 607 
606 N-(3,4,5-trimethoxyphenyl)acetamide 225.244 607 
607 2-(3-methoxyphenoxy)ethylamine 167.207 608 
608 5-benzyl-1H-1,2,3,4-tetraazole 160.178 608 
609 8-methoxy-1,2,3,4-tetrahydroquinoline 163.219 608 
610 (6-(1H-1,2,3,4-tetraazin-2-yl)-4-amino(1,3,5-triazin-2-yl))diethylamine 249.278 609 
611 10-methyl-3,10-dihydrobenzo[g]pteridine-2,4-dione 228.21 609 
612 2-aminobenzoic_acid 137.138 609 
613 7-aminoindole 132.165 609 
614 cyclohexanemethylamine 113.202 609 
615 
1,2-bis(2-morpholin-4-yl-2-oxoethyl)-4-phenyl-1,2,4-triazolidine-3,5-
dione 
431.447 610 
616 1-methoxy-2-(2-piperazinylethoxy)benzene 236.313 610 
617 3-(carboxymethyl)-2-methylindole-5-carboxylic_acid 233.223 610 
618 N,N-dimethyl-p-toluidine 135.208 610 
619 3-methyl-4-phenyl-1,2,4-triazole 159.19 611 
620 7-amino-4,8-dimethylhydroquinolin-2-one 188.229 611 
621 (4-methylphenyl)imidazole 158.202 612 
622 3,3-dimethyl-2-phenyl-1-pyrrolin-5-ol 189.257 612 
623 4-aminoindan 133.193 612 
624 5-methyl-1-(3-(1,2,3,4-tetraazolyl)phenyl)-1,2,3,4-tetraazole 228.216 612 
625 
6-(methylpropyl)-1-benzyl-1,3,5,6,7,8-hexahydro-6,8-diazaquinazoline-
2,4-dione 
314.386 612 
626 
dimethyl(4-{[(2,2,6,6-tetramethyl(4-
piperidyl))amino]methyl}phenyl)amine 
289.463 612 
627 propyl_3-[(3,5-dioxo-2H,4H-1,2,4-triazin-6-yl)amino]propanoate 242.234 612 
628 tripropylamine 143.272 612 
629 2-methoxy-3-methylbenzenecarbohydrazide 180.206 613 
630 3-phenoxypropylamine_chloride 151.208 613 
631 
N-(2-methoxyethyl)-2-(3-methyl-2-oxo(3-
hydrobenzimidazolyl))acetamide 
263.296 614 
632 
N-{(1E)-2-[4-(dimethylamino)phenyl]-1-azavinyl}-2-(3,5-dioxo(2H,4H-
1,2,4-triazin-6-yl))acetamide 
316.319 614 
633 1,12-diaminododecane 200.367 615 
634 1-acetylindoline-5-carboxylic_acid 205.213 615 
635 5-amino-1,3-dimethyl-6-piperidyl-3-hydrobenzimidazol-2-one 260.338 615 
636 N-methyl-o-toluidine 121.182 615 
637 1,3-dimethyl-2,4-dioxo-1,3-dihydroquinazoline-6-carboxylic_acid 234.211 616 
638 
1-(3,4-dimethylphenyl)-6-(methylpropyl)-1,3,5,6,7,8-hexahydro-6,8-
diazaquinazoline-2,4-dione 
328.413 617 
639 3-methyl-5-oxo-1-phenyl-3-pyrazoline-4-carbaldehyde 202.212 617 
640 4-methoxy-2,3-dimethylphenylamine 151.208 617 
641 4-methylpiperidyl_3-piperidyl_ketone 210.319 617 
642 2-(butylamino)-N-{4-[2-(butylamino)acetylamino]phenyl}acetamide 334.461 618 
643 
3,5-dimethyl-9-(2-phenylethyl)-3,5,7,9-tetraazabicyclo[4.4.0]decane-2,4-
dione 
302.375 618 
644 4-vinylaniline 119.166 618 
645 5-(cyclohexylamino)-6-methyl-2H-1,2,4-triazin-3-one 208.263 618 
646 3-{[2-(dimethylamino)ethyl]amino}-5-phenylcyclohex-2-en-1-one 258.363 619 
647 methylethyl_2-[(3,5-dioxo-2H,4H-1,2,4-triazin-6-yl)amino]propanoate 242.234 619 
648 2,4,8-trimethylquinoline 171.241 620 
649 N,N-dimethyl-m-toluidine 135.208 620 
650 triamterene 253.266 620 
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651 3-(2-aminoethyl)-4,6-dimethyl-3-hydropyrimidin-2-one 167.21 621 
652 5-aminoindan 133.193 621 
653 
N-(2-hydroxypropyl)[1-(4-methylphenyl)-5-oxopyrrolidin-3-
yl]carboxamide 
276.335 621 
654 [3-(2,5-dioxoazolidinyl)phenyl]-N-(2-pyridyl)carboxamide 295.297 622 
655 1,2-dimethylindole-5-ylamine 160.218 622 
656 
2-(4-methyl-1-oxo(2-hydrophthalazin-2-yl))-N-(2,2,6,6-tetramethyl(4-
piperidyl))acetamide 
356.467 622 
657 2,9-dimethylpyridino[3,2-h]quinoline 208.262 622 
658 3,5-dimethylaniline 121.182 622 
659 acridine-4-ylamine 194.235 622 
660 N-(4-methylphenyl)-3-(4-methylpiperazinyl)propanamide 261.366 622 
661 1-(2-phenylethyl)piperidine-3-carboxylic_acid 233.31 623 
662 [4-(2-aminoethyl)phenyl]dimethylamine 164.25 624 
663 2-(trimethylamino)ethyl_benzoate_chloride 208.28 624 
664 4-(N-phenylcarbamoyl)butanoic_acid 207.229 624 
665 acridine-9-ylamine 194.235 624 
666 
N-[(1E,3E)-4-(2-pyridylcarbonylamino)-1,4-diazabuta-1,3-dienyl]-2-
pyridylcarboxamide 
296.288 624 
667 1-(cyclohexylcarbonyl)-4-piperidylpiperidine-4-carboxamide 321.462 625 
668 3-amino-4-{[2-(diethylamino)ethyl]amino}chromen-2-one 275.35 625 
669 3-oxo-N-benzylbutanamide 191.229 625 
670 
5,5-dimethyl-3-[(1,2,3,4-tetrahydroisoquinolylmethyl)amino]cyclohex-2-
en-1-one 
284.4 625 
671 2-(2-methylpyridyl)-1-phenylethan-1-one_chloride 212.271 626 
672 
3-azatetracyclo[7.6.1.0<2,7>.0<10,15>]hexadeca-2(7),3,5,10(15),11,13-
hexaen-1-ol 
223.274 626 
673 ethyl_4,6-dimethyl-2-oxo-3,4,5-trihydropyrimidine-5-carboxylate 198.221 626 
674 N-(carbamoylmethyl)-2-quinolylcarboxamide 229.238 626 
675 
N-{(1E)-2-[5-(hydroxymethyl)-2,4-dimethylphenyl]-1-
azavinyl}aminoamide 
221.258 626 
676 N-ethyl-m-toluidine 135.208 626 
677 1-(tert-butyl)-2,3-dimethylpiperidin-4-one 183.293 627 
678 3-ethyl-9-hydroxy-2-methyl-5-hydropyridino[1,2-a]pyrimidin-4-one 204.228 627 
679 4-(dimethylamino)-2-methyl-1-phenylbutan-2-ol 207.315 627 
680 benzyltriethylazanium_chloride 192.324 627 
681 2-pyrrolylpropanoic_acid 139.154 628 
682 3-hydroxy-4-(iminoethyl)-1-methyl-5-phenyl-3-pyrrolin-2-one 230.266 628 
683 4-amino-3-(3,4-dimethoxyphenyl)azoline-2,5-dione 248.238 628 
684 4-methyl-2-[3-(methylamino)propyl]phenol 179.261 628 
685 7,7-dimethyl-3-benzyl-1,2,3,4,6,7,8-heptahydroquinazolin-5-one 270.374 628 
686 8-amino-6-methyl-1,3,4-trihydroquinolin-2-one 176.218 628 
687 dibutylamine 129.245 628 
688 1-phenyl-2-pyridylpropan-1-one 212.271 629 
689 2-pyridyl-N-[2-(2-pyridylcarbonylamino)ethyl]carboxamide 270.29 629 
690 N-ethyl-o-toluidine 135.208 629 
691 (2-methylphenyl)-N-(2,2,6,6-tetramethyl(4-piperidyl))carboxamide 274.405 630 
692 [4-(4-aminophenyl)piperazinyl]-N,N-diethylcarboxamide 276.381 630 
693 5-quinolylhydrazine 159.19 630 
694 6-[(2,3-dimethylphenyl)amino]-1,3-dihydropyrimidine-2,4-dione 231.254 630 
695 methyl_6-(methoxycarbonyl)pyridine-2-carboxylate 195.174 630 
696 (phenylamino)-N-(2,4,6-trimethyl(3-pyridyl))carboxamide 255.319 631 
697 1-benzyl-4-pyridylamine_bromide 185.248 631 
698 3,3-dimethyl-1-phenylurea 164.207 631 
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699 N-cyclohexylformamide 127.186 631 
700 hexyltrimethylazanium_bromide 144.279 632 
701 2-indol-3-ylbutanedioic_acid 233.223 633 
702 3-[(2-methylpropyl)amino]-3-phenylpropanoic_acid 221.299 633 
703 N-(4-methoxy-2,6-dimethylphenyl)acetamide 193.245 633 
704 2-acetyl-3-methyl-4-oxo-5,6,7-trihydroindole 191.229 634 
705 5-phenyl-5-hydro-1,2,3-triazolo[4,5-d]pyridazin-4-ol 213.198 634 
706 
N'-(2-methoxyethyl)-N-{[3-({[N-(2-
methoxyethyl)carbamoyl]carbonylamino}methyl)phenyl]methyl}ethane-
1,2-diamide 
394.427 634 
707 N-ethyl[4-(2-1,2,3,4-tetrahydroisoquinolylmethyl)phenyl]carboxamide 294.396 634 
708 (3,7-dimethyl(2-quinolyl))(3-pyridylmethyl)amine 263.341 636 
709 2-(1,3-dimethyl-2,5-dioxo(1,3-diazolidin-4-yl))-N-cyclohexylacetamide 267.327 636 
710 cyclohexyl_2-[(2,2,6,6-tetramethyl-4-piperidyl)amino]acetate 296.452 636 
711 indol-6-ylmethan-1-ol 147.176 636 
712 1-[2-(2-methoxyphenoxy)acetyl]imidazolidin-2-one 250.254 637 
713 phenylpurin-6-ylamine 211.226 637 
714 N,N-dimethylhexylamine 129.245 638 
715 2,3-dimethyl-6-phenylpyridine 183.252 639 
716 3-methylcyclohex-2-en-1-one 110.155 639 
717 
4-((1E)-2-(4-pyridyl)-1-azavinyl)-2,3-dimethyl-1-phenyl-3-pyrazolin-5-
one 
292.34 639 
718 2-amino-N-[2-(methylethyl)phenyl]acetamide 192.26 640 
719 
6-cyclopentyl-1-(2-phenylethyl)-1,3,5,6,7,8-hexahydro-6,8-
diazaquinazoline-2,4-dione 
340.424 640 
720 
N'-(2-methylpropyl)-N-(2,2,6,6-tetramethyl(4-piperidyl))ethane-1,2-
diamide 
283.413 640 
721 rolitetracycline 527.573 640 
722 4-{[4-(dimethylamino)phenyl]azamethylene}cyclohexa-2,5-dien-1-one 226.277 641 
723 benzyl-2-pyridylamine 184.24 642 
724 dimethyl[(4-vinylphenyl)methyl]amine 161.246 642 
725 
4-methyl-2-{4-[(4-methylpiperazinyl)carbonyl]phenyl}-2-
hydrophthalazin-1-one 
362.43 643 
726 N-methyldibutylamine 143.272 643 
727 4-(hydroxymethylene)-3-methyl-1-(4-methylphenyl)-1,2-diazolin-5-one 216.239 644 
728 5-acetyl-1,3-dimethyl-2-oxo-3-hydrobenzimidazole 204.228 644 
729 diethyl_2-{[(acetylamino)amino]aminomethylene}propane-1,3-dioate 259.261 644 
730 2H,4H-benzo[e]1,4-oxazin-3-one 149.149 645 
731 2-phenylbenzimidazole 194.235 645 
732 3,4-diacetyl-1,2,5-trimethylpyrrole 193.245 645 
733 methyl_2-(1,3,7-trimethyl-2,6,8-trioxo-1,3,7-trihydropurin-9-yl)acetate 282.255 645 
734 N-((1E)-2-phenyl-1-azavinyl)-4-pyridylcarboxamide 225.249 645 
735 
N-[(1E)-2-(2-methylindol-3-yl)-1-azavinyl]-3-(3-methyl-5-oxo(2-
pyrazolin-4-yl))propanamide 
325.369 645 
736 phenyl(1,2,5-trimethyl(4-piperidyl))amine 218.341 645 
737 2-amino-4-propylphenol 151.208 646 
738 2-oxoindoline-3-carbaldehyde 161.16 646 
739 3-phenylthiopropylamine 167.268 647 
740 4-(4-pyridylmethyl)phenylamine 184.24 647 
741 
dimethyl{3-[(5,6,7,8,9-pentahydro-4aH-carbazol-3-
ylmethyl)amino]propyl}amine 
285.431 647 
742 
(1R)-1-[((10S,11aS,9R)-9-ethyl-2,3-dimethoxy(5,6,7,11a-
tetrahydropiperidino[2,1-a]isoquinolin-10-yl))methyl]-6,7-dimethoxy-
1,2,3,4-tetrahydroisoquinoline_chloride_hydrate 
480.646 648 
743 2-[2-(2-aminophenoxy)ethoxy]phenylamine 244.293 648 
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744 2-methylbenzo[d]1,3-oxazin-4-one 161.16 649 
745 methyl_3-(3-amino-4-methylphenyl)propanoate 193.245 649 
746 1-(2-methylindolinyl)-2-(4-methylpiperazinyl)ethan-1-one 273.377 650 
747 
3-[(1E,3E)-4-(3-aminophenyl)-1-methyl-2,3-diazapenta-1,3-
dienyl]phenylamine 
266.345 650 
748 amino-N-[2-(2-methylindol-3-yl)ethyl]amide 217.27 650 
749 quinoline-5-carbaldehyde 157.171 650 
750 2-((1E)prop-1-enyl)-2-prop-2-enylpiperidine 165.278 651 
751 N-((1E)-2-phenyl-1-azaprop-1-enyl)-2-pyridylacetamide_chloride 254.311 652 
752 N-pentylformamide 115.175 652 
753 (cyclohexylamino)-N-(2,2,6,6-tetramethyl(4-piperidyl))carboxamide 281.44 653 
754 1,2,5-trimethylpyrrole 109.171 653 
755 2-[2-(4-oxo-3-hydroquinazolin-3-yl)acetylamino]benzamide 322.323 653 
756 6-(azaperhydroepin-2-ylideneazamethyl)-2H,3H-benzo[e]1,4-dioxane 246.308 653 
757 3-(2-aminophenyl)pentan-3-ol 179.261 654 
758 
4-[(2S,6S)-2,6-bis(2-methylprop-2-enyl)-4-1,2,5,6-
tetrahydropyridyl]hepta-1,6-dien-4-ylamine 
300.486 654 
759 
1-ethyl-3-[4-(2-oxo(3-hydrobenzimidazolyl))piperidyl]azolidine-2,5-
dione 
342.397 655 
760 7-methyl-4-(piperazinylmethyl)chromen-2-one 258.319 655 
761 diethyl[2-(2-methoxyphenoxy)ethyl]amine_ethanedioic_acid 223.314 655 
762 (2,6-dioxo(1,3-dihydropyrimidin-4-yl))-N-(2-ethoxyphenyl)carboxamide 275.263 656 
763 {[3-(dimethylamino)propyl]amino}-N-naphthylcarboxamide 271.361 656 
764 1-methyl-4-piperidyl_2-phenylacetate 233.31 657 
765 2-(1-cyclohexyl-2,5-dioxo(1,3-diazolidin-4-yl))-N-(3-pyridyl)acetamide 316.359 657 
766 5-(1,5-dimethylpyrrol-2-yl)-1H-1,2,3,4-tetraazole 163.182 657 
767 naphthyl-N-(3-pyridylmethyl)carboxamide 262.31 657 
768 [(3-amino-1-phenyl(2-naphthyl))methyl]dimethylamine 276.38 658 
769 {2-[(cyclohexylamino)methyl]phenyl}methan-1-ol 219.326 658 
770 
2-(2-methoxyphenyl)-2,5,6,7,8,8a-hexahydro-2,8a-diazaindolizine-1,3-
dione 
261.28 658 
771 1,2,5-trimethyl-4-phenylpyridine 198.287 659 
772 
1,5-dimethyl-3-(2-oxo-2-piperidylethyl)-1,3,5-triazaperhydroine-2,4,6-
trione 
282.299 659 
773 4-hydroxy-1-methylhydroquinolin-2-one 175.187 659 
774 quinoline-7-carbaldehyde 157.171 659 
775 (2-hydroxyphenyl)-N-methylcarboxamide 151.165 660 
776 
(4-methylphenyl)-N-{2-[(4-
methylpiperazinyl)carbonyl]phenyl}carboxamide 
337.421 660 
777 1-(4-piperidylphenyl)azoline-2,5-dione 256.304 660 
778 methyl_3-[((1R)-1-methyl-2-phenylethyl)amino]propanoate 221.299 660 
779 2-benzylbenzimidazole 208.262 662 
780 5,6-dimethyl-3-methylthio-1,2,4-triazine 155.217 662 
781 
3,3,9-trimethyl-2,3,4,5,6,7,8,9,4b,8a-decahydro-4b-azaphenanthrene-
1,10-dione 
261.363 663 
782 4,5-dihydro-6H-1,3-thiazin-2-yl(4-methylphenyl)amine 206.305 663 
783 6-propyl-2H-benzo[d]1,3-dioxolene-5-ylamine 179.218 663 
784 (2-phenylethyl)bis(4-pyridylmethyl)amine 303.406 665 
785 2,3-dimethyl-5,6,7-trihydroindol-4-one 163.219 665 
786 2,6-di(2-pyridyl)pyridine 233.272 665 
787 2-hydroxyphenyl_pyrrolidinyl_ketone 191.229 665 
788 5,8-dimethoxy-2,4-dimethylquinoline 217.267 665 
789 chromen-4-one 146.145 666 
790 2,4,7-trimethylpyridino[2,3-b]quinoline-5-ylamine 237.304 667 
791 amino-N-[(2-ethoxyphenyl)methyl]amide 194.233 667 
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792 N-cyclopentyl-2-(2-1,2,3,4-tetrahydroisoquinolyl)acetamide 258.363 667 
793 3,3-dimethyl-1-prop-2-enyl-1,2,3,4-tetrahydroisoquinoline 201.311 668 
794 5-(3-methylbutanoylamino)benzene-1,3-dicarboxylic_acid 265.265 668 
795 (tert-butyl)quinazolin-4-ylamine 201.271 669 
796 1-{[(2-phenylethyl)(hydroxyphosphoryl)]methyl}azaperhydroepin-2-one 295.318 669 
797 2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-8-ol 191.272 669 
798 2-amino-N-(2-naphthyl)propanamide_chloride 214.266 669 
799 3-[(4-morpholin-4-ylphenyl)azamethylene]-2H-benzo[c]azolidinimine 306.366 669 
800 (2-aminophenyl)-N-propylcarboxamide 178.233 670 
801 2,3,3-trimethyl-3H-pyrrolo[3,2-h]quinoline 210.278 670 
802 5,6,7,8,9-pentahydro-4aH-carbazole-3-ylamine 186.256 670 
803 
4-(1,3-dioxobenzo[c]azolidin-2-yl)-N-methyl-N-(1,2,2,6,6-
pentamethyl(4-piperidyl))butanamide 
399.532 671 
804 4-isopropylaniline 135.208 671 
805 5,6,7,8,10-pentahydroacridin-9-one 199.252 671 
806 4-propylaniline 135.208 674 
807 
N-{(1E)-2-[4-(dimethylamino)phenyl]-1-azavinyl}(3-
aminophenyl)carboxamide 
282.344 674 
808 4-[3-(1-carbamoyl-4-piperidyl)propyl]piperidinecarboxamide 296.412 675 
809 5-(3-pyrazolylphenyl)-1H-1,2,3,4-tetraazole 212.213 675 
810 N-[(1E)-2-(3-methylphenyl)-1-azavinyl]-2-pyridylacetamide_chloride 254.311 675 
811 indazole 118.138 676 
812 N-{2-[4-(dimethylamino)phenyl]ethyl}(cyclohexylamino)carboxamide 289.42 676 
813 1-phenyl-1,2,3,4-tetraazole 146.151 677 
814 3-(2H,3H-benzo[3,4-e]1,4-dioxan-6-ylazamethylene)isoindolylamine 279.298 677 
815 3-[(4-ethylpiperazinyl)methyl]-2,5-dimethylbenzaldehyde 260.378 677 
816 [4,6-bis(dimethylamino)(1,3,5-triazin-2-yl)]dimethylamine 210.281 678 
817 2-methyl-4-(phenylmethylene)-1,3-oxazolin-5-one 187.198 678 
818 3-(2-methylpyrimidin-4-yl)benzoic_acid 214.223 678 
819 N-{4-[4-(2-methylpropanoyl)piperazinyl]phenyl}propanamide 303.403 678 
820 4-hydroxy-5-phenylcyclopent-4-ene-1,3-dione 188.182 679 
821 2,4,6-trimethylaniline 135.208 681 
822 4-indol-3-ylbutanamide 202.255 681 
823 1-(5-methyl-2-pyridyl)-1,2,3,4-tetraazole 161.166 683 
824 2-cyclohexyl-1-methylbenzimidazole 214.31 684 
825 tris(4-aminophenyl)methan-1-ol 305.379 684 
826 (2-butylthioethyl)thiocarboxamidine 192.337 685 
827 2-(2,4,7-trimethylindol-3-yl)ethylamine 202.299 685 
828 3,4-dimethyl-1-(2-phenylethyl)pyridine 212.314 685 
829 6-(1,3-dioxobenzo[c]azolidin-2-yl)-N-(2-pyridylmethyl)hexanamide 351.404 685 
830 amino(4,8-dimethylquinazolin-2-yl)carboxamidine 215.257 685 
831 2-(2-naphthyloxy)ethylamine 187.241 686 
832 3-(phenylamino)cyclohex-2-en-1-one 187.241 687 
833 3-acetylindole 159.187 687 
834 4-[bis(4-hydroxyphenyl)methylene]cyclohexa-2,5-dien-1-one 290.318 687 
835 5-(4-methylphenyl)-2H-1,2,3,4-tetraazole 160.178 687 
836 5-imidazolyl-1-phenyl-1,2,3,4-tetraazole 212.213 687 
837 8-methoxy-2,4-dimethyl-2,3-dihydrofurano[3,2-c]quinoline 229.278 687 
838 
[4-({(1E)-2-[4-(N,N-dimethylcarbamoyl)phenyl]-2-
azavinyl}amino)phenyl]-N,N-dimethylcarboxamide 
338.408 688 
839 2-(diethylamino)-N-(2,4,6-trimethylphenyl)acetamide 248.367 688 
840 naphthyl-1,3-thiazolin-2-ylamine 228.311 688 
841 
(6Z,4E)-7-amino-3,3,4-trimethyl-7-(4-methylphenyl)-5,6-diazahepta-4,6-
dien-2-one_iodide 
259.35 689 
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842 6-phenylphenanthridine-3,8-diamine 285.348 689 
843 N-(6-methyl(2-pyridyl))quinoxalin-6-ylcarboxamide 264.286 689 
844 N-[4-(carbamoylmethoxy)phenyl](3,4,5-trimethoxyphenyl)carboxamide 360.366 689 
845 o-isopropylaniline 135.208 689 
846 1-(2-phenylethyl)-1,4-diazaperhydroine-2,6-dione 218.255 690 
847 1-naphthyl-5-oxopyrrolidine-3-carboxylic_acid 255.273 690 
848 methyl_3-[N-benzylcarbamoyl]propanoate 221.255 690 
849 2,7,8-trimethylquinolin-4-ol 187.241 691 
850 2-amino-6-methylheptane 129.245 691 
851 
6-(phenylethyl)-1-benzyl-1,3,5,6,7,8-hexahydro-6,8-diazaquinazoline-
2,4-dione 
362.43 691 
852 N-[(1E)-2-(2,4-dimethoxyphenyl)-1-azavinyl]aminoamide 223.231 691 
853 (2E)-3-(2-quinolyl)prop-2-enoic_acid 199.209 692 
854 3,6-bis(indol-3-ylmethyl)-1,4-diazaperhydroine-2,5-dione 372.426 692 
855 butyl_3-(3,5-dioxo-2H,4H-1,2,4-triazin-6-yl)propanoate 241.246 692 
856 4-hydroxy-3-propylhydroquinolin-2-one 203.24 693 
857 methyl_3-[(3-imino-2H-benzo[c]azolidinylidene)azamethyl]benzoate 279.298 693 
858 3-methyl-1-{4-[(3-methylphenyl)methyl]piperazinyl}butan-1-one 274.405 694 
859 
7-(4-hydroxyphenyl)-4-methyl-2-benzyl-3,4,6,7-tetrahydro-4,6-
diazaisoindole-1,5-dione 
349.388 694 
860 
[(3-amino-5-imino(1,2-diazolin-4-ylidene))azamethyl](4-
methoxyphenyl)amine 
232.244 695 
861 1-(indol-3-ylmethyl)-3,5,5-trimethyl-2-pyrazoline 241.335 695 
862 2-[(octan-2-yl)amino]ethan-1-ol 173.298 695 
863 5,6-dimethylbenzotriazole 147.179 695 
864 1-(4-methoxyphenyl)azoline-2,5-dione 203.197 696 
865 2-(spiro[3,4-dihydroisoquinoline-3,1'-cyclohexane]ylamino)acetic_acid 272.346 696 
866 3-oxo-5,6-diphenyl-2-hydropyridazine-4-carboxylic_acid 292.293 696 
867 
N-(3,4-dimethoxyphenyl)(3-oxo(2H,4H-benzo[3,4-e]1,4-oxazin-6-
yl))carboxamide 
328.324 696 
868 7-methyl-2-oxohydroquinoline-3-carboxylic_acid 203.197 697 
869 (4E)-hex-4-en-3-one 98.144 698 
870 3-(dimethylamino)-1-(2-naphthyl)propan-1-one 227.305 698 
871 6-amino-3-benzyl-3-hydroquinazolin-4-one 251.287 698 
872 
N'-(2-phenylethyl)-N-(2,2,6,6-tetramethyl(4-piperidyl))ethane-1,2-
diamide 
331.457 699 
873 bis[4-(dimethylamino)phenyl]methan-1-ol 270.374 700 
874 1-(4-methoxyphenyl)pyrrolidin-2-one 191.229 701 
875 
trimethyl[2-(5-methyl-5-phenyl(1,3-dioxolan-4-
ylidene))ethyl]amine_iodide 
248.344 701 
876 4-aminophenyl_4-methylpiperidyl_ketone 218.298 704 
877 5-methyl-1-[(phenylmethoxy)methyl]-1,3-dihydropyrimidine-2,4-dione 246.265 704 
878 8-ethyl-2-methylquinolin-4-ol 187.241 704 
879 2-propylaniline 135.208 705 
880 
3-({(1E)-2-[4-(dimethylamino)phenyl]-1-azavinyl}amino)-6-methyl-4H-
1,2,4-triazin-5-one 
272.309 706 
881 diethyl(4-methyl(2-quinolyl))amine 214.31 706 
882 N-allylaniline 133.193 706 
883 N-cyclohexyl-2-{4-[2-(cyclohexylamino)acetyl]piperazinyl}acetamide 364.53 706 
884 ((1Z)-1-morpholin-4-yl-2-phenyl-2-azavinyl)phenylamine 281.357 707 
885 (3-aminophenyl)phenylamine 184.24 707 
886 2-pyridyl-N-[3-(2-(4-pyridyl)ethyl)phenyl]carboxamide 303.363 708 
887 3-amino-5-(piperidylcarbonyl)phenyl_piperidyl_ketone 315.414 708 
888 1-(2-hydroxyphenyl)-2,6-dimethyl-5-phenylhydropyrimidin-4-one 292.337 709 
889 1-cyclohexylazoline-2,5-dione 179.218 709 
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890 3,4-diacetyl-1-ethyl-2,5-dimethylpyrrole 207.272 709 
891 3-indolinylpropylamine 176.261 709 
892 4-(1,2,3,4-tetrahydroquinolyl)-1,3,5-triazine-2-ylamine 227.268 709 
893 2-methyl-1H,3H-naphtho[1,2-e]1,3-oxazine 199.252 710 
894 
4,7-dimethoxy-5-[4-methyl-3-(morpholin-4-ylmethyl)(4,5-
dihydroisoxazol-5-yl)]-2H-benzo[d]1,3-dioxolene 
364.397 710 
895 2-[(2-methylindol-3-yl)methyl]benzimidazole 261.326 711 
896 4-(phenylmethoxy)phenylamine 199.252 711 
897 3,4,7,8-tetramethylpyridino[3,2-h]quinoline 236.316 712 
898 (2S,6R)-2,6-bis(2-methylprop-2-enyl)-1,2,5,6-tetrahydropyridine 191.316 713 
899 [2-(phenylamino)ethyl]benzylamine 226.321 713 
900 3-(6-methyl-2-oxohydropyridyl)propanoic_acid 181.191 713 
901 5-amino-3-phenyl-10-hydro-2-pyrrolino[1,2-a]quinazolin-2-one 275.309 713 
902 indeno[3,2-e]pyridino[2,3-b]pyrazin-10-one 233.229 713 
903 
methyl_3-(2,4-dioxo-3,10-dihydropyrimidino[4,5-b]quinolin-10-
yl)benzoate 
347.329 713 
904 N-(6-methyl(2-pyridyl))[(6-methyl(2-pyridyl))amino]carboxamide 242.28 713 
905 indol-3-yl-N-propylcarboxamide 202.255 714 
906 
N-[2-(diethylamino)ethyl]{2-[(N-
phenylcarbamoyl)amino]phenyl}carboxamide 
354.451 714 
907 N-phenyl-N'-{2-[4-benzylpiperazinyl]ethyl}ethane-1,2-diamide 366.462 714 
908 4-methyl-2-(4-methylquinazolin-2-yl)quinazoline 286.335 715 
909 N-[4-(dimethylamino)phenyl]-N'-(2-methylpropyl)ethane-1,2-diamide 263.339 715 
910 3,3,5-trimethyl-1-methylthio-3,4-dihydroisoquinoline 219.344 716 
911 4-(4-aminophenyl)piperazinyl_2-phenylphenyl_ketone 357.454 716 
912 (phenylcyclohexyl)prop-2-enylamine 215.338 718 
913 
N-(4-methoxyphenyl){[4-(2-morpholin-4-yl-2-
oxoethoxy)phenyl]amino}carboxamide 
385.419 719 
914 (2E)-4-indolinyl-4-oxobut-2-enoic_acid 217.224 720 
915 (3-pyridylmethyl)-1,2,3-trihydrocyclopenta[2,1-b]quinolin-9-ylamine 275.352 720 
916 7-methyl-5,6,7,8,10-pentahydroacridin-9-one 213.279 720 
917 N-[(1E)-2-(4-ethylphenyl)-1-azavinyl]-2-pyridylacetamide_chloride 268.338 720 
918 
2-(1-cyclohexyl-2,5-dioxo(1,3-diazolidin-4-yl))-N-[3-(2-(4-
pyridyl)ethyl)phenyl]acetamide 
420.51 721 
919 triisobutylamine 185.352 721 
920 2-(2-imino-3-methyl(3-hydrobenzimidazolyl))-1-phenylethan-1-one 265.314 723 
921 
2-[(4,4-dimethyl-2,6-dioxocyclohexyl)-3-pyridylmethyl]-5,5-
dimethylcyclohexane-1,3-dione 
369.46 723 
922 3-(dimethylamino)-1-[4-(methylethyl)phenyl]propan-1-one 219.326 724 
923 
5-[((1E)-2-indol-3-yl-1-azavinyl)amino]-6-methyl-2H-1,2,4-triazin-3-
one 
268.277 724 
924 5-hydroxy-2-azabicyclo[4.4.0]dec-2-yl_phenyl_ketone 259.347 724 
925 
N-(4-methylphenyl)-N'-{2-[4-(phenylcarbonyl)piperazinyl]ethyl}ethane-
1,2-diamide 
394.472 724 
926 
(1S,10S,11S,15S,2R,14R)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-
dimethyltetracyclo[8.7.0.0<2,7>.0<11,15>]heptadeca-3,6-diene-5,17-
dione 
358.433 725 
927 2-(3-pyridyl)indole 194.235 725 
928 indole-4-carbaldehyde 145.16 725 
929 3-(3-methylbutanoylamino)benzoic_acid 221.255 726 
930 4-(2-pyridylmethylthio)quinazoline 253.321 726 
931 (2-aminophenyl)-N-(cyclopentylideneazamethyl)carboxamide 217.27 727 
932 1-methylindole-3-carboxylic_acid 175.187 727 
933 2,3,4-trihydrobeta-carbolin-1-one 186.213 727 
934 (2-iminochromen-3-yl)-N-(4-methoxyphenyl)carboxamide 294.309 728 
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935 5-methyl-2-(1-methyl(4-pyridyl))indole 223.297 728 
936 
(4,6-dimethylpyrimidin-2-yl)[imino(5-phenyl(2-
pyrazolinyl))methyl]amine 
294.358 729 
937 1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carboxylic_acid 233.266 729 
938 6-methyl-2-(4-pyridyl)indole 208.262 729 
939 (4-phenylphenyl)-N-(4-pyridylmethyl)carboxamide 288.348 730 
940 
N-(4-{N-[(1E)-2-(3,4-dihydroxyphenyl)-1-
azavinyl]carbamoyl}phenyl)benzamide 
375.383 730 
941 (3,4-dimethylphenyl)(5-methyl(1,3-thiazolin-2-yl))amine 220.332 731 
942 
morpholin-4-yl-N-(4-{[4-(morpholin-4-
ylcarbonylamino)phenyl]methyl}phenyl)carboxamide 
424.499 731 
943 
N-((1E)-2-quinoxalin-2-yl-1-azavinyl)-2-(4-oxo(3-hydroquinazolin-3-
yl))acetamide 
358.359 731 
944 [(1E)-2-(4-methylphenyl)-1-azavinyl](4,6-dimethylpyrimidin-2-yl)amine 240.307 732 
945 1,7-dimethylbenzo[d]azolidine-2,3-dione 175.187 732 
946 1-benzyl-3-[4-benzylpiperazinyl]azolidine-2,5-dione 363.458 732 
947 
ethyl_(2E)-3-(N-{3-[N-(2,4-
dimethylphenyl)carbamoyl]propanoylamino}carbamoyl)prop-2-enoate 
361.397 732 
948 
N-[(1E)-2-(1-methylpyrrol-2-yl)-1-azavinyl]-N'-[(1E)-2-(1-methylpyrrol-
2-yl)-1-azavinyl]pentane-1,5-diamide 
342.4 732 
949 2-(3,3-dimethyl-2,3,4-trihydroisoquinolylidene)cyclohexane-1,3-dione 269.343 733 
950 1-(phenylmethylthio)-2-(4-pyridyl)ethane 229.339 734 
951 1-ethyl-2,5-dimethylpyrrole-3-carbaldehyde 151.208 735 
952 2-acetyl-1,2,3,4-tetrahydropyridino[4,3-b]indole 214.266 736 
953 3-[3-(1,3-dioxobenzo[c]azolidin-2-yl)propanoylamino]benzoic_acid 338.319 736 
954 4-((1E)-4-cyclohex-1-enyl-2-azabut-1-enyl)-1,2-dimethoxybenzene 273.374 736 
955 di-3-amino-4-methylphenyl_ketone 240.304 736 
956 methyl_4-cyclohexyl-5-oxo-1,2,4-triazoline-3-carboxylate 225.247 738 
957 N-(3,4-dimethoxyphenyl)[(3,4-dimethoxyphenyl)amino]carboxamide 332.355 738 
958 5-methylindole-3-carbaldehyde 159.187 739 
959 
2-(1,3-diethyl-2,5-dioxo(1,3-diazolidin-4-yl))-N-[2-(4-
methoxyphenyl)ethyl]acetamide 
347.413 741 
960 3-phenyl-N-[4-(4-pyridylmethyl)phenyl]propanamide 316.402 741 
961 N-[(1E)-2-(4-methylphenyl)-1-azavinyl](4-aminophenyl)carboxamide 253.303 741 
962 3-(3-aminophenyl)chromen-2-one 237.257 743 
963 [4-(2,5-dioxoazolidinyl)phenyl]-N-(4-methoxyphenyl)carboxamide 324.335 744 
964 diethyl[2-(naphthylamino)ethyl]amine 242.363 744 
965 [(4,6-dimethylpyrazolo[5,4-b]pyridin-3-yl)diazenyl]diethylamine 246.314 745 
966 
diethyl_2-{amino[(2-methylpropanoylamino)amino]methylene}propane-
1,3-dioate 
287.315 745 
967 (2-imidazolin-2-ylmethyl)phenylbenzylamine 265.357 746 
968 3-[(dimethylamino)amino]-5-phenylcyclohex-2-en-1-one 230.309 746 
969 2-{[4-benzylpiperidyl]methyl}pyridine 266.385 747 
970 N-[2-(4-methylphenoxy)ethyl]acetamide 193.245 747 
971 (2E)-3-(4-aminophenyl)-2-phenylprop-2-enoic_acid 239.273 748 
972 1,2-bis(2-pyridylmethyl)-4-phenyl-1,2,4-triazolidine-3,5-dione 359.387 748 
973 4-pyridyl-N-(2,4,6-trimethylphenyl)carboxamide 240.304 748 
974 methyl_3-(4-aminophenyl)-2-phenylpropanoate 255.316 749 
975 4-[6-(4-hydroxyphenyl)-2-pyridyl]phenol 263.295 750 
976 5-(6-methyl-2-quinolyl)-2H-1,2,3,4-tetraazole 211.226 750 
977 diethyl(2-(4-pyridyl)quinazolin-4-yl)amine 278.356 750 
978 N-(2,5-dimethylphenyl)-N'-(2-hydroxypropyl)ethane-1,2-diamide 250.297 750 
979 
N-[4-(dimethylamino)phenyl][1-(4-ethylphenyl)-5-oxopyrrolidin-3-
yl]carboxamide 
351.447 750 
980 4-(dimethylamino)phenyl_pyrrolidinyl_ketone 218.298 751 
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981 methylene_blue 284.398 752 
982 
(2,3-dimethyl-1,4-dioxo(2,3-dihydrophthalazin-6-yl))-N-(2-
quinolyl)carboxamide 
360.371 753 
983 (2-methyl(4-quinolyl))(3-methylphenyl)amine 248.327 753 
984 2-[5-methyl-2-(methylethyl)phenoxy]ethylamine 193.288 753 
985 
4-(phenylazamethylene)-5-hydro-1,3,5-triazino[6,1-b]benzothiazole-2-
ylamine 
293.345 753 
986 1,3-diethyl-2-oxo-3-hydrobenzimidazole-5-carbaldehyde 218.255 754 
987 11H-dibenzo[b,f]1,4-dioxepane-2-ylamine 213.235 754 
988 (phenylamino)-N-(2-pyridyl)carboxamide 213.238 755 
989 2-(2H,3H-benzo[e]1,4-dioxin-2-yl)-1-morpholin-4-ylethan-1-one 263.293 755 
990 N-[1-benzyl(4-piperidyl)]-2-propylpentanamide 316.486 755 
991 4-(2-hydroxy-2,2-diphenylethyl)-1,2,5-trimethylpiperidin-4-ol 339.477 756 
992 5-(2-phenyl-1,2,3-triazol-4-yl)-1H-1,2,3,4-tetraazole 213.201 756 
993 N-{4-[3,4-di(propanoylamino)phenoxy]phenyl}propanamide 383.446 756 
994 
((1E)-1-amino-5-methyl-2-azahex-1-enyl)(4,6-dimethylpyrimidin-2-
yl)amine 
235.331 757 
995 [(9-ethylcarbazol-3-yl)methyl]methylamine 238.332 757 
996 3-[4-(acetylamino)phenyl]-2-phenylpropanoic_acid 283.326 757 
997 1-(4-ethylphenyl)-5-oxopyrrolidine-3-carboxylic_acid 233.266 758 
998 2,2-dimethyl-N-(phenylamino)propanamide 192.26 758 
999 4-{[3-(butanoylamino)phenyl]carbonylamino}benzoic_acid 326.351 758 
1000 5-(azaethylidene)-2,3-diphenyl-1,2,4-thiadiazoline_chloride 267.348 758 
1001 3,4,5-trimethylpyrrole-2-carbaldehyde 137.181 759 
1002 6-(diphenylamino)-4-morpholin-4-yl-1H-1,3,5-triazin-2-one 349.391 759 
1003 cymarine 548.672 759 
1004 
2-({4-[(3-methylphenyl)methyl]piperazinyl}methyl)benzo[c]azoline-1,3-
dione 
349.432 760 
1005 3,7-dimethylindeno[2,3-c]pyridin-9-one 209.247 760 
1006 4-phenylmorpholine 163.219 760 
1007 6-cyclohexyl-1,4,5,7-tetramethylpyrrolo[3,4-d]pyridazine 257.378 760 
1008 N-[4-(5-phenyl-2-pyrazolin-3-yl)phenyl]acetamide 279.341 760 
1009 1,2,3-trimethylcyclohepta[1,2-c]pyrrol-6-one 187.241 761 
1010 
2-(2-imino-3-methyl(3-hydrobenzimidazolyl))-1-(4-methylphenyl)ethan-
1-one 
279.341 761 
1011 5-methyl-2-(2,4,5-trimethylphenyl)pyridine 211.306 761 
1012 dibenzo[c,e]1,2-dithiane-3,8-diamine 246.344 764 
1013 
(1-methyl-5-oxopyrrolidin-3-yl)-N-[3-
(phenylcarbonyl)phenyl]carboxamide 
322.363 765 
1014 
N-{(1E)-2-[4-(methylethyl)phenyl]-1-azavinyl}-2-
pyridylacetamide_chloride 
282.365 765 
1015 (3Z)-4-amino-4-phenylbut-3-en-2-one 161.203 766 
1016 2-naphthyl-1-[4-benzylpiperazinyl]ethan-1-one 344.455 766 
1017 (2S)-2-amino-N-(2-naphthyl)-3-phenylpropanamide 290.364 768 
1018 4-(2,5-dimethylphenyl)-2,5-dimethylpyridine 211.306 768 
1019 
methyl_2-{1-[(methoxycarbonyl)methyl]-2,4-dioxo-1,3-
dihydroquinazolin-3-yl}acetate 
306.274 771 
1020 methyl_quinoline-2-carboxylate 187.198 771 
1021 (4,6-dimethylpyrimidin-2-yl)[imino(naphthylamino)methyl]amine 291.355 772 
1022 1-(4-methoxyphenyl)-3-oxolan-2-ylazolidine-2,5-dione 275.304 772 
1023 2-(2,4-dimethylphenyl)-1-methylquinoxaline 249.335 772 
1024 (2E)-3-[N-(2,4-dimethylphenyl)carbamoyl]prop-2-enoic_acid 219.24 774 
1025 4-methyl-2-phenyl-3-pyrazolin-5-one 174.202 774 
1026 (2-ethylhexyl)(2-pyridylmethyl)amine_chloride_chloride 220.357 775 
1027 (4,6-dimethylpyrimidin-2-yl)(2-methylphenyl)amine 213.282 775 
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1028 
5-[(3,4-dimethoxyphenyl)methyl]-1-(4-methoxyphenyl)-1,3,5-
trihydropyrimidine-2,4,6-trione 
384.388 775 
1029 N'-ethyl-N-(2-indol-3-ylethyl)ethane-1,2-diamide 259.307 775 
1030 1-{2-[4-(methylethyl)phenoxy]acetyl}piperidine-4-carboxamide 304.388 776 
1031 ethyl_2-[3-(ethoxycarbonyl)-2-pyridyl]pyridine-3-carboxylate 300.313 776 
1032 
N-(phenylethyl)[4-(2-1,2,3,4-
tetrahydroisoquinolylmethyl)phenyl]carboxamide 
370.493 776 
1033 N-[4-(2-oxopyrrolidinyl)phenyl](3,4,5-trimethoxyphenyl)carboxamide 370.404 776 
1034 N-{(1E)-2-[4-(diethylamino)phenyl]-1-azavinyl}benzamide 295.383 776 
1035 (4-methoxyphenyl)(phenylethyl)amine 227.305 777 
1036 1,3-dibutylurea 172.27 777 
1037 
N-(2,5-dimethoxyphenyl)-2-(3,5-dimethyl-2,4,6-trioxo(1,3,5-
triazaperhydroinyl))acetamide 
350.33 777 
1038 2-butoxyphenylamine 165.235 778 
1039 3-acetyl-2-oxochromene 188.182 778 
1040 
ethyl_(3E)-4-{[4-(acetylamino)phenyl]carbonylamino}-3-methyl-2-
(methylethyl)-4-azabut-3-enoate 
347.413 778 
1041 methyl_4-[(propylamino)carbonylamino]benzoate 236.27 778 
1042 N-[4-(4-oxo-3-phenyl-1,2,3-trihydroquinazolin-2-yl)phenyl]acetamide 357.411 780 
1043 
2-[6-((4aS,9bR)-2,8-dimethylpiperidino[4,3-b]indolin-5-yl)-6-
oxohexyl]benzo[c]azoline-1,3-dione 
445.56 781 
1044 N-((1E)-2-indol-2-yl-1-azavinyl)benzamide 263.298 781 
1045 
5-[(1Z)-1-methyl-2-(phenylamino)-2-azavinyl]-4-methyl-6-phenyl-1,3,6-
trihydropyrimidin-2-one 
320.393 782 
1046 
9,10-dimethoxy-5,6-dihydro-2H-1,3-dioxoleno[4,5-g]isoquinolino[3,2-
a]isoquinoline 
336.366 783 
1047 1,2-bis(2-methylpropyl)benzimidazole 230.352 785 
1048 
5-{[(4-hydroxy-2-methylphenyl)amino]methylene}-1-(4-methylphenyl)-
1,3-dihydropyrimidine-2,4,6-trione 
351.361 785 
1049 benzyldi(2-pyridyl)amine 261.326 786 
1050 4,5-diphenyl-2-(3-pyridyl)imidazole 297.359 787 
1051 (2Z)-3-(dimethylamino)-1-(3-methylphenyl)prop-2-en-1-one 189.257 788 
1052 4-aminophenyl_3-phenylpyrrolidinyl_ketone 266.342 788 
1053 (4-aminophenyl)-N-(4-methylphenyl)carboxamide 226.277 789 
1054 
1-(2-methylphenyl)-5-[(1-methylpyrrol-2-yl)methylene]-1,3-
dihydropyrimidine-2,4,6-trione 
309.324 790 
1055 2,3,4-trimethylbenzo[h]quinoline 221.301 791 
1056 2-phenyl-3-hydroquinazolin-4-one 222.246 792 
1057 4-indol-3-ylbutanoic_acid 203.24 792 
1058 benzyl(hexyl)dimethylazanium_chloride 220.377 792 
1059 1-cyclohexyl-2-pyrrolino[2,3-b]quinoline-4-ylamine 267.373 793 
1060 ethyl_2-{N-[4-(methoxycarbonyl)phenyl]carbamoyl}acetate 265.265 793 
1061 (2-aminophenyl)(2-phenoxyethyl)amine 228.293 794 
1062 2-aminophenyl_2-methylpiperidyl_ketone 218.298 794 
1063 
[2-(5-hexyl-5-methyl(1,3-dioxolan-4-
ylidene))ethyl]trimethylamine_iodide 
256.408 795 
1064 1-methyl-4-phenoxyphthalazine 236.273 795 
1065 3-[N-(1,3-dioxobenzo[c]azolin-2-yl)carbamoyl]phenyl_acetate 324.292 796 
1066 N-(4-{N-[2-(5-methylindol-3-yl)ethyl]carbamoyl}phenyl)acetamide 335.405 796 
1067 
(4S)-2-{1-[(4S)-4-(tert-butyl)(1,3-oxazolin-2-yl)]-isopropyl}-4-(tert-
butyl)-1,3-oxazoline 
294.436 797 
1068 cyclopropyl[(9-ethylcarbazol-3-yl)methyl]amine 264.369 797 
1069 1-(indol-3-ylmethyl)-4-[(2-methylphenyl)methyl]piperazine 319.449 798 
1070 1-cyclohexyloxy-2-[4-(2-cyclohexyloxyethyl)piperazinyl]ethane 338.532 798 
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1071 
2,6,10-trimethylpyrazolo[1,5-c]pyrazolo[1,5-e]pyrazolo[1,5-a]1,3,5-
triazaperhydroine 
240.267 798 
1072 
6-methyl-1-{[2-(4-methylphenoxy)ethoxy]methyl}-1,3-
dihydropyrimidine-2,4-dione 
290.318 798 
1073 3-[N-(diphenylmethyl)carbamoyl]propanoic_acid 283.326 800 
1074 N-[(4-hydroxyphenyl)ethyl](4-methylphenyl)carboxamide 255.316 800 
1075 
(2E)-3-amino-3-[(3-methylquinoxalin-2-yl)amino]-1-phenyl-2-azaprop-
2-en-1-one 
305.338 801 
1076 (4-aminophenyl)-N-naphthylcarboxamide 262.31 801 
1077 
N-(1-carbamoyl-3-methylbutyl)(2-methoxy-3-
methylphenyl)carboxamide 
278.35 801 
1078 3-oxobenzo[f]chromene-2-carboxamide 239.23 802 
1079 2-(phenylcarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic_acid 281.31 804 
1080 3-(N-(2-5,6,7,8-tetrahydronaphthyl)carbamoyl)propanoic_acid 247.293 804 
1081 N-((1E)-2-(3-pyridyl)-1-azavinyl)[4-(tert-butyl)phenyl]carboxamide 281.357 804 
1082 N-(4-aminophenyl)[4-(tert-butyl)phenyl]carboxamide 268.358 804 
1083 
{(1E)-1-methyl-2-[4-(phenyldiazenyl)phenyl]-2-
azavinyl}dimethylamine_chloride 
266.345 805 
1084 3,3,6,6,9-pentamethyl-2,3,4,5,6,7,9,10-octahydroacridine-1,8-dione 287.401 805 
1085 methyl_indole-3-carboxylate 175.187 805 
1086 
N-[4-({[N-(2,4-
dimethylphenyl)carbamoyl]methyl}amino)phenyl]propanamide 
325.41 805 
1087 
1,3-dimethyl-5-[(2,3,4-trimethoxyphenyl)methyl]-1,3,5-
trihydropyrimidine-2,4,6-trione 
336.344 806 
1088 2-methyl-3-oxo-5,6-diphenyl-2-hydropyridazine-4-carboxylic_acid 306.32 806 
1089 3-(phenylcarbonyl)hydroquinoxalin-2-one 250.256 806 
1090 2-[N-(tert-butyl)carbamoyl]phenyl_acetate 235.282 807 
1091 5-(phenylcarbonyl)-5-azabicyclo[4.4.0]decan-2-one 257.332 807 
1092 
2-[4-(4-methylphenyl)-1-oxo(2-hydrophthalazin-2-yl)]-N-(3-
pyridyl)acetamide 
370.41 809 
1093 methyl_3-[N-(2,2-diphenylacetylamino)carbamoyl]propanoate 340.378 809 
1094 N-[4-(diethylamino)phenyl]-2-ethylhexanamide 290.448 810 
1095 (4,6-diimidazolyl(1,3,5-triazin-2-yl))methylphenylamine 318.34 811 
1096 ethyl_quinoxaline-2-carboxylate 202.212 811 
1097 
[4-(dimethylamino)phenyl]-N-(3-ethyl-4-oxo(3-hydroquinazolin-7-
yl))carboxamide 
336.393 812 
1098 6-amino-2-phenylbenzo[d]1,3-oxazin-4-one 238.245 812 
1099 1-pentyl-2-propylbenzimidazole 230.352 813 
1100 8-methylthioquinoline 175.248 813 
1101 N-(1,4-dioxo-3-pyrrolidinyl(2-naphthyl))-N-methylacetamide 298.341 813 
1102 N-(diphenylmethyl)-N'-(2-hydroxyethyl)ethane-1,2-diamide 298.341 813 
1103 (phenylamino)-N-[(3,4,5-trimethoxyphenyl)methyl]carboxamide 316.356 814 
1104 [6-(dimethylamino)-4-piperidyl(1,3,5-triazin-2-yl)]dimethylamine 250.346 814 
1105 3-(diethylamino)-1-cyclohexyl-1-phenylpropan-1-ol 289.46 815 
1106 4-(tert-butyl)phenyl_4-benzylpiperazinyl_ketone 336.476 815 
1107 2,5-dimethyl-1-(methylethyl)pyrrole-3-carbaldehyde 165.235 816 
1108 2-methylpiperidyl_5-[(2-methylpiperidyl)carbonyl](3-pyridyl)_ketone 329.441 816 
1109 1-(2-methylpropyl)-2-benzylbenzimidazole 264.369 817 
1110 N,N-dimethylnonylamine 171.325 817 
1111 5,6-diphenylpyrazin-2-ol 248.284 818 
1112 ethyl_2-(3-methyl-2-oxo-1,3,4-trihydroquinazolinyl)acetate 248.281 818 
1113 4,6-dimethoxyindole 177.202 821 
1114 N-[4-(4-pyridylmethyl)phenyl]-2-quinolylcarboxamide 339.396 821 
1115 1-methylindoline-5-carbaldehyde 161.203 822 
1116 indeno[3,2-b]pyridin-5-one 181.193 822 
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1117 (2E)-N-(6-methyl(2-pyridyl))-3-phenylprop-2-enamide 238.288 823 
1118 1-indol-3-yl-10-hydro-1,2,4-triazolo[4,3-a]quinoline 284.32 823 
1119 
3-{[(1E)-2-(2-hydroxyphenyl)-1-azavinyl]amino}-6-benzyl-2H-1,2,4-
triazin-5-one 
321.338 823 
1120 7,8-dimethoxy-2-phenyl-2-hydrophthalazin-1-one 282.298 823 
1121 2-[(1-propylindol-3-yl)methyl]propanedioic_acid 275.304 826 
1122 3-[4-(diphenylmethyl)piperazinyl]-1-phenylazolidine-2,5-dione 425.529 826 
1123 
N-cyclopentyl-2-[7-methyl-2,4-dioxo-1-phenyl-5-
(pyrrolidinylcarbonyl)(1,3-dihydropyridino[2,3-d]pyrimidin-3-
yl)]acetamide 
475.546 826 
1124 ((1Z)-1-phenyl-2-pyrazolylvinyl)pyrazole 236.276 828 
1125 6-methyl-2-(6-methyl(3-quinolyl))-5-quinolylamine 299.374 828 
1126 
(2S,5S,6S,9S)-5,9,13-trimethyl-3-oxatricyclo[7.4.0.0<2,6>]trideca-
1(13),10-diene-4,12-dione 
246.305 829 
1127 methyl_2-(methoxycarbonyl)indole-3-carboxylate 233.223 829 
1128 1-methylindole-5-carbaldehyde 159.187 830 
1129 (3,4-dimethylphenyl)-N-(2-pyridyl)carboxamide 226.277 831 
1130 2-methoxy-5-phenylphenylamine 199.252 831 
1131 3-(1,2,3,4-tetrahydroquinolyl)propanoic_acid 205.256 831 
1132 ethyl_4-(pyrrolidinylcarbonylamino)benzoate 262.308 831 
1133 N-((1E)-2-naphthyl-1-azavinyl)(4-aminophenyl)carboxamide 289.336 831 
1134 phenyl(prop-2-enylcyclohexyl)amine 215.338 831 
1135 [(4-methoxyphenyl)methyl]{[4-(methylethyl)phenyl]methyl}amine 269.386 834 
1136 2-(1,3-dioxobenzo[c]azolidin-2-yl)-3-methylbutanoic_acid 247.25 834 
1137 
4-({5-(2,2-dimethylpropanoylamino)-3-[N-(4-
carboxyphenyl)carbamoyl]phenyl}carbonylamino)benzoic_acid 
503.51 835 
1138 4-quinoxalin-2-ylphenol 222.246 835 
1139 
N-[(1E)-2-(2,4-dihydroxy-6-methylphenyl)-1-azavinyl](2-
hydroxyphenyl)carboxamide 
286.287 835 
1140 
{3-[(1,3-dimethyl-2,4-dioxo(1,3-dihydroquinazolin-6-
yl))carbonylamino]-4,5-dimethoxyphenyl}-N,N-diethylcarboxamide 
468.508 836 
1141 
5-[(2,4-dimethoxyphenyl)methyl]-1-phenyl-1,3,5-trihydropyrimidine-
2,4,6-trione 
354.362 836 
1142 [4-(diethylamino)phenyl]-N-(2-methylpropyl)carboxamide 248.367 837 
1143 N,N-bis(indol-4-ylmethyl)acetamide 317.39 838 
1144 ((1E)-2-(3-pyridyl)-1-azavinyl)(4,6-dipiperidyl(1,3,5-triazin-2-yl))amine 366.468 839 
1145 6-(diphenylamino)-4-ethoxy-1H-1,3,5-triazin-2-one 308.339 839 
1146 (1S,5S)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-one 150.22 840 
1147 1,2,3,4,9-pentahydro-4aH-carbazol-1-ol 187.241 840 
1148 3-[6-(1,3-dioxobenzo[c]azolidin-2-yl)hexanoylamino]benzoic_acid 380.399 840 
1149 
4-methyl-2-benzylspiro[2,4,5,6,3a,6a-hexahydro-2,5-diazapentalene-6,3'-
indoline]-1,3,10-trione 
361.399 840 
1150 N-[(1E)-2-(2,3-dimethoxyphenyl)-1-azavinyl]benzamide 284.314 840 
1151 
(1Z)-2-(4,4-dimethyl(1,3-oxazolin-2-yl))-1-(4-
methoxyphenyl)vinylamine 
246.308 841 
1152 1-methylindole-2-carboxylic_acid 175.187 841 
1153 4-{[4-(diphenylmethyl)piperazinyl]carbonyl}-2-hydrophthalazin-1-one 424.501 841 
1154 4-pyrrolylphenol 159.187 842 
1155 2-{(1E)-2-[4-(diethylamino)phenyl]-2-azavinyl}-5-(diethylamino)phenol 339.48 843 
1156 6-pyrrolyl-1H-indazole 183.212 843 
1157 methyl_3-[N-(2,4-dimethylphenyl)carbamoyl]propanoate 235.282 843 
1158 
{4-[(1E)-1-methyl-2-(phenylamino)-2-azavinyl]-2-methyl-6-oxo-1-(2-
pyridyl)(3-hydropyridyl)}-N-(2-pyridyl)carboxamide 
438.488 845 
1159 3-[((1E)-2-indol-3-yl-1-azavinyl)amino]-6-phenyl-4H-1,2,4-triazin-5-one 330.348 845 
1160 3-[1-(carboxymethyl)-5-(4-methylphenyl)pyrrol-2-yl]propanoic_acid 287.315 845 
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1161 
N-[2-(3,4-dimethoxyphenyl)ethyl](1,3-dimethyl-2,6-dioxo(1,3-
dihydropyrimidin-4-yl))carboxamide 
347.37 845 
1162 2-((1E)-2-phenyl-2-azavinyl)-5-(diethylamino)phenol 268.358 846 
1163 10-methyl-10-hydroacridin-9-one 209.247 848 
1164 2-(2-oxo-3-phenylhydroquinoxalinyl)acetic_acid 280.282 848 
1165 2-phenylquinoline-4-carboxylic_acid 249.268 848 
1166 N,N-bis(methylethyl)[4-(N-(2-pyridyl)carbamoyl)phenyl]carboxamide 325.41 848 
1167 N-[(4-hydroxyphenyl)ethyl]naphthylcarboxamide 291.349 848 
1168 
(1S,2R)-2-[N-(2,2-
diphenylacetylamino)carbamoyl]cyclohexanecarboxylic_acid 
380.443 849 
1169 2-acetyl-3,5-dimethyl-4-(phenylcarbonyl)pyrrole 241.289 850 
1170 3,5-bis(tert-butyl)phenyl_4-methylpiperazinyl_ketone 316.486 850 
1171 (4-methylphenyl)-N-(2-pyrrolylethyl)carboxamide 228.293 851 
1172 
N-[4-hydroxy-2-methyl-5-(methylethyl)phenyl]-2-(4-methyl-1-oxo(2-
hydrophthalazin-2-yl))acetamide 
365.431 852 
1173 3-(2,3,3-trimethylindolinyl)propanamide 232.325 853 
1174 dihexylamine 185.352 853 
1175 N-phenyl(2,4,5-trimethylpyrrol-3-yl)carboxamide 228.293 853 
1176 5,6,7,8,9-pentahydro-4aH-carbazole-3-carboxylic_acid 215.251 854 
1177 indol-3-yl-N-(2-indol-3-ylethyl)carboxamide 303.363 854 
1178 1,1,3,3-tetraethylurea 172.27 855 
1179 
2-[(3-methylquinoxalin-2-yl)methyl]-4,7,3a,7a-tetrahydroisoindole-1,3-
dione 
307.351 856 
1180 4-piperidyl-2-pyrrolidinylquinazoline 282.388 856 
1181 8-ethylthioquinoline 189.275 856 
1182 bis[2-(phenylmethoxy)ethyl]dimethylamine 314.447 856 
1183 
methyl_4-[2-(4-methyl-1-oxo-2-hydrophthalazin-2-
yl)acetylamino]benzoate 
351.361 856 
1184 2-methyl-3-(3-methylphenyl)-3-hydroquinazolin-4-one 250.299 857 
1185 
6-{[4-(diphenylmethyl)piperazinyl]carbonyl}-1,3-dimethyl-1,3-
dihydropyrimidine-2,4-dione 
418.494 857 
1186 8-(N-acetylacetylamino)-2-naphthyl_acetate 285.299 857 
1187 2-(2-(5,6,7,8,9-pentahydro-4aH-carbazol-9-yl)ethyl)benzimidazole 315.417 858 
1188 
2,15-dimethyltetracyclo[8.7.0.0<2,7>.0<11,15>]heptadec-6-ene-5,14,17-
trione 
300.397 858 
1189 
8-(4-methoxyphenyl)-5,7,8-trihydro-2H-1,3-dioxolano[4,5-g]quinolin-6-
one 
297.31 858 
1190 1-phenyl-2-pyrrolylethan-1-ol 187.241 859 
1191 2-(1-ethylindol-3-yl)ethan-1-ol 189.257 859 
1192 3-cyclohexyl-N-(4-oxo(3-hydroquinazolin-6-yl))propanamide 299.372 859 
1193 bis(2-cyclohexyloxyethyl)amine 269.426 859 
1194 phenyl(2-phenylquinazolin-4-yl)amine 297.359 859 
1195 phenylmethyl_4-carbamoyl-3-phenylbutanoate 297.353 859 
1196 (3E)-4-(4-methoxyphenyl)but-3-en-2-one 176.215 861 
1197 5-pyrrolyl-3-hydroisobenzofuran-1-one 199.209 861 
1198 
(2-{N-[2-(2-methylindol-3-yl)ethyl]carbamoyl}pyrrolidinyl)-N-
benzamide 
390.484 862 
1199 (3E)-4-phenylbut-3-en-2-one 146.188 862 
1200 2-(2-methylphenyl)-1,3-dioxobenzo[c]azoline-5-carboxylic_acid 281.267 862 
1201 2-(4-phenyl-3-1,4-dihydroquinolyl)quinoline 334.42 862 
1202 1-acetyl-3-(1,3-dioxo(4,5,6,7,3a,7a-hexahydroisoindol-2-yl))benzene 271.315 863 
1203 4-(4-indol-3-ylbutanoyl)-1,3,4-trihydroquinoxalin-2-one 333.389 863 
1204 
(2E)-3-(3,4-dimethoxyphenyl)-N-[2-(2-methoxyphenoxy)ethyl]prop-2-
enamide 
357.405 864 
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1205 
2-[5-(N,N-diethylcarbamoyl)-1,7-dimethyl-2,4-dioxo(1,3-
dihydropyridino[2,3-d]pyrimidin-3-yl)]-N-phenylacetamide 
423.471 864 
1206 indolo[2,3-b]quinoxaline 219.245 864 
1207 2,6-dimethyl-4-(3-methylphenoxy)quinoline 263.338 865 
1208 
4-[3-(1,3-dimethylpyrazol-4-yl)-1-(4-methylphenyl)pyrazol-5-yl]-1,3-
dimethylpyrazole 
346.434 865 
1209 2-[2-(8-methoxy-2-1,2,3,4-tetrahydroquinolyl)ethyl]phenylamine 282.385 866 
1210 4-(N-methyl-N-phenylcarbamoyl)phenyl_acetate 269.299 866 
1211 coproporphyrin 654.718 866 
1212 N-(2H,3H-benzo[3,4-e]1,4-dioxin-6-yl)(phenylamino)carboxamide 270.287 866 
1213 
N-[4-(tert-butyl)cyclohexyl](7-methyl-2,4-dioxo(1,3-
dihydropyridino[2,3-d]pyrimidin-5-yl))carboxamide 
358.439 866 
1214 N-(diphenylmethyl)-3-pyridylcarboxamide 288.348 867 
1215 
2-(1-cyclohexyl-2,5-dioxo(1,3-diazolidin-4-yl))-N-(2-indol-3-
ylethyl)acetamide 
382.461 868 
1216 2,6-bis(2-methylprop-2-enyl)-1-benzyl-1,2,5,6-tetrahydropyridine 281.44 868 
1217 
8-(2,3-dimethoxyphenyl)-5,7,8-trihydro-2H-1,3-dioxolano[4,5-
g]quinolin-6-one 
327.336 868 
1218 phenyl_pyridine-3-carboxylate 199.209 868 
1219 (1E,3E)-1,4-bis(2-methylindol-3-yl)-2,3-diazabuta-1,3-diene 314.389 870 
1220 3-(5-phenylpyrrol-2-yl)propanoic_acid 215.251 870 
1221 6-methyl-2,4-diphenylpyridine 245.323 870 
1222 (2E)-1-(2,4-dihydroxyphenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one 256.257 872 
1223 2-phenyl-4-piperidylquinoline 288.391 872 
1224 1-(2-phenoxyethyl)-3-hydrobenzimidazol-2-one 254.288 874 
1225 1-(3,5-dimethylphenyl)-1,2,3,4-tetraazole 174.205 875 
1226 1,2,3-trihydrobenzo[g]quinolin-4-one 197.236 875 
1227 3-[3-(3-aminophenoxy)phenoxy]phenylamine 292.337 876 
1228 
N-[(1E)-2-(3-hydroxyphenyl)-1-azavinyl](3-hydroxy(2-
naphthyl))carboxamide 
306.32 876 
1229 N-methyldihexylamine 199.379 876 
1230 (2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one 240.258 877 
1231 N-[2-(4-methyl-2-quinolyl)phenyl]acetamide 276.337 877 
1232 (2E)-3-(dimethylamino)-1-(2-naphthyl)prop-2-en-1-one 225.29 879 
1233 1-methyl-2-(3-(2-quinolyl)(4-quinolyl))benzimidazole 386.455 879 
1234 N,N-dimethyldecylamine 185.352 879 
1235 4-(phenylamino)chromen-2-one 237.257 880 
1236 5-(4-methylphenyl)pyrrole-2-carboxylic_acid 201.224 880 
1237 8-methoxy-2,2,4-trimethyl-1,2,3,4-tetrahydroquinoline 205.299 880 
1238 
methylethyl_6-cyclohex-3-enyl-4-methyl-2-oxo-1,3,6-
trihydropyrimidine-5-carboxylate 
278.35 880 
1239 2-(tert-butyl)-9-butyl-9-hydroimidazo[1,2-a]benzimidazole 269.389 882 
1240 
methyl_4-(2-{N-[4-
(methoxycarbonyl)phenyl]carbamoyl}acetylamino)benzoate 
370.361 883 
1241 2-(2,5-dimethylpyrrolyl)benzoic_acid 215.251 884 
1242 
11-phenyl-2,3,4,11,10a-pentahydrobenzo[1',2'-1,2]cyclopenta[3,4-
b]quinoline-1,10-dione 
327.382 885 
1243 [4-(tert-butyl)phenyl]-N-(4-piperidylphenyl)carboxamide 336.476 886 
1244 3-[(2,4-dimethylphenyl)amino]-1-phenylpropan-1-one 253.343 886 
1245 
3-methyl-N-[2-(2-methylindol-3-yl)ethyl]-2-(phenylcarbonylamino)but-
2-enamide 
375.469 886 
1246 3,5-bis[(4-methylphenyl)methylene]-1-methylazaperhydroin-4-one 317.43 887 
1247 4-indol-3-yl-6-phenyl-2,4,5-trihydropyridazin-3-one 289.336 888 
1248 2-(4-pyridyl)chromeno[4,3-d]pyrimidin-5-one 275.266 890 
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1249 
N-[(1E)-2-(1-methylpyrrol-2-yl)-1-azavinyl]-N'-[(1E)-2-(1-methylpyrrol-
2-yl)-1-azavinyl]nonane-1,9-diamide 
398.507 890 
1250 2-aminophenyl_indolinyl_ketone 238.288 891 
1251 ethyl_2-(phenylamino)acetate 179.218 891 
1252 
2-(1,3-dioxobenzo[c]azolin-2-yl)-N-[2-(2-methylindol-3-
yl)ethyl]acetamide 
361.399 892 
1253 hematoporphyrin 598.697 892 
1254 1-{1-[(2-methylphenyl)methyl]pyrazol-3-yl}-1,2,3,4-tetraazole 240.267 894 
1255 2,4-dimethylbenzo[h]quinoline 207.274 894 
1256 
2-{3-[4-(methylethyl)phenyl]-2-
(phenylcarbonylamino)propanoylamino}acetic_acid 
368.432 895 
1257 
N-((1E)-2-(2-5,6,7,8-tetrahydronaphthyl)-1-azaprop-1-enyl)-3-
pyridylcarboxamide 
293.368 895 
1258 undecylamine 171.325 895 
1259 decyltrimethylazanium_bromide 200.387 897 
1260 1,2,3,4,9-pentahydro-4aH-carbazolecarboxylic_acid 215.251 899 
1261 2,3,4,9-tetrahydro-4aH-carbazol-1-one 185.225 899 
1262 
2-{[(3-amino-5-oxo-1-phenyl-1,2-diazolin-4-
ylidene)azamethyl]amino}benzoic_acid 
323.31 899 
1263 (2-methylphenyl){2-[(2-methylphenyl)amino]quinazolin-4-yl}amine 340.427 900 
1264 
[1-(4-methoxyphenyl)-5-oxopyrrolidin-3-yl]-N-(2,4,6-
trimethylphenyl)carboxamide 
352.432 900 
1265 
N-(4-methoxyphenyl){3-[N-(4-methoxyphenyl)-N-
methylcarbamoyl]phenyl}-N-methylcarboxamide 
404.465 900 
1266 3,4-diphenyl-2-(phenylazamethylene)-1,3-thiazoline 328.431 901 
1267 (2E)-1-(2,5-dihydroxyphenyl)-3-phenylprop-2-en-1-one 240.258 902 
1268 3-(1-ethylindol-3-yl)propanoic_acid 217.267 902 
1269 brilliant_blue 749.887 902 
1270 (2E)-3-phenyl-1-(2,3,4-trihydroxyphenyl)prop-2-en-1-one 256.257 903 
1271 3-[4-(diphenylmethyl)piperazinyl]-1-naphthylazolidine-2,5-dione 475.589 903 
1272 
N-(2H-benzo[3,4-d]1,3-dioxolen-5-ylmethyl)-N-[1-(4-ethoxyphenyl)-
2,5-dioxoazolidin-3-yl]acetamide 
410.426 903 
1273 ethyl_4-(diethylamino)benzoate 221.299 904 
1274 N-[3-((1E)-2-(4-pyridyl)vinyl)phenyl]-2,2-diphenylacetamide 390.484 904 
1275 
phenylmethyl_4-methyl-2-oxo-6-phenyl-1,3,6-trihydropyrimidine-5-
carboxylate 
322.363 904 
1276 2-(4-methylphenyl)quinoline-4-carboxylic_acid 263.295 905 
1277 1,2-dimethylindole 145.204 906 
1278 1,5-diaminoanthracene-9,10-dione 238.245 906 
1279 3-indol-3-yl-3-hydroisobenzofuran-1-one 249.268 906 
1280 benzo[h]quinoline 179.221 906 
1281 phenyl[9-benzyl(9-hydro-1,2,4-triazolo[4,5-a]benzimidazol-3-yl)]amine 339.399 906 
1282 2-((1E)-2-(3-pyridyl)vinyl)-3-(2-phenylethyl)-3-hydroquinazolin-4-one 353.423 907 
1283 3-[(2,5-dimethylphenyl)amino]-5,5-dimethylcyclohex-2-en-1-one 243.348 907 
1284 
N-{[(dimethylamino)cyclohexyl]methyl}(4-
butylcyclohexyl)carboxamide 
322.533 907 
1285 N-[(4-methylphenyl)phenylmethyl]carboxamide 225.29 908 
1286 9-(4-methoxyphenyl)-2,3,4,5,6,7-hexahydroxanthene-1,8-dione 324.376 909 
1287 3,4-diacetyl-1-(2-indol-3-ylethyl)-2,5-dimethylpyrrole 322.406 910 
1288 
3-{4-[2,5-dioxo-1-(2-phenylethyl)azolidin-3-yl]piperazinyl}-1-(2-
phenylethyl)azolidine-2,5-dione 
488.585 910 
1289 
methylethyl_3,4-dimethyl-2-oxo-6-phenyl-1,3,6-trihydropyrimidine-5-
carboxylate 
288.346 910 
1290 1-(2-indol-3-ylethyl)-2,5-dimethylpyrrole-3-carboxylic_acid 282.341 911 
1291 
N-((1Z,3E)-4-phenyl-1-azabuta-1,3-dienyl)-2-(1-methylpyrrol-2-
yl)acetamide 
267.33 911 
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1292 4-hydroxy-5,7-dimethyl-3-benzylhydroquinolin-2-one 279.338 912 
1293 ethyl_3,5-dimethylpyrrole-2-carboxylate 167.207 912 
1294 2-(3,4-dimethoxyphenyl)-7,8-dimethoxychromen-4-one 342.348 913 
1295 7-methylindole 131.177 914 
1296 phenyl_2,4,5-trimethylpyrrol-3-yl_ketone 213.279 914 
1297 2-[(3,4-dimethylphenyl)azamethylene]-3-ethyl-4-phenyl-1,3-thiazoline 308.44 915 
1298 4-[(2,4-dimethylphenyl)amino]naphthalene-1,2-dione 277.322 915 
1299 5-{[1-(methylpropyl)indol-3-yl]methylene}-1,3-diazolidine-2,4-dione 283.329 915 
1300 diethyl_2-{[(2-aminophenyl)amino]methylene}propane-1,3-dioate 278.307 915 
1301 
N,N-bisbenzyl[4-(2-1,2,3,4-
tetrahydroisoquinolylmethyl)phenyl]carboxamide 
446.591 915 
1302 2-(4-pyrrolidinylphenyl)-1,2,3-trihydroquinazolin-4-one 293.368 919 
1303 (2-octylthioethyl)thiocarboxamidine 248.444 920 
1304 1,3-dicyclohexylurea 224.345 921 
1305 (4-methyl-6-phenylpyrimidin-2-yl)(4,6,8-trimethylquinazolin-2-yl)amine 355.441 922 
1306 
3-(7,10-dimethoxy-1,2,3,4,10b,4a-hexahydro-6H-benzo[c]chromen-6-
yl)phenylamine 
339.433 922 
1307 ethyl_(2E)-3-[N-(2,2-diphenylacetylamino)carbamoyl]prop-2-enoate 352.389 922 
1308 (2E)-1-(4-hydroxyphenyl)-3-phenylprop-2-en-1-one 224.259 923 
1309 [2-(2,5-dimethylpyrrolyl)phenyl]methan-1-ol 201.268 923 
1310 
4-{[4-(diphenylmethyl)piperazinyl]carbonyl}-2-methyl-2-
hydrophthalazin-1-one 
438.528 923 
1311 3,5-bis(1,5-dimethylpyrazol-4-yl)-4-methyl-1-(3-methylphenyl)pyrazole 360.461 924 
1312 1-morpholin-4-yl-3,3-diphenylpropan-1-one 295.38 925 
1313 2-phenylindole-3-carbaldehyde 221.258 926 
1314 N-butyl(4-oxo(3-hydroquinolyl))carboxamide 244.293 926 
1315 
(3,4-dimethoxyphenyl)-N,N-bis[(3,4-
dimethoxyphenyl)methyl]carboxamide 
481.544 927 
1316 
(7-ethyl-4-methylquinazolin-2-yl)(4,6,6-trimethyl(3,6-dihydropyrimidin-
2-yl))amine 
309.413 927 
1317 (2-aminophenyl)-N-(4-methylphenyl)carboxamide 226.277 928 
1318 (3-methyl-4-oxo(3-hydrophthalazinyl))-N-(2-phenoxyethyl)carboxamide 323.351 928 
1319 N-(3-acetylphenyl)[(4-methylphenyl)amino]carboxamide 268.315 929 
1320 
2-(3-methylpiperidyl)-4-oxo-5-hydropyridino[1,2-a]pyrimidine-3-
carbaldehyde 
271.318 930 
1321 N-(3-acetylphenyl)(4-methylphenyl)carboxamide 253.3 931 
1322 3-aminophenyl_3,4-dimethylphenyl_ketone 225.29 932 
1323 8-[(3-methylquinoxalin-2-yl)methylthio]quinoline 317.408 932 
1324 N-(3-acetylphenyl)-N'-(3-acetylphenyl)nonane-1,9-diamide 422.523 932 
1325 2-phenylquinoline 205.259 934 
1326 6-phenyl-1,2,3-trihydroquinolin-4-one 223.274 934 
1327 
methyl_4-[(3-methyl-2,4-dioxo-1,3-
dihydroquinazolinyl)methyl]benzoate 
324.335 934 
1328 5-methylindole 131.177 935 
1329 3-(2,5-dimethylpyrrolyl)benzoic_acid 215.251 936 
1330 (2-iminochromen-3-yl)-N-(4-phenoxyphenyl)carboxamide 356.38 939 
1331 5-ethyl-1,2-dimethylindole-3-carbaldehyde 201.268 939 
1332 
3-{N-[(1,3-dioxobenzo[c]azolidin-2-
yl)methyl]hexanoylamino}benzoic_acid 
394.426 940 
1333 5,6-dimethyl-1-[(2,3,5,6-tetramethylphenyl)methyl]benzimidazole 292.423 940 
1334 indeno[2,3-b]quinoxalin-11-one 232.241 940 
1335 2-(phenylthiomethyl)cyclopent-2-en-1-one 204.286 941 
1336 
(2-hydroxyphenyl)-N-{4-[(2-
hydroxyphenyl)carbonylamino]butyl}carboxamide 
328.367 942 
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1337 
3,3,6,6-tetramethyl-9-(4-methylphenyl)-2,3,4,5,6,7,9,10-
octahydroacridine-1,8-dione 
363.499 942 
1338 N-(2,4-dimethylphenyl)(2,4,5-trimethylpyrrol-3-yl)carboxamide 256.347 942 
1339 1,3-diphenyl-2-(3-pyridyl)imidazolidine 301.39 943 
1340 N-(oxolan-2-ylmethyl)-2-xanthen-9-ylacetamide 323.391 943 
1341 
(3E)-3-methyl-4-(2-phenylacetylamino)-N-[4-(phenylamino)phenyl]-4-
azabut-3-enamide 
400.479 944 
1342 
2,7,8-trimethoxy-12-methyl-12H,5aH-benzo[e]isoindolino[1,2-b]1,3-
oxazin-10-one 
341.363 944 
1343 3-acetyl-2-phenylindole 235.285 944 
1344 2-(4-naphthyl-3-1,4-dihydroquinolyl)quinoline 384.479 945 
1345 2-methylindolo[2,3-b]quinoxaline 233.272 945 
1346 4-(indolinylcarbonyl)phenyl_acetate 281.31 945 
1347 ethyl_4-[(1-cyclohexyl-5-oxopyrrolidin-3-yl)carbonylamino]benzoate 358.436 945 
1348 
2-(1,3-dioxobenzo[c]azolidin-2-yl)-N-{2-[(4-
phenylpiperazinyl)carbonyl]phenyl}acetamide 
468.511 946 
1349 3,5-bis[(2,4-dimethylphenyl)methylene]-1-methylazaperhydroin-4-one 345.483 946 
1350 2,5-dimethyl-1-phenylpyrrole-3-carbaldehyde 199.252 948 
1351 4-(2,5-dimethylpyrrolyl)benzoic_acid 215.251 948 
1352 phenyl-N-[6-(phenylcarbonylamino)(2-pyridyl)]carboxamide 317.346 949 
1353 
2,4,6,6-tetramethyl-2,4,12b,6a-tetrahydro-6H-pyrimidino[5',4'-
6,5]pyrano[3,4-c]chromane-1,3-dione 
328.367 950 
1354 butyl_4-aminobenzoate 193.245 952 
1355 dimethyl_2-[(phenylamino)azamethylene]propane-1,3-dioate 236.227 952 
1356 N-((1E)-2-naphthyl-1-azavinyl)(2-aminophenyl)carboxamide 289.336 952 
1357 
N-[(3-methylphenyl)carbonylamino][2-
(phenylcarbonyl)phenyl]carboxamide 
358.396 952 
1358 
3-(4-{[4-(diethylamino)phenyl]methylene}-3-methyl-5-oxo(1,2-
diazolinyl))-6-methyl-4H-1,2,4-triazin-5-one 
366.422 953 
1359 
4-((1E)-2-(2H-benzo[3,4-d]1,3-dioxolan-5-yl)-1-azavinyl)-3-methyl-6-
phenyl-1,2,4-triazin-5-one 
334.334 953 
1360 3-hexyloxyphenylamine 193.288 954 
1361 
N-(2-hydroxyphenyl){3-[N-(2-hydroxyphenyl)carbamoyl]-5-
(phenylcarbonylamino)phenyl}carboxamide 
467.48 955 
1362 N-[(1E)-2-(2-hydroxyphenyl)-1-azavinyl]-3-phenylpropanamide 268.315 955 
1363 (5S)-2-methyl-5-(1-methylvinyl)cyclohex-2-en-1-one 150.22 956 
1364 2-[(butylamino)methylene]-5-phenylcyclohexane-1,3-dione 271.358 956 
1365 5-methyl-2-pyrrolylphenol 173.214 956 
1366 7,7-dimethyl-4-naphthyl-3H-4,6,7,8-tetrahydrochromene-2,5-dione 320.387 956 
1367 N-(2-methylpropyl)(9-oxofluoren-4-yl)carboxamide 279.338 956 
1368 N-(6-methyl(2-pyridyl))(2-(2-pyridyl)(4-quinolyl))carboxamide 340.384 956 
1369 
N-[2-(3,4-dimethoxyphenyl)-3-phenylpropyl](4-oxo(3-
hydrophthalazinyl))carboxamide 
443.501 956 
1370 2,6-dimethyl-5-(phenylcarbonyl)(3-1,4-dihydropyridyl)_phenyl_ketone 317.387 957 
1371 1-acetyl-4-pyrrolylbenzene 185.225 958 
1372 2-(3,4-dimethoxyphenyl)-3-methoxychromen-4-one 312.321 958 
1373 4,6-dimethyl-2-[(3-methylquinoxalin-2-yl)methylthio]pyrimidine 296.389 958 
1374 11-carbamoyl-2-benzylundecanoic_acid 319.443 959 
1375 3,3,6,6-tetramethyl-2,3,4,5,6,7-hexahydroacridine-1,8-dione 271.358 961 
1376 4-(diethylamino)benzaldehyde 177.246 962 
1377 
2-[7-methyl-2,4-dioxo-1-phenyl-5-(piperidylcarbonyl)(1,3-
dihydropyridino[2,3-d]pyrimidin-3-yl)]-N-phenylacetamide 
497.552 964 
1378 
4-(4-ethylphenyl)-7,7-dimethyl-3H-4,6,7,8-tetrahydrochromene-2,5-
dione 
298.381 964 
1379 N-[3-(dimethylamino)phenyl]-2,2-diphenylacetamide 330.429 964 
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1380 1,2-dimethylindol-5-yl_acetate 203.24 965 
1381 2-(3,4-dimethylphenyl)quinoline-4-carboxylic_acid 277.322 966 
1382 2-(4-methylphenyl)quinoline 219.285 966 
1383 
3-(2-indolinyl-2-oxoethyl)-1,7-dimethyl-5-(piperidylcarbonyl)-1,3-
dihydropyridino[2,3-d]pyrimidine-2,4-dione 
461.519 966 
1384 5-(decanoylamino)pentanoic_acid 271.399 967 
1385 1,3-dimethoxy-2-[(3-methylquinoxalin-2-yl)methoxy]benzene 310.352 969 
1386 4-methyl-2-(phenylcarbonylamino)benzoic_acid 255.273 970 
1387 7,7-dimethyl-4-(2-naphthyl)-3H-4,6,7,8-tetrahydrochromene-2,5-dione 334.414 970 
1388 cyclohexyl-N-[2-(2-methylindol-3-yl)ethyl]carboxamide 284.4 971 
1389 
(2E)-3-(3,4-dimethoxyphenyl)-N-(2-methoxyphenyl)-2-
(phenylcarbonylamino)prop-2-enamide 
432.475 972 
1390 methyl_5,6-diphenyl-1,2,4-triazine-3-carboxylate 291.309 972 
1391 2-[(naphthylamino)methylene]cyclohexane-1,3-dione 265.311 973 
1392 5-amino-2-(2-naphthyl)benzo[c]azoline-1,3-dione 288.305 974 
1393 
2-methoxy-1-[6-(4-methoxyphenyl)(3-pyrazolino[5,4-d]1,2,3-triazolin-2-
yl)]benzene 
323.354 975 
1394 ethyl_2-methyl-4-phenylpyrrole-3-carboxylate 229.278 975 
1395 N-[2-(2-methylindol-3-yl)ethyl](4-methylphenyl)carboxamide 292.38 976 
1396 1,2-dimethyl-1,2,3,4-tetrahydroquinoline-6-carbaldehyde 189.257 977 
1397 7,8-dimethoxy-2-phenylchromen-4-one 282.295 977 
1398 
[(2-phenoxyethyl)amino]-N-(3-{[(2-
phenoxyethyl)amino]carbonylamino}phenyl)carboxamide 
434.494 978 
1399 5-methyl-2-pyrrolylphenylamine 172.229 978 
1400 9-ethylcarbazole-3-carboxylic_acid 239.273 978 
1401 ethyl_4-(methoxycarbonyl)-1-phenyl-2-pyrazoline-3-carboxylate 276.291 978 
1402 N-methyldodecylamine 199.379 980 
1403 3-[4-(tert-butyl)phenyl]-3-(phenylcarbonylamino)propanoic_acid 325.407 981 
1404 3-cyclopentyl-1-[4-(2-phenoxyacetyl)piperazinyl]propan-1-one 344.453 982 
1405 
{6-imidazolyl-4-[(4-methylphenyl)amino](1,3,5-triazin-2-yl)}(4-
methylphenyl)amine 
357.417 983 
1406 
3-[4-(dimethylamino)phenyl]-2-(4-ethylphenyl)-1,2,3-
trihydroquinazolin-4-one 
371.481 984 
1407 4,5-bis(4-methylphenyl)-2-indol-3-ylimidazole 363.461 984 
1408 
(15S,2R,14R)-14-acetyl-14-hydroxy-2,15-dimethyl-5-
oxotetracyclo[8.7.0.0<2,7>.0<11,15>]heptadeca-6,8-diene 
328.45 985 
1409 2,3-diphenyl-3-hydroquinazolin-4-one 298.343 985 
1410 3-phenyl-1-pyrrolidinyl-2-pyrrolylpropan-1-one 268.358 985 
1411 2-[N,N-bisbenzylcarbamoyl]benzoic_acid 345.397 986 
1412 
2-(N-(2-5,6,7,8-
tetrahydronaphthyl)carbamoyl)cyclohexanecarboxylic_acid 
301.385 987 
1413 N-(2,6-dimethylphenyl)-2-[(2-methylphenyl)amino]acetamide 268.358 987 
1414 
2-{2,5-dioxo-4-[(2,4,6-trimethoxyphenyl)methylene](1,3-diazolidinyl)}-
N-(4-methylphenyl)acetamide 
425.44 988 
1415 4-(N-hexylcarbamoyl)phenyl_acetate 263.336 988 
1416 ethyl_(2E)-3-[N-(2-cyclohex-1-enylethyl)carbamoyl]prop-2-enoate 251.325 990 
1417 
1,2,2-trimethylpropyl_4-methyl-2-oxo-6-phenyl-1,3,6-
trihydropyrimidine-5-carboxylate 
316.399 992 
1418 2-(2-methoxyphenyl)-N-(3-methylphenyl)acetamide 255.316 992 
1419 3-(1-phenylpyridino[3,2-f]quinolin-3-yl)phenol 348.403 992 
1420 2-(2-pyridylthiomethylthio)pyridine 234.333 993 
1421 2-[(1E)-2-(4-methoxyphenyl)vinyl]benzo[e]1,3-oxazin-4-one 279.295 993 
1422 2-{[4-(dimethylamino)phenyl]methylene}-1H-benzo[d]azolin-3-one 264.326 994 
1423 3-(4-phenylphenyl)pyrazole 220.273 994 
1424 malachite_green 329.464 994 
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1425 [4-(4,4-diethyl(1H,2H-benzo[d]1,3-oxazin-2-yl))phenyl]diethylamine 338.492 995 
1426 7-(diethylamino)chromen-2-one 217.267 995 
1427 N-(4-methylphenyl)[2-(4-pyridylcarbonylamino)phenyl]carboxamide 331.373 996 
1428 N,N-dimethyldodecylamine 213.406 998 
1429 4-phenyl-2-(phenylazamethylene)-3-(2-phenylethyl)-1,3-thiazoline 356.484 999 
1430 2-[2-(acetylamino)phenyl]-N-(4-ethylphenyl)-2-oxoacetamide 310.352 1000 
1431 1-acetyl-2-methyl-4-(phenylamino)-1,2,3,4-tetrahydroquinoline 280.369 1001 
1432 
2-methoxy-12-methyl-12H,5aH-benzo[e]isoindolino[1,2-b]1,3-oxazin-
10-one 
281.31 1001 
1433 8-quinolyl_benzoate 249.268 1001 
1434 
N-[(N-{(1E)-2-[4-(dimethylamino)phenyl]-1-azaprop-1-
enyl}carbamoyl)methyl]-2,2-diphenylacetamide 
428.533 1001 
1435 2-(phenylmethylthio)-1,3-thiazoline 209.324 1002 
1436 4-piperidylbenzaldehyde 189.257 1002 
1437 3-isoindolin-2-ylphenol 211.263 1003 
1438 4-quinoxalin-2-ylphenyl_acetate 264.283 1004 
1439 1-benzylindole-3-carbaldehyde 235.285 1006 
1440 
1-(tert-butyl)-5-(indol-2-ylmethylene)-1,3-dihydropyrimidine-2,4,6-
trione 
311.34 1007 
1441 N-(2,2-dimethylpropyl)(2-hydroxyphenyl)carboxamide 207.272 1008 
1442 2-phenylindolizine-1,3-dicarbaldehyde 249.268 1009 
1443 ethyl_4-[(3-amino-2-oxochromen-4-yl)amino]benzoate 324.335 1009 
1444 4-(phenyldiazenyl)phenol 198.224 1010 
1445 
methyl_2-amino-5-{[4-amino-3-
(methoxycarbonyl)phenyl]methyl}benzoate 
314.34 1010 
1446 
1-methyl-4-(2-oxo-2-(2-5,6,7,8-tetrahydronaphthyl)ethyl)-1,4-
dihydroquinoxaline-2,3-dione 
348.401 1011 
1447 7-hydroquinazolino[4,3-b]quinazolin-8-one 247.256 1011 
1448 (3,5-dimethylphenyl)[(4-methoxyphenyl)methyl]amine 241.332 1014 
1449 tridecylamine 199.379 1014 
1450 4-(5-pentyl-2-pyridyl)benzoic_acid 269.343 1017 
1451 5-[(3-methylquinoxalin-2-yl)methoxy]-2H-benzo[d]1,3-dioxolene 294.309 1017 
1452 6-methoxy-3-[(2-methylphenyl)carbonyl]chromen-4-one 294.306 1017 
1453 
N-(3-phenylpropyl)-2-(1,5,7-trimethyl-2,4-dioxo(1,3-
dihydropyridino[2,3-d]pyrimidin-3-yl))acetamide 
380.446 1017 
1454 8-pyrrolylnaphthalen-2-ol 209.247 1018 
1455 methyl_4-(N-octylcarbamoyl)butanoate 257.372 1019 
1456 
2-[2-(2-methylindol-3-yl)ethyl]-4,5,6,7,3a,7a-hexahydroisoindole-1,3-
dione 
310.395 1020 
1457 methyl_2-(2-oxo-3-phenylhydroquinoxalinyl)acetate 294.309 1020 
1458 N-((1E)-2-indol-3-yl-1-azavinyl)[4-(tert-butyl)phenyl]carboxamide 319.405 1020 
1459 (2E)-1-(2,4-dihydroxyphenyl)-3-phenylprop-2-en-1-one 240.258 1021 
1460 
N-{(1E)-2-[4-(diethylamino)phenyl]-1-azavinyl}-2-(2-
naphthylamino)propanamide 
388.511 1021 
1461 
(4-{[4-(dimethylamino)phenyl][4-
(methylamino)phenyl]methylene}cyclohexa-2,5-
dienylidene)dimethylamine_chloride 
358.505 1022 
1462 4-[(3,4-dimethylphenyl)amino]chromen-2-one 265.311 1022 
1463 
4-methylphenyl_4-(4-{3-[(4-
methylphenyl)oxycarbonyl]propanoyl}piperazinyl)-4-oxobutanoate 
466.533 1022 
1464 4-methoxy-1-[(3-methylquinoxalin-2-yl)methoxy]benzene 280.326 1023 
1465 
butyl_6-(4-ethylphenyl)-4-methyl-2-oxo-1,3,6-trihydropyrimidine-5-
carboxylate 
316.399 1024 
1466 indeno[3,2-b]quinolin-10-one 231.253 1024 
1467 
N-(1-acetyl-2-methyl(4-1,2,3,4-tetrahydroquinolyl))(3-methoxyphenyl)-
N-benzamide 
414.503 1024 
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1468 (4-aminophenyl)-N-methyl-N-octylcarboxamide 262.394 1025 
1469 
1,3-dimethyl-5-phenyl-6-benzyl-1,3-dihydropyrrolo[3,4-d]pyrimidine-
2,4-dione 
345.4 1025 
1470 bis(2-ethylhexyl)amine 241.459 1025 
1471 
N-{[4-hydroxy-2-methyl-5-(methylethyl)phenyl]methyl}(2-
hydroxyphenyl)carboxamide 
299.369 1026 
1472 methyl_blue 755.831 1027 
1473 
N-(4-{N-[(1E)-2-(3-phenoxyphenyl)-1-azavinyl]carbamoyl}-3-
ethoxyphenyl)acetamide 
417.463 1027 
1474 
2-({(1E)-2-[4-(dimethylamino)phenyl]-1-azavinyl}amino)-3-phenyl-3-
hydroquinazolin-4-one 
383.452 1028 
1475 methyl_4-[(N-naphthylcarbamoyl)amino]benzoate 320.347 1028 
1476 N-(3,4-dimethoxyphenyl)(3,4,5-triethoxyphenyl)carboxamide 389.447 1032 
1477 
2-(5,7-dimethyl-2,4-dioxo-1-phenyl(1,3-dihydropyridino[2,3-
d]pyrimidin-3-yl))-N-(3-methylbutyl)acetamide 
394.472 1033 
1478 3-(5,6,7,8,9-pentahydro-4aH-carbazol-9-yl)propanoic_acid 243.305 1035 
1479 methyl_3-pyrrolylindole-2-carboxylate 240.261 1035 
1480 [4,6-bis(3,5-dimethylpyrazolyl)(1,3,5-triazin-2-yl)]phenylamine 360.421 1036 
1481 3-butyl-4-hydroxy-1-phenylhydroquinolin-2-one 293.365 1036 
1482 (2E)-3-(3,4-dimethoxyphenyl)-1-phenylprop-2-en-1-one 268.312 1037 
1483 1-(2-naphthylmethyl)-2-(naphthylmethyl)benzimidazole 398.506 1037 
1484 
2-(cyclohexylmethylamino)-4-oxo-5-hydropyridino[1,2-a]pyrimidine-3-
carbaldehyde 
285.345 1037 
1485 
5-[(4-ethoxyphenyl)methyl]-1-(4-ethylphenyl)-1,3,5-trihydropyrimidine-
2,4,6-trione 
366.416 1037 
1486 1-(4-methoxyphenyl)-4-{[4-benzylpiperidyl]carbonyl}pyrrolidin-2-one 392.497 1038 
1487 (2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one 240.258 1039 
1488 isoquinolylthioisoquinoline 288.366 1039 
1489 
N-[(1E)-2-(2-methylphenyl)-1-azavinyl]-2-hydroxy-2,2-
diphenylacetamide 
344.412 1039 
1490 (2E)-3-[2,5-dimethyl-1-(4-methylphenyl)pyrrol-3-yl]prop-2-enoic_acid 255.316 1041 
1491 (3,5-diaminophenyl)-N-(4-methylphenyl)-N-(2-naphthyl)carboxamide 367.449 1041 
1492 1-cyclohexyl-2,5-dimethylpyrrole-3-carbaldehyde 205.299 1041 
1493 1-methylpyrrolidine 85.1486 428 
1494 N-methylpiperidine 99.1754 493 
1495 TEMED 116.206 518 
1496 N,N-diisopropylethylamine 129.245 546 
1497 triallylamine 137.224 575 
1498 benzphetamine 239.36 776 
1499 cyclobenzaprine 275.393 836 
1500 amitriptyline 277.408 851 
1501 alverine 281.44 899 
1502 pyridine 79.1012 404 
1503 2-vinylpyridine 105.139 512 
1504 2,4,6-collidine 121.182 544 
1505 tetrabutylammonium 242.467 941 
1506 androstenedione 286.413 1023 
1507 putrescine 88.1522 473 
1508 piperidine 85.1486 492 
1509 hexmethyleneimine 99.1754 493 
1510 3-methyladenine 149.155 493 
1511 diallylamine 97.1596 520 
1512 diisopropylamine 101.191 524 
1513 N-methylbutylamine 87.1644 534 
1514 benzylamine 107.155 552 
Appendix 
182 
 
1515 cyclohexylamine 99.1754 554 
1516 spermidine 145.247 564 
1517 1-phenylethylamine 121.182 578 
1518 di-sec-butylamine 129.245 586 
1519 spermine 202.342 588 
1520 phenethylamine 121.182 595 
1521 L-amphetamine 135.208 612 
1522 phentermine 149.235 629 
1523 mephentermine 163.262 642 
1524 dibenzylamine 197.279 690 
1525 dicyclohexylamine 181.32 692 
1526 octylamine 129.245 727 
1527 nonylamine 143.272 785 
1528 nortriptyline 263.382 839 
1529 maprotiline 277.408 840 
1530 apomorphine 267.327 631 
1531 levorphanol 257.375 659 
1532 levallorphan 283.413 703 
1533 pentazocine 271.402 739 
1534 4-methylmorpholine 101.148 375 
1535 nefopam 253.343 726 
1536 dextromethorphan 271.402 761 
1537 diphenhydramine 255.359 779 
1538 imipramine 280.412 836 
1539 1-propyl-4-piperidone 141.213 495 
1540 tetramisole 204.289 622 
1541 hydrocortisone 362.465 735 
1542 cortisone 360.449 745 
1543 corticosterone 346.466 836 
1544 cortexolone 346.466 856 
1545 11a-hydroxyprogesterone 330.466 882 
1546 nandrolone 274.402 932 
1547 testosterone 288.429 979 
1548 deoxycorticosterone 330.466 1001 
1549 17a-methyltestosterone 302.456 1039 
1550 1,3-dimethyluracil 140.141 487 
1551 N-phenylmaleimide 173.171 508 
1552 1-methyl-2-piperidone 113.159 534 
1553 1,1,3,3-tetramethylurea 116.163 543 
1554 N-vinyl-2-pyrrolidinone 111.143 567 
1555 N,N-dimethylbenzamide 149.192 646 
1556 1-phenyl-2-pyrrolidinone 161.203 715 
1557 praziquantel 312.411 936 
1558 indole 117.15 843 
1559 3-methylindole 131.177 946 
1560 carbazole 167.21 1041 
1561 1-vinylimidazole 94.1158 474 
1562 4-dimethylaminopyridine 122.169 533 
1563 m-toluidine 107.155 577 
1564 allantoin 158.116 243 
1565 2-hydroxypyrimidine 96.0884 282 
1566 uracil 112.088 288 
1567 dihydrouracil 114.104 290 
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1568 2,4-diamino-6-hydroxypyrimidine 126.118 348 
1569 cytosine 111.103 374 
1570 dihydrothymine 128.13 377 
1571 thymine 126.115 377 
1572 creatinine 113.119 378 
1573 2-pyrrolidinone 85.1054 380 
1574 2-hydroxypyridine 95.1006 401 
1575 3,7-dimethyluric_acid 196.165 464 
1576 1,9-dimethyluric_acid 196.165 468 
1577 1,3-dimethyluric_acid 196.165 477 
1578 1,3,7-trimethyluric_acid 210.192 517 
1579 acetanilide 135.165 620 
1580 2-hydroxyquinoline 145.16 628 
1581 aprobarbital 210.232 696 
1582 secbutabarbital 212.248 699 
1583 phenytoin 252.272 784 
1584 mephobarbital 246.265 811 
1585 secobarbital 238.286 821 
1586 glutethimide 217.267 825 
1587 cyheptamide 237.301 848 
1588 cotinine 176.218 505 
1589 fentanyl 336.476 777 
1590 oxyphenbutazone 324.379 918 
1591 3-methyl-2-oxazolidinone 101.105 373 
1592 hydrocodone 299.369 617 
1593 meperidine 247.336 702 
1594 dimefline 323.391 726 
1595 mebeverine 429.555 852 
1596 drofenine 317.47 929 
1597 2-dimethylaminoethanol 89.137 343 
1598 triethanolamine 149.189 343 
1599 cyclopentanone_oxime 99.1322 555 
1600 procyclidine 287.444 825 
1601 methcathinone 163.219 601 
1602 quinolinic_acid 167.121 252 
1603 niacin 123.111 309 
1604 3-pyridylacetic_acid 137.138 373 
1605 2-dimethylaminobenzoic_acid 165.191 498 
1606 3-dimethylaminobenzoic_acid 165.191 618 
1607 4-dimethylaminobenzoic_acid 165.191 731 
1608 dimethylglycine 103.121 246 
1609 betaine 118.155 246 
1610 2-aminopyrimidine 95.1036 445 
1611 proflavine 209.25 645 
1612 aminoquinoline 144.176 691 
1613 ethidium 314.409 769 
1614 4-aminophenol 109.127 418 
1615 p-anisidine 123.154 551 
1616 xylazine 220.332 685 
1617 dopamine 153.18 506 
1618 dobutamine 301.385 638 
1619 mescaline 211.26 595 
1620 methoxyphenamine 179.261 651 
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1621 desipramine 266.385 827 
1622 promazine 284.418 812 
1623 thiethylperazine 399.611 916 
1624 tripelennamine 255.362 722 
1625 detomidine 186.256 694 
1626 oxindole 133.149 607 
1627 doxylamine 270.374 646 
1628 R-apocodeine 281.354 694 
1629 choline 104.172 343 
1630 2-amino-3-phosphonopropionic_acid 169.074 222 
1631 taurine 125.142 236 
1632 L-aspartic_acid 133.104 241 
1633 diaminopimelic_acid 190.199 250 
1634 D-glutamic_acid 147.13 253 
1635 L-proline 115.132 260 
1636 L-alpha-aminobutyric_acid 103.121 278 
1637 guanidinosuccinic_acid 175.144 283 
1638 2-aminoisobutyric_acid 103.121 287 
1639 aminoadipic_acid 161.157 288 
1640 guanidoacetic_acid 117.107 291 
1641 creatine 131.134 297 
1642 pipecolinic_acid 129.158 310 
1643 D-valine 117.147 326 
1644 L-lysine 146.189 326 
1645 L-arginine 174.202 340 
1646 homo-L-arginine 188.229 394 
1647 5-aminopentanoic_acid 117.147 449 
1648 2-phenylglycine 151.165 458 
1649 L-isoleucine 131.174 482 
1650 4-guanidinobutanoic_acid 145.161 488 
1651 leucine 131.174 494 
1652 L-norleucine 131.174 502 
1653 6-aminocaproic_acid 131.174 506 
1654 N-methyl-a-aminoisobutyric_acid 117.147 508 
1655 beta-leucine 131.174 521 
1656 phenylalanine 165.191 521 
1657 2-(N-morpholino)ethanesulfonic_acid 195.233 243 
1658 morpholinopropane_sulfonic_acid 209.26 246 
1659 3-amino-1,2-propanediol 91.1096 321 
1660 D-glucosamine 179.172 322 
1661 trizma 121.136 326 
1662 2-amino-2-methyl-1,3-propanediol 105.136 347 
1663 heptaminol 145.244 555 
1664 N-benzylethanolamine 151.208 560 
1665 ephedrin 165.235 599 
1666 scopolamine 303.357 605 
1667 oxycodone 315.368 607 
1668 ethylmorphine 321.459 625 
1669 atropine 289.374 636 
1670 tramadol 263.379 669 
1671 cinchonine 294.396 633 
1672 hydroxybutorphanol 343.465 625 
1673 lidocaine 234.341 656 
Appendix 
185 
 
1674 ropivacaine 274.405 706 
1675 bupivicaine 288.432 750 
1676 2-oxazolidinone 87.078 277 
1677 urethane 89.0938 400 
1678 meprobamate 218.252 662 
1679 acetaminophen 151.165 494 
1680 hydroxyphenytoin 268.271 668 
1681 niacinamide 122.126 432 
1682 1-phenyl-3-pyrazolidinone 162.191 642 
1683 1-methylnicotinamide 137.161 366 
1684 methyprylon 183.25 649 
1685 lipoamide 205.333 713 
1686 3,5-diaminobenzoic_acid 152.152 388 
1687 m-aminobenzoic_acid 137.138 503 
1688 kynurenic_acid 189.17 509 
1689 N-phenylglycine 151.165 599 
1690 N-2-carboxyphenylglycine 195.174 656 
1691 3,5-dimethylanthranilic_acid 165.191 745 
1692 N-ethylanthranilic_acid 165.191 776 
1693 2-ethylanilinoacetic_acid 179.218 794 
1694 nalidixic_acid 232.238 790 
1695 diphenylamine-4-sulfonic_acid 249.284 531 
1696 indole-3-carboxylic_acid 161.16 640 
1697 indole-3-acetic_acid 175.187 678 
1698 3-indolepropionic_acid 189.213 741 
1699 1-methyl-4-imidazoleacetic_acid 140.141 348 
1700 tolmetin 257.288 871 
1701 L-homoserine_lactone 101.105 338 
1702 glycine_methyl_ester 89.0938 361 
1703 glycine_ethyl_ester 103.121 475 
1704 L-phenylalanine_ethyl_ester 193.245 641 
1705 methylphenidate 233.31 680 
1706 3-methoxytyramine 167.207 547 
1707 doxapram 378.513 695 
1708 alfentanil 416.522 754 
1709 ethamivan 223.271 673 
1710 methyl-2-oxo-1-pyrrolidine-acetate 157.169 508 
1711 pyridoxal 167.164 484 
1712 pyridoxine 169.18 510 
1713 acepromazine 326.456 795 
1714 propiomazine 340.482 848 
1715 phosphorylcholine 184.152 234 
1716 prostaglandin_B1 336.47 978 
1717 resorufin 213.192 680 
1718 benzocaine 165.191 767 
1719 1-methylhistamine 125.173 527 
1720 tryptamine 160.218 613 
1721 trimethoprim 290.321 624 
1722 pyrilamine 285.388 719 
1723 7-methyladenine 149.155 475 
1724 6-dimethylaminopurine 163.182 536 
1725 ipratropium 332.462 659 
1726 indoxyl_acetate 175.187 834 
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1727 benzydamine 309.41 807 
1728 caffeine 194.193 548 
1729 2,4-quinoline_diol 161.16 609 
1730 L-serine_methyl_ester 119.12 375 
1731 nadolol 309.405 599 
1732 metoprolol 267.367 660 
1733 toliprolol 223.314 692 
1734 oxprenolol 265.352 711 
1735 bisoprolol 325.447 717 
1736 propranolol 259.347 742 
1737 betaxolol 307.432 763 
1738 bitolterol 461.557 993 
1739 epinephrine 183.207 470 
1740 phenylephrine 167.207 531 
1741 albuterol 239.314 554 
1742 ritodrine 287.358 611 
1743 norbutorphanol 259.347 616 
1744 ractopamine 301.385 638 
1745 L-cystine 240.292 243 
1746 allocystathionine 222.259 246 
1747 homocystine 268.345 324 
1748 L-methionine 149.207 339 
1749 L-dopa 197.19 342 
1750 L-tyrosine 181.191 465 
1751 o-tyrosine 181.191 513 
1752 phosphoserine 185.073 207 
1753 5-aminolevulinic_acid 131.131 347 
1754 N-acetyl-L-glutamine 188.183 277 
1755 L-pyroglutamic_acid 129.115 287 
1756 isovalerylglycine 159.185 523 
1757 suberylglycine 231.248 529 
1758 phenylacetyl_L-glutamine 264.28 550 
1759 phenylacetylglycine 193.202 565 
1760 nalorphine 311.38 589 
1761 naloxone 327.379 591 
1762 naltrexone 341.406 606 
1763 nalbuphine 357.449 623 
1764 quinidine 324.422 652 
1765 N-acetylputrescine 130.189 451 
1766 MEGX 206.287 624 
1767 prilocaine 220.314 655 
1768 3-hydroxylidocaine 250.34 586 
1769 fenspiride 260.335 621 
1770 7-methylxanthine 166.139 444 
1771 theobromine 180.166 490 
1772 paraxanthine 180.166 514 
1773 etamiphylline 279.341 564 
1774 propentofylline 306.364 733 
1775 hepes 238.301 266 
1776 fexofenadine 501.664 828 
1777 glycerophosphocholine 258.231 235 
1778 L-carnitine 162.208 344 
1779 procaine 236.313 605 
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1780 anileridine 352.475 726 
1781 tetracaine 264.367 773 
1782 methylhippuric_acid 193.202 617 
1783 colchicine 399.443 673 
1784 remifentanil 376.452 699 
1785 imidazoleacetic_acid 126.115 339 
1786 urocanic_acid 138.126 481 
1787 5-hydroxyindoleacetic_acid 191.186 542 
1788 xanthurenic_acid 205.17 484 
1789 1-aminoanthraquinone-2-sulfonic_acid 303.289 610 
1790 2-methoxyanilinoacetic_acid 181.191 670 
1791 adenine 135.128 465 
1792 6-methyladenine 149.155 508 
1793 benzoylecgonine 289.33 610 
1794 L-acetylcarnitine 204.245 486 
1795 stanozolol 328.497 966 
1796 5-hydroxytryptophol 177.202 530 
1797 histamine 111.146 524 
1798 reserpine 608.687 891 
1799 N,N-diallyltartardiamide 228.247 461 
1800 buspirone 385.508 734 
1801 serine 105.093 238 
1802 hydroxyproline 131.131 241 
1803 tricine 179.172 242 
1804 L-threonine 119.12 245 
1805 L-homoserine 119.12 249 
1806 morphine-3-glucuronide 461.468 499 
1807 8-hydroxy-2-deoxyguanosine 283.243 463 
1808 cytidine 243.219 468 
1809 deoxycytidine 227.219 485 
1810 thymidine 242.231 634 
1811 riboflavin 376.368 537 
1812 biotin 244.308 556 
1813 penicillin_G 334.389 744 
1814 nicotinuric_acid 180.163 443 
1815 N-carbobenzyloxy-L-aspartic_acid 267.238 639 
1816 3-methylhistidine 169.183 318 
1817 1-methylhistidine 169.183 335 
1818 tryptophan 204.228 554 
1819 leucylproline 228.291 570 
1820 lisinopril 405.493 580 
1821 xanthine 152.112 326 
1822 melatonin 232.282 662 
1823 pyridoxamine 168.195 501 
1824 isoxsuprine 301.385 707 
1825 L-thyronine 273.288 589 
1826 benzyl_L-glutamate 237.255 597 
1827 omeprazole 345.415 676 
1828 yohimbine 354.448 684 
1829 dibucaine 343.468 846 
1830 procainamide 235.328 561 
1831 indolelactic_acid 205.213 622 
1832 L-asparagine 132.119 240 
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1833 glutamine 146.146 246 
1834 citrulline 175.187 253 
1835 glycyl-glycine 132.119 293 
1836 N6-acetyl-L-lysine 188.226 323 
1837 N-alpha-acetyllysine 188.226 383 
1838 glycyl-L-leucine 188.226 565 
1839 prolylisoleucine 228.291 574 
1840 L-aspartyl-L-phenylalanine 280.28 577 
1841 diprotin_A 341.45 617 
1842 pantothenic_acid 219.237 473 
1843 taurocholic_acid 515.704 657 
1844 glycocholic_acid 465.629 789 
1845 glycodeoxycholate 449.629 937 
1846 histidine 155.156 325 
1847 L-5-hydroxytryptophan 220.227 501 
1848 5-methoxytryptophan 234.254 554 
1849 bambuterol 367.444 685 
1850 deacetyldiltiazem 372.481 741 
1851 7-methylguanine 165.154 480 
1852 1-methylguanine 165.154 481 
1853 adenosine 267.244 489 
1854 pindolol 248.324 629 
1855 hypoxanthine 136.113 320 
1856 4-aminohippuric_acid 194.19 463 
1857 formoterol 344.41 668 
1858 cytidine_monophosphate 323.199 248 
1859 dCMP 307.199 285 
1860 flavin_mononucleotide 456.348 479 
1861 procaterol 290.361 568 
1862 labetalol 328.41 714 
1863 carteolol 292.377 601 
1864 guanine 151.127 311 
1865 fenbendazole 299.347 875 
1866 biocytin 372.482 522 
1867 5-methylthioadenosine 297.331 550 
1868 ADP 427.204 213 
1869 adenosinemonophosphate 347.224 283 
1870 adenylsuccinic_acid 463.297 300 
1871 dAMP 331.224 301 
1872 cyclic_AMP 329.209 416 
1873 citicoline 489.336 244 
1874 nicotinamideribotide 335.23 256 
1875 amoxicillin 365.403 547 
1876 guanosine 283.243 449 
1877 deoxyguanosine 267.244 458 
1878 carnosine 226.235 411 
1879 7-methylguanosine 298.278 496 
1880 inosinic_acid 348.209 234 
1881 GMP 363.223 246 
1882 2-deoxyguanosine-5-monophosphate 347.224 284 
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Appendix 2. The scripts used for filtering 
2.1 log D similarity searching 
The absolute difference of the log D molecular descriptor values of compounds in 
database to the target compound was calculated as a filter. The threshold used for the log D 
approach was 0.2, compounds with the absolute difference of the log D less than 0.2 were 
used as the training set to build QSRR models for the target compound [2]. The scripts are 
supposed to run on a Matlab platform and are listed below. 
clear all 
clc 
values=xlsread('lgD_88 compounds.xlsx','lgD','a1:a88'); % put the right name of the Excel name, 
the worksheet name and the matrix contains the values of the log D for all the compounds. 
number=zeros(max(size(values)),1); 
selected_ID=zeros(max(size(values)),max(size(values))); 
selected_values=zeros(max(size(values)),max(size(values))); 
difference=zeros(max(size(values)),max(size(values))); 
maxdiff=0.5; % put the threshold of the log D filter here 
ID=1:max(size(values)); 
ID=ID.'; 
for ref=1:max(size(values)) 
j=0; 
        for i=1:max(size(values)) 
            difference(i,ref)=abs(values(ref)-values(i)); 
            if abs(difference(i,ref))<maxdiff && abs(difference(i,ref))>0  
                j=j+1; 
                number(ref,1)=j; 
            end 
        end 
    [sort_difference(:,ref),index]=sort(difference(:,ref)); 
    sort_ID(:,ref)=ID(index);         
    sort_values(:,ref)=values(index);        
end 
for ref=1:max(size(values)) 
    number(ref,1)=0; 
    j=2; 
    while sort_difference(j,ref)<maxdiff || j>max(size(values)) 
        number(ref,1)=j-1; 
        j=j+1; 
    end 
    selected_ID(1:number(ref,1)+1,ref)=sort_ID(1:number(ref,1)+1,ref); 
end 
2.2 log P similarity searching 
The ratio of the log P molecular descriptor values of compounds in database to the target 
compound was also evaluated as a filter. The threshold used for the log P approach was 1.2, 
compounds with the ratio of the log P less than 1.2 were used as the training set to build QSRR 
models for the target compound. The scripts are supposed to run on a Matlab platform and are 
listed below. 
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Y=xlsread('lgP_88 compounds.xlsx','lgP','a1:a88'); % put the right name of the Excel name, the 
worksheet name and the matrix contains the values of the log P for all the compounds. 
ID=1:max(size(Y)); 
ID=ID.'; 
ratio=zeros(max(size(Y)),max(size(Y))); 
selected_ID=zeros(max(size(Y)),max(size(Y))); 
mink = 0; 
maxratio = 1.1; % put the threshold of the log P filter here 
%ranking k-values: 
for unseen=1:max(size(Y)) 
    if Y(unseen)>mink 
        for i=1:max(size(Y)) 
            if Y(i)<mink 
               ratio(i,unseen)=999; 
            else 
               ratio(i,unseen)=Y(i)./Y(unseen); 
            end 
            %ratio must be positive 
            if ratio(i,unseen)<1 
               ratio(i,unseen)=Y(unseen)./Y(i); 
            end 
        end 
    else 
        ratio(:,unseen)=333; 
    end 
    [sort_ratio(:,unseen),index]=sort(ratio(:,unseen)); 
    sort_ID(:,unseen)=ID(index); 
end 
2.3 Local training set for single target compound 
This local QSRR model provides a separate prediction of retention for each target 
compound. Using the scripts, predictions for all the target compounds can be performed on 
the Matlab platform automatically.  To perform local QSRR modelling, scripts are listed below. 
clear all 
clc 
ID=xlsread('D:\yabin\5 new\5 new compounds.xlsx','ID','a1:ew11'); % put the id of compounds 
in training set of target compounds. 
X=xlsread('D:\yabin\5 new\5 new compounds.xlsx','descriptors','a2:dv154'); % put the matrix of 
the molecular descriptors of all the compounds 
Y=xlsread('D:\yabin\5 new\5 new compounds.xlsx','eta','a2:a154'); % put the responses (solute 
coefficients or retention times) of all the compounds. 
[niets, descriptorsAll] =xlsread('D:\yabin\5 new\5 new compounds.xlsx','descriptors','a1:dv1'); % 
put the matrix of the names of the selected molecular descriptors. 
meanAbsError=zeros(size(X,1),1); 
meanError=zeros(size(X,1),1); 
ErrorPLS=zeros(size(X,1),1); 
Q2_max_PLS=zeros(size(X,1),1); 
Error=zeros(size(X,1),5); 
Error_all=zeros(size(X,1),6); 
medianError=zeros(size(X,1),1); 
origid=zeros(size(X,2),size(X,1)); 
for unseen=1:size(X,1) % put the initial number of the compound need to be calculated. 
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       Ind=ID(:,unseen); 
        sz=sum(Ind~=0); 
        if sz > 4 % min training set size ≥ 5 
        XX=X(Ind(1:sz),:); 
        yy=Y(Ind(1:sz)); 
        id_ct= find( arrayfun( @(c) numel( unique( XX(:, c) )), 1:size(XX, 2 )) > 16 ); 
        descriptors=descriptorsAll(id_ct); 
        descriptors=descriptors.';  
        Xcal=XX(2:end,id_ct); 
        ycal=yy(2:end); 
        Xunseen=XX(1,id_ct); 
        yunseen=yy(1); 
        [PLS_LOO_ref,n]=plscv_Eva(Xcal,ycal,5,size(Xcal,1),'autoscaling',1,2);  
        PLS_ref_nlv=pls(Xcal,ycal,n,'autoscaling'); % n = opt. # LV obtained 
        PLS_pred_nlv=plstest(PLS_ref_nlv,Xunseen,yunseen,n); % it gives prediction error for 
target. 
        ErrorPLS(unseen,1) = [PLS_pred_nlv.error].'; 
        Q2_max_PLS(unseen,1) = [PLS_LOO_ref.Q2_max].'; 
        gapls_loop 
       var=logical(variable_index);   
        loop_CV; 
        F1 = struct('Q2', {F(1:5).Q2}, 'optLV', {F(1:5).optLV});  
        pred_loop 
        Error(unseen,1:5)= [P.error]; % prediction error for 5-times GA-PLS  
        meanError(unseen,1)=mean([P.error].'); % mean error 
        meanAbsError(unseen,1)=mean(abs([P.error].')); % mean absolute error 
        medianError(unseen,1)=median([P.error].'); % median error 
        freq=sum(variable_index == 1,2); 
        id=find(freq>0); 
        OID=id_ct(id); 
        selected_desc=[num2cell(OID).' descriptorsAll(OID).']; 
        origid(:,unseen)=ismember((1:size(X,2)),OID).';  
        filename = [ '5 new compounds Tanimoto_' num2str(unseen) '.mat' ]; 
        save(filename); 
catch 
      filename = [ '5 new compounds Tanimoto_' num2str(unseen) '.mat' ]; 
        save(filename); 
 end 
    else 
        ErrorPLS(unseen,1) = 999; 
        Q2_max_PLS(unseen,1) = 999; 
        Error (unseen,1:5)= 999.*ones(1,5); 
        meanAbsError(unseen,1)= 999;  
        medianError(unseen,1)= 999; 
        meanError(unseen,1)= 999; 
        id(unseen,1)=999; 
        Error_all(unseen,:)=[Q2_max_PLS(unseen) ErrorPLS(unseen) abs(ErrorPLS(unseen)) 
meanAbsError(unseen) medianError(unseen) meanError(unseen) ]; 
        end 
        Error_all(unseen,:)=[Q2_max_PLS(unseen) ErrorPLS(unseen) abs(ErrorPLS(unseen)) 
meanAbsError(unseen) medianError(unseen) meanError(unseen) ]; 
end 
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2.4 Local training set for a group of target compounds 
These QSRR models were formed for the prediction of solute coefficients and retention 
times [3]. Unlike above-mentioned local QSRR models, each target compound has its own 
specific training set to build its own QSRR model. Here, predictions were performed for a 
group of compounds that generated using different filtering approaches. To perform QSRR 
modelling manually, scripts are listed below. 
[Train,Test,Text,Qual,Xtr,Xts,Xtx] = main_mt(name,number); % split compounds into training 
and test set, 70% in training set and 30% in test set. Put the name of the worksheet which 
contains the variables (retention times) of compounds, put the number of compounds in 
training set as well. 
Training sets are used to build QSRR models, test sets are taken to verify the predictive 
ability of the formed QSRR models. To run the codes on the Matlab, five matrices need to be 
prepared first. The molecular descriptors of compounds in training set, the retention times (or 
solute coefficients) of compounds in training set, the molecular descriptors of compounds in 
test set and the retention times (or solute coefficients) of compounds in test set. The last matrix 
needed is the one which contains the parameters of the genetic algorithm (GA).  The first four 
matrices are named Xcal, ycal, Xtest and ytest, respectively. 
Xcal=xlsread('    ','    ','    ');  
ycal=xlsread('    ','    ','    ');  
Xtest=xlsread('    ','    ','    ');  
ytest= xlsread('    ','    ','    '); % prepare the file contains the above-mentioned data, put the 
corresponding names, values, matrix of locations correctly in spaces. 
options = ga_options('pls','auto',100); % parameters of the GA are embedded. 
options.max_param = 5; % y-randomization to determine optimum # evaluations. 
ga=ga_model(Xcal,ycal,options,n); % enter the optimum # obtained into options. 
ga1 = ga_model(Xcal,ycal,options,0) % build GA-PLS models 5 times. 
ga2 = ga_model(Xcal,ycal,options,0) 
ga3 = ga_model(Xcal,ycal,options,0) 
ga4 = ga_model(Xcal,ycal,options,0) 
ga5 = ga_model(Xcal,ycal,options,0) 
ga1_step_selection = sortrows(ga1.step_selection',-2) % 5 times step selection. 
ga2_step_selection = sortrows(ga2.step_selection',-2) 
ga3_step_selection = sortrows(ga3.step_selection',-2) 
ga4_step_selection = sortrows(ga4.step_selection',-2) 
ga5_step_selection = sortrows(ga5.step_selection',-2) 
ps=ga_postselection_short(Xcal,ycal,m,n,nan) % choose the subset and run post selection. 
ps_step_select=sortrows([(1:size(ps.as.step_selection,1))', ps.as.step_selection],-3); % select 
final subset 
var_sel_nlv=ps.as.var_selected{1,n} 
desc_sel_name=descriptors(var_sel_nlv) % extract names of the selected descriptors. 
PLS_nLV=plsfit(Xcal(:,var_sel_nlv),ycal,n,'auto') % using optimum # of LV to build PLS model for 
training set. 
pred_reg_param = calc_external_reg_param(ycal,ytest,pred_nLV.yc) % using the same optimum 
# of LV to build PLS model for test set. 
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Appendix 3. User manual for QSRR modelling 
In the present study, a variety of software tools were employed in the QSRR modelling, 
for processes such as conformer searching, molecular descriptor calculation, GA-PLS on the 
Matlab platform and other steps. Here, a step-by-step guide is presented to show the exact 
procedures that have been used. All scripts used (bash scripts and Matlab scripts etc.) are 
included in Appendix 2. 
3.1 Dragon for the generation of molecular descriptors  
Obtaining the structures of compounds is the first step. Marvin Sketch (ChemAxon) was 
employed in the present study to draw the structures of compounds directly. Structures of 
compounds need to be saved as .sdf files. 
To find the protonation state of each molecule, first decide a pH value that is relevant to 
the situation, then create folders for each charge state: minus one, neutral, etc. After that, open 
Marvin Sketch and follow the next instructions: 
1. Open the .sdf file. 
2. Click on “Calculations”, then “Protonation”, then click on “Major Microspecies” 
 
3. Choose the pH value, then the protonation state of the compound at that pH will be 
displayed. 
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Another method of finding the state is to click on “Calculations”, then “Protonation”, then 
click on “pKa” and choose “Enter”. The program will then show a graph of the major 
protonation states available for the compound. Once the major microspecies are found under 
a user-defined pH, correct the structure and add charges if needed using the charge buttons (+ 
and –) in Marvin Sketch. Finally, save the structure of each compound to the folder with the 
correct charge state. 
Conformer searching was performed using MMFF94 to find the 50 lowest energy 
conformers for each compound. Conformers were calculated using a forcefield for the 
appropriate solvent, but this also could be done in the gas phase if required. For the searching 
of conformers, the program Balloon and a bash script written by Georg Schuster was utilised. 
The scripts needed for conformer searching in acetonitrile are called: 
"config_search_solvent.bat " 
 "config_search_solvent.sh" 
To perform the calculation, put a copy of the scripts into the charge state folders. Double 
click the .bat script and follow the instructions given in the command line. The commands are 
shown below: 
–1 
OPT 
2 
50 
1 
B3LYP 
6-31+G(d) 
opt freq 
acetonitrile 
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Output from conformer searching: each compound will be assigned into a separate folder, 
and the 50 different conformers will be kept in that folder. Also, an excel spreadsheet listing 
the conformers in order of energy with the lowest energy (most stable) conformer placed first 
on the list will be generated. It is worth pointing out that a new folder for the most stable 
conformer (the one to use for descriptor calculations) will be given within that molecule folder. 
In each molecule folder, there are a few different files including: 
.arc 
.aux 
.com – this file is for use in DFT calculations using gaussian 
.dat 
.mol2 – this file is to use for descriptor calculations (PM7 geometry) using Dragon 
.out – this is the output file from the geometry optimisation in MOPAC 
.xyz – this file can be read by Avogadro to check the geometry 
_1scf.mol2 – this is the one you use if the geometry of the optimised structure is wrong. 
Once the step of conformer searching is done, the molecular descriptors then can be 
generated using Dragon 6: 
1. Launch Dragon 6 and select "Molecules" and click on "Add" to import the files. 
Locate the ".mol2" files obtained from the conformer search (PM7 method). 
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2. The following window will appear, in which you can see your data file. Click OK to 
upload your dataset into Dragon. 
 
3. When the "Descriptors" tab in the toolbar is activated, click on it to start. 
 
4. A variety of molecular descriptors (shown as blocks) will be displayed, click on "Select 
All" to choose all the available descriptors and then click "Calculate". 
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5. Once the calculation finished, click on "View Results" tab to view the generated 
molecular descriptors. The first column is the number of compounds, in each row, the values 
of molecular descriptors are listed for each compound. 
 
6. To save the output, click on "Export" and then click on "Option" tab and select the 
options as seen below then click on "Save" to save the results as a text file. To avoid chance 
correlation, some molecular descriptors need to be excluded, such as constant or near constant 
values, descriptors with a standard deviation less than 0.0001, descriptors strongly correlated 
to others (coefficient of determination > 0.90), and descriptors not available for all compounds. 
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7. At this point the molecular descriptors are ready to export. The following message 
box will appear which shows the number of descriptors that have been exported. 
 
8. The last step is transfer the generated molecular descriptors from the text file to a MS 
Excel file for its subsequent use Open the saved text file. 
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9. Transfer all the data using the functions "copy" and “paste”, and save the Excel file.  
 
3.2 VolSurf+ for the generation of molecular descriptors 
The VolSurf+ software is much more user-friendly to generate molecular descriptors as 
almost all the prerequisite steps before descriptor calculations, including 3D structure 
generation, conformational analysis and geometry optimisation are performed automatically 
by the software, making descriptor calculation both user- and platform-independent and 
therefore less prone to error. 
1. Extract the SMILE string for each compound in Excel and save the file in a .csv file. 
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2. Open the VS+Modeller, the operation panel shows as below. 
 
3. Click the green button to import the .csv file, then choose “SMILES List File” button. 
 
4. Import the .csv file, and click on OK icon, then select the “Smiles String” from the 
menu of “Assign tokens”. 
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5. Go to “Directives” menu to set up the pH for the calculation of molecular descriptors, 
normalise a pH value as required. Then click OK icon. 
 
6. Then the software will start calculating the molecular descriptors, the panel shows the 
prepress of calculation and at the bottom you can see the generated molecular descriptors for 
each compound. 
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7. Once 100% finished, we need to export data matrix of molecular descriptors. Click 
“File” icon, then select “Export data matrix” to a file you want, here we choose “CSV file”. 
 
8. To set up the export of data matrix, select all the objects and all the descriptors, then 
click on OK icon to finish and save your file. 
  
9. Lastly, check the calculated molecular descriptors, VolSurf+ generates 128 descriptors 
for each compound. The first column is the number of compounds, in each row, the values of 
molecular descriptors are listed for each compound. 
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3.3 Similarity searching 
This section highlights various filtering methods used to identify appropriate training sets 
for QSRR modelling. In the similarity searching procedure, the target compound is matched 
against each compound of the database in turn, with the chosen similarity measure being used 
to compute the degree of resemblance in each case. The resulting set of similarity scores is 
then ranked in decreasing similarity order. Structural similarity searching is carried out using 
Tanimoto similarity coefficients (calculated using ChemAxon) with a user-defined threshold 
value. 
Tanimoto similarity searching: 
1. Prepare a Tanimoto similarity (TS) matrix for an entire dataset. In the menu "JChem", 
click on "From 'any' Text" to convert cell text to structure. 
 
Then, the corresponding structures of compounds are converted. 
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2. Prepare a matrix of compound structures for the calculation of similarity. Copy the 
structures of compounds from the column and then paste them in the row. 
 
3. Open the menu “Formulas”, click on "Insert functions" and then select the category 
“JChemExcel”. Functions and choose the function of “JCDissimilarityCFTanimoto”. 
 
4. Define the two molecules that you want to compare (subject to pairwise Tanimoto 
similarity) in the pop-up windows: 
 
5. The function of “JCDissimilarityCFTanimoto” generates the score of dissimilarity of 
compounds, so here another formula "1-JCDissimilarityCFTanimoto" is used to calculate 
pairwise Tanimoto similarity index. 
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6. Using the same formula to other cells in the grid and making sure the correct compounds 
are compared. A similarity matrix consisting of compounds in the entire dataset is then 
obtained. 
 
7. Each compound in the entire dataset is used sequentially as a target compound. The 
remaining compounds in the dataset are ranked according to their pair-wise similarity to the 
target. Sort the compounds based on their similarity scores as below. (the compound ID is in 
column A and the Tanimoto similarity values are in column B). 
 
8. The training sets can be built using either a user-defined cut-off of similarity score, or 
a number of top similar compounds. For the QSRR modelling process, a minimum number of 
five compounds are needed for a training set. By selecting the most similar compounds or 
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picking compounds with TS values greater than a user-defined threshold, the training set for 
each target compound is prepared. 
 
Retention factor-ratio (k-ratio) similarity searching: The ratio of retention factor for 
compounds in database to the retention factor of the target compound is calculated (the ratio 
is always ≥ 1). A k-ratio threshold is utilised as a similarity criteria. Compounds having a k-
ratio smaller than the threshold are included in training set for the corresponding target 
compound. 
Log P/Log D similarity searching: Log P/Log D similarity searching is similar to the k-
ratio similarity searching. The ratio of the log P (or the absolute difference of the log D) for 
compounds in the dataset to the log P (or log D) of the target compound is calculated. After 
that, compounds can be sorted based on the ratio of the log P (or the difference of the log D) 
values to the target. For log P or log D methods, the training set is also formed by sorting the 
dataset relative to the target and choosing the compounds based on the cut-off value or the top 
similar compounds. In the present study, a threshold of 0.2 was used in the log D approach, 
and a threshold of 1.2 was taken in the log P approach.    
Dual filtering-based similarity searching: For the dual filtering-based similarity searching, 
structurally similar compounds to a target compound are clustered (the initial subset) using a 
TS threshold as the primary filter. Then, the most similar compound to the target is selected 
as a surrogate by utilising a molecular descriptor which is highly correlated to retention 
(coefficient of correlation > 0.8). Instead of using the target compound, the k-ratio similarity 
searching is finally applied to the surrogate compound as the secondary filter, to build a final 
subset (obtained from the initial subset) with chromatographically similar compounds for the 
QSRR modelling. The steps of dual filtering-based similarity searching are listed below. 
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1. Load the target compound and rank compounds in the dataset based on the TS scores 
of compounds to the target. Find the TS subset by applying a TS threshold (using cut-off 0.45 
as an example here). 
  
2. Finding the highly correlated (>0.8) molecular descriptor (MD) to retention time (tR) in 
the initial subset using a correlation matrix. First, click on “Data Analysis”.  
 
3. Choose “correlation” in the pop-up window and then fill in the input and output range. 
Check on “Labels” in first row'. 
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4. On the first column in the correlation matrix, find the molecular descriptor (MD) having 
the highest value of the correlation coefficient (r) between the MD and tR (e.g., SM6_B(m) 
[r=0.94]). 
 
5. Calculate the absolute difference for the selected MD between the target and the 
compounds in the initial subset. Identify the most similar neighbour (i.e., the surrogate 
compound) which shows the lowest value of the absolute difference for the chosen MD. After 
picking the surrogate compound, apply the secondary filter: k-ratio similarity to the surrogate 
compound, to cluster compounds (e.g., 14, 12, 11, 6, and 3) into the final training set. Those 
final training sets are used to build QSRR models and predict retentions for the target 
compounds. 
 
3.4 Local QSRR modelling for single target compound 
A local QSRR model provides a separate prediction of retention for each target compound, 
where each target compound has its own specific training set to build its own QSRR model. 
To perform local QSRR modelling, instructions are listed below. 
1. Prepare the dataset (e.g., Excel file CS17_87_570md). The dataset consists of the 
following tabs (e.g., Descriptors, TR, number, ID_TS) in an excel spreadsheet. 
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2. Locate the dataset from the folder “Matlab”. 
 
3. Launch Matlab. Right-click on the folder having the corresponding code (i.e., 
GAPLS_Automation_by Eva) and click on “Selected Folders and Subfolders”, then click on 
“Add to Path”. 
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4. In the current folder, click on “Eva_loop_arc_rev.m”. 
 
5. The editor window appears for the next input. 
 
6. Adjust the coverage area according to the dataset for the following 5 inputs: ID of sorted 
compounds fulfilling the selection criteria (e.g., TS cut-off), number of non-zero elements in 
the selected ID matrix, X of descriptor values, Y of response values (e.g. tR values), and the 
names of descriptors. Input the accurate location of each piece of information in that Excel 
file to make sure the modelling process can be performed smoothly. 
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7. Type the ID numbers of compounds (e.g. 1:87) to be modelled. 
 
8. Define the minimal and maximal number of compounds in the training set to build the 
model, the minimum number of compounds in a training set is five. 
 
9. Update the file name accordingly.  
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10. Then,  run the code: “Eva_loop_arc_rev”. 
 
11. Once finished, the generated models will appear in the current folder in Matlab. Click 
on the file (e.g., CS17_87_570md_a_model1.mat) in the current folder, which shows the result 
for the model of compound ID1. 
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12. The result for the model 1 will appear in the workspace. Statistics like the mean 
absolute error (MAE), median Error and others are shown. For further error calculations, 
choose an appropriate error reporting according to the conditions. 
 
3.5 Local QSRR modelling for a group of target compounds 
A global QSRR model is one which can predict the retention times for many target 
compounds (more than one compound) at once. On the contrary, local QSRR model can be 
built ether for an individual target compound, or a group of test compounds. Two types of 
filtering approaches were employed during the QSRR modelling to yield training set for the 
prediction of a group of test compounds. 
Local Compound Type (LCT) filtering: compounds are grouped into three clusters based 
on their chemical nature: acids (that can donate a proton), bases (that can accept a proton), and 
neutral compounds. Here, 199 neutral compounds are taken as an example. 
1. Launch Matlab. Right-click on the folder having the corresponding code (i.e., 
GAPLS_Codes_toolbox_From Yabin) and click on “Selected Folders and Subfolders” on the 
“Add to Path”. 
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2. Click on “modelling.mat” in the current folder, which contains necessary parameters 
(dataset, descriptors, options, X and Y) for the modelling in the workspace (see the figure 
below). First, click on “dataset” in workspace and type “dataset=0;” in “Command Window”. 
 
3. Input the dataset (consisting of retention parameters for the neutral compounds and their 
molecular descriptors) from the Excel spreadsheet and then paste it on the worksheet in the 
editor window. 
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4. Input the data for X matrix and Y matrix following the same procedure. Here, X 
represents independent variables in the modelling process (should be molecular descriptors of 
compounds), Y represents dependent parameters in the modelling process (should be retention 
times of compounds). 
5. Input the names of molecular descriptors, click on “Import Data” to upload the Excel 
file which contains the names of molecular descriptors in a row. 
 
6. The names of molecular descriptors are different from numbers, therefore upload the 
names as a “Cell Array”, and then click on “Import Selection”. 
 
7. Rename the uploaded cell array. 
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8. To generate training and test sets using the D-optimal algorithm, use the code “[Train, 
Test, Text, Qual, Xtr, Xts, Xtx] = main_mt (Y, dim);” in the command window. 70% of 
compounds in each cluster were selected as the training set and the remaining compounds 
(30%) were used as a test set. Y is the matrix which contains of retention times for 119 neutral 
compounds, 84 is the number of compounds that will be allocated into the training set. 
 
9. After running the D-optimal code, the ID of compounds in training set and test set are 
given in the “Train” and “Test” matrix, respectively. Meanwhile, the responses (retention 
times) of compounds in training and test set are also generated automatically and saved in 
the “Xtr” and “Xts” matrix. Rename these two matrixes as “Ycal” and “Ytest” in the 
workspace for subsequent use. 
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10. Having the ID of compounds for training and test set, now the corresponding variables 
(molecular descriptors) are ready to generate by running the code of “Xcal = X (Train,:);” and 
“Xtest=X(Test,:);” in command window. The Xcal matrix contains the values of molecular 
descriptors for training compounds, where the Xtest matrix include the values of molecular 
descriptors for test compounds. Then, the GA-PLS modelling can be performed. Click on the 
file “modelling_Code.txt” in the current folder and then the instruction file appears in the 
editor window. 
 
11. Follow the instructions for running the GA process, (e.g., ga=ga_model(Xcal, Ycal, 
options,2);) by pasting the code in the command window. 
 
12. The GA process is run five times to choose the most informative descriptors for the 
construction of QSRR models. After that, PLS is used to build QSRR models by running the 
code of “pred_nLV = plstest(Xtest(:,var_sel_nlv),PLS_nLV);”. n is the number of latent 
variables (LV), here an optimum number of LV need to be entered. 
13. The PLS model gives the prediction of retention for compounds in both training and 
test sets, as well as the selected descriptors used to build the QSRR models, to review the 
selected descriptors, click on the “desc_sel_name” matrix generated in the workspace. 
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14. To see the performance of the QSRR model, click on “pred_reg_param” matrix in the 
workspace to review the statistic parameters including the RMSE, and the predicted retention 
for training and test compounds. 
 
Local Second Dominant Interaction (LSDI) filtering: using this method compounds are 
clustered based on their secondary dominant interaction after hydrophobicity, namely: 
Hydrophobic interaction only – ' 
Steric bulk – σ' 
Hydrogen bonding basicity– β' 
Hydrogen bonding acidity – α' 
Ionic interaction (charge) – κ' 
More than one type of secondary interaction - cluster 6 
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Each of these six clusters was modelled individually by utilising approximately 70% of 
its compounds (using the D-optimal approach as above) as the training set and the rest as the 
external test set. To allocate new test compounds into the corresponding cluster so that the 
right model can be utilised, Tanimoto similarity (TS) searching was introduced. The structural 
similarity of each new compound was investigated against the training compounds in each 
cluster with the aim of finding one training compound with a highest pairwise Tanimoto 
structural similarity score (at least 0.5). For example, a compound with a highest Tanimoto 
score against training compounds is around 0.41 (less than 0.5), so this compound will be 
excluded in the modelling. If such a compound is found, this target compound will be assigned 
into the same LDSI cluster, allowing the correct model is used for its retention prediction. 
Compounds will be excluded if their pairwise TS indices are less than 0.5 when calculated 
against compounds in the training set.  
 
The training set was used to build QSRR models in the same way as outlined above using 
the GA-PLS method in Matlab, the predictive ability of the models was verified using test sets. 
3.6 Sum of ranking difference analysis 
The overall performance of the generated models using different filtering approaches can 
be compared using the sum of ranking difference (SRD) approach. In this work, objects 
including R2, Q2, the %RMSEP of the test set, and the slope of the regression line were selected 
and evaluated. Moreover, the number of test compounds, the average number of descriptors 
used for modelling, the number of constructed models for each approach and the prediction 
frequency with an absolute error less than 30s and 60s were also considered. A given 
benchmark was used as the gold standard. The program can be run using a “SRDrep_V5_E10” 
script on the Excel file. The instructions for performing a SRD analysis are listed below.   
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1. Prepare the input matrix with objects (parameters) and variables (models) for the SRD 
analysis.   
 
2. Make an input file as an Excel file, containing worksheets by a given structure as below. 
Put the values of gold standard in the “Read” column.  
 
3. Click on the pink start button below, then the program shows the usual GetOpenFile 
window, click on it to input the above-mentioned file. Once uploaded, click on the next to run 
the program. 
 
4. Results can be reviewed in another worksheet in the same Excel file. From the SRD 
graph and the ranking table, the validity of the generated models and the best model are 
evaluated. 
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